0001641489-22-000015.txt : 20221110 0001641489-22-000015.hdr.sgml : 20221110 20221110170643 ACCESSION NUMBER: 0001641489-22-000015 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 69 CONFORMED PERIOD OF REPORT: 20220930 FILED AS OF DATE: 20221110 DATE AS OF CHANGE: 20221110 FILER: COMPANY DATA: COMPANY CONFORMED NAME: vTv Therapeutics Inc. CENTRAL INDEX KEY: 0001641489 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 473916571 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-37524 FILM NUMBER: 221378442 BUSINESS ADDRESS: STREET 1: 3980 PREMIER DR STREET 2: SUITE 310 CITY: HIGH POINT STATE: NC ZIP: 27265 BUSINESS PHONE: 336-841-0300 MAIL ADDRESS: STREET 1: 3980 PREMIER DR STREET 2: SUITE 310 CITY: HIGH POINT STATE: NC ZIP: 27265 FORMER COMPANY: FORMER CONFORMED NAME: VTV Therapeutics Inc. DATE OF NAME CHANGE: 20150506 10-Q 1 vtvt-20220930.htm 10-Q vtvt-20220930
000164148912-312022Q3false0.500016414892022-01-012022-09-300001641489us-gaap:CommonClassAMember2022-11-10xbrli:shares0001641489us-gaap:CommonClassBMember2022-11-1000016414892022-09-30iso4217:USD00016414892021-12-310001641489us-gaap:CommonClassAMember2022-09-30iso4217:USDxbrli:shares0001641489us-gaap:CommonClassAMember2021-12-310001641489us-gaap:CommonClassBMember2022-09-300001641489us-gaap:CommonClassBMember2021-12-3100016414892022-07-012022-09-3000016414892021-07-012021-09-3000016414892021-01-012021-09-300001641489us-gaap:CommonClassAMember2022-07-012022-09-300001641489us-gaap:CommonClassAMember2021-07-012021-09-300001641489us-gaap:CommonClassAMember2022-01-012022-09-300001641489us-gaap:CommonClassAMember2021-01-012021-09-300001641489us-gaap:NoncontrollingInterestMembervtvt:RedeemableNoncontrollingInterestsMember2022-06-300001641489us-gaap:CommonStockMemberus-gaap:CommonClassAMember2022-06-300001641489us-gaap:CommonClassBMemberus-gaap:CommonStockMember2022-06-300001641489us-gaap:CommonClassAMemberus-gaap:ReceivablesFromStockholderMember2022-06-300001641489us-gaap:AdditionalPaidInCapitalMember2022-06-300001641489us-gaap:RetainedEarningsMember2022-06-3000016414892022-06-300001641489us-gaap:NoncontrollingInterestMembervtvt:RedeemableNoncontrollingInterestsMember2022-07-012022-09-300001641489us-gaap:RetainedEarningsMember2022-07-012022-09-300001641489us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-300001641489us-gaap:CommonStockMemberus-gaap:CommonClassAMember2022-07-012022-09-300001641489us-gaap:CommonClassAMemberus-gaap:ReceivablesFromStockholderMember2022-07-012022-09-300001641489us-gaap:CommonClassAMemberus-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-300001641489us-gaap:NoncontrollingInterestMembervtvt:RedeemableNoncontrollingInterestsMember2022-09-300001641489us-gaap:CommonStockMemberus-gaap:CommonClassAMember2022-09-300001641489us-gaap:CommonClassBMemberus-gaap:CommonStockMember2022-09-300001641489us-gaap:CommonClassAMemberus-gaap:ReceivablesFromStockholderMember2022-09-300001641489us-gaap:AdditionalPaidInCapitalMember2022-09-300001641489us-gaap:RetainedEarningsMember2022-09-300001641489us-gaap:NoncontrollingInterestMembervtvt:RedeemableNoncontrollingInterestsMember2021-06-300001641489us-gaap:CommonStockMemberus-gaap:CommonClassAMember2021-06-300001641489us-gaap:CommonClassBMemberus-gaap:CommonStockMember2021-06-300001641489us-gaap:AdditionalPaidInCapitalMember2021-06-300001641489us-gaap:RetainedEarningsMember2021-06-3000016414892021-06-300001641489us-gaap:NoncontrollingInterestMembervtvt:RedeemableNoncontrollingInterestsMember2021-07-012021-09-300001641489us-gaap:RetainedEarningsMember2021-07-012021-09-300001641489us-gaap:AdditionalPaidInCapitalMember2021-07-012021-09-300001641489us-gaap:CommonStockMemberus-gaap:CommonClassAMember2021-07-012021-09-300001641489us-gaap:NoncontrollingInterestMembervtvt:RedeemableNoncontrollingInterestsMember2021-09-300001641489us-gaap:CommonStockMemberus-gaap:CommonClassAMember2021-09-300001641489us-gaap:CommonClassBMemberus-gaap:CommonStockMember2021-09-300001641489us-gaap:AdditionalPaidInCapitalMember2021-09-300001641489us-gaap:RetainedEarningsMember2021-09-3000016414892021-09-300001641489us-gaap:CommonStockMemberus-gaap:CommonClassAMember2021-12-310001641489us-gaap:CommonClassBMemberus-gaap:CommonStockMember2021-12-310001641489us-gaap:AdditionalPaidInCapitalMember2021-12-310001641489us-gaap:RetainedEarningsMember2021-12-310001641489us-gaap:RetainedEarningsMember2022-01-012022-09-300001641489us-gaap:AdditionalPaidInCapitalMember2022-01-012022-09-300001641489us-gaap:CommonStockMemberus-gaap:CommonClassAMember2022-01-012022-09-300001641489us-gaap:CommonClassAMemberus-gaap:AdditionalPaidInCapitalMember2022-01-012022-09-300001641489us-gaap:CommonClassAMemberus-gaap:ReceivablesFromStockholderMember2022-01-012022-09-300001641489us-gaap:ReceivablesFromStockholderMember2022-01-012022-09-3000016414892020-12-310001641489us-gaap:CommonStockMemberus-gaap:CommonClassAMember2020-12-310001641489us-gaap:CommonClassBMemberus-gaap:CommonStockMember2020-12-310001641489us-gaap:AdditionalPaidInCapitalMember2020-12-310001641489us-gaap:RetainedEarningsMember2020-12-310001641489us-gaap:RetainedEarningsMember2021-01-012021-09-300001641489us-gaap:AdditionalPaidInCapitalMember2021-01-012021-09-300001641489us-gaap:CommonStockMemberus-gaap:CommonClassAMember2021-01-012021-09-300001641489us-gaap:CommonClassAMemberus-gaap:AdditionalPaidInCapitalMember2021-01-012021-09-300001641489us-gaap:CommonClassBMemberus-gaap:CommonStockMember2021-01-012021-09-300001641489vtvt:CollaborationPartnerMember2022-01-012022-09-300001641489vtvt:CollaborationPartnerMember2021-01-012021-09-300001641489vtvt:CinRxMember2022-01-012022-09-300001641489vtvt:CinRxMember2021-01-012021-09-300001641489vtvt:VTvLLCMember2022-01-012022-09-30xbrli:pure0001641489vtvt:G2InvestmentMember2022-09-300001641489vtvt:CinRxInvestmentMember2022-09-300001641489vtvt:CantorFitzgeraldMemberus-gaap:CommonClassAMember2022-01-012022-09-300001641489vtvt:LPCPurchaseAgreementMemberus-gaap:CommonClassAMember2022-09-300001641489us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMembervtvt:CustomerOneMember2022-07-012022-09-300001641489us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMembervtvt:CustomerOneMember2022-01-012022-09-300001641489us-gaap:CustomerConcentrationRiskMembervtvt:TwoCustomersMemberus-gaap:SalesRevenueNetMember2021-07-012021-09-300001641489us-gaap:CustomerConcentrationRiskMembervtvt:ThreeCustomersMemberus-gaap:SalesRevenueNetMember2021-01-012021-09-300001641489vtvt:G42InvestmentsMember2022-05-312022-05-310001641489vtvt:G42InvestmentsMember2022-05-310001641489vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMembervtvt:G42InvestmentsMember2022-05-312022-05-310001641489vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMembervtvt:G42InvestmentsMember2022-09-300001641489vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMembervtvt:G42InvestmentsMember2022-05-310001641489vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMembervtvt:CognaMember2022-05-31utr:Rate0001641489vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMembervtvt:CognaMember2022-05-312022-05-310001641489vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMemberus-gaap:CommonClassAMembervtvt:G42InvestmentsMember2022-05-310001641489vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMembervtvt:G42InvestmentsMember2022-01-012022-09-300001641489us-gaap:CollaborativeArrangementMembervtvt:ReneoPharmaceuticalsIncMember2021-01-012021-09-300001641489us-gaap:CollaborativeArrangementMembervtvt:ReneoPharmaceuticalsIncMember2022-01-012022-09-300001641489us-gaap:CollaborativeArrangementMembervtvt:ReneoPharmaceuticalsIncMember2022-07-012022-09-300001641489us-gaap:CollaborativeArrangementMembervtvt:ReneoPharmaceuticalsIncMember2021-07-012021-09-300001641489us-gaap:CollaborativeArrangementMembervtvt:PhaseTwoMultiRegionalClinicalTrialMembervtvt:HangzhouZhongmeiHuadongPharmaceuticalCompanyLimitedMember2021-01-140001641489us-gaap:CollaborativeArrangementMembervtvt:PhaseTwoMultiRegionalClinicalTrialMembervtvt:HangzhouZhongmeiHuadongPharmaceuticalCompanyLimitedMember2021-09-300001641489us-gaap:CollaborativeArrangementMembervtvt:PhaseTwoMultiRegionalClinicalTrialMembervtvt:LicenseAndTechnologyTransferServicesOfChemistryAndManufacturingKnowHowMembervtvt:HangzhouZhongmeiHuadongPharmaceuticalCompanyLimitedMember2021-01-012021-09-300001641489us-gaap:CollaborativeArrangementMembervtvt:PhaseTwoMultiRegionalClinicalTrialMembervtvt:LicenseAndTechnologyTransferServicesOfChemistryAndManufacturingKnowHowMembervtvt:HangzhouZhongmeiHuadongPharmaceuticalCompanyLimitedMember2022-01-012022-09-300001641489us-gaap:CollaborativeArrangementMembervtvt:NewsoaraBiopharmaCoLtdMember2021-07-012021-09-300001641489us-gaap:CollaborativeArrangementMembervtvt:NewsoaraBiopharmaCoLtdMembervtvt:LicenseAndTechnologyTransferServicesMember2022-07-012022-09-300001641489us-gaap:CollaborativeArrangementMembervtvt:NewsoaraBiopharmaCoLtdMembervtvt:LicenseAndTechnologyTransferServicesMember2022-01-012022-09-300001641489us-gaap:CollaborativeArrangementMembervtvt:NewsoaraBiopharmaCoLtdMember2022-01-012022-09-300001641489us-gaap:CollaborativeArrangementMembervtvt:NewsoaraBiopharmaCoLtdMember2022-07-012022-09-300001641489us-gaap:CollaborativeArrangementMembervtvt:JDRFInternationalMember2017-08-310001641489us-gaap:CollaborativeArrangementMembervtvt:JDRFInternationalMember2022-01-012022-09-300001641489us-gaap:CollaborativeArrangementMembervtvt:JDRFInternationalMember2017-08-012017-08-310001641489us-gaap:EmployeeStockOptionMember2022-01-012022-09-300001641489us-gaap:EmployeeStockOptionMember2022-09-300001641489us-gaap:EmployeeStockOptionMember2021-01-012021-09-3000016414892022-03-292022-03-290001641489vtvt:StrategicAdvisorMember2022-03-290001641489vtvt:StrategicAdvisorMember2022-03-292022-03-290001641489us-gaap:ResearchAndDevelopmentExpenseMember2022-07-012022-09-300001641489us-gaap:ResearchAndDevelopmentExpenseMember2021-07-012021-09-300001641489us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-09-300001641489us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-09-300001641489us-gaap:GeneralAndAdministrativeExpenseMember2022-07-012022-09-300001641489us-gaap:GeneralAndAdministrativeExpenseMember2021-07-012021-09-300001641489us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-09-300001641489us-gaap:GeneralAndAdministrativeExpenseMember2021-01-012021-09-300001641489vtvt:ReneoPharmaceuticalsIncMember2022-09-300001641489us-gaap:CommonStockMembervtvt:ReneoPharmaceuticalsIncMember2022-09-300001641489us-gaap:CommonStockMembervtvt:ReneoPharmaceuticalsIncMember2021-12-310001641489vtvt:AnterisBioIncMemberus-gaap:PreferredStockMember2022-09-300001641489vtvt:AnterisBioIncMemberus-gaap:PreferredStockMember2021-12-310001641489vtvt:ReneoPharmaceuticalsIncMember2022-07-012022-09-300001641489vtvt:ReneoPharmaceuticalsIncMember2022-01-012022-09-300001641489vtvt:ReneoPharmaceuticalsIncMember2021-07-012021-09-300001641489vtvt:ReneoPharmaceuticalsIncMember2021-01-012021-09-300001641489vtvt:TypeOneDiabetesMembervtvt:DevelopmentalAndRegulatoryMilestonePaymentMembervtvt:NovoLicenseAgreementMember2007-02-280001641489vtvt:TypeTwoDiabetesMembersrt:MaximumMembervtvt:DevelopmentalAndRegulatoryMilestonePaymentMembervtvt:NovoLicenseAgreementMember2007-02-280001641489srt:MaximumMembervtvt:DevelopmentalAndRegulatoryMilestonePaymentMembervtvt:NovoLicenseAgreementMembervtvt:OtherIndicationMember2007-02-280001641489vtvt:SalesBasedMilestonesPaymentMembervtvt:NovoLicenseAgreementMember2007-02-280001641489vtvt:SatisfactionOfMilestonePaymentMembervtvt:NovoLicenseAgreementMember2021-12-310001641489vtvt:ExchangeOfRedeemableNonControllingInterestToClassACommonStockMemberus-gaap:CommonClassAMember2022-01-012022-09-300001641489us-gaap:CommonClassAMember2020-12-310001641489us-gaap:CommonClassAMember2021-05-040001641489us-gaap:CommonClassAMember2021-05-042021-05-040001641489us-gaap:CommonStockMember2020-12-310001641489us-gaap:CommonStockMember2021-05-0400016414892021-05-040001641489vtvt:CinRxInvestmentMember2022-07-222022-07-220001641489vtvt:CinRxInvestmentMember2022-07-220001641489vtvt:CinRxInvestmentMemberus-gaap:CommonClassAMember2022-07-222022-07-220001641489vtvt:CinRxInvestmentMemberus-gaap:CommonClassAMember2022-07-220001641489vtvt:CinRxInvestmentMemberus-gaap:CommonStockMember2022-07-220001641489vtvt:AtTheMarketOfferingMembervtvt:CantorFitzgeraldMemberus-gaap:CommonClassAMember2020-04-300001641489vtvt:AtTheMarketOfferingMembervtvt:CantorFitzgeraldMemberus-gaap:CommonClassAMember2020-04-012020-04-300001641489vtvt:AtTheMarketOfferingMembervtvt:CantorFitzgeraldMemberus-gaap:CommonClassAMember2022-01-012022-09-300001641489vtvt:AtTheMarketOfferingMembervtvt:CantorFitzgeraldMemberus-gaap:CommonClassAMember2021-01-142021-01-140001641489vtvt:AtTheMarketOfferingMembervtvt:CantorFitzgeraldMemberus-gaap:CommonClassAMember2021-06-252021-06-250001641489vtvt:AtTheMarketOfferingMembervtvt:CantorFitzgeraldMemberus-gaap:CommonClassAMember2021-01-012021-09-300001641489vtvt:AtTheMarketOfferingMembervtvt:CantorFitzgeraldMemberus-gaap:CommonClassAMember2021-07-012021-09-300001641489vtvt:AtTheMarketOfferingMembervtvt:CantorFitzgeraldMemberus-gaap:CommonClassAMember2022-07-012022-09-300001641489srt:MaximumMembervtvt:LPCPurchaseAgreementMemberus-gaap:CommonClassAMember2020-11-242020-11-240001641489vtvt:LPCPurchaseAgreementMemberus-gaap:CommonClassAMember2022-01-012022-09-300001641489vtvt:LPCPurchaseAgreementMemberus-gaap:CommonClassAMember2022-07-012022-09-300001641489vtvt:LPCPurchaseAgreementMemberus-gaap:CommonClassAMember2021-01-012021-09-300001641489vtvt:MacAndrewsAndForbesIncorporatedMemberus-gaap:CommonClassBMember2022-09-300001641489vtvt:MacAndrewsAndForbesIncorporatedMemberus-gaap:CommonClassAMember2022-09-300001641489vtvt:MacAndrewsAndForbesIncorporatedMember2022-01-012022-09-300001641489srt:AffiliatedEntityMemberus-gaap:SubsequentEventMembervtvt:MasterServiceAgreementMember2022-10-100001641489vtvt:CinRxPharmaLLCMemberus-gaap:CommonClassAMember2022-09-300001641489vtvt:MFTTPHoldingsLLCMember2022-07-012022-09-300001641489us-gaap:CommonClassBMember2022-01-012022-09-300001641489us-gaap:CommonClassBMember2021-01-012021-09-300001641489us-gaap:EmployeeStockOptionMember2022-01-012022-09-300001641489us-gaap:EmployeeStockOptionMember2021-01-012021-09-300001641489us-gaap:WarrantMember2022-01-012022-09-300001641489us-gaap:WarrantMember2021-01-012021-09-300001641489us-gaap:FairValueMeasurementsRecurringMember2022-09-300001641489us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2022-09-300001641489us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001641489us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2022-09-300001641489us-gaap:FairValueMeasurementsRecurringMembervtvt:WarrantLiabilityRelatedPartyMemberus-gaap:FairValueInputsLevel1Member2022-09-300001641489us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMembervtvt:WarrantLiabilityRelatedPartyMember2022-09-300001641489us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Membervtvt:WarrantLiabilityRelatedPartyMember2022-09-300001641489us-gaap:FairValueMeasurementsRecurringMember2021-12-310001641489us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2021-12-310001641489us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001641489us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2021-12-310001641489us-gaap:FairValueMeasurementsRecurringMembervtvt:WarrantLiabilityRelatedPartyMemberus-gaap:FairValueInputsLevel1Member2021-12-310001641489us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMembervtvt:WarrantLiabilityRelatedPartyMember2021-12-310001641489us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Membervtvt:WarrantLiabilityRelatedPartyMember2021-12-310001641489us-gaap:FairValueInputsLevel3Membervtvt:WarrantLiabilityRelatedPartyMember2021-12-310001641489us-gaap:FairValueInputsLevel3Membervtvt:WarrantLiabilityRelatedPartyMember2022-01-012022-09-300001641489us-gaap:FairValueInputsLevel3Membervtvt:WarrantLiabilityRelatedPartyMember2022-09-300001641489us-gaap:FairValueInputsLevel3Member2021-12-310001641489us-gaap:FairValueInputsLevel3Member2022-01-012022-09-300001641489us-gaap:FairValueInputsLevel3Member2022-09-300001641489us-gaap:FairValueInputsLevel3Membervtvt:WarrantLiabilityRelatedPartyMember2020-12-310001641489us-gaap:FairValueInputsLevel3Membervtvt:WarrantLiabilityRelatedPartyMember2021-01-012021-09-300001641489us-gaap:FairValueInputsLevel3Membervtvt:WarrantLiabilityRelatedPartyMember2021-09-300001641489us-gaap:FairValueInputsLevel3Member2020-12-310001641489us-gaap:FairValueInputsLevel3Member2021-01-012021-09-300001641489us-gaap:FairValueInputsLevel3Member2021-09-300001641489us-gaap:MeasurementInputPriceVolatilityMembervtvt:LetterAgreementWarrantsMembersrt:MinimumMember2022-09-300001641489us-gaap:MeasurementInputPriceVolatilityMembersrt:MaximumMembervtvt:LetterAgreementWarrantsMember2022-09-300001641489us-gaap:MeasurementInputPriceVolatilityMembersrt:WeightedAverageMembervtvt:LetterAgreementWarrantsMember2022-09-300001641489us-gaap:MeasurementInputPriceVolatilityMembervtvt:LetterAgreementWarrantsMembersrt:MinimumMember2021-12-310001641489us-gaap:MeasurementInputPriceVolatilityMembersrt:MaximumMembervtvt:LetterAgreementWarrantsMember2021-12-310001641489us-gaap:MeasurementInputPriceVolatilityMembersrt:WeightedAverageMembervtvt:LetterAgreementWarrantsMember2021-12-310001641489vtvt:LetterAgreementWarrantsMembersrt:MinimumMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2022-09-300001641489srt:MaximumMembervtvt:LetterAgreementWarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2022-09-300001641489srt:WeightedAverageMembervtvt:LetterAgreementWarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2022-09-300001641489vtvt:LetterAgreementWarrantsMembersrt:MinimumMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2021-12-310001641489srt:MaximumMembervtvt:LetterAgreementWarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2021-12-310001641489srt:WeightedAverageMembervtvt:LetterAgreementWarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2021-12-310001641489us-gaap:MeasurementInputPriceVolatilityMembervtvt:CinRxWarrantsMember2022-09-300001641489vtvt:CinRxWarrantsMember2022-09-300001641489vtvt:CinRxWarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2022-09-300001641489us-gaap:MeasurementInputExpectedDividendRateMembervtvt:CinRxWarrantsMember2022-09-30

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________________________
FORM 10-Q
_____________________________
(Mark One)
xQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2022
Or
oTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from              to              
Commission file number: 001-37524
_____________________________
vTv Therapeutics Inc.
(Exact name of registrant as specified in its charter)
_____________________________
Delaware47-3916571
(State or other jurisdiction of
incorporation or organization)		(I.R.S. Employer
Identification No.)
3980 Premier Dr, Suite 310
High Point, NC
27265
(Address of principal executive offices)(Zip Code)
(336) 841-0300
(Registrant’s telephone number, including area code)
(Former name, former address and former fiscal year, if changed since last report)
_____________________________
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Class A common stock, par value $0.01 per shareVTVT
NASDAQ Capital Market
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated fileroAccelerated filero
Non-accelerated fileroSmaller reporting companyx
Emerging growth companyo
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x
Class of Stock
Shares Outstanding as of November 10, 2022
Class A common stock, par value $0.01 per share81,483,600 
Class B common stock, par value $0.01 per share23,093,860 

vTv THERAPEUTICS INC. AND SUBSIDIARIES
INDEX TO FORM 10-Q
FOR THE QUARTER ENDED SEPTEMBER 30, 2022
PAGE
NUMBER
 
2
PART I – FINANCIAL INFORMATION
The financial statements and other disclosures contained in this report include those of vTv Therapeutics Inc. (“we”, the “Company” or the “Registrant”), which is the registrant, and those of vTv Therapeutics LLC (“vTv LLC”), which is the principal operating subsidiary of the Registrant. Unless the context suggests otherwise, references in this Quarterly Report on Form 10-Q to the “Company”, “we”, “us” and “our” refer to vTv Therapeutics Inc. and its consolidated subsidiaries.
3
vTv Therapeutics Inc.
Condensed Consolidated Balance Sheets
(in thousands, except number of shares and per share data)
September 30,
2022		December 31,
2021
(Unaudited)
Assets
Current assets:
Cash and cash equivalents$15,339 $13,415 
Accounts receivable57 57 
Promissory note receivable12,091 — 
Prepaid expenses and other current assets1,281 2,049 
Current deposits15 100 
Total current assets28,783 15,621 
Property and equipment, net230 278 
Operating lease right-of-use assets328 402 
Long-term investments6,175 9,173 
Total assets$35,516 $25,474 
Liabilities, Redeemable Noncontrolling Interest and Stockholders’ Deficit
Current liabilities:
Accounts payable and accrued expenses$6,676 $8,023 
Current portion of operating lease liabilities208 184 
Current portion of contract liabilities26 35 
Current portion of notes payable557 256 
Total current liabilities7,467 8,498 
Contract liabilities, net of current portion18,669 — 
Operating lease liabilities, net of current portion333 492 
Warrant liability, related party1,409 1,262 
Total liabilities27,878 10,252 
Commitments and contingencies
Redeemable noncontrolling interest24,207 24,962 
Stockholders’ deficit:
Class A common stock, $0.01 par value; 200,000,000 shares authorized, 81,483,600 and 66,942,777 shares outstanding as of September 30, 2022, and December 31, 2021
815 669 
Class B common stock, $0.01 par value; 100,000,000 shares authorized, and 23,093,860 outstanding as of September 30, 2022, and December 31, 2021
232 232 
Promissory note receivable for common stock (4,000)— 
Additional paid-in capital253,446 238,193 
Accumulated deficit(267,062)(248,834)
Total stockholders’ deficit attributable to vTv Therapeutics Inc.(16,569)(9,740)
Total liabilities, redeemable noncontrolling interest and stockholders’ deficit$35,516 $25,474 
The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.
4
vTv Therapeutics Inc.
Condensed Consolidated Statements of Operations - Unaudited
(in thousands, except number of shares and per share data)
Three Months Ended
September 30,		Nine Months Ended
September 30,
2022202120222021
Revenue$— $3,000 $2,009 $3,996 
Operating expenses:
Research and development3,055 2,382 8,393 7,922 
General and administrative2,634 2,221 9,813 6,627 
Total operating expenses5,689 4,603 18,206 14,549 
Operating loss(5,689)(1,603)(16,197)(10,553)
Other income (expense)403 (1,084)(2,998)1,814 
Other income (expense) – related party(324)1,328 221 611 
Interest income150 — 200 1 
Interest expense(8)(6)(9)(6)
Loss before income taxes and noncontrolling interest(5,468)(1,365)(18,783)(8,133)
Income tax provision— 100 200 115 
Net loss before noncontrolling interest(5,468)(1,465)(18,983)(8,248)
Less: net loss attributable to noncontrolling interest(1,207)(378)(4,564)(2,312)
Net loss attributable to vTv Therapeutics Inc.$(4,261)$(1,087)$(14,419)$(5,936)
Net loss attributable to vTv Therapeutics Inc. common shareholders$(4,261)$(1,087)$(14,419)$(5,936)
Net loss per share of vTv Therapeutics Inc. Class A common stock, basic and diluted$(0.05)$(0.02)$(0.20)$(0.10)
Weighted average number of vTv Therapeutics Inc. Class A common stock, basic and diluted80,490,121 61,073,280 72,649,531 58,737,170 
The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.
5
vTv Therapeutics Inc.
Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders’ Deficit - Unaudited
(in thousands, except number of shares)

For the three months ended September 30, 2022
Class A Common StockClass B Common Stock
Redeemable
Noncontrolling
Interest		SharesAmountSharesAmountNote Receivable for Common StockAdditional
Paid-in
Capital		Accumulated DeficitTotal Stockholders' Deficit
Balances at June 30, 2022$15,916 77,329,051 $773 23,093,860 $232 $— $243,772 $(253,303)$(8,526)
Net loss(1,207)— — — — — — (4,261)(4,261)
Share-based compensation— — — — — — 338 — 338 
Issuance of Class A common stock under CinRx purchase agreement, net of offering cost— 4,154,549 42 — — (4,000)9,336 — 5,378 
Change in redemption value of noncontrolling interest9,498 — — — — — — (9,498)(9,498)
Balances at September 30, 2022$24,207 81,483,600 $815 23,093,860 $232 $(4,000)$253,446 $(267,062)$(16,569)


For the three months ended September 30, 2021
Class A Common StockClass B Common Stock
Redeemable
Noncontrolling
Interest		SharesAmountSharesAmountAdditional
Paid-in
Capital		Accumulated DeficitTotal Stockholders' Deficit
Balances at June 30, 2021$60,190 60,193,967 $602 23,093,860 $232 $224,457 $(273,114)$(47,823)
Net loss(378)— — — — — (1,087)(1,087)
Share-based compensation— — — — — 474 — 474 
Issuance of Class A common stock under ATM offering— 6,277,209 63 — — 11,626 — 11,689 
Change in redemption value of noncontrolling interest(15,202)— — — — — 15,202 15,202 
Balances at September 30, 2021$44,610 66,471,176 $665 23,093,860 $232 $236,557 $(258,999)$(21,545)
The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.

6
vTv Therapeutics Inc.
Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders’ Deficit - Unaudited
(in thousands, except number of shares)

For the nine months ended September 30, 2022
Class A Common StockClass B Common Stock
Redeemable
Noncontrolling
Interest		SharesAmountShares AmountNote Receivable for Common StockAdditional
Paid-in
Capital		Accumulated Deficit Total Stockholders' Deficit
Balances at December 31, 2021$24,962 66,942,777 $669 23,093,860 $232 $— $238,193 $(248,834)$(9,740)
Net loss(4,564)— — — — — — (14,419)(14,419)
Share-based compensation— — — — — — 981 — 981 
Issuance of Class A common stock to collaboration partner, net of offering costs— 10,386,274 104 — — — 4,936 — 5,040 
Issuance of Class A common stock under CinRx purchase agreement, net of offering costs— 4,154,549 42 — — (4,000)9,336 — 5,378 
Change in redemption value of noncontrolling interest3,809 — — — — — — (3,809)(3,809)
Balances at September 30, 2022$24,207 81,483,600 $815 23,093,860 $232 $(4,000)$253,446 $(267,062)$(16,569)

For the nine months ended September 30, 2021
Class A Common StockClass B Common Stock
Redeemable
Noncontrolling
Interest		SharesAmountShares AmountAdditional
Paid-in
Capital		Accumulated Deficit Total Stockholders' Deficit
Balances at December 31, 2020$83,895 54,050,710 $541 23,094,221 $232 $209,161 $(290,036)$(80,102)
Net loss(2,312)— — — — — (5,936)(5,936)
Share-based compensation— — — — — 1,362 — 1,362 
Issuance of Class A common stock under ATM offering— 8,457,546 85 — — 16,939 — 17,024 
Exchange of Class B common stock for Class A common stock— 361 — (361)— — — — 
Exercise of stock options— 20,833 — — — 47 — 47 
Issuance of Class A common stock under LPC Agreement— 3,941,726 39 — — 9,048 — 9,087 
Change in redemption value of noncontrolling interest(36,973)— — — — — 36,973 36,973 
Balances at September 30, 2021$44,610 66,471,176 $665 23,093,860 $232 $236,557 $(258,999)$(21,545)
The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.
7
vTv Therapeutics Inc.
Condensed Consolidated Statements of Cash Flows - Unaudited
(in thousands)
Nine Months Ended September 30,
20222021
Cash flows from operating activities:
Net loss before noncontrolling interest$(18,983)$(8,248)
Adjustments to reconcile net loss before noncontrolling interest to net cash used in operating activities:
Depreciation expense69 67 
Non-cash interest income (200)— 
Interest expense9 — 
Share-based compensation expense981 1,362 
Change in fair value of investments2,998 (1,814)
Change in fair value of warrants, related party(221)(611)
Changes in assets and liabilities:
Accounts receivable— (770)
Prepaid expenses and other assets853 (367)
Accounts payable and accrued expenses(1,417)(1,514)
Contract liabilities6,769 (996)
Net cash used in operating activities(9,142)(12,891)
Cash flows from investing activities:
Purchases of property and equipment(21)— 
Net cash used in investing activities(21)— 
Cash flows from financing activities:
Proceeds from sale of Class A common stock to collaboration partner, net of offering costs5,040 — 
Proceeds from sale of Class A common stock and warrants, net of offering costs5,746 — 
Proceeds from sale of Class A common stock, net of offering costs— 26,111 
Proceeds from exercise of stock options— 47 
Proceeds from debt issuance776 887 
Repayment of notes payable(475)(335)
Net cash provided by financing activities11,087 26,710 
Net increase in cash and cash equivalents1,924 13,819 
Total cash and cash equivalents, beginning of period13,415 5,747 
Total cash and cash equivalents, end of period$15,339 $19,566 
Non-cash activities:
Change in redemption value of noncontrolling interest$3,809 $(36,973)
Notes receivable recorded at fair value from collaboration partner$11,891 $— 
Notes receivable for common stock from CinRx purchase agreement$4,000 $— 
The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.
8
vTv Therapeutics Inc.
Notes to Condensed Consolidated Financial Statements – Unaudited
(dollar amounts are in thousands, unless otherwise noted)
Note 1: Description of Business, Basis of Presentation and Going Concern
Description of Business
vTv Therapeutics Inc. (the “Company,” the “Registrant,” “we” or “us”) was incorporated in the state of Delaware in April 2015. The Company is a clinical stage pharmaceutical company focused on treating metabolic diseases to minimize their long-term complications through end-organ protection.
Principles of Consolidation
vTv Therapeutics Inc. is a holding company, and its principal asset is a controlling equity interest in vTv Therapeutics LLC (“vTv LLC”), the Company’s principal operating subsidiary, which is a clinical stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs.
The Company has determined that vTv LLC is a variable-interest entity (“VIE”) for accounting purposes and that vTv Therapeutics Inc. is the primary beneficiary of vTv LLC because (through its managing member interest in vTv LLC and the fact that the senior management of vTv Therapeutics Inc. is also the senior management of vTv LLC) it has the power and benefits to direct all of the activities of vTv LLC, which include those that most significantly impact vTv LLC’s economic performance. vTv Therapeutics Inc. has therefore consolidated vTv LLC’s results pursuant to Accounting Standards Codification Topic 810, “Consolidation” in its Condensed Consolidated Financial Statements. As of September 30, 2022, various holders own non-voting interests in vTv LLC, representing a 22.1% economic interest in vTv LLC, effectively restricting vTv Therapeutics Inc.’s interest to 77.9% of vTv LLC’s economic results, subject to increase in the future, should vTv Therapeutics Inc. purchase additional non-voting common units (“vTv Units”) of vTv LLC, or should the holders of vTv Units decide to exchange such units (together with shares of Class B common stock) for shares of Class A common stock (or cash) pursuant to the Exchange Agreement (as defined in Note 9). vTv Therapeutics Inc. has provided financial and other support to vTv LLC in the form of its purchase of vTv Units with the net proceeds of the Company’s initial public offering (“IPO”) in 2015, its registered direct offering in March 2019, and its agreeing to be a co-borrower under the Venture Loan and Security Agreement (the “Loan Agreement”) with Horizon Technology Finance Corporation and Silicon Valley Bank (together, the “Lenders”) which was entered into in 2016. vTv Therapeutics Inc. entered into the letter agreements with MacAndrews and Forbes Group LLC (“M&F Group”), a related party and an affiliate of MacAndrews & Forbes Incorporated (together with its affiliates “MacAndrews”) in December 2017, July 2018, December 2018, March 2019, September 2019, and December 2019 (each a “Letter Agreement” and collectively, the “Letter Agreements”). In addition, vTv Therapeutics Inc. also entered into the Controlled Equity OfferingSM Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co. (“Cantor Fitzgerald”) (the “ATM Offering”), the purchase agreement with Lincoln Park Capital Fund, LLC (“Lincoln Park”) (the “LPC Purchase Agreement”), the common stock purchase agreement with G42 Investments AI Holding RSC Ltd (“G42 Investments”) (the “G42 Purchase Agreement”) and the common stock and warrant purchase agreement with CinPax, LLC and CinRx, LLC, respectively (the “CinRx Purchase Agreement”). vTv Therapeutics Inc. will not be required to provide financial or other support for vTv LLC. However, vTv Therapeutics Inc. will control its business and other activities through its managing member interest in vTv LLC, and its management is the management of vTv LLC. Nevertheless, because vTv Therapeutics Inc. will have no material assets other than its interests in vTv LLC, any financial difficulties at vTv LLC could result in vTv Therapeutics Inc. recognizing a loss.
Going Concern and Liquidity
To date, the Company has not generated any product revenue and has not achieved profitable operations. The continuing development of our drug candidates will require additional financing. From its inception through September 30, 2022, the Company has funded its operations primarily through a combination of private placements of common and preferred equity, research collaboration agreements, upfront and milestone payments for license agreements, debt and equity financings and the completion of its IPO in August 2015. As of September 30, 2022, the Company had an accumulated deficit of $267.1 million and has generated net losses in each year of its existence.
As of September 30, 2022, the Company’s liquidity sources included cash and cash equivalents of $15.3 million. To meet our future funding requirements into the fourth quarter of 2023, including funding the on-going and future clinical trials of TTP399, we are evaluating several financing strategies, including direct equity investments and the potential licensing and
9
monetization of other Company programs such as HPP737. The Company also has promissory notes of $12.5 million and $4.0 million under the G42 Purchase Agreement and CinRx Purchase Agreement payable to the Company, respectively. The G42 promissory note is due on or before May 31, 2023, and the CinRx promissory note is due on or before November 22, 2022 (see Note 9).
The Company may also use its remaining availability of $37.3 million under our Sales Agreement with Cantor Fitzgerald pursuant to which the Company may offer and sell, from time to time shares of the Company’s Class A common stock (the “ATM Offering”) and the ability to sell an additional 9,437,376 shares of Class A common stock under the LPC Purchase Agreement based on the remaining number of registered shares. However, the ability to use these sources of capital is dependent on a number of factors, including the prevailing market price of and the volume of trading in the Company’s Class A common stock. See Note 9 for further details.
These conditions raise substantial doubt about the Company’s ability to continue as a going concern. If we are unable to raise additional capital as and when needed, or upon acceptable terms, such failure would have a significant negative impact on our financial condition.
The Company’s financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. The Condensed Consolidated Financial Statements do not include adjustments to reflect the possible future effects on the recoverability and classification of recorded assets or the amounts of liabilities that might be necessary should the Company be unable to continue as a going concern.
Note 2: Summary of Significant Accounting Policies
Unaudited Interim Financial Information
The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying Condensed Consolidated Balance Sheet as of September 30, 2022, Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2022, and 2021, Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders’ Deficit for the three and nine months ended September 30, 2022, and 2021 and Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2022, and 2021 are unaudited. These unaudited financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. These financial statements should be read in conjunction with the audited financial statements and the accompanying notes for the year ended December 31, 2021, contained in the Company’s Annual Report on Form 10-K. The unaudited interim financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company’s financial position as of September 30, 2022, the results of operations for the three and nine months ended September 30, 2022, and 2021 and cash flows for the nine months ended September 30, 2022, and 2021. The December 31, 2021 Condensed Consolidated Balance Sheet included herein was derived from the audited financial statements but does not include all disclosures or notes required by GAAP for complete financial statements.
The financial data and other information disclosed in these notes to the financial statements related to the three and nine months ended September 30, 2022, and 2021 are unaudited. Interim results are not necessarily indicative of results for an entire year.
The Company does not have any components of other comprehensive income recorded within its Condensed Consolidated Financial Statements, and, therefore, does not separately present a statement of comprehensive income in its Condensed Consolidated Financial Statements.
Use of Estimates
The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
On an ongoing basis, the Company evaluates its estimates, including those related to the grant date fair value of equity awards, the fair value of warrants to purchase shares of its Class A common stock, the fair value of the Class B common stock, the useful lives of property and equipment, the fair value of derivative liabilities, the fair value of the promissory note
10
receivable, and the fair value of the Company’s debt, among others. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable, the results of which form the basis for making judgments about the carrying value of assets and liabilities.
Concentration of Credit Risk
Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash on deposit with one financial institution. The balances of these cash accounts frequently exceed insured limits.
One customer represented 100% of the revenue earned during the nine months ended September 30, 2022, two customers represented 100% of the revenue earned during the three months ended September 30, 2021 and three customers represented 100% of the revenue earned during the nine months ended September 30, 2021.
Cash and Cash Equivalents
The Company considers any highly liquid investments with an original maturity of three months or less to be cash and cash equivalents.
Investments
Investments in entities in which the Company has no control or significant influence, is not the primary beneficiary, and have a readily determinable fair value are classified as equity investments with readily determinable fair value. The investments are measured at fair value based on a quoted market price per unit in active markets multiplied by the number of units held without consideration of transaction costs (Level 1). Gains and losses are recorded in other income (expense), net on the Consolidated Statements of Operations.
Equity investments without readily determinable fair value include ownership rights that do not provide the Company with control or significant influence and these investments do not have readily determinable fair values. The Company has elected to measure its equity investments without readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment.
Revenue Recognition
The Company uses the revenue recognition guidance established by ASC Topic 606, Revenue From Contracts With Customers (“ASC 606”). When an agreement falls under the scope of other standards, such as ASC Topic 808, Collaborative Arrangements (“ASC 808”), the Company will apply the recognition, measurement, presentation, and disclosure guidance in ASC 606 to the performance obligations in the agreements if those performance obligations are with a customer. Revenue recognized by analogizing to ASC 606, is recorded as collaboration revenue on the statements of operations.
The majority of the Company’s revenue results from its license and collaboration agreements associated with the development of investigational drug products. The Company accounts for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. For each contract meeting these criteria, the Company identifies the performance obligations included within the contract. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. The Company then recognizes revenue under each contract as the related performance obligations are satisfied.
The transaction price under the contract is determined based on the value of the consideration expected to be received in exchange for the transferred assets or services. Development, regulatory and sales milestones included in the Company’s collaboration agreements are considered to be variable consideration. The amount of variable consideration expected to be received is included in the transaction price when it becomes probable that the milestone will be met. For contracts with multiple performance obligations, the contract’s transaction price is allocated to each performance obligation using the Company’s best estimate of the standalone selling price of each distinct good or service in the contract. The primary method used to estimate standalone selling price is the expected cost-plus margin approach.
Research and Development
Major components of research and development costs include cash and share-based compensation, costs of preclinical studies, clinical trials and related clinical manufacturing, costs of drug development, costs of materials and supplies, regulatory and compliance costs, fees paid to consultants and other entities that conduct certain research and development
11
activities on the Company’s behalf, facilities costs, and overhead costs. Research and development costs are expensed as incurred.
The Company records accruals based on estimates of the services received, efforts expended, and amounts owed pursuant to contracts with numerous contract research organizations. In the normal course of business, the Company contracts with third parties to perform various clinical study activities in the ongoing development of potential products. The financial terms of these agreements are subject to negotiation and variation from contract to contract and may result in uneven payment flows. Payments under the contracts depend on factors such as the achievement of certain events and the completion of portions of the clinical study or similar conditions. The objective of the Company’s accrual policy is to match the recording of expenses in its financial statements to the actual services received and efforts expended. As such, expense accruals related to clinical studies are recognized based on the Company’s estimate of the degree of completion of the event or events specified in the specific clinical study.
The Company records nonrefundable advance payments it makes for future research and development activities as prepaid expenses. Prepaid expenses are recognized as expense in the Condensed Consolidated Statements of Operations as the Company receives the related goods or services.
Research and development costs that are reimbursed under a cost-sharing arrangement are reflected as a reduction of research and development expense.
Recently Issued Accounting Pronouncements
Fair Value Measurements: In June 2022, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2022-03 “Fair Value Measurements (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions.” These amendments clarify that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. This guidance is effective for public business entities for fiscal years, including interim periods within those fiscal years, beginning after December 15, 2023. Early adoption is permitted. The Company has assessed ASU 2022-03 and early adopted the guidance during the second quarter of 2022. The adoption did not have a material impact on the Company's Condensed Consolidated Financial Statements.
Note 3: Collaboration Agreements
G42 Purchase Agreement and Cogna Collaborative and License Agreement
The Company and G42 Investments AI Holding RSC Ltd, a private limited company (“G42 Investments”), entered into a Common Stock Purchase Agreement (the “G42 Purchase Agreement”), pursuant to which the Company sold to G42 Investments 10,386,274 shares of the Company’s Class A common stock, par value $0.01 per share (the “G42 Common Stock) at a price per share of approximately $2.41, for an aggregate purchase price of $25.0 million, which was paid (i) $12.5 million in cash at the closing and (ii) $12.5 million in the form of a promissory note of G42 Investments to be paid at the one-year anniversary of the execution of the G42 Purchase Agreement. As part of the G42 Purchase Agreement, G42 Investments put forward a director as appointee and the Company’s board of directors approved appointing the new director to the Company’s board.
G42 Investments has agreed to certain transfer restrictions (including restrictions on short sales or similar transactions) and restrictions on further acquisitions of shares, in each case subject to specified exceptions. Following the expiration of a lock up period, from the period May 31, 2022 until December 31, 2024 (or if earlier, the date of receipt of U.S. Food and Drug Administration (“FDA”) approval in the U.S. for TTP399 (the “FDA Approval”) of TTP399), the Company has granted to G42 Investments certain shelf and piggyback registration rights with respect to those shares of Class A common stock issued to G42 Investments pursuant to the G42 Purchase Agreement, including the ability to conduct an underwritten offering to resell such shares under certain circumstances. The registration rights include customary cooperation, cut-back, expense reimbursement, and indemnification provisions.
Contemporaneously with the G42 Purchase Agreement, effective on May 31, 2022, the Company entered into a collaboration and license agreement (the “Cogna Agreement”) with Cogna Technology Solutions LLC, an affiliate of G42 Investments (“Cogna”) (“Collaboration Partner”), which requires Cogna to work with the Company in performing Phase 3 clinical trials for the Company’s TTP399 compound (the “Licensed Product”) as well as jointly creating a global development plan to develop, market, and commercialize TTP399 in certain countries in the Middle East, Africa, and Central Asia (the “Partner Territory”). Under the terms of the Cogna Agreement, Cogna will obtain rights to the Company’s license of TTP399, for purposes of performing Phase 3 clinical trials in the Partner Territory, but will not have access to the various intellectual property (“IP”) related to the license and TTP399. Specifically, the Company will share various protocols with Cogna related to conducting the clinical trials and will provide the patient dosages and placebo of TTP399 needed to conduct
12
the trials. Separately, the Company will conduct its Phase 3 clinical trials for TTP399 in the U.S. at its own cost that similarly will not be reimbursed. The results of each party’s Phase 3 clinical trials will be combined by the Company to seek FDA approval in the U.S. for TTP399.

Under the Cogna Agreement, Cogna has the right to develop and commercialize the Licensed Product in the Partner Territory at its own cost once restrictions on the use of the IP have been lifted by the Company. The Cogna Agreement determined which specific countries in the Partner Territory that Cogna may pursue development and commercialization and provides the Company with the ability to determine when Cogna can benefit from this IP through the powers granted to the Company to approve the global development plan. Further, the Company may supply at cost, or Cogna may manufacture, TTP399 for commercial sale under terms to be agreed upon by the parties at a later date.
The G42 Purchase Agreement also provides for, following the receipt of FDA approval of the Licensed Product, at the option of G42 Investments, either (a) the issuance of the Company’s Class A common stock (the “Milestone Shares”) having an aggregate value equal to $30.0 million or (b) the payment by the Company of $30.0 million in cash (the “Milestone Cash Payment”). The issuance of the Milestone Shares or the payment of the Milestone Cash Payment, as applicable, are conditioned upon receipt of the FDA Approval and subject to certain limitations and conditions set forth in the G42 Purchase Agreement. There can be no assurance that the FDA Approval will be granted or as to the timing thereof.
Once commercialization takes place in the Partner Territories, the Company will receive royalties of 8% from Cogna on the sale of the Licensed Product for ten years after the first commercial sale of the Licensed Product.
Common stock is generally recorded at fair value at the date of issuance. In determining the fair value of the Class A common stock issued to G42 Investments, the Company considered the closing price of the common stock on the effective date. The Company did not make an adjustment to the fair value for sale restrictions on the stock in accordance with guidance recently adopted in ASU 2022-03. See the “Recently Issued Accounting Guidance” in this 10-Q for details of the ASU. Accordingly, the Company determined that cash consideration of $5.7 million should be recorded as fair value of the Class A common stock at the effective date, utilizing the Class A common stock closing price of $0.55 at the effective date.
A premium was paid on the Class A common stock by G42 Investments of $18.7 million, net of a note receivable discount of $0.6 million. This premium is determined to be the transaction price for all remaining obligations under the agreements, which will be accounted for under ASC 808 or ASC 606 based on determination of the unit of account.
The Company determined that certain commitments under the agreements are in the scope of ASC 808 as both the Company and Cogna are active participants in the clinical trials of the Licensed Product, and both are exposed to significant risks and rewards based on the success of the clinical trials and subsequent FDA approval. Cogna is determined to be a vendor of the Company during the clinical trial phase, working on the Company’s behalf to complete R&D activities, and not in a customer capacity. The Company accounted for the commitments related to the clinical trials, which includes transfer of trial protocols, supply of clinical trial dosages, and collaboration on the joint development committee (“JDC”) as an ASC 808 unit of account, applying the recognition and measurement principles of ASC 606 by analogy. The Company will recognize collaboration revenue for its development activities under ASC 808 over time based on the estimated period of performance.
By applying the principals in ASC 606 by analogy, the Company identified the performance obligation and considered the timing of satisfaction of the obligation to account for the pattern of revenue recognition. In order to recognize collaboration revenue, generally, the Company would begin satisfying its performance obligation and Cogna would need to be able to use and benefit from delivery of the assets or services. The performance obligation under the agreements that fall within the 808 unit of account are concentrated in the Phase 3 clinical trials. As of September 30, 2022, the Phase 3 clinical trials had not commenced. Accordingly, no collaboration revenue was recognized for the ASC 808 unit of account during the three and nine months ended September 30, 2022.
The Company identified certain commitments that are in the scope of ASC 606 as Cogna’s relationship is that of a customer for these commitments. The significant performance obligations that are in the scope of ASC 606 are (1) the development, commercialization and manufacturing license of the IP once restrictions on the use of the IP have been lifted by the Company and (2) a potential material right to a commercial supply agreement. The Company will recognize revenue from the development, commercial and manufacturing license at a point in time when the Company releases the restrictions on the use of the IP, which is expected to be after the Licensed Product is approved by the FDA. The Company will recognize revenue from the material right related to Cogna’s ability to purchase the commercial supply at cost as Cogna purchases the commercial supply from the Company, which will occur after the completion of the initial clinical trials (if Cogna decides to purchase the clinical supply from the Company). As a result, the Company has not recognized any revenue under the ASC 606 unit of account during the three and nine months ended September 30, 2022.
13
As of September 30, 2022, the Company has recognized the cash and a non-interest bearing promissory note receivable of with a principal balance of $12.5 million. The promissory note receivable was classified and accounted for under ASC 310 and was initially measured at its fair value of $11.9 million and will be subsequently remeasured at its amortized cost through its maturity date. The Company also recorded the $18.7 million as deferred revenue in the Consolidated Balance Sheets, as none of the underlying performance obligations had been satisfied as of and for the three and nine months ended September 30, 2022.
Reneo License Agreement
The Company is party to a license agreement with Reneo Pharmaceuticals, Inc. (“Reneo”) (the “Reneo License Agreement”), under which Reneo obtained an exclusive, worldwide, sublicensable license to develop and commercialize the Company’s peroxisome proliferation activated receptor delta (PPAR-δ) agonist program, including the compound HPP593, for therapeutic, prophylactic or diagnostic application in humans.
The Company has fully allocated the transaction price to the license and the technology transfer services, which represents a single combined performance obligation because they were not capable of being distinct on their own. The revenue related to this performance obligation was recognized on a straight-line basis over the technology transfer service period.
The revenue related to this performance obligation has been fully recognized and no revenue related to this performance obligation was recognized for the three and nine months ended September 30, 2022. There have been no adjustments to the transaction price for the performance obligations under the Reneo License Agreement during the three and nine months ended September 30, 2022. In the third quarter of 2021, the transaction price for this performance obligation was increased by $2.0 million due to the satisfaction of a development milestone under the Reneo License Agreement. This amount was fully recognized as revenue during the three and nine months ended September 30, 2021, as the related performance obligation was fully satisfied.
Huadong License Agreement
The Company is party to a license agreement with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (“Huadong”) (the “Huadong License Agreement”), under which Huadong obtained an exclusive and sublicensable license to develop and commercialize the Company’s glucagon-like peptide-1 receptor agonist (“GLP-1r”) program, including the compound TTP273, for therapeutic uses in humans or animals, in China and certain other pacific rim countries, including Australia and South Korea (collectively, the “Huadong License Territory”). Additionally, under the Huadong License Agreement, the Company obtained a non-exclusive, sublicensable, royalty-free license to develop and commercialize certain Huadong patent rights and know-how related to the Company’s GLP-1r program for therapeutic uses in humans or animals outside of the Huadong License Territory.
On January 14, 2021, the Company entered into the first amendment to the Huadong License Agreement ( the “First Huadong Amendment”) which eliminated the Company’s obligation to sponsor a multi-region clinical trial (the “Phase 2 MRCT”), and corresponding obligation to contribute up to $3.0 million in support of such trial. The amendment also reduced the total potential development and regulatory milestone payments by $3.0 million.
Prior to the First Amendment, the Company had allocated a portion of the transaction price to the obligation to sponsor and conduct a portion of the Phase 2 MRCT. Upon the removal of this performance obligation, the Company evaluated the impact of the modification under the provisions of ASC Topic 606 and performed a reallocation of the transaction price among the remaining performance obligations. This resulted in the recognition of approximately $1.0 million of revenue on a cumulative catch-up basis during the nine months ended September 30, 2021. The majority of the transaction price originally allocated to the Phase 2 MRCT performance obligation was reallocated to the license and technology transfer services combined performance obligation discussed below, which had already been completed. The reallocation of the purchase price in connection with the First Huadong Amendment was made based on the relative estimated selling prices of the remaining performance obligations.
The significant performance obligations under the Huadong License Agreement, as amended, were determined to be (i) the exclusive license to develop and commercialize the Company’s GLP-1r program, (ii) technology transfer services related to the chemistry and manufacturing know-how for a defined period after the effective date, (iii) the Company’s obligation to participate on a joint development committee (the “JDC”), and (iv) other obligations considered to be de minimis in nature.
The Company has determined that the license and technology transfer services related to the chemistry and manufacturing know-how represent a combined performance obligation because they were not capable of being distinct on
14
their own. The Company also determined that there was no discernible pattern in which the technology transfer services would be provided during the transfer service period. As such, the Company recognized the revenue related to this combined performance obligation using the straight-line method over the transfer service period. This combined performance obligation was considered complete as of September 30, 2021. The Company recognized $1.0 million of revenue related to this combined performance obligation during the nine months ended September 30, 2021. During the nine months ended September 30, 2022, the transaction price for this performance obligation was increased by $2.0 million due to the satisfaction of a development milestone under the Huadong License Agreement, as amended. This amount was fully recognized as revenue during the nine months ended September 30, 2022, as the related performance obligation was fully satisfied.
A portion of the transaction price allocated to the obligation to participate in the JDC to oversee the development of products and the Phase 2 MRCT in accordance with the development plan remained deferred as of September 30, 2022, and revenue will be recognized using the proportional performance model over the period of the Company’s participation on the JDC. The unrecognized amount of the transaction price allocated to this performance obligation as of September 30, 2022, was de minimis. An immaterial amount of revenue for this performance obligation has been recognized during nine months ended September 30, 2022, and 2021.
Newsoara License Agreement-
The Company is party to a license agreement with Newsoara Biopharma Co., Ltd., (“Newsoara”) (the “Newsoara License Agreement”) under which Newsoara obtained an exclusive and sublicensable license to develop and commercialize the Company’s phosphodiesterase type 4 inhibitors (“PDE4”) program, including the compound HPP737, in China, Hong Kong, Macau, Taiwan and other pacific rim countries (collectively, the “Newsoara License Territory”). Additionally, under the Newsoara License Agreement, the Company obtained a non-exclusive, sublicensable, royalty-free license to develop and commercialize certain Newsoara patent rights and know-how related to the Company’s PDE4 program for therapeutic uses in humans outside of the Newsoara License Territory.
The Company has fully allocated the transaction price to the license and the technology transfer services which represents a single performance obligation because they were not capable of being distinct on their own. The Company recognized revenue for this performance obligation using the straight-line method over the transfer service period. The revenue for this performance obligation has been fully recognized as of September 30, 2022. In the third quarter of 2021, the transaction price for this performance obligation was increased by $1.0 million due to the satisfaction of a development milestone under the Newsoara License Agreement. This amount was fully recognized as revenue during the three and nine months ended September 30, 2021, as the related performance obligation was fully satisfied. No revenue related to this performance obligation was recognized and there have been no changes to the transaction price during the three and nine months ended September 30, 2022.
JDRF Agreement
In August 2017, the Company entered into a research and collaboration agreement with JDRF International (the “JDRF Agreement”) to support the funding of the Simplici-T1 Study, a Phase 2 study to explore the effects of TTP399 in patients with type 1 diabetes. The JDRF Agreement was amended in June 2021 to provide additional funding for the Company’s mechanistic study exploring the effects of TTP399 on ketone body formation during a period of insulin withdrawal in people with type 1 diabetes. Consistent with the terms of the JDRF Agreement, JDRF provided research funding of $3.4 million based on the achievement of research and development milestones, with the total funding provided by JDRF not to exceed approximately one-half of the total cost of the project. Additionally, the Company has the obligation to make certain milestone payments to JDRF upon the commercialization, licensing, sale or transfer of TTP399 as a treatment for type 1 diabetes.
Payments that the Company receives from JDRF under this agreement were recorded as restricted cash and current liabilities and recognized as an offset to research and development expense, based on the progress of the project, and only to the extent that the restricted cash is utilized to fund such development activities. As of September 30, 2022, the Company had received funding under this agreement of $3.4 million. Research and development costs have been offset by the $3.4 million of cash received over the course of this agreement.
15
Contract Liabilities
Contract liabilities related to the Company’s collaboration agreements consisted of the following (in thousands):
September 30, 2022December 31, 2021
Current portion of contract liabilities$26 $35 
Contract liabilities, net of current portion18,669 — 
Total contract liabilities$18,695 $35 
Changes in short-term and long-term contract liabilities for the nine months ended September 30, 2022, were as follows:
Contract Liabilities
Balance on January 1, 2022$35 
Reclassification of the beginning contract liabilities to revenue, as the result of performance obligations satisfied(9)
Consideration received in advance and not recognized as revenue18,669 
Balance on September 30, 2022$18,695 
Note 4: Share-Based Compensation
The Company has issued non-qualified stock option awards to management, other key employees, consultants, and non-employee directors. These option awards generally vest ratably over a three-year period and the option awards expire after a term of ten years from the date of grant. As of September 30, 2022, the Company had total unrecognized stock-based compensation expense for its outstanding stock option awards of approximately $2.6 million, which is expected to be recognized over a weighted average period of 2.7 years. The weighted average grant date fair value of options granted during the nine months ended September 30, 2022, and 2021 was $0.68 and $2.21 per option, respectively. The aggregate intrinsic value of the in-the-money awards outstanding at September 30, 2022, was de minimis.
On February 27, 2022, Ms. Deepa Prasad notified the Board of Directors (the “Board”) of the Company of her decision to resign from her positions as Chief Executive Officer, President, and Board member, effective as of March 29, 2022, and served in these roles through March 29, 2022 (the “Effective Date”). Ms. Prasad agreed to serve as a Strategic Advisor to the Company for six months after the Effective Date. Ms. Prasad will retain 624,659 of the outstanding options previously granted to her, which will vest at the end of the 15-month period following the Effective Date. As a result of the separation agreement, these options were modified to accelerate vesting at the Effective Date. These options will remain exercisable for the original ten-year period and the remaining 1,873,976 of her options were cancelled. The additional stock compensation expense for the modification during the nine months ended September 30, 2022, was de minimis.
The following table summarizes the activity related to the stock option awards for the nine months ended September 30, 2022:
Number of Shares Weighted
Average Exercise Price
Awards outstanding at December 31, 20217,056,035 $3.19 
Granted4,047,333 0.78 
Forfeited(3,384,424)2.37 
Awards outstanding at September 30, 20227,718,944 $2.28 
Options exercisable at September 30, 20222,563,810 $4.75 
Weighted average remaining contractual term6.3 Years
Options vested and expected to vest at September 30, 20226,664,874 $2.49 
Weighted average remaining contractual term8.2 Years
16
Compensation expense related to the grants of stock options is included in research and development and general and administrative expense as follows (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Research and development$109 $186 $289 $542 
General and administrative229 288 692 820 
Total share-based compensation expense$338 $474 $981 $1,362 
Note 5: Investments
In connection with the Reneo License Agreement and the Anteris License Agreement, the Company has received equity ownership interests of less than 20% of the voting equity of the investee. Further, the Company does not have the ability to exercise significant influence over the investees. The investments are classified as long-term investments in the Company’s Consolidated Balance Sheets.
Reneo completed its initial public offering in April 2021. Prior to Reneo becoming a publicly traded company, the Company’s investment in Reneo did not have a readily determinable fair value and was measured at cost less impairment, adjusted for any changes in observable prices, under the measurement alternative. Subsequent to Reneo’s initial public offering, the Company’s investment in Reneo is considered to have a readily determinable fair value and, as such, is adjusted to its fair value each period with changes in fair value recognized as a component of net loss.
The Company’s investment in Anteris does not have a readily determinable fair value and is measured at cost less impairment, adjusted for any changes in observable prices.
The Company’s investments consist of the following:
September 30, 2022December 31, 2021
Equity investment with readily determinable fair value:
Reneo common stock$1,930 $4,928 
Equity investment without readily determinable fair values assessed under the measurement alternative:
Anteris preferred stock4,245 4,245 
Total$6,175 $9,173 
No adjustments have been made to the value of the Company’s investment in Anteris since its initial measurement either due to impairment or based on observable price changes. The Company recognized an unrealized gain on its investment in Reneo of $0.4 million and an unrealized loss of $3.0 million for the three and nine months ended September 30, 2022, respectively. The Company recognized an unrealized loss on its investment in Reneo of $1.1 million and an unrealized gain of $1.8 million for the three months and nine months ended September 30, 2021, respectively. These adjustments were recognized as a component of other income/(expense) in the Company’s Condensed Consolidated Statements of Operations.
Note 6: Commitments and Contingencies
Legal Matters
From time to time, the Company is involved in various legal proceedings arising in the normal course of business. If a specific contingent liability is determined to be probable and can be reasonably estimated, the Company accrues and discloses the amount. The Company is not currently a party to any material legal proceedings.
Novo Nordisk
In February 2007, the Company entered into an Agreement Concerning Glucokinase Activator Project with Novo Nordisk A/S (the “Novo License Agreement”) whereby the Company obtained an exclusive, worldwide, sublicensable license under certain Novo Nordisk intellectual property rights to discover, develop, manufacture, have manufactured, use and commercialize products for the prevention, treatment, control, mitigation or palliation of human or animal diseases or conditions. As part of this license grant, the Company obtained certain worldwide rights to Novo Nordisk’s GKA program, including rights to preclinical and clinical compounds such as TTP399. This agreement was amended in May 2019 to create
17
milestone payments applicable to certain specific and non-specific areas of therapeutic use. Under the terms of the amended Novo License Agreement, the Company has potential developmental and regulatory milestone payments totaling up to $9.0 million for approval of a product for the treatment of type 1 diabetes, $50.5 million for approval of a product for the treatment of type 2 diabetes, or $115.0 million for approval of a product in any other indication. The Company may also be obligated to pay an additional $75.0 million in potential sales-based milestones, as well as royalty payments, at mid-single digit royalty rates, based on tiered sales of commercialized licensed products. During the fourth quarter of 2021, the Company made a payment of $2.0 million related to the satisfaction of the milestone to complete the phase 2 trials for TTP399 under this agreement.
Note 7: Leases
The Company leases office space for its headquarters location under an operating lease. This lease commenced in November 2019 after the completion of certain tenant improvements made by the lessor. The lease includes an option to renew for a five-year term as well as an option to terminate after three years, neither of which have been recognized as part of its related right of use assets or lease liabilities as their election was not considered reasonably certain. The Company has notified the lessor that it intends to exercise the early termination option and is negotiating an amendment to the lease. Further, this lease does not include any material residual value guarantee or restrictive covenants.
At each of September 30, 2022, and December 31, 2021, the weighted average incremental borrowing rate for the operating leases held by the Company was 13.1%. At September 30, 2022, and December 31, 2021, the weighted average remaining lease terms for the operating leases held by the Company were 2.3 years and 3.1 years, respectively.
Maturities of lease liabilities for the Company’s operating leases as of September 30, 2022, were as follows (in thousands):
2022 (remaining three months)$65 
2023268 
2024275 
202523 
2026— 
Thereafter— 
Total lease payments631 
Less: imputed interest(90)
Present value of lease liabilities$541 
Operating lease cost and the related operating cash flows for the nine months ended September 30, 2022, and 2021 were immaterial amounts.
Note 8: Redeemable Noncontrolling Interest
The Company is subject to the Exchange Agreement with respect to the vTv Units representing the 22.1% noncontrolling interest in vTv LLC outstanding as of September 30, 2022 (see Note 9). The Exchange Agreement requires the surrender of an equal number of vTv Units and Class B common stock for (i) shares of Class A common stock on a one-for-one basis or (ii) cash (based on the fair market value of the Class A common stock as determined pursuant to the Exchange Agreement), at the Company’s option (as the managing member of vTv LLC), subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications. The exchange value is determined based on a 20-day volume weighted average price of the Class A common stock as defined in the Exchange Agreement, subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications.
The redeemable noncontrolling interest is recognized at the higher of (1) its initial fair value plus accumulated earnings/losses associated with the noncontrolling interest or (2) the redemption value as of the balance sheet date. At September 30, 2022, and December 31, 2021, the redeemable noncontrolling interest was recorded based on the redemption value as of the balance sheet date of $24.2 million and $25.0 million, respectively.
Changes in the Company’s ownership interest in vTv LLC while the Company retains its controlling interest in vTv LLC are accounted for as equity transactions, and the Company is required to adjust noncontrolling interest and equity for
18
such changes. The following is a summary of net income attributable to vTv Therapeutics Inc. and transfers to noncontrolling interest:
For the Three Months Ended September 30,For the Nine Months Ended September 30,
2022202120222021
Net loss attributable to vTv Therapeutics Inc. common shareholders$(4,261)$(1,087)$(14,419)$(5,936)
(Increase) in vTv Therapeutics Inc. accumulated deficit for purchase of LLC Units as a result of common stock issuances(1,174)(2,773)(103)(5,298)
Change from net loss attributable to vTv Therapeutics Inc. common shareholders and transfers to noncontrolling interest$(5,435)$(3,860)$(14,522)$(11,234)
Note 9: Stockholders’ Deficit
Amendment to Certificate of Incorporation
On May 4, 2021, the Company filed an amendment to its Amended and Restated Certificate of Incorporation (the “Charter Amendment”) to increase the number of shares of Class A common stock that the Company is authorized to issue from 100,000,000 shares of Class A common stock to 200,000,000 shares of Class A common stock, representing an increase of 100,000,000 shares of authorized Class A common stock, with a corresponding increase in the total authorized common stock, which includes Class A common stock and Class B common stock, from 200,000,000 to 300,000,000, and a corresponding increase in the total authorized capital stock, which includes common stock and preferred stock, from 250,000,000 shares to 350,000,000 shares.
G42 Investments Transaction
On May 31, 2022, the Company and G42 Investments entered in to the G42 Purchase Agreement (see Note 3), pursuant to which the Company agreed to sell to G42 Investments 10,386,274 shares of the Company's Class A common stock, par value $0.01 per share at a price per share of approximately $2.41, for an aggregate purchase price of $25.0 million, consisting of (i) $12.5 million in cash at the closing of the transaction and (ii) $12.5 million in the form of a promissory note of G42 Investments to be paid at the one-year anniversary of the execution of the G42 Purchase Agreement.
CinPax and CinRx Transaction
On July 22, 2022 (the “Transaction Date”), the Company entered into the CinRx Purchase Agreement with CinPax and CinRx, pursuant to which the Company agreed to sell to CinPax 4,154,549 shares of the Company’s Class A common stock, par value $0.01 per share (the “Common Stock” and such shares, the “Closing Shares”) at a price per share of approximately $2.41, for an aggregate purchase price of $10.0 million, which was paid (i) $6.0 million in cash at the closing of the transaction and (ii) $4.0 million in the form of a non-interest-bearing promissory note with CinPax to be paid at the four-month anniversary of the execution of the CinRx Purchase Agreement. The promissory note receivable was classified and accounted for under ASC 505 as contra-equity. The CinRx Purchase Agreement provides CinPax the right to put forward a director to be approved to sit on vTv’s Board of Directors and a board observer, which was subsequently approved by the Company’s board.
Common stock is generally recorded at fair value at the date of issuance. In determining the fair value of the Class A common stock issued to CinPax, the Company considered the closing price of the common stock on the Transaction Date. The Company did not make an adjustment to the fair value for sale restrictions on the stock in accordance with guidance recently adopted in ASU 2022-03. See the “Recently Issued Accounting Guidance” in this 10-Q for details of the ASU. Accordingly, the Company determined that cash consideration of $3.0 million should be recorded as fair value of the Class A common stock at the effective date, utilizing the Class A common stock closing price of $0.72 at the effective date.
The CinRx Purchase Agreement also provides CinRx warrants to purchase up to 1,200,000 shares of Common Stock at an initial exercise of price of approximately $0.72 per share (the “CinRx Warrants”). The CinRx Warrants were initially measured at fair value of $0.4 million using the Black Scholes option model at the time of issuance and will be recorded in Warrant liability related party in the Condensed Consolidated Balance Sheets and will be subsequently remeasured at fair value through earnings on a recurring basis. (see Note 13)
19
The CinRx Warrants will become exercisable by CinRx only if (i) the Company receives approval from the U.S. Food and Drug Administration (“FDA Approval”) to market and distribute the pharmaceutical product containing the Company’s proprietary candidate, TTP399 (the “Product”), or (ii) the Company is acquired by a third party, sells all or substantially all of its assets related to the Product to a third party or grants a third party an exclusive license to develop, commercialize and manufacture the Product in the United States (an “Exit Event”). If neither of these events happen within five years of the date of the issuance of the CinRx Warrants, the CinRx Warrants will expire and not be exercisable by CinRx. The exercise price of the CinRx Warrants and the number of shares issuable upon exercise of the CinRx Warrants are subject to adjustments in accordance with the terms of the CinRx Warrants.
Additionally, in conjunction with the CinRx Purchase Agreement the Company and CinRx entered into a Master Service Agreement (“CinRx MSA”) whereby CinRx provides the Company with consulting, pre-clinical and clinical trial services, as enumerated in project proposals negotiated between the Company and CinRx from time to time. (see Note 10)
The Company did not identify any other promises in the CinRx Purchase Agreement (aside from the issuance of common shares and the CinRx Warrants) and determined since there is no value ascribed to the CinRx MSA, the right to appoint a member and observer to the board of directors, that the remaining unallocated amount meets the definition of contributed equity and represents the amount in excess of par.
ATM Offering
In April 2020, the Company entered into the Sales Agreement with Cantor Fitzgerald as the sales agent, pursuant to which the Company may offer and sell, from time to time, through Cantor, shares of its Class A common stock, par value $0.01 per share, having an aggregate offering price of up to $13.0 million by any method deemed to be an “at the market offering” as defined in Rule 415(a)(4) under the Securities Act (the “ATM Offering”). The shares are offered and sold pursuant to the Company’s shelf registration statement on Form S-3. In no event will the Company sell Class A common stock under this registration statement with a value exceeding more than one-third of the “public float” (the market value of our Class A common stock and any other equity securities that we may issue in the future that are held by non-affiliates) in any 12-calendar month period so long as our public float remains below $75 million.
On January 14, 2021, and June 25, 2021, the Company filed a prospectus supplement in connection with the ATM Offering to increase the size of the at-the-market offering pursuant to which the Company may offer and sell, from time to time, through or to Cantor, as sales agent or principal, shares of the Company’s Class A common stock, by an aggregate offering price of $5.5 million and $50.0 million, respectively.
During the three and nine months ended September 30, 2021, the Company sold 8,457,546 shares of its Class A common stock under the ATM Offering for net proceeds of $17.0 million.
During the three and nine months ended September 30, 2022, the Company did not sell any shares under the ATM Offering.
Lincoln Park Capital Transaction
On November 24, 2020, the Company entered into the LPC Purchase Agreement and a registration rights agreement (the “Registration Rights Agreement”), pursuant to which the Company has the right to sell to Lincoln Park shares of the Company’s Class A common stock having an aggregate value of up to $47.0 million, subject to certain limitations and conditions set forth in the LPC Purchase Agreement. The Company will control the timing and amount of any sales of shares to Lincoln Park. pursuant to the LPC Purchase Agreement. During the three and nine months ended September 30, 2022, the Company did not sell any shares under the LPC Purchase Agreement. During the nine months ended September 30, 2021, the Company sold 3,941,726 shares under the LPC Purchase Agreement for total proceeds of $9.1 million.
Note 10: Related-Party Transactions
MacAndrews & Forbes Incorporated
As of September 30, 2022, subsidiaries and affiliates of MacAndrews & Forbes Incorporated (collectively “MacAndrews”) indirectly controlled 23,084,267 shares of the Company’s Class B common stock and 36,519,212 shares of the Company’s Class A common stock. As a result, MacAndrews’ holdings represent approximately 57.0% of the combined voting power of the Company’s outstanding common stock.
The Company has entered into several agreements with MacAndrews or its affiliates as further detailed below:
20
Letter Agreements
The Company has previously entered into the Letter Agreements with MacAndrews. Under the terms of the Letter Agreements, during the one year commitment period beginning on the date of each License Agreement, the Company had the right to sell to MacAndrews shares of its Class A common stock at a specified price per share, and MacAndrews had the right (exercisable up to three times) to require the Company to sell to it shares of Class A common stock at the same price. The commitment period of each of the Letter Agreements has now expired. In addition, in connection with and as a commitment fee for the entrance into certain of these Letter Agreements, the Company also issued MacAndrews warrants (the “Letter Agreement Warrants”) to purchase additional shares of the Company’s Class A common stock.
The Letter Agreement Warrants have been recorded as warrant liability, related party within the Company’s Condensed Consolidated Balance Sheets based on their fair value. The issuance of the Letter Agreement Warrants was considered to be a cost of equity recorded as a reduction to additional paid-in capital.
Exchange Agreement
The Company and MacAndrews are party to an exchange agreement (the “Exchange Agreement”) pursuant to which the vTv Units (along with a corresponding number of shares of the Class B common stock) are exchangeable for (i) shares of the Company’s Class A common stock on a one-for-one basis or (ii) cash (based on the fair market value of the Class A common stock as determined pursuant to the Exchange Agreement), at the Company’s option (as the managing member of vTv LLC), subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications. Any decision to require an exchange for cash rather than shares of Class A common stock will ultimately be determined by the entire board of directors of vTv Therapeutics Inc. (the “Board of Directors”). As of September 30, 2022, MacAndrews had not exchanged any shares under the provisions of the Exchange Agreement.
Tax Receivable Agreement
The Company and MacAndrews are party to a tax receivable agreement (the “Tax Receivable Agreement”), which provides for the payment by the Company to M&F TTP Holdings Two LLC (“M&F”), as successor in interest to vTv Therapeutics Holdings, LLC (“vTv Therapeutics Holdings”), and M&F TTP Holdings LLC (or certain of its transferees or other assignees) of 85% of the amount of cash savings, if any, in U.S. federal, state and local income tax or franchise tax that the Company actually realizes (or, in some circumstances, the Company is deemed to realize) as a result of (a) the exchange of Class B commons stock, together with the corresponding number of vTv Units, for shares of the Company’s Class A common stock (or for cash), (b) tax benefits related to imputed interest deemed to be paid by the Company as a result of the Tax Receivable Agreement and (c) certain tax benefits attributable to payments under the Tax Receivable Agreement.
As no shares have been exchanged by MacAndrews pursuant to the Exchange Agreement (discussed above), the Company has not recognized any liability, nor has it made any payments pursuant to the Tax Receivable Agreement as of September 30, 2022.
Investor Rights Agreement
The Company is party to an investor rights agreement with M&F, as successor in interest to vTv Therapeutics Holdings (the “Investor Rights Agreement”). The Investor Rights Agreement provides M&F with certain demand, shelf, and piggyback registration rights with respect to its shares of Class A common stock and also provides M&F with certain governance rights, depending on the size of its holdings of Class A common stock. Under the Investor Rights Agreement, M&F was initially entitled to nominate a majority of the members of the Board of Directors and designate the members of the committees of the Board of Directors.
CinRx Pharma, LLC
Master Services Agreement
On July 22, 2022, the Company entered into a Master Services Agreement with CinRx Pharma, LLC (“CinRx”) (the “CinRx MSA”). Under the CinRx MSA, CinRx provides the Company with consulting, pre-clinical and clinical trial services, as enumerated in project proposals negotiated between the Company and CinRx from time to time. As of October 10, 2022, the Company has agreed to pay CinRx fees of up to $0.2 million per month until approximately December 2024 in respect of ongoing agreed project proposals under the CinRx MSA, plus out-of-pocket expenses incurred by CinRx on the Company’s behalf. Dr. Jonathan Isaacsohn, who was appointed as chair of the Company’s board of directors on August 9, 2022, is the President and Chief Executive Officer of CinRx. CinPax, LLC, a subsidiary of CinRx, currently holds 4,154,549 shares of the Company’s Class A Common Stock.
21
Note 11: Income Taxes
The Company is subject to U.S. federal income taxes as well as state taxes. The Company did not record an income tax provision for the three months ended September 30, 2022. The Company’s income tax provision for the nine months ended September 30, 2022, was $0.2 million related to foreign withholding taxes. The Company’s income tax provision for the three and nine months ended September 30, 2021 was $0.1 million related to foreign withholding taxes.
Management has evaluated the positive and negative evidence surrounding the realization of its deferred tax assets, including the Company’s history of losses, and under the applicable accounting standards determined that it is more-likely-than-not that the deferred tax assets will not be realized. The difference between the effective tax rate of the Company and the U.S. statutory tax rate of 21% on September 30, 2022, is due to the valuation allowance against the Company’s expected net operating losses.
As discussed in Note 10, the Company is party to a tax receivable agreement with a related party which provides for the payment by the Company to M&F (or certain of its transferees or other assignees) of 85% of the amount of cash savings, if any, in U.S. federal, state and local income tax or franchise tax that the Company actually realizes (or, in some circumstances, the Company is deemed to realize) as a result of certain transactions. As no transactions have occurred which would trigger a liability under this agreement, the Company has not recognized any liability related to this agreement as of September 30, 2022.
Note 12: Net Loss per Share
Basic loss per share is computed by dividing net loss attributable to vTv Therapeutics Inc. by the weighted average number of shares of Class A common stock outstanding during the period. Diluted loss per share is computed giving effect to all potentially dilutive shares. Diluted loss per share for all periods presented is the same as basic loss per share as the inclusion of potentially issuable shares would be antidilutive.
A reconciliation of the numerator and denominator used in the calculation of basic and diluted net loss per share of Class A common stock is as follows (in thousands, except share and per share amounts):
For the Three Months Ended September 30,For the Nine Months Ended September 30,
2022202120222021
Numerator:
Net loss$(5,468)$(1,465)$(18,983)$(8,248)
Less: Net loss attributable to noncontrolling interests(1,207)(378)(4,564)(2,312)
Net loss attributable to common shareholders of vTv Therapeutics Inc., basic and diluted(4,261)(1,087)(14,419)(5,936)
Denominator:
Weighted average vTv Therapeutics Inc. Class A common stock, basic and diluted80,490,121 61,073,280 72,649,531 58,737,170 
Net loss per share of vTv Therapeutics Inc. Class A common stock, basic and diluted$(0.05)$(0.02)$(0.20)$(0.10)
Potentially dilutive securities not included in the calculation of diluted net loss per share are as follows:
September 30, 2022September 30, 2021
Class B common stock (1)
23,093,860 23,093,860 
Common stock options granted under the Plan7,718,944 4,474,403 
Common stock warrants3,214,503 2,014,503 
Total34,027,307 29,582,766 
_____________________________
(1)Shares of Class B common stock do not share in the Company’s earnings and are not participating securities. Accordingly, separate presentation of loss per share of Class B common stock under the two-class method has not been provided. Each share of Class B common stock (together with a corresponding vTv Unit) is exchangeable for one share of Class A common stock.
22
Note 13: Fair Value of Financial Instruments
The carrying amount of certain of the Company’s financial instruments, including cash and cash equivalents, net accounts receivable, note receivable, accounts payable, and other accrued liabilities, approximate fair value due to their short-term nature.
Assets and Liabilities Measured at Fair Value on a Recurring Basis
The Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level in which to classify them for each reporting period. This determination requires significant judgments. The Company determined that the promissory note receivable was level 2 and the fair value measurement was based on the market yield curves. The following table summarizes the conclusions reached regarding fair value measurements as of September 30, 2022, and December 31, 2021 (in thousands):
Balance at September 30, 2022Quoted Prices in Active
Markets for Identical Assets
(Level 1)		Significant Other Observable
Inputs
(Level 2)		Significant Unobservable Inputs
(Level 3)
Assets:
Equity securities with readily determinable fair value$1,930 $1,930 $— $— 
Total$1,930 $1,930 $— $— 
Liabilities:
Warrant liability, related party (1)
$1,409 $— $— $1,409 
Total$1,409 $— $— $1,409 
Balance at December 31, 2021Quoted Prices in Active
Markets for Identical Assets
(Level 1)		Significant Other Observable
Inputs
(Level 2)		Significant Unobservable Inputs
(Level 3)
Assets:
Equity securities with readily determinable fair value$4,928 $4,928 $— $— 
Total$4,928 $4,928 $— $— 
Liabilities:
Warrant liability, related party (1)
$1,262 $— $— $1,262 
Total$1,262 $— $— $1,262 
_____________________________
(1)Fair value determined using the Black-Scholes option pricing model. Expected volatility is based on the historical volatility of the Company’s common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation.
23
Changes in Level 3 instruments for the nine months ended September 30,
Balance at January 1Net Change in
fair value included in
earnings		Purchases /
Issuance		Sales /
Repurchases		Balance at September 30,
2022
Warrant liability, related party$1,262 $(221)$368 $— $1,409 
Total$1,262 $(221)$368 $— $1,409 
2021
Warrant liability, related party$2,871 $(611)$— $— $2,260 
Total$2,871 $(611)$— $— $2,260 
During the nine months ended September 30, 2021, Reneo completed its initial public offering. As a result, the fair value of the Company’s investment in Reneo’s common stock now has a readily determinable market value and is no longer eligible for the practical expedient for investments without readily determinable fair market values. As such, the Company’s investment in Reneo is adjusted each reporting period to its fair value based on its most recent closing price, which is considered a Level 1 fair value measurement under the fair value hierarchy.
There were no transfers into or out of level 3 instruments and/or between level 1 and level 2 instruments during the three and nine months ended September 30, 2022. Gains and losses recognized due to the change in fair value of the warrant liability, related party are recognized as a component of other (expense) income, related party in the Condensed Consolidated Statements of Operations.
The fair value of the Letter Agreement Warrants was determined using the Black-Scholes option pricing model or option pricing models based on the Company’s current capitalization. Expected volatility is based on the historical volatility of the Company’s common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation. Significant inputs utilized in the valuation of the Letter Agreement Warrants as of September 30, 2022, and December 31, 2021, were:
September 30, 2022December 31, 2021
RangeWeighted AverageRangeWeighted Average
Expected volatility
81.70% - 109.73%
95.51%
82.68% - 142.86%
128.13%
Risk-free interest rate
4.13% - 4.25%
4.20%
0.95% - 1.26%
1.15%
The fair value of the CinRx Warrants was determined using the Black-Scholes option pricing model. Expected volatility is based on the historical volatility of the Company’s common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation. Significant inputs utilized in the valuation of the CinRx Warrants as of September 30, 2022, were:
Expected volatility 85.2 %
Expected life of options in years3.1
Risk-free interest rate4.3 %
Expected dividend yield— %
The weighted average expected volatility and risk-free interest rate was based on the relative fair values of the warrants.
Changes in the unobservable inputs noted above would impact the amount of the liability for the Letter Agreement and CinRx Warrants. Increases (decreases) in the estimates of the Company’s annual volatility would increase (decrease) the liability and an increase (decrease) in the annual risk-free rate would increase (decrease) the liability.
Note 14: Subsequent Events
The Company evaluated subsequent events through November 10, 2022, and determined that there have been no events that have occurred that would require adjustments to our disclosures or the unaudited condensed consolidated financial statements.
24
ITEM 2.    MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
As used in this Quarterly Report on Form 10-Q, the “Company”, the “Registrant”, “we” or “us” refer to vTv Therapeutics Inc. and “vTv LLC” refers to vTv Therapeutics LLC. The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our financial statements and related notes that appear elsewhere in this report. In addition to historical financial information, the following discussion contains forward-looking statements that reflect our plans, estimates, assumptions and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to these differences include those discussed below and elsewhere in this report under “Part II, Other Information—Item 1A, Risk Factors.” Forward-looking statements include information concerning our possible or assumed future results of operations, business strategies and operations, financing plans, potential growth opportunities, potential market opportunities, potential results of our drug development efforts or trials, and the effects of competition. Forward-looking statements include all statements that are not historical facts and can be identified by terms such as “anticipates,” “believes,” “could,” “seeks,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “should,” “will,” “would” or similar expressions and the negatives of those terms. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Also, forward-looking statements represent our management’s plans, estimates, assumptions and beliefs only as of the date of this report. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
Company Overview
We are a clinical stage pharmaceutical company focused on treating metabolic and inflammatory diseases to minimize their long-term complications and improve the lives of patients. We have an innovative pipeline of first-in-class small molecule clinical and preclinical drug candidates. Our lead program is TTP399, an orally administered, small molecule, liver-selective glucokinase activator (“GKA”) for the treatment of type 1 diabetes.
Recent Developments
On July 27, 2022, the Company appointed Paul Sekhri as President, Chief Executive Officer (CEO) effective August 1, 2022, and was confirmed as a member of the board of directors on August 9, 2022. Mr. Sekhri brings nearly 30 years of healthcare experience, including serving as President and CEO of several healthcare companies, experience in several senior business development and strategy roles and he has been a director on more than 30 private, public company and non-profit boards.
Based upon the positive results of our Simplici-T1 Study, we requested Breakthrough Therapy Designation (“BTD”) with the FDA which was granted in April 2021. In October 2021, we began to implement a strategy to focus our efforts on the continued development of TTP399 as a potential treatment for patients with type 1 diabetes (“T1D”).
After several meetings with the FDA BTD-team, the Company is planning two pivotal, placebo-controlled clinical trials of TTP399 in subjects with T1D. The studies will recruit a total of approximately 1,000 patients and at least one of the studies will be one year of treatment. The FDA confirmed that the effect size of TTP399 on events of hypoglycemia as demonstrated in the Phase 2 SimpliciT-1 Study is clinically meaningful and has agreed on the primary endpoint for the studies as the difference between placebo and TTP399-treated group in number of hypoglycemia events.
The results of the mechanistic study provided additional evidence to support the idea that treatment with TTP399 will not increase the risk of diabetic ketoacidosis (“DKA”) in patients with T1D. The data demonstrate that in contrast to agents such as SGLT2 inhibitors and GLP‐1RAs, TTP399 does not increase the risk of ketoacidosis when used as an adjunctive therapy to insulin in individuals with T1D. Moreover, these findings support prior studies that demonstrate that TTP399 improves glucose control and reduces hypoglycemia and suggests a protective effect of TTP399 against acidosis in people with T1D. Thus, accumulating data suggest that TTP399 has robust potential as an adjunctive therapy for T1D. Full study results were published in the Diabetes Obesity and Metabolism journal in conjunction with the 82nd American Diabetes Association Scientific Sessions on June 6, 2022.

25
The following table summarizes our drug candidates, their partnership status, and their respective stages of development:
vtvt-20220930_g1.jpg
Our Type 1 Diabetes Program – TTP399
The Company is planning two pivotal, placebo-controlled clinical trials of TTP399 in subjects with T1D and has engaged with the FDA on the optimal clinical trial designs for these studies. The studies will recruit a total of approximately 1000 patients and at least one of the studies will be one year of treatment. The FDA and the company have agreed on the primary endpoint for the studies as the difference between placebo and TTP399-treated group in number of hypoglycemia events. We expect site-specific startup activities and patient enrollment for these pivotal studies to begin in the first quarter of 2023.
In October 2021, we announced positive results of a mechanistic study of TTP399 in patients with T1D. The study demonstrated that patients with T1D taking TTP399 experienced no increase in ketone levels relative to placebo during a period of acute insulin withdrawal, indicating no increased risk of ketoacidosis. Consistent with previous clinical studies, improved fasting plasma glucose levels and fewer hypoglycemic events were observed in the TTP399 treated group during the week of treatment prior to the insulin withdrawal test. The FDA has declined to approve SGLT2 inhibitors as an adjunctive therapy in T1D, with concerns over the potential risks of diabetic ketoacidosis (“DKA”) in focus. DKA can lead to hospitalization and, if untreated, death. To address these concerns, vTv, following the FDA’s recommendation, conducted this mechanistic study to demonstrate that treatment with TTP399, a liver-selective glucokinase activator, will not result in increased production of ketones, a precursor to ketoacidosis.
In April 2021, we announced that the FDA granted BTD for TTP399 as an adjunctive therapy to insulin for the treatment of T1D. This designation provides a sponsor with added support and the potential to expedite development and review timelines for a promising new investigational medicine.
G42 Investments
On May 31, 2022, the Company announced entry into agreements that include a $25.0 million investment by G42 Investments. Under the terms of the agreements, the Company agreed to sell G42 Investments 10,386,274 shares of the Company’s Class A common stock at an issue price of $2.41 per share, with $12.5 million paid in cash at closing, and the remaining amount of $12.5 million payable on May 31, 2023. The agreements also provide for the potential issuance of $30.0 million in additional shares of Class A common stock to G42 Investments (or cash in lieu of such issuance at the option of G42 Investments) if the FDA approves the marketing and sale of a pharmaceutical product containing TTP399, a liver selective glucokinase activator, as the active ingredient for treatment of T1D in the United States. The agreements set forth
26
the terms under which the Company and Cogna, an affiliate of G42 Investments, plan to collaborate on clinical trials for pharmaceutical products that contain TTP399, including Cogna funding a portion of the Phase 3 clinical trials for TTP399, and the Company granting Cogna an exclusive license to develop and commercialize pharmaceutical products containing TTP399 in a specified territory, principally consisting of the Middle East, Africa and Central Asia.
CinRx Purchase Agreement
On July 25, 2022, the Company announced entry into agreements that include a $10 million investment by CinPax, LLC (“CinPax”), a subsidiary of CinRx Pharma, LLC (“CinRx”). Under the terms of the agreements, CinPax acquired 4,154,549 shares of Class A Common Stock of vTv at an issue price of approximately $2.41 per share, with $6.0 million paid in cash at closing, and the remaining amount of $4.0 million payable on November 22, 2022. The agreements also provide for the issuance of 1,200,000 warrants to CinRx to acquire additional shares of Class A common stock that become exercisable upon agreed vesting triggers (including FDA approval of TTP399). In addition to the investment, the Company and CinRx entered into a Master Service Agreement (“MSA”) whereby CinRx provides the Company with consulting, pre-clinical and clinical trial services, as enumerated in project proposals negotiated between the Company and CinRx from time to time.
Holding Company Structure
vTv Therapeutics Inc. is a holding company, and its principal asset is a controlling equity interest in vTv Therapeutics LLC, the principal operating subsidiary. We have determined that vTv LLC is a variable-interest entity (“VIE”) for accounting purposes and that vTv Therapeutics Inc. is the primary beneficiary of vTv LLC because (through its managing member interest in vTv LLC and the fact that the senior management of vTv Therapeutics Inc. is also the senior management of vTv LLC) it has the power to direct all of the activities of vTv LLC, which include those that most significantly impact vTv LLC’s economic performance. vTv Therapeutics Inc. has therefore consolidated vTv LLC’s results under the VIE accounting model in its consolidated financial statements.
Financial Overview
Revenue
To date, we have not generated any revenue from drug sales. Our revenue has been primarily derived from up-front proceeds, milestones and research fees under collaboration and license agreements.
In the future, we may generate revenue from a combination of product sales, license fees, milestone payments and royalties from the sales of products developed under licenses of our intellectual property. We expect that any revenue we generate will fluctuate from quarter to quarter as a result of the timing and amount of license fees, milestone and other payments, and the amount and timing of payments that we receive upon the sale of our products, to the extent any are successfully commercialized. If we fail to complete the development of our drug candidates in a timely manner or obtain regulatory approval for them, our ability to generate future revenue and our results of operations and financial position will be materially adversely affected.
Research and Development Expenses
Since our inception, we have focused our resources on our research and development activities, including conducting preclinical studies and clinical trials, manufacturing development efforts, and activities related to regulatory filings for our drug candidates. We recognize research and development expenses as they are incurred. Our direct research and development expenses consist primarily of external costs such as fees paid to investigators, consultants, central laboratories, and clinical research organizations (“CRO(s)”) in connection with our clinical trials, and costs related to acquiring and manufacturing clinical trial materials. Our indirect research and development costs consist primarily of cash and share-based compensation costs, the cost of employee benefits, and related overhead expenses for personnel in research and development functions. Since we typically use our employee and infrastructure resources across multiple research and development programs such costs are not allocated to the individual projects.
From our inception, including our predecessor companies, through September 30, 2022, we have incurred approximately $608.5 million in research and development expenses.
27
Our research and development expenses by project for the three and nine months ended September 30, 2022, and 2021 were as follows (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Direct research and development expense:
TTP399$2,309 $729 $6,438 $1,365 
HPP737(111)482 (66)2,249 
Azeliragon52 — — 887 
Other projects232 97 483 329 
Indirect research and development expense573 1,074 1,538 3,092 
Total research and development expense$3,055 $2,382 $8,393 $7,922 
We plan to continue to incur significant research and development expenses for the foreseeable future as we continue the development of TTP399 and further advance the development of our other drug candidates, subject to the availability of additional funding.
The successful development of our clinical and preclinical drug candidates is highly uncertain. At this time, we cannot reasonably estimate the nature, timing, or costs of the efforts that will be necessary to complete the remainder of the development of any of our clinical or preclinical drug candidates or the period, if any, in which material net cash inflows from these drug candidates may commence. This is due to the numerous risks and uncertainties associated with the development of our drug candidates, including:
•the uncertainty of the scope, rate of progress, and expense of our ongoing, as well as any additional, clinical trials and other research and development activities;
•the potential benefits of our candidates over other therapies;
•our ability to market, commercialize, and achieve market acceptance for any of our drug candidates that we are developing or may develop in the future;
•future clinical trial results;
•our ability to enroll patients in our clinical trials;
•the timing and receipt of any regulatory approvals; and
•the filing, prosecuting, defending, and enforcing of patent claims and other intellectual property rights, and the expense of doing so.
A change in the outcome of any of these variables with respect to the development of a drug candidate could mean a significant change in the costs and timing associated with the development of that drug candidate. For example, if the FDA or another regulatory authority were to require us to conduct clinical trials beyond those that we currently anticipate will be required for the completion of clinical development of a drug candidate, or if we experience significant delays in enrollment in any of our clinical trials, we could be required to expend significant additional financial resources and time with respect to the development of that drug candidate.
General and Administrative Expenses
General and administrative expenses consist primarily of salaries, benefits, and related costs for employees in executive, finance, corporate development, human resources, and administrative support functions. Other significant general and administrative expenses include accounting and legal services, expenses associated with obtaining and maintaining patents, cost of various consultants, occupancy costs, and information systems.
Interest Income
The Company’s interest expense is immaterial.
Interest Expense
The Company’s interest expense is immaterial.
28
Other Income (Expense), Net
Other income/expense primarily consists of unrealized gains or losses attributable to the changes in fair value of the equity investments held by our licensees, as well as the recognition of changes in fair value of the warrants to purchase shares of our Class A common stock held by related parties.
Results of Operations
Comparison of the three months ended September 30, 2022, and 2021
The following table sets forth certain information concerning our results of operations for the periods shown:
(dollars in thousands)Three Months Ended September 30,
Statement of operations data:20222021Change
Revenue $—$3,000$(3,000)
Operating expenses:
Research and development 3,0552,382673
General and administrative 2,6342,221413
Total operating expenses 5,6894,6031,086
Operating loss(5,689)(1,603)(4,086)
Interest income150—150
Interest expense(8)(6)(2)
Other income, net79244(165)
Loss before income taxes(5,468)(1,365)(4,103)
Income tax provision—100(100)
Net loss before noncontrolling interest(5,468)(1,465)(4,003)
Less: Net loss attributable to noncontrolling interest(1,207)(378)(829)
Net loss attributable to vTv Therapeutics Inc.$(4,261)$(1,087)$(3,174)
Revenue
There was no revenue for the three months ended September 30, 2022. Revenue for the three months ended September 30, 2021, included increases to the transaction prices for the license performance obligations under the license agreement with Newsoara Biopharma Co., Ltd., (“Newsoara”) (the “Newsoara License Agreement”) and Reneo Pharmaceuticals, Inc. (“Reneo) (the “Reneo License agreement”) due to the satisfaction of development milestones.
Research and Development Expenses
Research and development expenses were $3.1 million and $2.4 million for the three months ended September 30, 2022, and 2021, respectively. The increase in research and development expenses during this period of $0.7 million or 28.3%, was primarily driven by i) higher spending on TTP399 of $1.6 million, due to increases in drug product related costs as well as higher spending on trial preparation costs, partially offset by ii) decreased spending of $0.6 million related to the multiple ascending dose study for HPP737, due to its completion in 2021 and iii) decreases in indirect costs and other projects of $0.3 million.
General and Administrative Expenses
General and administrative expenses were $2.6 million and $2.2 million for the three months ended September 30, 2022, and 2021, respectively. The increase in general and administrative expenses during this period of $0.4 million, or 18.6%, was primarily driven by i) increases of $0.5 million in legal expense, ii) increases of $0.4 million other general and administrative costs, partially offset by iii) decreases in payroll costs of $0.5 million due to the reduction in workforce at year-end 2021.
Interest income
Interest income for the three months ended September 30, 2022, of $0.2 million is related to imputed interest on the promissory notes. Interest income for the three months ended September 30, 2021, was insignificant.
29
Interest Expense
Interest expense for the three months ended September 30, 2022, and 2021, was insignificant.
Other (Expense) / Income
Other expense was $0.1 million for the three months ended September 30, 2022, and was driven by an unrealized gain related to our investment in Reneo as well as the losses related to the change in the fair value of the outstanding warrants to purchase shares of our own stock issued to related parties (“Related Party Warrants”). Other income was $0.2 million for the three months ended September 30, 2021, and was related to the unrealized loss recognized related to our investment in Reneo as well as gains related to the change in the fair value of the outstanding warrants in our own stock held by a related party.

Comparison of the nine months ended September 30, 2022, and 2021
The following table sets forth certain information concerning our results of operations for the periods shown:
(dollars in thousands)Nine Months Ended September 30,
Statement of operations data:20222021Change
Revenue $2,009$3,996$(1,987)
Operating expenses:
Research and development 8,3937,922471
General and administrative 9,8136,6273,186
Total operating expenses 18,20614,5493,657
Operating loss(16,197)(10,553)(5,644)
Interest income2001199
Interest expense(9)(6)(3)
Other (expense) income, net(2,777)2,425(5,202)
Loss before income taxes(18,783)(8,133)(10,650)
Income tax provision20011585
Net loss before noncontrolling interest(18,983)(8,248)(10,735)
Less: Net loss attributable to noncontrolling interest(4,564)(2,312)(2,252)
Net loss attributable to vTv Therapeutics Inc.$(14,419)$(5,936)$(8,483)
Revenue
Revenue for the nine months ended September 30, 2022, includes a $2.0 million increase to the transaction price for the license performance obligations under the amended license agreement with Huadong due to the satisfaction of a development milestone. Revenue for the nine months ended September 30, 2021, relates to the reallocation of revenue to the license and technology transfer performance obligation made in connection with the First Huadong Amendment as well as increases to the transaction prices for the license performance obligations under the Newsoara License Agreement and the Reneo License Agreement due to the satisfaction of development milestones.
Research and Development Expenses
Research and development expenses were $8.4 million and $7.9 million for the nine months ended September 30, 2022, and 2021, respectively. The increase in research and development expenses during the period of $0.5 million, or 5.9%, was primarily driven by i) higher spending on TTP399 of $5.1 million due to increases in drug product related costs as well as higher spending on trial preparation costs, partially offset by ii) a decrease in clinical trial costs of $0.8 million for azeliragon which was driven by discontinuance of its development as a potential treatment of Alzheimer’s disease in patients with type 2 diabetes, iii) decreased spending of $2.3 million related to the multiple ascending dose study for HPP737, due to its completion in 2021, and iii) decreases in indirect costs of $1.5 million primarily related to payroll costs due to the reduction in workforce at year-end of 2021.
General and Administrative Expenses
General and administrative expenses were $9.8 million and $6.6 million for the nine months ended September 30, 2022, and 2021, respectively. The increase of $3.2 million has been primarily driven by i) increases of $3.2 million in legal
30
expense, ii) increases of $0.8 million in severance costs, iii) increases of $1.0 million in other general and administrative costs, partially offset by iv) decreases of $0.1 million in shared based expense, and v) decreases of $1.7 million in payroll costs due to the reduction in workforce at year-end of 2021.
Interest income
Interest income for the nine months ended September 30, 2022, of $0.2 million is related to imputed interest on the promissory note. Interest income for the nine months ended September 30, 2021, was insignificant.
Interest Expense
Interest expense for the nine months ended September 30, 2022, and 2021, was insignificant.
Other Income / (Expense)
Other expense was $2.8 million for the nine months ended September 30, 2022, and is driven by an unrealized loss recognized related to the Company’s investment in Reneo as well as the losses related to the change in the fair value of the outstanding warrants to purchase shares of our own stock issued to related parties. Other income was $2.4 million for the nine months ended September 30, 2021, and was driven by an unrealized gain recognized related to the Company’s investment in Reneo as well as gains related to the change in fair value of the outstanding warrants in our own stock held by a related party.
Liquidity and Capital Resources
Liquidity and Going Concern
As of September 30, 2022, we have an accumulated deficit of $267.1 million as well as a history of negative cash flows from operating activities. We anticipate that we will continue to incur losses for the foreseeable future as we continue our clinical trials. Further, we expect that we will need additional capital to continue to fund our operations. As of September 30, 2022, our liquidity sources included cash and cash equivalents of $15.3 million. In addition to available cash and cash equivalents discussed above, we are evaluating several financing strategies to fund the on-going and future clinical trials of TTP399, including direct equity investments and the potential licensing and monetization of other Company programs such as HPP737. The Company has a promissory note of $12.5 million under the G42 Purchase Agreement payable to the Company on or before May 31, 2023, and a promissory note of $4.0 million under the CinRx Purchase Agreement payable to the Company on November 22, 2022 (see Note 9).
Based on our current operating plan, we may use the remaining availability of $37.3 million under our Sales Agreement with Cantor Fitzgerald pursuant to which we could offer and sell, from time to time, shares of our Class A common stock under the ATM Offering and our ability to sell approximately 9.4 million shares of Class A common stock to Lincoln Park pursuant and subject to the limitations of the LPC Purchase Agreement. However, the ability to use these sources of capital is dependent on a number of factors, including the prevailing market price of and the volume of trading in our Class A common stock. These factors raise substantial doubt about our ability to continue as a going concern.
ATM Offering
We have entered into the Sales Agreement with Cantor Fitzgerald pursuant to which we may offer and sell, from time to time, through or to Cantor Fitzgerald, as sales agent or principal, shares of our Class A common stock having an aggregate offering price of up to $68.5 million. We are not obligated to sell any shares under the Sales Agreement. Under the terms of the Sales Agreement, we will pay Cantor Fitzgerald a commission of up to 3% of the aggregate proceeds from the sale of shares and reimburse certain legal fees or other disbursements. As of September 30, 2022, we have sold $31.2 million worth of Class A common stock under the ATM Offering for net proceeds of $30.3 million, leaving $37.3 million available to be sold. The shares are offered and sold pursuant to the Company’s shelf registration statement on Form S-3. In no event will we sell Class A common stock under this registration statement with a value exceeding more than one-third of the “public float” (the market value of our Class A common stock and any other equity securities that we may issue in the future that are held by non-affiliates) in any 12-calendar month period so long as our public float remains below $75 million.
Lincoln Park Purchase Agreement
We have entered into the LPC Purchase Agreement, pursuant to which we have the right to sell to Lincoln Park shares of the Company’s Class A common stock having an aggregate value of up to $47.0 million. As of September 30, 2022, we have issued 5,331,306 of these shares for gross proceeds of approximately $11.1 million, leaving $35.9 million available to be sold.
31
Over the 36-month term of the LPC Purchase Agreement, we have the right, but not the obligation, from time to time, in our sole discretion, to direct Lincoln Park to purchase up to 250,000 shares per day (the “Regular Purchase Share Limit”) of the Class A common stock (each such purchase, a “Regular Purchase”). The Regular Purchase Share Limit will increase to 275,000 shares per day if the closing price of the Class A common stock on the applicable purchase date is not below $4.00 per share and will further increase to 300,000 shares per day if the closing price of the Class A common stock on the applicable purchase date is not below $5.00 per share. In any case, Lincoln Park’s maximum obligation under any single Regular Purchase will not exceed $2,000,000. The purchase price for shares of Class A common stock to be purchased by Lincoln Park under a Regular Purchase will be equal to the lower of (in each case, subject to the adjustments described in the LPC Purchase Agreement): (i) the lowest sale price for the Class A common stock on the applicable purchase date and (ii) the arithmetic average of the three lowest closing sales prices for the Class A common stock during the 10 consecutive trading days prior to the purchase date.
If we direct Lincoln Park to purchase the maximum number of shares of Class A common stock that we may sell in a Regular Purchase, then in addition to such Regular Purchase, and subject to certain conditions and limitations in the LPC Purchase Agreement, we may direct Lincoln Park to make an “accelerated purchase” and an “additional accelerated purchase”, each of an additional number of shares of Class A common stock which may not exceed the lesser of: (i) 300% of the number of shares purchased pursuant to the corresponding Regular Purchase and (ii) 30% of the total number of shares of the common stock traded during a specified period on the applicable purchase date as set forth in the LPC Purchase Agreement. The purchase price for such shares will be the lesser of (i) 97% of the volume weighted average price of the Class A common stock over a certain portion of the date of sale as set forth in the LPC Purchase Agreement and (ii) the closing sale price of the Class A common stock on the date of sale (an “Accelerated Purchase”). Under certain circumstances and in accordance with the LPC Purchase Agreement, we may direct Lincoln Park to purchase shares in multiple Accelerated Purchases on the same trading day.
The LPC Purchase Agreement also prohibits us from directing Lincoln Park to purchase any shares of its Class A common stock if those shares, when aggregated with all other shares of Class A common stock then beneficially owned by Lincoln Park and its affiliates, would result in Lincoln Park and its affiliates having beneficial ownership, at any single point in time, of more than 9.99% of the then total outstanding shares of Class A common stock as calculated pursuant to Section 13(d) of the Securities Exchange Act of 1934, as amended, and Rule 13d-3 thereunder.
Cash Flows
Nine Months Ended September 30,
20222021
(dollars in thousands)
Net cash used in operating activities$(9,142)$(12,891)
Net cash used in investing activities(21)— 
Net cash provided by financing activities11,087 26,710 
Net increase in cash and cash equivalents$1,924 $13,819 
Operating Activities
For the nine months ended September 30, 2022, our net cash used in operating activities decreased by $3.7 million from the nine months ended September 30, 2021. The significant contributor to the change in cash used during the year was driven by working capital changes offset by $6.8 million of cash received in excess of the fair value of the Class A common stock issued to G42 investments.
Investing Activities
For the nine months ended September 30, 2022, net cash used in investing activities was insignificant. There were no cash flows from investing activities for the nine months ended September 30, 2021.
Financing Activities
For the nine months ended September 30, 2022, net cash provided by financing activities was driven by sales of our Class A common stock to a collaboration partner and from the CinRx Purchase Agreement. For the nine months ended September 30, 2021, net cash provided by financing activities was driven by sales of shares of our Class A common stock during the nine months ended September 30, 2021.
32
Future Funding Requirements
To date, we have not generated any revenue from drug product sales. We do not know when, or if, we will generate any revenue from drug product sales. We do not expect to generate revenue from drug sales unless and until we obtain regulatory approval of and commercialize any of our drug candidates. At the same time, we expect our expenses to continue or to increase in connection with our ongoing development activities, particularly as we continue the research, development, and clinical trials of, and seek regulatory approval for, our drug candidates. In addition, subject to obtaining regulatory approval of any of our drug candidates, we expect to incur significant commercialization expenses for product sales, marketing, manufacturing, and distribution. We anticipate that we will need substantial additional funding in connection with our continuing operations.
We plan to finance our operations into the third quarter of 2023 through the use of our cash and cash equivalents and based on current operating plans, we are evaluating several financing strategies to fund the on-going and future clinical trials of TTP399, including direct equity investments and the potential licensing and monetization of other Company programs such as HPP737. The Company has a promissory note of $12.5 million under the G42 Purchase Agreement payable to the Company on or before May 31, 2023, and a promissory note of $4.0 million under the CinRx Purchase Agreement payable to the Company on November 22, 2022 (see Note 9). The timing of any such transactions is not certain, and we may not be able to complete such transactions on acceptable terms, or at all. Even if we are able to complete such transactions, it may contain restrictions on our operations or cause substantial dilution to our stockholders. We have based our estimates on assumptions that may prove to be wrong, and we may use our available capital resources sooner than we currently expect. We have based our estimates on assumptions that may prove to be wrong, and we may use our available capital resources sooner than we currently expect. Because of the numerous risks and uncertainties associated with the development and commercialization of our drug candidates, we are unable to estimate the amounts of increased capital outlays and operating expenditures necessary to complete the development of our drug candidates. Additionally, we may rely on our ability to sell shares of our Class A common stock pursuant to the ATM Offering and LPC Purchase Agreement. However, the ability to use these sources of capital is dependent on a number of factors, including the prevailing market price of and the volume of trading in the Company’s Class A common stock, and we may use our available capital resources sooner than we currently expect.
Our future capital requirements will depend on many factors, including:
•The progress, costs, results, and timing of our planned trials to evaluate TTP399 as a potential treatment of T1D;
•the willingness of the FDA to rely upon our completed and planned clinical and preclinical studies and other work, as the basis for review and approval of our drug candidates;
•the outcome, costs, and timing of seeking and obtaining FDA and any other regulatory approvals;
•the number and characteristics of drug candidates that we pursue, including our drug candidates in preclinical development;
•the ability of our drug candidates to progress through clinical development successfully;
•our need to expand our research and development activities;
•the costs associated with securing, establishing, and maintaining commercialization capabilities;
•the costs of acquiring, licensing, or investing in businesses, products, drug candidates and technologies;
•our ability to maintain, expand and defend the scope of our intellectual property portfolio, including the amount and timing of any payments we may be required to make, or that we may receive, in connection with the licensing, filing, prosecution, defense and enforcement of any patents or other intellectual property rights;
•our need and ability to hire additional management and scientific and medical personnel;
•the effect of competing technological and market developments;
•our need to implement additional internal systems and infrastructure, including financial and reporting systems;
•the economic and other terms, timing and success of our existing licensing arrangements and any collaboration, licensing, or other arrangements into which we may enter in the future;
•the amount of any payments we are required to make to M&F TTP Holdings Two LLC in the future under the Tax Receivable Agreement; and
•the impact and duration of the COVID-19 outbreak / pandemic.
33
Until such time, if ever, as we can generate substantial revenue from drug sales, we expect to finance our cash needs through a combination of equity offerings, debt financings, marketing and distribution arrangements and other collaborations, strategic alliances, and licensing arrangements. We currently have committed external source of funds available through the ATM Offering, LPC Purchase Agreement and Promissory Notes under the G42 Purchase Agreement and the CinRx Purchase Agreement.
To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of our common stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants that will further limit or restrict our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends. If we raise additional funds through collaborations, strategic alliances or marketing, distribution, or licensing arrangements with third parties, we may be required to relinquish valuable rights to our technologies, future revenue streams or drug candidates or grant licenses on terms that may not be favorable to us. If we are unable to obtain additional funding, we could be forced to delay, reduce, or eliminate our research and development programs or commercialization efforts, or pursue one or more alternative strategies, such as restructuring, any of which could adversely affect our business prospects.
Off-Balance Sheet Arrangements
As of September 30, 2022, we did not have outstanding any off-balance sheet arrangements as defined under SEC rules.
Discussion of Critical Accounting Policies
For a discussion of our critical accounting policies and estimates, please refer to Part II, Item 7. “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, 2021. There have been no material changes to our critical accounting policies and estimates in 2022.
Forward-Looking Statements
This quarterly report includes certain forward-looking statements within the meaning of the federal securities laws regarding, among other things, our management’s intentions, plans, beliefs, expectations, or predictions of future events, which are considered forward-looking statements. You should not place undue reliance on those statements because they are subject to numerous uncertainties and factors relating to our operations and business environment, all of which are difficult to predict and many of which are beyond our control. Forward-looking statements include information concerning our possible or assumed future results of operations, including descriptions of our business strategy. These statements often include words such as “may,” “will,” “should,” “believe,” “expect,” “outlook”, “anticipate,” “intend,” “plan,” “estimate” or similar expressions. These statements are based upon assumptions that we have made in light of our experience in the industry, as well as our perceptions of historical trends, current conditions, expected future developments and other factors that we believe are appropriate under the circumstances. As you read this quarterly report, you should understand that these statements are not guarantees of performance or results. They involve known and unknown risks, uncertainties, and assumptions, including those described under the heading “Risk Factors” under Item 1A of Part I in our Annual Report on Form 10-K and under Item 1A of Part II of this Quarterly Report on Form 10-Q. Although we believe that these forward-looking statements are based upon reasonable assumptions, you should be aware that many factors, including those described under the heading “Risk Factors” under Item 1A of Part I in our Annual Report on Form 10-K and under Item 1A of Part II of this Quarterly Report on Form 10-Q, could affect our actual financial results or results of operations and could cause actual results to differ materially from those in the forward-looking statements.
Our forward-looking statements made herein are made only as of the date of this quarterly report. We expressly disclaim any intent, obligation or undertaking to update or revise any forward-looking statements made herein to reflect any change in our expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based. All subsequent written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements contained in this quarterly report.
Effect of Recent Accounting Pronouncements
See discussion of recent accounting pronouncements in Note 2, “Summary of Significant Accounting Policies”, to the Condensed Consolidated Financial Statements in this Form 10-Q.
34
ITEM 3.    QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Interest Rate Risk
We do not currently have any material interest rate exposure.
Market Risk
Our exposure to market risk is limited to our cash and cash equivalents, all of which have maturities of one year or less. The goals of our investment strategy are preservation of capital, fulfillment of liquidity needs and fiduciary control of cash and investments. We also seek to maximize income from our investments without assuming significant risk. To achieve our goals, we maintain a portfolio of cash equivalents in a financial institution that management believes to be of high credit quality. Because of the short-term maturities of our investments, we do not believe that an increase in market rates would have a material negative impact on the value of our investment portfolio.
Foreign Currency Risk
We do not have any material foreign currency exposure.
ITEM 4.    CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
Under the supervision and with the participation of our Chief Executive Officer and Chief Accounting Officer, management has evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e) of the Securities Exchange Act of 1934) as of September 30, 2022. Based upon that evaluation, our Chief Executive Officer and Chief Accounting Officer concluded that, as of September 30, 2022, our disclosure controls and procedures were effective in causing material information relating to us (including our consolidated subsidiaries) to be recorded, processed, summarized, and reported by management on a timely basis and to ensure the quality and timeliness of our public disclosures pursuant to SEC disclosure obligations.
Our management, including our Chief Executive Officer and Chief Accounting Officer, does not expect that our disclosure controls and procedures will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, with the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error and mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of controls.
The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, a control may become inadequate because of changes in conditions or because the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and may not be detected.
Changes to Internal Control over Financial Reporting
There have been no changes in our internal control over financial reporting during our most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Website Availability of Reports and other Corporate Governance Information
The Company maintains a comprehensive corporate governance program, including Corporate Governance Guidelines for its Board of Directors, Board Guidelines for Assessing Director Independence, and charters for its Audit Committee, Nominating and Corporate Governance Committee and Compensation Committee. The Company maintains a corporate investor relations website, www.vtvtherapeutics.com, where stockholders and other interested persons may review, without charge, among other things, corporate governance materials and certain SEC filings, which are generally available on the same business day as the filing date with the SEC on the SEC’s website http://www.sec.gov. The contents of our website are not made a part of this Quarterly Report on Form 10-Q.
35
PART II – OTHER INFORMATION
ITEM 1.    LEGAL PROCEEDINGS
We are not currently a party to any material legal proceedings.
ITEM 1A.    RISK FACTORS
Our risk factors are set forth under the heading “Risk Factors” under Item 1A of Part I in our Annual Report on Form 10-K for the year ended December 31, 2021. There have been no material changes to our risk factors from those previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2021.
ITEM 2.    UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
During the three months ended September 30, 2022, the Company issued the following unregistered securities:
In July 2022, the Company sold 4,154,549 shares of the Company’s Class A common stock at a price per share of approximately $2.41, for an aggregate purchase price of $10.0 million.
ITEM 3.    DEFAULTS UPON SENIOR SECURITIES
None.
ITEM 4.    MINE SAFETY DISCLOSURES
None.
ITEM 5.    OTHER INFORMATION
None.
ITEM 6.    EXHIBITS
Exhibit
Number		Description
31.1*
31.2*
32.1*
32.2*
101.INSInline XBRL Instance Document
101.SCHInline XBRL Taxonomy Extension Schema
101.CALInline XBRL Taxonomy Extension Calculation Linkbase
101.DEFInline XBRL Taxonomy Extension Definition Document
101.LABInline XBRL Taxonomy Extension Label Linkbase
101.PREInline XBRL Taxonomy Extension Presentation Linkbase
104Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)
___________________________
††    Confidential treatment received with respect to portions of this exhibit.
*    Filed herewith
36
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Date: November 10, 2022
VTV THERAPEUTICS INC.
(Registrant)
By:/s/ Paul J. Sekhri
Paul J. Sekhri
President and Chief Executive Officer
By:/s/ Barry Brown
Barry Brown
Chief Accounting Officer
37
 EX-31.1 2 vtvt-20220930xexx311.htm EX-31.1 Document

Exhibit 31.1
SECTION 302 CERTIFICATION
I, Paul J. Sekhri, certify that:
1.I have reviewed this quarterly report on Form 10-Q of vTv Therapeutics Inc. (the “registrant”);
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Securities Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: November 10, 2022
By:/s/ Paul J. Sekhri
Paul J. Sekhri
President and Chief Executive Officer

 EX-31.2 3 vtvt-20220930xexx312.htm EX-31.2 Document

Exhibit 31.2
SECTION 302 CERTIFICATION
I, Barry Brown, certify that:
1.I have reviewed this quarterly report on Form 10-Q of vTv Therapeutics Inc. (the “registrant”);
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Securities Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: November 10, 2022
By:/s/ Barry Brown
 Barry Brown
 Chief Accounting Officer

 EX-32.1 4 vtvt-20220930xexx321.htm EX-32.1 Document

Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of vTv Therapeutics Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Paul J. Sekhri, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, in my capacity as an officer of the Company that, to my knowledge:
1.The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and
2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: November 10, 2022
By:/s/ Paul J. Sekhri
Paul J. Sekhri
President and Chief Executive Officer

 EX-32.2 5 vtvt-20220930xexx322.htm EX-32.2 Document

Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of vTv Therapeutics Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Barry Brown, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, in my capacity as an officer of the Company that, to my knowledge:
1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: November 10, 2022
By:/s/ Barry Brown
Barry Brown
Chief Financial Officer

 EX-101.SCH 6 vtvt-20220930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - Condensed Consolidated Statements of Operations - Unaudited link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders' Deficit - Unaudited link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - Condensed Consolidated Statements of Cash Flows - Unaudited link:presentationLink link:calculationLink link:definitionLink 0000007 - Disclosure - Description of Business, Basis of Presentation and Going Concern link:presentationLink link:calculationLink link:definitionLink 0000008 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - Collaboration Agreements link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Share-Based Compensation link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Investments link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Redeemable Noncontrolling Interest link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Stockholders' Deficit link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Related-Party Transactions link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Net Loss per Share link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Fair Value of Financial Instruments link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 0000022 - Disclosure - Collaboration Agreements (Tables) link:presentationLink link:calculationLink link:definitionLink 0000023 - Disclosure - Share-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 0000024 - Disclosure - Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 0000025 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 0000026 - Disclosure - Redeemable Noncontrolling Interest (Tables) link:presentationLink link:calculationLink link:definitionLink 0000027 - Disclosure - Net Loss per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 0000028 - Disclosure - Fair Value of Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 0000029 - Disclosure - Description of Business, Basis of Presentation and Going Concern (Detail) link:presentationLink link:calculationLink link:definitionLink 0000030 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 0000031 - Disclosure - Collaboration Agreements - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 0000032 - Disclosure - Collaboration Agreements - Summary of Contract Liabilities Related to Company's Collaboration Agreements (Detail) link:presentationLink link:calculationLink link:definitionLink 0000033 - Disclosure - Collaboration Agreements - Contract with Customer, Contract Asset, Contract Liability, and Receivable Changes (Details) link:presentationLink link:calculationLink link:definitionLink 0000034 - Disclosure - Share-Based Compensation - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 0000035 - Disclosure - Share-Based Compensation - Summary of Stock Award Activity for the Period (Detail) link:presentationLink link:calculationLink link:definitionLink 0000036 - Disclosure - Share-Based Compensation - Summary of Compensation Expense Related to Grants of Stock Options (Detail) link:presentationLink link:calculationLink link:definitionLink 0000037 - Disclosure - Investments - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 0000038 - Disclosure - Investments - Schedule of Equity Investments with and without Readily Determinable Fair Values Assessed (Detail) link:presentationLink link:calculationLink link:definitionLink 0000039 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 0000040 - Disclosure - Leases - (Details) link:presentationLink link:calculationLink link:definitionLink 0000041 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities for Operating Leases (Detail) link:presentationLink link:calculationLink link:definitionLink 0000041 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities for Operating Leases (Detail) link:presentationLink link:calculationLink link:definitionLink 0000042 - Disclosure - Redeemable Noncontrolling Interest - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 0000043 - Disclosure - Redeemable Noncontrolling Interest - Summary of Net Income Attributable to Vtv Therapeutics Inc (Detail) link:presentationLink link:calculationLink link:definitionLink 0000044 - Disclosure - Stockholders' Deficit - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 0000045 - Disclosure - Related-Party Transactions - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 0000046 - Disclosure - Income Taxes - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 0000047 - Disclosure - Net Loss per Share - Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Loss per Share of Class A Common Stock (Detail) link:presentationLink link:calculationLink link:definitionLink 0000048 - Disclosure - Net Loss per Share - Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss per Share (Detail) link:presentationLink link:calculationLink link:definitionLink 0000049 - Disclosure - Fair Value of Financial Instruments - Summarizes the Conclusions Reached Regarding Fair Value Measurements (Detail) link:presentationLink link:calculationLink link:definitionLink 0000050 - Disclosure - Fair Value of Financial Instruments - Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation (Details) link:presentationLink link:calculationLink link:definitionLink 0000051 - Disclosure - Fair Value of Financial Instruments - Fair Value Measurement Inputs and Valuation Techniques (Detail) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 vtvt-20220930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 vtvt-20220930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 vtvt-20220930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Stock conversion ratio Redeemable Non Controlling Interest Exchange Agreement Stock Conversion Ratio Redeemable non controlling interest exchange agreement stock conversion ratio. vTv Therapeutics LLC V Tv L L C [Member] vTv LLC. Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Total lease payments Lessee, Operating Lease, Liability, to be Paid Net loss before noncontrolling interest Net loss before noncontrolling interest Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Related Party Transactions [Abstract] Related Party Transactions [Abstract] License Agreement Obligations License Agreement Obligations [Domain] License agreement obligations. Entity Address, Postal Zip Code Entity Address, Postal Zip Code Non-cash interest income Interest Income, Operating Revenue from Contract with Customer [Roll Forward] Change in Contract with Customer, Liability [Roll Forward] Change in Contract with Customer, Liability Change in redemption value of noncontrolling interest Noncontrolling Interest, Change in Redemption Value Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Equity investment with readily determinable fair value: Equity Investments With Readily Determinable Fair Value Equity investments with readily determinable fair value. Collaborative arrangement, contingent consideration Collaborative Arrangement, Contingent Consideration Transferred, Aggregate Share Value Collaborative Arrangement, Contingent Consideration Transferred, Aggregate Share Value (Increase) in vTv Therapeutics Inc. accumulated deficit for purchase of LLC Units as a result of common stock issuances Consolidation Changes Wholly Owned Subsidiary Parent Ownership Interest Changes Purchase Of Interest By Parent Consolidation changes wholly owned subsidiary parent ownership interest changes purchase of interest by parent. Financial Instruments Financial Instruments [Domain] CinRx CinRx [Member] CinRx Stock options cancelled (in shares) Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled. Statistical Measurement Statistical Measurement [Domain] Depreciation expense Depreciation Proceeds from debt issuance Proceeds from Issuance of Debt Exercise of stock options, shares (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period MacAndrews & Forbes Incorporated Mac Andrews And Forbes Incorporated [Member] MacAndrews and Forbes Incorporated. Weighted average incremental borrowing rate Operating Lease, Weighted Average Discount Rate, Percent Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Additional paid-in capital Additional Paid in Capital, Common Stock Type 2 Diabetes Type Two Diabetes [Member] Type 2 diabetes. Lessee, operating lease, termination period Lessee, Operating Lease, Termination Period Lessee, Operating Lease, Termination Period G2 Investment G2 Investment [Member] G2 Investment Organization Consolidation And Presentation Of Financial Statements [Line Items] Organization Consolidation And Presentation Of Financial Statements [Line Items] Organization consolidation and presentation of financial statements. Net loss attributable to vTv Therapeutics Inc. Net loss Net Income (Loss) Attributable to Parent Measurement Input Type Measurement Input Type [Domain] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Potentially dilutive securities not included in calculation of dilutive net loss per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Document Information [Line Items] Document Information [Line Items] Receivables from Stockholder Receivables from Stockholder [Member] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Lessee, Operating Lease, Liability, Payment, Due [Abstract] Lessee, Operating Lease, Liability, to be Paid [Abstract] Equity Component Equity Component [Domain] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Equity securities with readily determinable fair value - Total Assets, Fair Value Disclosure Leases Lessee, Operating Leases [Text Block] Investment, Name [Domain] Investment, Name [Domain] Related Party Related Party [Domain] Variable Interests And Equity Method Investments Disclosure [Abstract] Variable Interests And Equity Method Investments Disclosure [Abstract] Variable Interests And Equity Method Investments Disclosure [Abstract] Funding received Funding Received Funding received. Expected dividend yield Measurement Input, Expected Dividend Rate [Member] Forfeited (in usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Noncontrolling Interest [Abstract] Noncontrolling Interest [Abstract] 2022 (remaining three months) Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Proceeds from sale of Class A common stock to collaboration partner, net of offering costs Proceeds From Sale Of Common Stock Proceeds From Sale Of Common Stock Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Common stock, value Common Stock, Value, Outstanding Entity Address, State or Province Entity Address, State or Province Quoted Prices in Active Markets for Identical Assets (Level 1) Fair Value, Inputs, Level 1 [Member] Cantor Fitzgerald Cantor Fitzgerald [Member] Cantor fitzgerald member. Award Type Award Type [Axis] Novo License Agreement Novo License Agreement [Member] Novo license agreement. Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Current portion of operating lease liabilities Operating Lease, Liability, Current Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Related Party Transaction [Domain] Related Party Transaction [Domain] Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Redeemable Noncontrolling Interest Redeemable Noncontrolling Interests [Member] Redeemable noncontrolling interests. Transaction Transaction [Domain] Phase 2 MRCT Phase Two Multi Regional Clinical Trial [Member] Phase two multi-regional clinical trial. Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Other Commitments Other Commitments [Domain] Liability Class [Axis] Liability Class [Axis] Legal Entity Legal Entity [Axis] Promissory note receivable for common stock Stockholders' Equity Note, Subscriptions Receivable Total liabilities Liabilities Remaining operating lease term Operating Lease, Weighted Average Remaining Lease Term Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Issuance of Class A common stock to collaboration partner, net of offering cost Stock issued during period Stock Issued During Period, Value, New Issues Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward] Increase (Decrease) in Temporary Equity [Roll Forward] Entity Common Stock, Shares Outstanding (in shares) Entity Common Stock, Shares Outstanding Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Domain] Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Document Type Document Type Stock Conversion Description Stock Conversion Description [Axis] Concentration Risk Benchmark Concentration Risk Benchmark [Domain] Equity Securities Without Readily Determinable Fair Value [Line Items] Equity Securities without Readily Determinable Fair Value [Line Items] Redemption amount of noncontrolling interest Redeemable Noncontrolling Interest Temporary Equity Redemption Value Redeemable noncontrolling interest temporary equity redemption value. Product and Service Product and Service [Domain] Entity Shell Company Entity Shell Company Class B Common Stock Common Class B [Member] Net Change in fair value included in earnings Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Gain (Loss) Included in Earnings 2023 Lessee, Operating Lease, Liability, to be Paid, Year One Commitment Contingency And Related Party Transactions [Abstract] Commitment Contingency And Related Party Transactions [Abstract] Commitment, Contingency And Related Party Transactions [Abstract] Financial Instrument Financial Instrument [Axis] Affiliated Entity Affiliated Entity [Member] Subsequent Event Subsequent Event [Member] Revenue Revenue Benchmark [Member] Summary of Contract Liabilities Related to Company's Collaboration Agreements Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Document Period End Date Document Period End Date Sale of stock, consideration received on transaction, gross Sale of Stock, Consideration Received on Transaction, Gross Sale of Stock, Consideration Received on Transaction, Gross Total assets Assets Earnings Per Share [Abstract] Earnings Per Share [Abstract] Income Statement Location Income Statement Location [Axis] Assets: Equity Securities, FV-NI, Current Antidilutive Securities Antidilutive Securities [Axis] Change in redemption value of noncontrolling interest Temporary Equity, Change In Redemption Value Temporary Equity, Change In Redemption Value Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Accounting Policies [Abstract] Accounting Policies [Abstract] Long-term investments Long-Term Investments Other Commitments Other Commitments [Axis] Loss before income taxes and noncontrolling interest Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Stockholders’ deficit: Stockholders' Equity Attributable to Parent [Abstract] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Net Loss per Share Earnings Per Share [Text Block] Redeemable Noncontrolling Interest Noncontrolling Interest Disclosure [Text Block] Customer [Axis] Customer [Axis] Commitments And Contingencies [Line Items] Commitments And Contingencies [Line Items] Commitments and Contingencies. CinRx Warrants CinRx Warrants [Member] CinRx Warrants Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Award Type Award Type [Domain] Number of securities called by warrants or rights (in shares) Class of Warrant or Right, Number of Securities Called by Warrants or Rights Weighted average period to recognize unrecognized share-based compensation cost Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Options exercisable, weighted average remaining contractual term Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Anteris Bio Inc Anteris Bio Inc [Member] Anteris Bio, Inc. Entity Registrant Name Entity Registrant Name Amount of cash savings percentage Percentage Of Amount Of Cash Savings Percentage of amount of cash savings. Collaborate arrangement, contingent consideration transferred, cash Collaborate Arrangement, Contingent Consideration Transferred, Cash Collaborate Arrangement, Contingent Consideration Transferred, Cash Issuance of Class A Common Stock to Collaboration Partner (in shares) Stock Issued During Period, Shares, New Issues Collaboration Partner Collaboration Partner [Member] Collaboration Partner Type 1 Diabetes Type One Diabetes [Member] Type 1 diabetes. Subsequent Events Subsequent Events [Text Block] Research and Development Arrangement, Contract to Perform for Others, Type Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Entity Address, City or Town Entity Address, City or Town ATM Offering At The Market Offering [Member] At the market offering. G42 Investments G42 Investments [Member] G42 Investments Leases [Abstract] Leases [Abstract] Income Taxes [Table] Income Taxes [Table] Income taxes. Operating expenses: Operating Expenses [Abstract] Schedule Of Earnings Per Share [Line Items] Schedule Of Earnings Per Share [Line Items] Schedule Of Earnings Per Share [Line Items] Minimum Minimum [Member] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Common stock par value (in usd per share) Common Stock, Par or Stated Value Per Share Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Fair Value of Financial Instruments Fair Value Disclosures [Text Block] Investment, Name [Axis] Investment, Name [Axis] Share price (usd per share) Share Price Trading Symbol Trading Symbol Entity File Number Entity File Number Contract liabilities, net of current portion Contract with Customer, Liability, Noncurrent Research and development Research and Development Expense Transaction Type Transaction Type [Axis] Options vested and expected to vest, weighted average remaining contractual term Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term Issuance of Class A Common Stock under LPC Agreement Stock Issued During Period, Value, Purchase Agreement Stock Issued During Period, Value, Purchase Agreement Fair Value by Liability Class [Domain] Fair Value by Liability Class [Domain] Summary Of Significant Accounting Policies [Table] Summary Of Significant Accounting Policies [Table] Summary Of Significant Accounting Policies [Table] Title of Individual Title of Individual [Axis] Concentration Risk Benchmark Concentration Risk Benchmark [Axis] Risk-free interest rate Measurement Input, Risk Free Interest Rate [Member] Use of Estimates Use of Estimates, Policy [Policy Text Block] Warrant liability, related party Due to Related Parties, Noncurrent Beginning Balance Ending Balance Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Concentration risk percentage Concentration Risk, Percentage Subsequent Events [Abstract] Subsequent Events [Abstract] Investments Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Accounts payable and accrued expenses Increase (Decrease) in Accounts Payable and Accrued Liabilities Income Taxes Income Tax Disclosure [Text Block] Exercise price of warrants or rights (in usd per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Net loss per share of vTv Therapeutics Inc. Class A Common Stock, basic (in usd per share) Earnings Per Share, Basic CinRx Pharma, LLC CinRx Pharma, LLC [Member] CinRx Pharma, LLC Issuance Of Class A Common Stock Under ATM Offering (in shares) Issuance Of Class A Common Stock Under ATM Offering Issuance Of Class A Common Stock Under ATM Offering 2025 Lessee, Operating Lease, Liability, to be Paid, Year Three Award requisite service period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period Consideration receivable, payment period Sale Of Stock, Consideration Receivable, Payment Period Sale Of Stock, Consideration Receivable, Payment Period Concentration Risk Type Concentration Risk Type [Domain] Counterparty Name [Domain] Counterparty Name [Domain] Total stockholders’ deficit attributable to vTv Therapeutics Inc. Beginning balance Ending balance Stockholders' Equity Attributable to Parent Organization Consolidation And Presentation Of Financial Statements [Table] Organization Consolidation And Presentation Of Financial Statements [Table] Organization Consolidation And Presentation Of Financial Statements [Table] Proceeds from sale of Class A common stock and warrants, net of offering costs Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants Number of days used to determine exchange value based on weighted average price of Class A common stock Period Used To Determine Exchange Value Based On Weighted Average Price Of Class Common Stock Period used to determine exchange value based on weighted average price of Class A common stock. Newsoara Biopharma Co Ltd Newsoara Biopharma Co Ltd [Member] Newsoara Biopharma Co Ltd. Entity Interactive Data Current Entity Interactive Data Current Noncontrolling Interest [Line Items] Noncontrolling Interest [Line Items] Shares sold (in shares) Sale of Stock, Number of Shares Issued in Transaction Less: imputed interest Operating Leases Imputed Interest Operating leases imputed interest. Changes in assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Numerator: Net Income (Loss) Attributable to Parent [Abstract] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Accumulated Deficit Retained Earnings [Member] Unrecognized compensation cost related to non-vested share-based compensation arrangements Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount JDRF J D R F International [Member] JDRF international. Common Stock Common Stock [Member] Summary of Compensation Expense Related to Grants of Stock Options Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Class of Stock Class of Stock [Axis] Statement [Table] Statement [Table] Summary of Net Income Attributable to Vtv Therapeutics Inc Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table Text Block] Lessee, operating lease, renewal term Lessee, Operating Lease, Renewal Term Document Quarterly Report Document Quarterly Report Current assets: Assets, Current [Abstract] Operating lease liabilities, net of current portion Operating Lease, Liability, Noncurrent Fair Value Measurement Inputs and Valuation Techniques Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Statistical Measurement Statistical Measurement [Axis] Related Party Transaction [Axis] Related Party Transaction [Axis] Accumulated deficit Accumulated deficit Retained Earnings (Accumulated Deficit) Accounts receivable Accounts Receivable, after Allowance for Credit Loss, Current Equity Components Equity Components [Axis] M&F TTP Holdings LLC M F T T P Holdings L L C [Member] M&F TTP Holdings LLC. Fair Value, Measurements, Recurring Fair Value, Recurring [Member] Options exercisable (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Related-Party Transactions Related Party Transactions Disclosure [Text Block] Document Fiscal Year Focus Document Fiscal Year Focus Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Statement [Line Items] Statement [Line Items] Warrants, term Expected life of options in years Warrants and Rights Outstanding, Term Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table] Fair Value Measurement Inputs and Valuation Techniques [Table] Potential milestone payment Potential Milestone Payment Potential milestone payment. Receivables, fair value disclosure Receivables, Fair Value Disclosure Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Axis] Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Equity method investments, ownership percentage Investment Ownership Percentage Investment ownership percentage. Schedule of Equity Investments with and without Readily Determinable Fair Values Assessed Equity Securities With And Without Readily Determinable Fair Value Table [Table Text Block] Tabular disclosure of investment in equity security with and without readily determinable fair value. Fair Value Of Assets And Liabilities Measured On Recurring Basis [Table] Fair Value Of Assets And Liabilities Measured On Recurring Basis [Table] Fair value of assets and liabilities measured on recurring basis table. Document Transition Report Document Transition Report Local Phone Number Local Phone Number Summary of Stock Award Activity for the Period Share-Based Payment Arrangement, Option, Activity [Table Text Block] Operating loss Operating Income (Loss) Recently Issued Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Equity investment without readily determinable fair values assessed under the measurement alternative: Equity Securities without Readily Determinable Fair Value, Amount Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Document Information [Table] Document Information [Table] Common stock, shares outstanding (in shares) Beginning balance, shares (in shares) Ending balance, shares (in shares) Common Stock, Shares, Outstanding Potential development and regulatory milestone payments Potential Development And Regulatory Milestone Payments Receivable Potential development and regulatory milestone payments receivable. Liabilities: Liabilities, Fair Value Disclosure Adjustments to reconcile net loss before noncontrolling interest to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Income tax provision Income Tax Expense (Benefit) Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] 2026 Lessee, Operating Lease, Liability, to be Paid, Year Four Income Statement [Abstract] Income Statement [Abstract] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Additional Paid-in Capital Additional Paid-in Capital [Member] Document Fiscal Period Focus Document Fiscal Period Focus Satisfaction of Milestone Payment Satisfaction Of Milestone Payment [Member] Satisfaction of milestone payment. Discount on note receivable Collaborative Arrangement, Note Receivable, Discount Paid Collaborative Arrangement, Note Receivable, Discount Paid Income Taxes [Line Items] Income Taxes [Line Items] Income taxes. Weighted-average number of vTv Therapeutics Inc. Class A Common Stock, diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Issuance of class A common stock under LPC agreement, shares (in shares) Stock Issued During Period, Shares, Purchase Agreement Issuance of Class A Common Stock under LPC agreement shares.. Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items] Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items] Fair value of assets and liabilities measured on recurring basis. Collaborative Arrangement and Arrangement Other than Collaborative Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Current portion of notes payable Notes Payable, Current Collaborative Arrangements Collaborative Arrangement [Member] Accounts payable and accrued expenses Accounts Payable and Accrued Liabilities, Current Common stock value Common Stock, Value, Issued Preferred Stock Preferred Stock [Member] Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Change in fair value of warrants, related party Change In Fair Value Of Warrants Related Party Change in fair value of warrants related party. Summarizes the Conclusions Reached Regarding Fair Value Measurements Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Total cash, cash equivalents and restricted cash and cash equivalents, beginning of period Total cash, cash equivalents and restricted cash and cash equivalents, end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Less: net loss attributable to noncontrolling interest Less: Net loss attributable to noncontrolling interests Net Income (Loss) Attributable to Noncontrolling Interest Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Inputs utilized in the valuation of warrants Warrants and Rights Outstanding, Measurement Input Current liabilities: Liabilities, Current [Abstract] Proceeds from exercise of stock options Proceeds from Stock Options Exercised Net loss attributable to vTv Therapeutics Inc. common shareholders Net loss attributable to common shareholders of vTv Therapeutics Inc., basic Net Income (Loss) Available to Common Stockholders, Basic CinRx Investment CinRx Investment [Member] CinRx Investment Purchases / Issuance Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases Current portion of contract liabilities Contract with Customer, Liability, Current Warrants, fair value Warrants and Rights Outstanding Income Statement Location Income Statement Location [Domain] Interest expense Interest Expense, Other Amendment Flag Amendment Flag Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Developmental and Regulatory Milestone Payment Developmental And Regulatory Milestone Payment [Member] Developmental and regulatory milestone payment. Investments Investment, Policy [Policy Text Block] Share-based Payment Arrangement, Disclosure [Abstract] Share-Based Payment Arrangement, Disclosure [Abstract] Entity Current Reporting Status Entity Current Reporting Status Royalties receivable, period Collaborative Arrangement, Royalties Receivable, Period Collaborative Arrangement, Royalties Receivable, Period Contract with Customer, Contract Asset, Contract Liability, and Receivable Changes Contract with Customer, Contract Asset, Contract Liability, and Receivable Changes [Table Text Block] Contract with Customer, Contract Asset, Contract Liability, and Receivable Changes Options exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Thereafter Lessee, Operating Lease, Liability, to be Paid, After Year Four Lessee, Operating Lease, Liability, to be Paid, After Year Four Repayment of notes payable Repayments of Notes Payable Counterparty Name [Axis] Counterparty Name [Axis] Outstanding stock options (in shares) Awards outstanding, Beginning balance (in shares) Awards outstanding, Ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Other Indication Other Indication [Member] Other indication. Capital stock, shares authorized (in shares) Common Stock And Preferred Stock Shares Authorized Common stock and preferred stock shares authorized. Notes receivable recorded at fair value Notes Assumed Schedule Of Stock By Class [Table] Schedule of Stock by Class [Table] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Sales / Repurchases Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Sales Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Property and equipment, net Property, Plant and Equipment, Net Percentage of non-voting economic interest of vTv Therapeutics Inc in vTv LLC Percentage Of Non Voting Economic Interest By Parent Percentage of non voting economic interest by parent. Issuance of Class A common stock under ATM offering Issuance Of Class A Common Stock Under ATM Offering Value Issuance Of Class A Common Stock Under ATM Offering Value Stock Option Common stock options granted under the Plan Share-Based Payment Arrangement, Option [Member] Maximum funding percentage of research and development milestones Maximum Funding Percentage Of Research And Development Milestones Maximum funding percentage of research and development milestones. Title of Individual Title of Individual [Domain] G2 Investments Purchase Agreement And Cogna Collaborative And License Agreement G2 Investments Purchase Agreement And Cogna Collaborative And License Agreement [Member] G2 Investments Purchase Agreement And Cogna Collaborative And License Agreement Exercise of stock options Stock Issued During Period, Value, Stock Options Exercised Other income (expense) Other Nonoperating Income (Expense) Sale of stock, price per share (in usd per shares) Sale of Stock, Price Per Share Common stock, shares authorized (in shares) Common Stock, Shares Authorized Schedule Of Related Party Transactions By Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Total operating expenses Operating Expenses Maximum Maximum [Member] Strategic Advisor Strategic Advisor [Member] Strategic advisor. Consideration received in advance and not recognized as revenue Contract with Customer, Liability, Increase (Decrease) for Contract Acquired in Business Combination Class A Common Stock Common Class A [Member] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Contract liabilities Increase (Decrease) in Contract with Customer, Liability Total current assets Assets, Current Research and Development Arrangement, Contract to Perform for Others, Type Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Contract with customer, liability, revenue recognized Reclassification of the beginning contract liabilities to revenue, as the result of performance obligations satisfied Contract with Customer, Liability, Revenue Recognized Entity Small Business Entity Small Business Measurement Frequency Measurement Frequency [Domain] Stockholders' Deficit Stockholders' Equity Note Disclosure [Text Block] Weighted Average Exercise Price Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward] Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Exchange of Redeemable Non controlling Interest To Class A Common Stock Exchange Of Redeemable Non Controlling Interest To Class A Common Stock [Member] Exchange of redeemable non controlling interest to class A common stock. Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Current deposits Deposits Assets, Current Schedule Of Earnings Per Share [Table] Schedule Of Earnings Per Share [Table] Schedule Of Earnings Per Share [Table] Change from net loss attributable to vTv Therapeutics Inc. common shareholders and transfers to noncontrolling interest Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Change Due to Net Income Attributable to Parent and Effects of Changes, Net Sales-based Milestones Payment Sales Based Milestones Payment [Member] Sales-based milestones payment. Accounts receivable Increase (Decrease) in Accounts Receivable Title of 12(b) Security Title of 12(b) Security Master Service Agreement Master Service Agreement [Member] Master Service Agreement Aggregate offering price Aggregate Offering Price Of Shares Aggregate offering price of shares. Sale of stock, consideration, receivables, payment term Sale Of Stock, Consideration, Receivable, Term Sale Of Stock, Consideration, Receivable, Term Class Of Stock [Line Items] Class of Stock [Line Items] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Present value of lease liabilities Operating Lease, Liability Expected volatility Measurement Input, Price Volatility [Member] Summary Of Significant Accounting Policies [Line Items] Summary Of Significant Accounting Policies [Line Items] Summary of significant accounting policies. Investments, Debt and Equity Securities [Abstract] Investments, Debt and Equity Securities [Abstract] Minority Interest [Table] Noncontrolling Interest [Table] Liabilities, Redeemable Noncontrolling Interest and Stockholders’ Deficit Liabilities and Equity [Abstract] Granted (in usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Adjustments to transaction price for performance obligations Adjustments To Transaction Price For Performance Obligations Adjustments to transaction price for performance obligations. Denominator: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Percentage of non-voting economic interest of vTv Therapeutics Holdings LLC in vTv LLC Noncontrolling interest ownership percentage Percentage Of Non Voting Economic Interest Percentage of non voting economic interest. Sale of stock, consideration received on transaction Sale of Stock, Consideration Received on Transaction Unaudited Interim Financial Information Unaudited Interim Financial Information Policy [Policy Text Block] Unaudited interim financial information policy. Common stock warrants Warrant [Member] Entity Filer Category Entity Filer Category Proceeds from sale of Class A common stock, net of offering costs Net proceeds from issuance of common stock Proceeds from Issuance of Common Stock Weighted-average number of vTv Therapeutics Inc. Class A Common Stock, basic (in shares) Weighted Average Number of Shares Outstanding, Basic Options vested and expected to vest (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price LPC Purchase Agreement L P C Purchase Agreement [Member] LPC purchase agreement. Total share-based compensation expense Share-Based Payment Arrangement, Expense Commitments and contingencies Commitments and Contingencies Security Exchange Name Security Exchange Name Awards outstanding, Beginning balance (in usd per share) Awards outstanding, Ending balance (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Customer Three Three Customers [Member] Three Customers Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] Redeemable noncontrolling interest Beginning balance Ending balance Redeemable Noncontrolling Interest, Equity, Carrying Amount General and administrative General and Administrative Expense [Member] Share-based Payment Arrangement, Noncash Expense [Abstract] Share-Based Payment Arrangement, Noncash Expense [Abstract] Revenue Revenue from Contract with Customer, Excluding Assessed Tax Exchange of Class B common stock for class A common stock, shares (in shares) Stock Issued During Period, Shares, Conversion of Convertible Securities Warrant liability, related party Warrant Liability Related Party [Member] Warrant liability, related party. Common stock, capital shares reserved for future issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance Cover [Abstract] Cover [Abstract] Letter Agreement Warrants Letter Agreement Warrants [Member] Letter agreement warrants. Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Shares held by related party (in shares) Investments in and Advances to Affiliates, Balance, Shares Share-Based Compensation Share-Based Payment Arrangement [Text Block] Increase in shares authorized (in shares) Increase In Common Stock Shares Authorized Increase in common stock shares authorized. Other income (expense) – related party Other Income Expenses Related Party The net amount of other related party income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items. Customer One Customer One [Member] Customer One Redeemable Noncontrolling Interest Noncontrolling Interest [Member] Maximum contribution amount to clinical trial Maximum Sponsoring Contribution Amount Maximum sponsoring contribution amount. Cogna Cogna [Member] Cogna Total liabilities, redeemable noncontrolling interest and stockholders’ deficit Liabilities and Equity Public float Public Float Public float. Collaborative Arrangement and Arrangement Other than Collaborative Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Related Party Related Party [Axis] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Current Fiscal Year End Date Current Fiscal Year End Date Net loss attributable to common shareholders of vTv Therapeutics Inc., diluted Net Income (Loss) Available to Common Stockholders, Diluted Net loss per share of vTv Therapeutics Inc. Class A Common Stock, diluted (in usd per share) Earnings Per Share, Diluted Commitments And Contingencies [Table] Commitments And Contingencies [Table] Commitments And Contingencies [Table] Non-qualified stock option awards vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Royalties receivable, percent Collaborative Arrangement, Royalties Receivable, Percentage Collaborative Arrangement, Royalties Receivable, Percentage Share-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Concentration Risk Type Concentration Risk Type [Axis] Total current liabilities Liabilities, Current 2024 Lessee, Operating Lease, Liability, to be Paid, Year Two Net loss Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest Customer Customer Concentration Risk [Member] License And Technology Transfer Services License And Technology Transfer Services [Member] License and technology transfer services. Unrecognized amount of transaction price allocated to performance obligation Revenue, Remaining Performance Obligation, Amount Non-qualified stock option awards expiration term Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Options vested and expected to vest (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number Schedule of Maturities of Lease Liabilities for Operating Leases Lessee, Operating Lease, Liability, Maturity [Table Text Block] Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, Address Line One Entity Address, Address Line One Total contract liabilities Beginning balance Ending balance Contract with Customer, Liability Change in fair value of investments Change in fair value of investments Unrealized Gain (Loss) on Investments Product and Service Product and Service [Axis] Class of Stock Class of Stock [Domain] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Interest expense Interest Expense Deferred Revenue Disclosure [Abstract] Deferred Revenue Disclosure [Abstract] Maximum research funding receivable achievement based on research and development milestones Maximum Research Funding Receivable Based On Achievement Of Research And Development Milestones Maximum research funding receivable based on achievement of research and development milestones. License and Technology Transfer Services of Chemistry and Manufacturing Know-How License And Technology Transfer Services Of Chemistry And Manufacturing Know How [Member] License and technology transfer services of chemistry and manufacturing know-how. Equity Securities Without Readily Determinable Fair Value [Table] Equity Securities without Readily Determinable Fair Value [Table] Customers Two Two Customers [Member] Two Customers Equity [Abstract] Equity [Abstract] Entity Tax Identification Number Entity Tax Identification Number Due To Related Parties, Monthly Amount Due To Related Parties, Monthly Amount Due To Related Parties, Monthly Amount Promissory note receivable Notes Receivable, Current Notes Receivable, Current Revenue from Contract with Customer [Abstract] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Remaining available stock value Remaining Availability Stock Issued During Period Value New Issues Remaining availability under our controlled equity offering sales agreement License Agreement Obligations License Agreement Obligations [Axis] License agreement obligations. Net increase in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Entity Central Index Key Entity Central Index Key Antidilutive Securities, Name Antidilutive Securities, Name [Domain] Interest income Investment Income, Interest Measurement Frequency Measurement Frequency [Axis] Research and Development Research and Development Expense, Policy [Policy Text Block] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Collaboration Agreements Collaborative Arrangement Disclosure [Text Block] Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Hangzhou Zhongmei Huadong Pharmaceutical Company Limited [Member] Hangzhou Zhongmei Huadong Pharmaceutical Company Limited. Concentration of Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Measurement Input Type Measurement Input Type [Axis] Entity Entity [Domain] City Area Code City Area Code General and administrative General and Administrative Expense Assets Assets [Abstract] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Non-cash activities: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Share-based compensation expense Share-Based Payment Arrangement, Noncash Expense Weighted average grant date fair value of options granted (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Revenue recognized from change in estimated transaction prices Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Accounts and financing receivable, after allowance for credit loss Accounts and Financing Receivable, after Allowance for Credit Loss, Current Research and development Research and Development Expense [Member] Weighted Average Weighted Average [Member] Ownership percentage of majority owner Ownership Percentage Of Majority Owner Ownership percentage of majority owner. Reneo Reneo Pharmaceuticals Inc [Member] Reneo Pharmaceuticals Inc. Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Loss per Share of Class A Common Stock Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Conversion of Stock, Name Conversion of Stock, Name [Domain] Description of Business, Basis of Presentation and Going Concern Business Description and Basis of Presentation [Text Block] Customer [Domain] Customer [Domain] EX-101.PRE 10 vtvt-20220930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 11 vtvt-20220930_g1.jpg begin 644 vtvt-20220930_g1.jpg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�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end XML 12 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Cover - shares
 9 Months Ended
Sep. 30, 2022
Nov. 10, 2022
Document Information [Line Items]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2022  
Document Transition Report false  
Entity File Number 001-37524  
Entity Registrant Name vTv Therapeutics Inc.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 47-3916571  
Entity Address, Address Line One 3980 Premier Dr  
Entity Address, Address Line Two Suite 310  
Entity Address, City or Town High Point  
Entity Address, State or Province NC  
Entity Address, Postal Zip Code 27265  
City Area Code 336  
Local Phone Number 841-0300  
Title of 12(b) Security Class A common stock, par value $0.01 per share  
Trading Symbol VTVT  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Central Index Key 0001641489  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2022  
Document Fiscal Period Focus Q3  
Amendment Flag false  
Class A Common Stock    
Document Information [Line Items]    
Entity Common Stock, Shares Outstanding (in shares)   81,483,600
Class B Common Stock    
Document Information [Line Items]    
Entity Common Stock, Shares Outstanding (in shares)   23,093,860

XML 13 R2.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Current assets:    
Cash and cash equivalents $ 15,339 $ 13,415
Accounts receivable 57 57
Promissory note receivable 12,091 0
Prepaid expenses and other current assets 1,281 2,049
Current deposits 15 100
Total current assets 28,783 15,621
Property and equipment, net 230 278
Operating lease right-of-use assets 328 402
Long-term investments 6,175 9,173
Total assets 35,516 25,474
Current liabilities:    
Accounts payable and accrued expenses 6,676 8,023
Current portion of operating lease liabilities 208 184
Current portion of contract liabilities 26 35
Current portion of notes payable 557 256
Total current liabilities 7,467 8,498
Contract liabilities, net of current portion 18,669 0
Operating lease liabilities, net of current portion 333 492
Warrant liability, related party 1,409 1,262
Total liabilities 27,878 10,252
Commitments and contingencies
Redeemable noncontrolling interest 24,207 24,962
Stockholders’ deficit:    
Additional paid-in capital 253,446 238,193
Accumulated deficit (267,062) (248,834)
Total stockholders’ deficit attributable to vTv Therapeutics Inc. (16,569) (9,740)
Total liabilities, redeemable noncontrolling interest and stockholders’ deficit 35,516 25,474
Class A Common Stock    
Stockholders’ deficit:    
Common stock value 815 669
Class B Common Stock    
Stockholders’ deficit:    
Common stock value 232 232
Promissory note receivable for common stock $ (4,000) $ 0
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
Sep. 30, 2022
Dec. 31, 2021
Class A Common Stock    
Common stock par value (in usd per share) $ 0.01 $ 0.01
Common stock, shares authorized (in shares) 200,000,000 200,000,000
Common stock, shares outstanding (in shares) 81,483,600 66,942,777
Class B Common Stock    
Common stock par value (in usd per share) $ 0.01 $ 0.01
Common stock, shares authorized (in shares) 100,000,000 100,000,000
Common stock, shares outstanding (in shares) 23,093,860 23,093,860
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Statements of Operations - Unaudited - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Revenue $ 0 $ 3,000 $ 2,009 $ 3,996
Operating expenses:        
Research and development 3,055 2,382 8,393 7,922
General and administrative 2,634 2,221 9,813 6,627
Total operating expenses 5,689 4,603 18,206 14,549
Operating loss (5,689) (1,603) (16,197) (10,553)
Other income (expense) 403 (1,084) (2,998) 1,814
Other income (expense) – related party (324) 1,328 221 611
Interest income 150 0 200 1
Interest expense (8) (6) (9) (6)
Loss before income taxes and noncontrolling interest (5,468) (1,365) (18,783) (8,133)
Income tax provision 0 100 200 115
Net loss before noncontrolling interest (5,468) (1,465) (18,983) (8,248)
Less: net loss attributable to noncontrolling interest (1,207) (378) (4,564) (2,312)
Net loss attributable to vTv Therapeutics Inc. (4,261) (1,087) (14,419) (5,936)
Net loss attributable to vTv Therapeutics Inc. common shareholders $ (4,261) $ (1,087) $ (14,419) $ (5,936)
Class A Common Stock        
Operating expenses:        
Net loss per share of vTv Therapeutics Inc. Class A Common Stock, basic (in usd per share) $ (0.05) $ (0.02) $ (0.20) $ (0.10)
Net loss per share of vTv Therapeutics Inc. Class A Common Stock, diluted (in usd per share) $ (0.05) $ (0.02) $ (0.20) $ (0.10)
Weighted-average number of vTv Therapeutics Inc. Class A Common Stock, basic (in shares) 80,490,121 61,073,280 72,649,531 58,737,170
Weighted-average number of vTv Therapeutics Inc. Class A Common Stock, diluted (in shares) 80,490,121 61,073,280 72,649,531 58,737,170
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders' Deficit - Unaudited - USD ($)
$ in Thousands
Total
Class A Common Stock
Class B Common Stock
Redeemable Noncontrolling Interest
Redeemable Noncontrolling Interest
Common Stock
Class A Common Stock
Common Stock
Class B Common Stock
Receivables from Stockholder
Receivables from Stockholder
Class A Common Stock
Additional Paid-in Capital
Additional Paid-in Capital
Class A Common Stock
Accumulated Deficit
Beginning balance at Dec. 31, 2020 $ 83,895                    
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]                      
Net loss (2,312)                    
Change in redemption value of noncontrolling interest (36,973)                    
Ending balance at Sep. 30, 2021 44,610     $ 44,610              
Beginning balance, shares (in shares) at Dec. 31, 2020         54,050,710 23,094,221          
Beginning balance at Dec. 31, 2020 (80,102)       $ 541 $ 232     $ 209,161   $ (290,036)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                      
Net loss (5,936)                   (5,936)
Share-based compensation 1,362               1,362    
Issuance of Class A Common Stock to Collaboration Partner (in shares)         8,457,546            
Issuance of Class A common stock to collaboration partner, net of offering cost 17,024       $ 85         $ 16,939  
Exchange of Class B common stock for class A common stock, shares (in shares)         361 (361)          
Exercise of stock options, shares (in shares)         20,833            
Exercise of stock options 47               47    
Issuance of class A common stock under LPC agreement, shares (in shares)         3,941,726            
Issuance of Class A Common Stock under LPC Agreement 9,087       $ 39       9,048    
Change in redemption value of noncontrolling interest 36,973                   36,973
Ending balance, shares (in shares) at Sep. 30, 2021         66,471,176 23,093,860          
Ending balance at Sep. 30, 2021 (21,545)       $ 665 $ 232     236,557   (258,999)
Beginning balance at Jun. 30, 2021       60,190              
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]                      
Net loss       (378)              
Change in redemption value of noncontrolling interest       (15,202)              
Ending balance at Sep. 30, 2021 44,610     44,610              
Beginning balance, shares (in shares) at Jun. 30, 2021         60,193,967 23,093,860          
Beginning balance at Jun. 30, 2021 (47,823)       $ 602 $ 232     224,457   (273,114)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                      
Net loss (1,087)                   (1,087)
Share-based compensation 474               474    
Issuance Of Class A Common Stock Under ATM Offering (in shares)         6,277,209            
Issuance of Class A common stock under ATM offering 11,689       $ 63       11,626    
Change in redemption value of noncontrolling interest 15,202                   15,202
Ending balance, shares (in shares) at Sep. 30, 2021         66,471,176 23,093,860          
Ending balance at Sep. 30, 2021 (21,545)       $ 665 $ 232     236,557   (258,999)
Beginning balance at Dec. 31, 2021 24,962                    
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]                      
Net loss (4,564)                    
Change in redemption value of noncontrolling interest 3,809                    
Ending balance at Sep. 30, 2022 24,207     24,207              
Beginning balance, shares (in shares) at Dec. 31, 2021   66,942,777 23,093,860   66,942,777 23,093,860          
Beginning balance at Dec. 31, 2021 (9,740)       $ 669 $ 232     238,193   (248,834)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                      
Net loss (14,419)                   (14,419)
Share-based compensation 981               981    
Issuance of Class A Common Stock to Collaboration Partner (in shares)         10,386,274            
Issuance of Class A common stock to collaboration partner, net of offering cost 5,040       $ 104         4,936  
Issuance of class A common stock under LPC agreement, shares (in shares)         4,154,549            
Issuance of Class A Common Stock under LPC Agreement 5,378       $ 42   $ (4,000) $ (4,000)   9,336  
Change in redemption value of noncontrolling interest (3,809)                   (3,809)
Ending balance, shares (in shares) at Sep. 30, 2022   81,483,600 23,093,860   81,483,600 23,093,860          
Ending balance at Sep. 30, 2022 (16,569)       $ 815 $ 232   (4,000) 253,446   (267,062)
Beginning balance at Jun. 30, 2022       15,916              
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]                      
Net loss       (1,207)              
Change in redemption value of noncontrolling interest       9,498              
Ending balance at Sep. 30, 2022 24,207     $ 24,207              
Beginning balance, shares (in shares) at Jun. 30, 2022         77,329,051 23,093,860          
Beginning balance at Jun. 30, 2022 (8,526)       $ 773 $ 232   0 243,772   (253,303)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                      
Net loss (4,261)                   (4,261)
Share-based compensation 338               338    
Issuance of class A common stock under LPC agreement, shares (in shares)         4,154,549            
Issuance of Class A Common Stock under LPC Agreement 5,378       $ 42     (4,000)   $ 9,336  
Change in redemption value of noncontrolling interest (9,498)                   (9,498)
Ending balance, shares (in shares) at Sep. 30, 2022   81,483,600 23,093,860   81,483,600 23,093,860          
Ending balance at Sep. 30, 2022 $ (16,569)       $ 815 $ 232   $ (4,000) $ 253,446   $ (267,062)
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Statements of Cash Flows - Unaudited - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Cash flows from operating activities:    
Net loss before noncontrolling interest $ (18,983) $ (8,248)
Adjustments to reconcile net loss before noncontrolling interest to net cash used in operating activities:    
Depreciation expense 69 67
Non-cash interest income (200) 0
Interest expense 9 0
Share-based compensation expense 981 1,362
Change in fair value of investments 2,998 (1,814)
Change in fair value of warrants, related party (221) (611)
Changes in assets and liabilities:    
Accounts receivable 0 (770)
Prepaid expenses and other assets 853 (367)
Accounts payable and accrued expenses (1,417) (1,514)
Contract liabilities 6,769 (996)
Net cash used in operating activities (9,142) (12,891)
Cash flows from investing activities:    
Purchases of property and equipment (21) 0
Net cash used in investing activities (21) 0
Cash flows from financing activities:    
Proceeds from sale of Class A common stock to collaboration partner, net of offering costs 5,040 0
Proceeds from sale of Class A common stock and warrants, net of offering costs 5,746 0
Proceeds from sale of Class A common stock, net of offering costs 0 26,111
Proceeds from exercise of stock options 0 47
Proceeds from debt issuance 776 887
Repayment of notes payable (475) (335)
Net cash provided by financing activities 11,087 26,710
Net increase in cash and cash equivalents 1,924 13,819
Total cash, cash equivalents and restricted cash and cash equivalents, beginning of period 13,415 5,747
Total cash, cash equivalents and restricted cash and cash equivalents, end of period 15,339 19,566
Non-cash activities:    
Change in redemption value of noncontrolling interest (3,809) 36,973
Collaboration Partner    
Non-cash activities:    
Notes receivable recorded at fair value 11,891 0
CinRx    
Non-cash activities:    
Notes receivable recorded at fair value $ 4,000 $ 0
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.22.2.2
Description of Business, Basis of Presentation and Going Concern
 9 Months Ended
Sep. 30, 2022
Accounting Policies [Abstract]  
Description of Business, Basis of Presentation and Going Concern Description of Business, Basis of Presentation and Going Concern
Description of Business
vTv Therapeutics Inc. (the “Company,” the “Registrant,” “we” or “us”) was incorporated in the state of Delaware in April 2015. The Company is a clinical stage pharmaceutical company focused on treating metabolic diseases to minimize their long-term complications through end-organ protection.
Principles of Consolidation
vTv Therapeutics Inc. is a holding company, and its principal asset is a controlling equity interest in vTv Therapeutics LLC (“vTv LLC”), the Company’s principal operating subsidiary, which is a clinical stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs.
The Company has determined that vTv LLC is a variable-interest entity (“VIE”) for accounting purposes and that vTv Therapeutics Inc. is the primary beneficiary of vTv LLC because (through its managing member interest in vTv LLC and the fact that the senior management of vTv Therapeutics Inc. is also the senior management of vTv LLC) it has the power and benefits to direct all of the activities of vTv LLC, which include those that most significantly impact vTv LLC’s economic performance. vTv Therapeutics Inc. has therefore consolidated vTv LLC’s results pursuant to Accounting Standards Codification Topic 810, “Consolidation” in its Condensed Consolidated Financial Statements. As of September 30, 2022, various holders own non-voting interests in vTv LLC, representing a 22.1% economic interest in vTv LLC, effectively restricting vTv Therapeutics Inc.’s interest to 77.9% of vTv LLC’s economic results, subject to increase in the future, should vTv Therapeutics Inc. purchase additional non-voting common units (“vTv Units”) of vTv LLC, or should the holders of vTv Units decide to exchange such units (together with shares of Class B common stock) for shares of Class A common stock (or cash) pursuant to the Exchange Agreement (as defined in Note 9). vTv Therapeutics Inc. has provided financial and other support to vTv LLC in the form of its purchase of vTv Units with the net proceeds of the Company’s initial public offering (“IPO”) in 2015, its registered direct offering in March 2019, and its agreeing to be a co-borrower under the Venture Loan and Security Agreement (the “Loan Agreement”) with Horizon Technology Finance Corporation and Silicon Valley Bank (together, the “Lenders”) which was entered into in 2016. vTv Therapeutics Inc. entered into the letter agreements with MacAndrews and Forbes Group LLC (“M&F Group”), a related party and an affiliate of MacAndrews & Forbes Incorporated (together with its affiliates “MacAndrews”) in December 2017, July 2018, December 2018, March 2019, September 2019, and December 2019 (each a “Letter Agreement” and collectively, the “Letter Agreements”). In addition, vTv Therapeutics Inc. also entered into the Controlled Equity OfferingSM Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co. (“Cantor Fitzgerald”) (the “ATM Offering”), the purchase agreement with Lincoln Park Capital Fund, LLC (“Lincoln Park”) (the “LPC Purchase Agreement”), the common stock purchase agreement with G42 Investments AI Holding RSC Ltd (“G42 Investments”) (the “G42 Purchase Agreement”) and the common stock and warrant purchase agreement with CinPax, LLC and CinRx, LLC, respectively (the “CinRx Purchase Agreement”). vTv Therapeutics Inc. will not be required to provide financial or other support for vTv LLC. However, vTv Therapeutics Inc. will control its business and other activities through its managing member interest in vTv LLC, and its management is the management of vTv LLC. Nevertheless, because vTv Therapeutics Inc. will have no material assets other than its interests in vTv LLC, any financial difficulties at vTv LLC could result in vTv Therapeutics Inc. recognizing a loss.
Going Concern and Liquidity
To date, the Company has not generated any product revenue and has not achieved profitable operations. The continuing development of our drug candidates will require additional financing. From its inception through September 30, 2022, the Company has funded its operations primarily through a combination of private placements of common and preferred equity, research collaboration agreements, upfront and milestone payments for license agreements, debt and equity financings and the completion of its IPO in August 2015. As of September 30, 2022, the Company had an accumulated deficit of $267.1 million and has generated net losses in each year of its existence.
As of September 30, 2022, the Company’s liquidity sources included cash and cash equivalents of $15.3 million. To meet our future funding requirements into the fourth quarter of 2023, including funding the on-going and future clinical trials of TTP399, we are evaluating several financing strategies, including direct equity investments and the potential licensing and
monetization of other Company programs such as HPP737. The Company also has promissory notes of $12.5 million and $4.0 million under the G42 Purchase Agreement and CinRx Purchase Agreement payable to the Company, respectively. The G42 promissory note is due on or before May 31, 2023, and the CinRx promissory note is due on or before November 22, 2022 (see Note 9).
The Company may also use its remaining availability of $37.3 million under our Sales Agreement with Cantor Fitzgerald pursuant to which the Company may offer and sell, from time to time shares of the Company’s Class A common stock (the “ATM Offering”) and the ability to sell an additional 9,437,376 shares of Class A common stock under the LPC Purchase Agreement based on the remaining number of registered shares. However, the ability to use these sources of capital is dependent on a number of factors, including the prevailing market price of and the volume of trading in the Company’s Class A common stock. See Note 9 for further details.
These conditions raise substantial doubt about the Company’s ability to continue as a going concern. If we are unable to raise additional capital as and when needed, or upon acceptable terms, such failure would have a significant negative impact on our financial condition.
The Company’s financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. The Condensed Consolidated Financial Statements do not include adjustments to reflect the possible future effects on the recoverability and classification of recorded assets or the amounts of liabilities that might be necessary should the Company be unable to continue as a going concern.
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.22.2.2
Summary of Significant Accounting Policies
 9 Months Ended
Sep. 30, 2022
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies Summary of Significant Accounting Policies
Unaudited Interim Financial Information
The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying Condensed Consolidated Balance Sheet as of September 30, 2022, Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2022, and 2021, Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders’ Deficit for the three and nine months ended September 30, 2022, and 2021 and Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2022, and 2021 are unaudited. These unaudited financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. These financial statements should be read in conjunction with the audited financial statements and the accompanying notes for the year ended December 31, 2021, contained in the Company’s Annual Report on Form 10-K. The unaudited interim financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company’s financial position as of September 30, 2022, the results of operations for the three and nine months ended September 30, 2022, and 2021 and cash flows for the nine months ended September 30, 2022, and 2021. The December 31, 2021 Condensed Consolidated Balance Sheet included herein was derived from the audited financial statements but does not include all disclosures or notes required by GAAP for complete financial statements.
The financial data and other information disclosed in these notes to the financial statements related to the three and nine months ended September 30, 2022, and 2021 are unaudited. Interim results are not necessarily indicative of results for an entire year.
The Company does not have any components of other comprehensive income recorded within its Condensed Consolidated Financial Statements, and, therefore, does not separately present a statement of comprehensive income in its Condensed Consolidated Financial Statements.
Use of Estimates
The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
On an ongoing basis, the Company evaluates its estimates, including those related to the grant date fair value of equity awards, the fair value of warrants to purchase shares of its Class A common stock, the fair value of the Class B common stock, the useful lives of property and equipment, the fair value of derivative liabilities, the fair value of the promissory note
receivable, and the fair value of the Company’s debt, among others. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable, the results of which form the basis for making judgments about the carrying value of assets and liabilities.
Concentration of Credit Risk
Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash on deposit with one financial institution. The balances of these cash accounts frequently exceed insured limits.
One customer represented 100% of the revenue earned during the nine months ended September 30, 2022, two customers represented 100% of the revenue earned during the three months ended September 30, 2021 and three customers represented 100% of the revenue earned during the nine months ended September 30, 2021.
Cash and Cash Equivalents
The Company considers any highly liquid investments with an original maturity of three months or less to be cash and cash equivalents.
Investments
Investments in entities in which the Company has no control or significant influence, is not the primary beneficiary, and have a readily determinable fair value are classified as equity investments with readily determinable fair value. The investments are measured at fair value based on a quoted market price per unit in active markets multiplied by the number of units held without consideration of transaction costs (Level 1). Gains and losses are recorded in other income (expense), net on the Consolidated Statements of Operations.
Equity investments without readily determinable fair value include ownership rights that do not provide the Company with control or significant influence and these investments do not have readily determinable fair values. The Company has elected to measure its equity investments without readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment.
Revenue Recognition
The Company uses the revenue recognition guidance established by ASC Topic 606, Revenue From Contracts With Customers (“ASC 606”). When an agreement falls under the scope of other standards, such as ASC Topic 808, Collaborative Arrangements (“ASC 808”), the Company will apply the recognition, measurement, presentation, and disclosure guidance in ASC 606 to the performance obligations in the agreements if those performance obligations are with a customer. Revenue recognized by analogizing to ASC 606, is recorded as collaboration revenue on the statements of operations.
The majority of the Company’s revenue results from its license and collaboration agreements associated with the development of investigational drug products. The Company accounts for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. For each contract meeting these criteria, the Company identifies the performance obligations included within the contract. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. The Company then recognizes revenue under each contract as the related performance obligations are satisfied.
The transaction price under the contract is determined based on the value of the consideration expected to be received in exchange for the transferred assets or services. Development, regulatory and sales milestones included in the Company’s collaboration agreements are considered to be variable consideration. The amount of variable consideration expected to be received is included in the transaction price when it becomes probable that the milestone will be met. For contracts with multiple performance obligations, the contract’s transaction price is allocated to each performance obligation using the Company’s best estimate of the standalone selling price of each distinct good or service in the contract. The primary method used to estimate standalone selling price is the expected cost-plus margin approach.
Research and Development
Major components of research and development costs include cash and share-based compensation, costs of preclinical studies, clinical trials and related clinical manufacturing, costs of drug development, costs of materials and supplies, regulatory and compliance costs, fees paid to consultants and other entities that conduct certain research and development
activities on the Company’s behalf, facilities costs, and overhead costs. Research and development costs are expensed as incurred.
The Company records accruals based on estimates of the services received, efforts expended, and amounts owed pursuant to contracts with numerous contract research organizations. In the normal course of business, the Company contracts with third parties to perform various clinical study activities in the ongoing development of potential products. The financial terms of these agreements are subject to negotiation and variation from contract to contract and may result in uneven payment flows. Payments under the contracts depend on factors such as the achievement of certain events and the completion of portions of the clinical study or similar conditions. The objective of the Company’s accrual policy is to match the recording of expenses in its financial statements to the actual services received and efforts expended. As such, expense accruals related to clinical studies are recognized based on the Company’s estimate of the degree of completion of the event or events specified in the specific clinical study.
The Company records nonrefundable advance payments it makes for future research and development activities as prepaid expenses. Prepaid expenses are recognized as expense in the Condensed Consolidated Statements of Operations as the Company receives the related goods or services.
Research and development costs that are reimbursed under a cost-sharing arrangement are reflected as a reduction of research and development expense.
Recently Issued Accounting Pronouncements
Fair Value Measurements: In June 2022, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2022-03 “Fair Value Measurements (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions.” These amendments clarify that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. This guidance is effective for public business entities for fiscal years, including interim periods within those fiscal years, beginning after December 15, 2023. Early adoption is permitted. The Company has assessed ASU 2022-03 and early adopted the guidance during the second quarter of 2022. The adoption did not have a material impact on the Company's Condensed Consolidated Financial Statements.
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.22.2.2
Collaboration Agreements
 9 Months Ended
Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Collaboration Agreements Collaboration Agreements
G42 Purchase Agreement and Cogna Collaborative and License Agreement
The Company and G42 Investments AI Holding RSC Ltd, a private limited company (“G42 Investments”), entered into a Common Stock Purchase Agreement (the “G42 Purchase Agreement”), pursuant to which the Company sold to G42 Investments 10,386,274 shares of the Company’s Class A common stock, par value $0.01 per share (the “G42 Common Stock) at a price per share of approximately $2.41, for an aggregate purchase price of $25.0 million, which was paid (i) $12.5 million in cash at the closing and (ii) $12.5 million in the form of a promissory note of G42 Investments to be paid at the one-year anniversary of the execution of the G42 Purchase Agreement. As part of the G42 Purchase Agreement, G42 Investments put forward a director as appointee and the Company’s board of directors approved appointing the new director to the Company’s board.
G42 Investments has agreed to certain transfer restrictions (including restrictions on short sales or similar transactions) and restrictions on further acquisitions of shares, in each case subject to specified exceptions. Following the expiration of a lock up period, from the period May 31, 2022 until December 31, 2024 (or if earlier, the date of receipt of U.S. Food and Drug Administration (“FDA”) approval in the U.S. for TTP399 (the “FDA Approval”) of TTP399), the Company has granted to G42 Investments certain shelf and piggyback registration rights with respect to those shares of Class A common stock issued to G42 Investments pursuant to the G42 Purchase Agreement, including the ability to conduct an underwritten offering to resell such shares under certain circumstances. The registration rights include customary cooperation, cut-back, expense reimbursement, and indemnification provisions.
Contemporaneously with the G42 Purchase Agreement, effective on May 31, 2022, the Company entered into a collaboration and license agreement (the “Cogna Agreement”) with Cogna Technology Solutions LLC, an affiliate of G42 Investments (“Cogna”) (“Collaboration Partner”), which requires Cogna to work with the Company in performing Phase 3 clinical trials for the Company’s TTP399 compound (the “Licensed Product”) as well as jointly creating a global development plan to develop, market, and commercialize TTP399 in certain countries in the Middle East, Africa, and Central Asia (the “Partner Territory”). Under the terms of the Cogna Agreement, Cogna will obtain rights to the Company’s license of TTP399, for purposes of performing Phase 3 clinical trials in the Partner Territory, but will not have access to the various intellectual property (“IP”) related to the license and TTP399. Specifically, the Company will share various protocols with Cogna related to conducting the clinical trials and will provide the patient dosages and placebo of TTP399 needed to conduct
the trials. Separately, the Company will conduct its Phase 3 clinical trials for TTP399 in the U.S. at its own cost that similarly will not be reimbursed. The results of each party’s Phase 3 clinical trials will be combined by the Company to seek FDA approval in the U.S. for TTP399.

Under the Cogna Agreement, Cogna has the right to develop and commercialize the Licensed Product in the Partner Territory at its own cost once restrictions on the use of the IP have been lifted by the Company. The Cogna Agreement determined which specific countries in the Partner Territory that Cogna may pursue development and commercialization and provides the Company with the ability to determine when Cogna can benefit from this IP through the powers granted to the Company to approve the global development plan. Further, the Company may supply at cost, or Cogna may manufacture, TTP399 for commercial sale under terms to be agreed upon by the parties at a later date.
The G42 Purchase Agreement also provides for, following the receipt of FDA approval of the Licensed Product, at the option of G42 Investments, either (a) the issuance of the Company’s Class A common stock (the “Milestone Shares”) having an aggregate value equal to $30.0 million or (b) the payment by the Company of $30.0 million in cash (the “Milestone Cash Payment”). The issuance of the Milestone Shares or the payment of the Milestone Cash Payment, as applicable, are conditioned upon receipt of the FDA Approval and subject to certain limitations and conditions set forth in the G42 Purchase Agreement. There can be no assurance that the FDA Approval will be granted or as to the timing thereof.
Once commercialization takes place in the Partner Territories, the Company will receive royalties of 8% from Cogna on the sale of the Licensed Product for ten years after the first commercial sale of the Licensed Product.
Common stock is generally recorded at fair value at the date of issuance. In determining the fair value of the Class A common stock issued to G42 Investments, the Company considered the closing price of the common stock on the effective date. The Company did not make an adjustment to the fair value for sale restrictions on the stock in accordance with guidance recently adopted in ASU 2022-03. See the “Recently Issued Accounting Guidance” in this 10-Q for details of the ASU. Accordingly, the Company determined that cash consideration of $5.7 million should be recorded as fair value of the Class A common stock at the effective date, utilizing the Class A common stock closing price of $0.55 at the effective date.
A premium was paid on the Class A common stock by G42 Investments of $18.7 million, net of a note receivable discount of $0.6 million. This premium is determined to be the transaction price for all remaining obligations under the agreements, which will be accounted for under ASC 808 or ASC 606 based on determination of the unit of account.
The Company determined that certain commitments under the agreements are in the scope of ASC 808 as both the Company and Cogna are active participants in the clinical trials of the Licensed Product, and both are exposed to significant risks and rewards based on the success of the clinical trials and subsequent FDA approval. Cogna is determined to be a vendor of the Company during the clinical trial phase, working on the Company’s behalf to complete R&D activities, and not in a customer capacity. The Company accounted for the commitments related to the clinical trials, which includes transfer of trial protocols, supply of clinical trial dosages, and collaboration on the joint development committee (“JDC”) as an ASC 808 unit of account, applying the recognition and measurement principles of ASC 606 by analogy. The Company will recognize collaboration revenue for its development activities under ASC 808 over time based on the estimated period of performance.
By applying the principals in ASC 606 by analogy, the Company identified the performance obligation and considered the timing of satisfaction of the obligation to account for the pattern of revenue recognition. In order to recognize collaboration revenue, generally, the Company would begin satisfying its performance obligation and Cogna would need to be able to use and benefit from delivery of the assets or services. The performance obligation under the agreements that fall within the 808 unit of account are concentrated in the Phase 3 clinical trials. As of September 30, 2022, the Phase 3 clinical trials had not commenced. Accordingly, no collaboration revenue was recognized for the ASC 808 unit of account during the three and nine months ended September 30, 2022.
The Company identified certain commitments that are in the scope of ASC 606 as Cogna’s relationship is that of a customer for these commitments. The significant performance obligations that are in the scope of ASC 606 are (1) the development, commercialization and manufacturing license of the IP once restrictions on the use of the IP have been lifted by the Company and (2) a potential material right to a commercial supply agreement. The Company will recognize revenue from the development, commercial and manufacturing license at a point in time when the Company releases the restrictions on the use of the IP, which is expected to be after the Licensed Product is approved by the FDA. The Company will recognize revenue from the material right related to Cogna’s ability to purchase the commercial supply at cost as Cogna purchases the commercial supply from the Company, which will occur after the completion of the initial clinical trials (if Cogna decides to purchase the clinical supply from the Company). As a result, the Company has not recognized any revenue under the ASC 606 unit of account during the three and nine months ended September 30, 2022.
As of September 30, 2022, the Company has recognized the cash and a non-interest bearing promissory note receivable of with a principal balance of $12.5 million. The promissory note receivable was classified and accounted for under ASC 310 and was initially measured at its fair value of $11.9 million and will be subsequently remeasured at its amortized cost through its maturity date. The Company also recorded the $18.7 million as deferred revenue in the Consolidated Balance Sheets, as none of the underlying performance obligations had been satisfied as of and for the three and nine months ended September 30, 2022.
Reneo License Agreement
The Company is party to a license agreement with Reneo Pharmaceuticals, Inc. (“Reneo”) (the “Reneo License Agreement”), under which Reneo obtained an exclusive, worldwide, sublicensable license to develop and commercialize the Company’s peroxisome proliferation activated receptor delta (PPAR-δ) agonist program, including the compound HPP593, for therapeutic, prophylactic or diagnostic application in humans.
The Company has fully allocated the transaction price to the license and the technology transfer services, which represents a single combined performance obligation because they were not capable of being distinct on their own. The revenue related to this performance obligation was recognized on a straight-line basis over the technology transfer service period.
The revenue related to this performance obligation has been fully recognized and no revenue related to this performance obligation was recognized for the three and nine months ended September 30, 2022. There have been no adjustments to the transaction price for the performance obligations under the Reneo License Agreement during the three and nine months ended September 30, 2022. In the third quarter of 2021, the transaction price for this performance obligation was increased by $2.0 million due to the satisfaction of a development milestone under the Reneo License Agreement. This amount was fully recognized as revenue during the three and nine months ended September 30, 2021, as the related performance obligation was fully satisfied.
Huadong License Agreement
The Company is party to a license agreement with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (“Huadong”) (the “Huadong License Agreement”), under which Huadong obtained an exclusive and sublicensable license to develop and commercialize the Company’s glucagon-like peptide-1 receptor agonist (“GLP-1r”) program, including the compound TTP273, for therapeutic uses in humans or animals, in China and certain other pacific rim countries, including Australia and South Korea (collectively, the “Huadong License Territory”). Additionally, under the Huadong License Agreement, the Company obtained a non-exclusive, sublicensable, royalty-free license to develop and commercialize certain Huadong patent rights and know-how related to the Company’s GLP-1r program for therapeutic uses in humans or animals outside of the Huadong License Territory.
On January 14, 2021, the Company entered into the first amendment to the Huadong License Agreement ( the “First Huadong Amendment”) which eliminated the Company’s obligation to sponsor a multi-region clinical trial (the “Phase 2 MRCT”), and corresponding obligation to contribute up to $3.0 million in support of such trial. The amendment also reduced the total potential development and regulatory milestone payments by $3.0 million.
Prior to the First Amendment, the Company had allocated a portion of the transaction price to the obligation to sponsor and conduct a portion of the Phase 2 MRCT. Upon the removal of this performance obligation, the Company evaluated the impact of the modification under the provisions of ASC Topic 606 and performed a reallocation of the transaction price among the remaining performance obligations. This resulted in the recognition of approximately $1.0 million of revenue on a cumulative catch-up basis during the nine months ended September 30, 2021. The majority of the transaction price originally allocated to the Phase 2 MRCT performance obligation was reallocated to the license and technology transfer services combined performance obligation discussed below, which had already been completed. The reallocation of the purchase price in connection with the First Huadong Amendment was made based on the relative estimated selling prices of the remaining performance obligations.
The significant performance obligations under the Huadong License Agreement, as amended, were determined to be (i) the exclusive license to develop and commercialize the Company’s GLP-1r program, (ii) technology transfer services related to the chemistry and manufacturing know-how for a defined period after the effective date, (iii) the Company’s obligation to participate on a joint development committee (the “JDC”), and (iv) other obligations considered to be de minimis in nature.
The Company has determined that the license and technology transfer services related to the chemistry and manufacturing know-how represent a combined performance obligation because they were not capable of being distinct on
their own. The Company also determined that there was no discernible pattern in which the technology transfer services would be provided during the transfer service period. As such, the Company recognized the revenue related to this combined performance obligation using the straight-line method over the transfer service period. This combined performance obligation was considered complete as of September 30, 2021. The Company recognized $1.0 million of revenue related to this combined performance obligation during the nine months ended September 30, 2021. During the nine months ended September 30, 2022, the transaction price for this performance obligation was increased by $2.0 million due to the satisfaction of a development milestone under the Huadong License Agreement, as amended. This amount was fully recognized as revenue during the nine months ended September 30, 2022, as the related performance obligation was fully satisfied.
A portion of the transaction price allocated to the obligation to participate in the JDC to oversee the development of products and the Phase 2 MRCT in accordance with the development plan remained deferred as of September 30, 2022, and revenue will be recognized using the proportional performance model over the period of the Company’s participation on the JDC. The unrecognized amount of the transaction price allocated to this performance obligation as of September 30, 2022, was de minimis. An immaterial amount of revenue for this performance obligation has been recognized during nine months ended September 30, 2022, and 2021.
Newsoara License Agreement-
The Company is party to a license agreement with Newsoara Biopharma Co., Ltd., (“Newsoara”) (the “Newsoara License Agreement”) under which Newsoara obtained an exclusive and sublicensable license to develop and commercialize the Company’s phosphodiesterase type 4 inhibitors (“PDE4”) program, including the compound HPP737, in China, Hong Kong, Macau, Taiwan and other pacific rim countries (collectively, the “Newsoara License Territory”). Additionally, under the Newsoara License Agreement, the Company obtained a non-exclusive, sublicensable, royalty-free license to develop and commercialize certain Newsoara patent rights and know-how related to the Company’s PDE4 program for therapeutic uses in humans outside of the Newsoara License Territory.
The Company has fully allocated the transaction price to the license and the technology transfer services which represents a single performance obligation because they were not capable of being distinct on their own. The Company recognized revenue for this performance obligation using the straight-line method over the transfer service period. The revenue for this performance obligation has been fully recognized as of September 30, 2022. In the third quarter of 2021, the transaction price for this performance obligation was increased by $1.0 million due to the satisfaction of a development milestone under the Newsoara License Agreement. This amount was fully recognized as revenue during the three and nine months ended September 30, 2021, as the related performance obligation was fully satisfied. No revenue related to this performance obligation was recognized and there have been no changes to the transaction price during the three and nine months ended September 30, 2022.
JDRF Agreement
In August 2017, the Company entered into a research and collaboration agreement with JDRF International (the “JDRF Agreement”) to support the funding of the Simplici-T1 Study, a Phase 2 study to explore the effects of TTP399 in patients with type 1 diabetes. The JDRF Agreement was amended in June 2021 to provide additional funding for the Company’s mechanistic study exploring the effects of TTP399 on ketone body formation during a period of insulin withdrawal in people with type 1 diabetes. Consistent with the terms of the JDRF Agreement, JDRF provided research funding of $3.4 million based on the achievement of research and development milestones, with the total funding provided by JDRF not to exceed approximately one-half of the total cost of the project. Additionally, the Company has the obligation to make certain milestone payments to JDRF upon the commercialization, licensing, sale or transfer of TTP399 as a treatment for type 1 diabetes.
Payments that the Company receives from JDRF under this agreement were recorded as restricted cash and current liabilities and recognized as an offset to research and development expense, based on the progress of the project, and only to the extent that the restricted cash is utilized to fund such development activities. As of September 30, 2022, the Company had received funding under this agreement of $3.4 million. Research and development costs have been offset by the $3.4 million of cash received over the course of this agreement.
Contract Liabilities
Contract liabilities related to the Company’s collaboration agreements consisted of the following (in thousands):
September 30, 2022December 31, 2021
Current portion of contract liabilities$26 $35 
Contract liabilities, net of current portion18,669 — 
Total contract liabilities$18,695 $35 
Changes in short-term and long-term contract liabilities for the nine months ended September 30, 2022, were as follows:
Contract Liabilities
Balance on January 1, 2022$35 
Reclassification of the beginning contract liabilities to revenue, as the result of performance obligations satisfied(9)
Consideration received in advance and not recognized as revenue18,669 
Balance on September 30, 2022$18,695 
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.22.2.2
Share-Based Compensation
 9 Months Ended
Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]  
Share-Based Compensation Share-Based Compensation
The Company has issued non-qualified stock option awards to management, other key employees, consultants, and non-employee directors. These option awards generally vest ratably over a three-year period and the option awards expire after a term of ten years from the date of grant. As of September 30, 2022, the Company had total unrecognized stock-based compensation expense for its outstanding stock option awards of approximately $2.6 million, which is expected to be recognized over a weighted average period of 2.7 years. The weighted average grant date fair value of options granted during the nine months ended September 30, 2022, and 2021 was $0.68 and $2.21 per option, respectively. The aggregate intrinsic value of the in-the-money awards outstanding at September 30, 2022, was de minimis.
On February 27, 2022, Ms. Deepa Prasad notified the Board of Directors (the “Board”) of the Company of her decision to resign from her positions as Chief Executive Officer, President, and Board member, effective as of March 29, 2022, and served in these roles through March 29, 2022 (the “Effective Date”). Ms. Prasad agreed to serve as a Strategic Advisor to the Company for six months after the Effective Date. Ms. Prasad will retain 624,659 of the outstanding options previously granted to her, which will vest at the end of the 15-month period following the Effective Date. As a result of the separation agreement, these options were modified to accelerate vesting at the Effective Date. These options will remain exercisable for the original ten-year period and the remaining 1,873,976 of her options were cancelled. The additional stock compensation expense for the modification during the nine months ended September 30, 2022, was de minimis.
The following table summarizes the activity related to the stock option awards for the nine months ended September 30, 2022:
Number of Shares Weighted
Average Exercise Price
Awards outstanding at December 31, 20217,056,035 $3.19 
Granted4,047,333 0.78 
Forfeited(3,384,424)2.37 
Awards outstanding at September 30, 20227,718,944 $2.28 
Options exercisable at September 30, 20222,563,810 $4.75 
Weighted average remaining contractual term6.3 Years
Options vested and expected to vest at September 30, 20226,664,874 $2.49 
Weighted average remaining contractual term8.2 Years
Compensation expense related to the grants of stock options is included in research and development and general and administrative expense as follows (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Research and development$109 $186 $289 $542 
General and administrative229 288 692 820 
Total share-based compensation expense$338 $474 $981 $1,362 
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.22.2.2
Investments
 9 Months Ended
Sep. 30, 2022
Investments, Debt and Equity Securities [Abstract]  
Investments Investments
In connection with the Reneo License Agreement and the Anteris License Agreement, the Company has received equity ownership interests of less than 20% of the voting equity of the investee. Further, the Company does not have the ability to exercise significant influence over the investees. The investments are classified as long-term investments in the Company’s Consolidated Balance Sheets.
Reneo completed its initial public offering in April 2021. Prior to Reneo becoming a publicly traded company, the Company’s investment in Reneo did not have a readily determinable fair value and was measured at cost less impairment, adjusted for any changes in observable prices, under the measurement alternative. Subsequent to Reneo’s initial public offering, the Company’s investment in Reneo is considered to have a readily determinable fair value and, as such, is adjusted to its fair value each period with changes in fair value recognized as a component of net loss.
The Company’s investment in Anteris does not have a readily determinable fair value and is measured at cost less impairment, adjusted for any changes in observable prices.
The Company’s investments consist of the following:
September 30, 2022December 31, 2021
Equity investment with readily determinable fair value:
Reneo common stock$1,930 $4,928 
Equity investment without readily determinable fair values assessed under the measurement alternative:
Anteris preferred stock4,245 4,245 
Total$6,175 $9,173 
No adjustments have been made to the value of the Company’s investment in Anteris since its initial measurement either due to impairment or based on observable price changes. The Company recognized an unrealized gain on its investment in Reneo of $0.4 million and an unrealized loss of $3.0 million for the three and nine months ended September 30, 2022, respectively. The Company recognized an unrealized loss on its investment in Reneo of $1.1 million and an unrealized gain of $1.8 million for the three months and nine months ended September 30, 2021, respectively. These adjustments were recognized as a component of other income/(expense) in the Company’s Condensed Consolidated Statements of Operations.
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.22.2.2
Commitments and Contingencies
 9 Months Ended
Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
Legal Matters
From time to time, the Company is involved in various legal proceedings arising in the normal course of business. If a specific contingent liability is determined to be probable and can be reasonably estimated, the Company accrues and discloses the amount. The Company is not currently a party to any material legal proceedings.
Novo Nordisk
In February 2007, the Company entered into an Agreement Concerning Glucokinase Activator Project with Novo Nordisk A/S (the “Novo License Agreement”) whereby the Company obtained an exclusive, worldwide, sublicensable license under certain Novo Nordisk intellectual property rights to discover, develop, manufacture, have manufactured, use and commercialize products for the prevention, treatment, control, mitigation or palliation of human or animal diseases or conditions. As part of this license grant, the Company obtained certain worldwide rights to Novo Nordisk’s GKA program, including rights to preclinical and clinical compounds such as TTP399. This agreement was amended in May 2019 to create
milestone payments applicable to certain specific and non-specific areas of therapeutic use. Under the terms of the amended Novo License Agreement, the Company has potential developmental and regulatory milestone payments totaling up to $9.0 million for approval of a product for the treatment of type 1 diabetes, $50.5 million for approval of a product for the treatment of type 2 diabetes, or $115.0 million for approval of a product in any other indication. The Company may also be obligated to pay an additional $75.0 million in potential sales-based milestones, as well as royalty payments, at mid-single digit royalty rates, based on tiered sales of commercialized licensed products. During the fourth quarter of 2021, the Company made a payment of $2.0 million related to the satisfaction of the milestone to complete the phase 2 trials for TTP399 under this agreement.
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.22.2.2
Leases
 9 Months Ended
Sep. 30, 2022
Leases [Abstract]  
Leases Leases
The Company leases office space for its headquarters location under an operating lease. This lease commenced in November 2019 after the completion of certain tenant improvements made by the lessor. The lease includes an option to renew for a five-year term as well as an option to terminate after three years, neither of which have been recognized as part of its related right of use assets or lease liabilities as their election was not considered reasonably certain. The Company has notified the lessor that it intends to exercise the early termination option and is negotiating an amendment to the lease. Further, this lease does not include any material residual value guarantee or restrictive covenants.
At each of September 30, 2022, and December 31, 2021, the weighted average incremental borrowing rate for the operating leases held by the Company was 13.1%. At September 30, 2022, and December 31, 2021, the weighted average remaining lease terms for the operating leases held by the Company were 2.3 years and 3.1 years, respectively.
Maturities of lease liabilities for the Company’s operating leases as of September 30, 2022, were as follows (in thousands):
2022 (remaining three months)$65 
2023268 
2024275 
202523 
2026— 
Thereafter— 
Total lease payments631 
Less: imputed interest(90)
Present value of lease liabilities$541 
Operating lease cost and the related operating cash flows for the nine months ended September 30, 2022, and 2021 were immaterial amounts.
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.22.2.2
Redeemable Noncontrolling Interest
 9 Months Ended
Sep. 30, 2022
Noncontrolling Interest [Abstract]  
Redeemable Noncontrolling Interest Redeemable Noncontrolling Interest
The Company is subject to the Exchange Agreement with respect to the vTv Units representing the 22.1% noncontrolling interest in vTv LLC outstanding as of September 30, 2022 (see Note 9). The Exchange Agreement requires the surrender of an equal number of vTv Units and Class B common stock for (i) shares of Class A common stock on a one-for-one basis or (ii) cash (based on the fair market value of the Class A common stock as determined pursuant to the Exchange Agreement), at the Company’s option (as the managing member of vTv LLC), subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications. The exchange value is determined based on a 20-day volume weighted average price of the Class A common stock as defined in the Exchange Agreement, subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications.
The redeemable noncontrolling interest is recognized at the higher of (1) its initial fair value plus accumulated earnings/losses associated with the noncontrolling interest or (2) the redemption value as of the balance sheet date. At September 30, 2022, and December 31, 2021, the redeemable noncontrolling interest was recorded based on the redemption value as of the balance sheet date of $24.2 million and $25.0 million, respectively.
Changes in the Company’s ownership interest in vTv LLC while the Company retains its controlling interest in vTv LLC are accounted for as equity transactions, and the Company is required to adjust noncontrolling interest and equity for
such changes. The following is a summary of net income attributable to vTv Therapeutics Inc. and transfers to noncontrolling interest:
For the Three Months Ended September 30,For the Nine Months Ended September 30,
2022202120222021
Net loss attributable to vTv Therapeutics Inc. common shareholders$(4,261)$(1,087)$(14,419)$(5,936)
(Increase) in vTv Therapeutics Inc. accumulated deficit for purchase of LLC Units as a result of common stock issuances(1,174)(2,773)(103)(5,298)
Change from net loss attributable to vTv Therapeutics Inc. common shareholders and transfers to noncontrolling interest$(5,435)$(3,860)$(14,522)$(11,234)
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stockholders' Deficit
 9 Months Ended
Sep. 30, 2022
Equity [Abstract]  
Stockholders' Deficit Stockholders’ Deficit
Amendment to Certificate of Incorporation
On May 4, 2021, the Company filed an amendment to its Amended and Restated Certificate of Incorporation (the “Charter Amendment”) to increase the number of shares of Class A common stock that the Company is authorized to issue from 100,000,000 shares of Class A common stock to 200,000,000 shares of Class A common stock, representing an increase of 100,000,000 shares of authorized Class A common stock, with a corresponding increase in the total authorized common stock, which includes Class A common stock and Class B common stock, from 200,000,000 to 300,000,000, and a corresponding increase in the total authorized capital stock, which includes common stock and preferred stock, from 250,000,000 shares to 350,000,000 shares.
G42 Investments Transaction
On May 31, 2022, the Company and G42 Investments entered in to the G42 Purchase Agreement (see Note 3), pursuant to which the Company agreed to sell to G42 Investments 10,386,274 shares of the Company's Class A common stock, par value $0.01 per share at a price per share of approximately $2.41, for an aggregate purchase price of $25.0 million, consisting of (i) $12.5 million in cash at the closing of the transaction and (ii) $12.5 million in the form of a promissory note of G42 Investments to be paid at the one-year anniversary of the execution of the G42 Purchase Agreement.
CinPax and CinRx Transaction
On July 22, 2022 (the “Transaction Date”), the Company entered into the CinRx Purchase Agreement with CinPax and CinRx, pursuant to which the Company agreed to sell to CinPax 4,154,549 shares of the Company’s Class A common stock, par value $0.01 per share (the “Common Stock” and such shares, the “Closing Shares”) at a price per share of approximately $2.41, for an aggregate purchase price of $10.0 million, which was paid (i) $6.0 million in cash at the closing of the transaction and (ii) $4.0 million in the form of a non-interest-bearing promissory note with CinPax to be paid at the four-month anniversary of the execution of the CinRx Purchase Agreement. The promissory note receivable was classified and accounted for under ASC 505 as contra-equity. The CinRx Purchase Agreement provides CinPax the right to put forward a director to be approved to sit on vTv’s Board of Directors and a board observer, which was subsequently approved by the Company’s board.
Common stock is generally recorded at fair value at the date of issuance. In determining the fair value of the Class A common stock issued to CinPax, the Company considered the closing price of the common stock on the Transaction Date. The Company did not make an adjustment to the fair value for sale restrictions on the stock in accordance with guidance recently adopted in ASU 2022-03. See the “Recently Issued Accounting Guidance” in this 10-Q for details of the ASU. Accordingly, the Company determined that cash consideration of $3.0 million should be recorded as fair value of the Class A common stock at the effective date, utilizing the Class A common stock closing price of $0.72 at the effective date.
The CinRx Purchase Agreement also provides CinRx warrants to purchase up to 1,200,000 shares of Common Stock at an initial exercise of price of approximately $0.72 per share (the “CinRx Warrants”). The CinRx Warrants were initially measured at fair value of $0.4 million using the Black Scholes option model at the time of issuance and will be recorded in Warrant liability related party in the Condensed Consolidated Balance Sheets and will be subsequently remeasured at fair value through earnings on a recurring basis. (see Note 13)
The CinRx Warrants will become exercisable by CinRx only if (i) the Company receives approval from the U.S. Food and Drug Administration (“FDA Approval”) to market and distribute the pharmaceutical product containing the Company’s proprietary candidate, TTP399 (the “Product”), or (ii) the Company is acquired by a third party, sells all or substantially all of its assets related to the Product to a third party or grants a third party an exclusive license to develop, commercialize and manufacture the Product in the United States (an “Exit Event”). If neither of these events happen within five years of the date of the issuance of the CinRx Warrants, the CinRx Warrants will expire and not be exercisable by CinRx. The exercise price of the CinRx Warrants and the number of shares issuable upon exercise of the CinRx Warrants are subject to adjustments in accordance with the terms of the CinRx Warrants.
Additionally, in conjunction with the CinRx Purchase Agreement the Company and CinRx entered into a Master Service Agreement (“CinRx MSA”) whereby CinRx provides the Company with consulting, pre-clinical and clinical trial services, as enumerated in project proposals negotiated between the Company and CinRx from time to time. (see Note 10)
The Company did not identify any other promises in the CinRx Purchase Agreement (aside from the issuance of common shares and the CinRx Warrants) and determined since there is no value ascribed to the CinRx MSA, the right to appoint a member and observer to the board of directors, that the remaining unallocated amount meets the definition of contributed equity and represents the amount in excess of par.
ATM Offering
In April 2020, the Company entered into the Sales Agreement with Cantor Fitzgerald as the sales agent, pursuant to which the Company may offer and sell, from time to time, through Cantor, shares of its Class A common stock, par value $0.01 per share, having an aggregate offering price of up to $13.0 million by any method deemed to be an “at the market offering” as defined in Rule 415(a)(4) under the Securities Act (the “ATM Offering”). The shares are offered and sold pursuant to the Company’s shelf registration statement on Form S-3. In no event will the Company sell Class A common stock under this registration statement with a value exceeding more than one-third of the “public float” (the market value of our Class A common stock and any other equity securities that we may issue in the future that are held by non-affiliates) in any 12-calendar month period so long as our public float remains below $75 million.
On January 14, 2021, and June 25, 2021, the Company filed a prospectus supplement in connection with the ATM Offering to increase the size of the at-the-market offering pursuant to which the Company may offer and sell, from time to time, through or to Cantor, as sales agent or principal, shares of the Company’s Class A common stock, by an aggregate offering price of $5.5 million and $50.0 million, respectively.
During the three and nine months ended September 30, 2021, the Company sold 8,457,546 shares of its Class A common stock under the ATM Offering for net proceeds of $17.0 million.
During the three and nine months ended September 30, 2022, the Company did not sell any shares under the ATM Offering.
Lincoln Park Capital Transaction
On November 24, 2020, the Company entered into the LPC Purchase Agreement and a registration rights agreement (the “Registration Rights Agreement”), pursuant to which the Company has the right to sell to Lincoln Park shares of the Company’s Class A common stock having an aggregate value of up to $47.0 million, subject to certain limitations and conditions set forth in the LPC Purchase Agreement. The Company will control the timing and amount of any sales of shares to Lincoln Park. pursuant to the LPC Purchase Agreement. During the three and nine months ended September 30, 2022, the Company did not sell any shares under the LPC Purchase Agreement. During the nine months ended September 30, 2021, the Company sold 3,941,726 shares under the LPC Purchase Agreement for total proceeds of $9.1 million.
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.22.2.2
Related-Party Transactions
 9 Months Ended
Sep. 30, 2022
Related Party Transactions [Abstract]  
Related-Party Transactions Related-Party Transactions
MacAndrews & Forbes Incorporated
As of September 30, 2022, subsidiaries and affiliates of MacAndrews & Forbes Incorporated (collectively “MacAndrews”) indirectly controlled 23,084,267 shares of the Company’s Class B common stock and 36,519,212 shares of the Company’s Class A common stock. As a result, MacAndrews’ holdings represent approximately 57.0% of the combined voting power of the Company’s outstanding common stock.
The Company has entered into several agreements with MacAndrews or its affiliates as further detailed below:
Letter Agreements
The Company has previously entered into the Letter Agreements with MacAndrews. Under the terms of the Letter Agreements, during the one year commitment period beginning on the date of each License Agreement, the Company had the right to sell to MacAndrews shares of its Class A common stock at a specified price per share, and MacAndrews had the right (exercisable up to three times) to require the Company to sell to it shares of Class A common stock at the same price. The commitment period of each of the Letter Agreements has now expired. In addition, in connection with and as a commitment fee for the entrance into certain of these Letter Agreements, the Company also issued MacAndrews warrants (the “Letter Agreement Warrants”) to purchase additional shares of the Company’s Class A common stock.
The Letter Agreement Warrants have been recorded as warrant liability, related party within the Company’s Condensed Consolidated Balance Sheets based on their fair value. The issuance of the Letter Agreement Warrants was considered to be a cost of equity recorded as a reduction to additional paid-in capital.
Exchange Agreement
The Company and MacAndrews are party to an exchange agreement (the “Exchange Agreement”) pursuant to which the vTv Units (along with a corresponding number of shares of the Class B common stock) are exchangeable for (i) shares of the Company’s Class A common stock on a one-for-one basis or (ii) cash (based on the fair market value of the Class A common stock as determined pursuant to the Exchange Agreement), at the Company’s option (as the managing member of vTv LLC), subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications. Any decision to require an exchange for cash rather than shares of Class A common stock will ultimately be determined by the entire board of directors of vTv Therapeutics Inc. (the “Board of Directors”). As of September 30, 2022, MacAndrews had not exchanged any shares under the provisions of the Exchange Agreement.
Tax Receivable Agreement
The Company and MacAndrews are party to a tax receivable agreement (the “Tax Receivable Agreement”), which provides for the payment by the Company to M&F TTP Holdings Two LLC (“M&F”), as successor in interest to vTv Therapeutics Holdings, LLC (“vTv Therapeutics Holdings”), and M&F TTP Holdings LLC (or certain of its transferees or other assignees) of 85% of the amount of cash savings, if any, in U.S. federal, state and local income tax or franchise tax that the Company actually realizes (or, in some circumstances, the Company is deemed to realize) as a result of (a) the exchange of Class B commons stock, together with the corresponding number of vTv Units, for shares of the Company’s Class A common stock (or for cash), (b) tax benefits related to imputed interest deemed to be paid by the Company as a result of the Tax Receivable Agreement and (c) certain tax benefits attributable to payments under the Tax Receivable Agreement.
As no shares have been exchanged by MacAndrews pursuant to the Exchange Agreement (discussed above), the Company has not recognized any liability, nor has it made any payments pursuant to the Tax Receivable Agreement as of September 30, 2022.
Investor Rights Agreement
The Company is party to an investor rights agreement with M&F, as successor in interest to vTv Therapeutics Holdings (the “Investor Rights Agreement”). The Investor Rights Agreement provides M&F with certain demand, shelf, and piggyback registration rights with respect to its shares of Class A common stock and also provides M&F with certain governance rights, depending on the size of its holdings of Class A common stock. Under the Investor Rights Agreement, M&F was initially entitled to nominate a majority of the members of the Board of Directors and designate the members of the committees of the Board of Directors.
CinRx Pharma, LLC
Master Services Agreement
On July 22, 2022, the Company entered into a Master Services Agreement with CinRx Pharma, LLC (“CinRx”) (the “CinRx MSA”). Under the CinRx MSA, CinRx provides the Company with consulting, pre-clinical and clinical trial services, as enumerated in project proposals negotiated between the Company and CinRx from time to time. As of October 10, 2022, the Company has agreed to pay CinRx fees of up to $0.2 million per month until approximately December 2024 in respect of ongoing agreed project proposals under the CinRx MSA, plus out-of-pocket expenses incurred by CinRx on the Company’s behalf. Dr. Jonathan Isaacsohn, who was appointed as chair of the Company’s board of directors on August 9, 2022, is the President and Chief Executive Officer of CinRx. CinPax, LLC, a subsidiary of CinRx, currently holds 4,154,549 shares of the Company’s Class A Common Stock.
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.22.2.2
Income Taxes
 9 Months Ended
Sep. 30, 2022
Income Tax Disclosure [Abstract]  
Income Taxes Income Taxes
The Company is subject to U.S. federal income taxes as well as state taxes. The Company did not record an income tax provision for the three months ended September 30, 2022. The Company’s income tax provision for the nine months ended September 30, 2022, was $0.2 million related to foreign withholding taxes. The Company’s income tax provision for the three and nine months ended September 30, 2021 was $0.1 million related to foreign withholding taxes.
Management has evaluated the positive and negative evidence surrounding the realization of its deferred tax assets, including the Company’s history of losses, and under the applicable accounting standards determined that it is more-likely-than-not that the deferred tax assets will not be realized. The difference between the effective tax rate of the Company and the U.S. statutory tax rate of 21% on September 30, 2022, is due to the valuation allowance against the Company’s expected net operating losses.
As discussed in Note 10, the Company is party to a tax receivable agreement with a related party which provides for the payment by the Company to M&F (or certain of its transferees or other assignees) of 85% of the amount of cash savings, if any, in U.S. federal, state and local income tax or franchise tax that the Company actually realizes (or, in some circumstances, the Company is deemed to realize) as a result of certain transactions. As no transactions have occurred which would trigger a liability under this agreement, the Company has not recognized any liability related to this agreement as of September 30, 2022.
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.22.2.2
Net Loss per Share
 9 Months Ended
Sep. 30, 2022
Earnings Per Share [Abstract]  
Net Loss per Share Net Loss per Share
Basic loss per share is computed by dividing net loss attributable to vTv Therapeutics Inc. by the weighted average number of shares of Class A common stock outstanding during the period. Diluted loss per share is computed giving effect to all potentially dilutive shares. Diluted loss per share for all periods presented is the same as basic loss per share as the inclusion of potentially issuable shares would be antidilutive.
A reconciliation of the numerator and denominator used in the calculation of basic and diluted net loss per share of Class A common stock is as follows (in thousands, except share and per share amounts):
For the Three Months Ended September 30,For the Nine Months Ended September 30,
2022202120222021
Numerator:
Net loss$(5,468)$(1,465)$(18,983)$(8,248)
Less: Net loss attributable to noncontrolling interests(1,207)(378)(4,564)(2,312)
Net loss attributable to common shareholders of vTv Therapeutics Inc., basic and diluted(4,261)(1,087)(14,419)(5,936)
Denominator:
Weighted average vTv Therapeutics Inc. Class A common stock, basic and diluted80,490,121 61,073,280 72,649,531 58,737,170 
Net loss per share of vTv Therapeutics Inc. Class A common stock, basic and diluted$(0.05)$(0.02)$(0.20)$(0.10)
Potentially dilutive securities not included in the calculation of diluted net loss per share are as follows:
September 30, 2022September 30, 2021
Class B common stock (1)
23,093,860 23,093,860 
Common stock options granted under the Plan7,718,944 4,474,403 
Common stock warrants3,214,503 2,014,503 
Total34,027,307 29,582,766 
_____________________________
(1)Shares of Class B common stock do not share in the Company’s earnings and are not participating securities. Accordingly, separate presentation of loss per share of Class B common stock under the two-class method has not been provided. Each share of Class B common stock (together with a corresponding vTv Unit) is exchangeable for one share of Class A common stock.
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.22.2.2
Fair Value of Financial Instruments
 9 Months Ended
Sep. 30, 2022
Fair Value Disclosures [Abstract]  
Fair Value of Financial Instruments Fair Value of Financial Instruments
The carrying amount of certain of the Company’s financial instruments, including cash and cash equivalents, net accounts receivable, note receivable, accounts payable, and other accrued liabilities, approximate fair value due to their short-term nature.
Assets and Liabilities Measured at Fair Value on a Recurring Basis
The Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level in which to classify them for each reporting period. This determination requires significant judgments. The Company determined that the promissory note receivable was level 2 and the fair value measurement was based on the market yield curves. The following table summarizes the conclusions reached regarding fair value measurements as of September 30, 2022, and December 31, 2021 (in thousands):
Balance at September 30, 2022Quoted Prices in Active
Markets for Identical Assets
(Level 1)		Significant Other Observable
Inputs
(Level 2)		Significant Unobservable Inputs
(Level 3)
Assets:
Equity securities with readily determinable fair value$1,930 $1,930 $— $— 
Total$1,930 $1,930 $— $— 
Liabilities:
Warrant liability, related party (1)
$1,409 $— $— $1,409 
Total$1,409 $— $— $1,409 
Balance at December 31, 2021Quoted Prices in Active
Markets for Identical Assets
(Level 1)		Significant Other Observable
Inputs
(Level 2)		Significant Unobservable Inputs
(Level 3)
Assets:
Equity securities with readily determinable fair value$4,928 $4,928 $— $— 
Total$4,928 $4,928 $— $— 
Liabilities:
Warrant liability, related party (1)
$1,262 $— $— $1,262 
Total$1,262 $— $— $1,262 
_____________________________
(1)Fair value determined using the Black-Scholes option pricing model. Expected volatility is based on the historical volatility of the Company’s common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation.
Changes in Level 3 instruments for the nine months ended September 30,
Balance at January 1Net Change in
fair value included in
earnings		Purchases /
Issuance		Sales /
Repurchases		Balance at September 30,
2022
Warrant liability, related party$1,262 $(221)$368 $— $1,409 
Total$1,262 $(221)$368 $— $1,409 
2021
Warrant liability, related party$2,871 $(611)$— $— $2,260 
Total$2,871 $(611)$— $— $2,260 
During the nine months ended September 30, 2021, Reneo completed its initial public offering. As a result, the fair value of the Company’s investment in Reneo’s common stock now has a readily determinable market value and is no longer eligible for the practical expedient for investments without readily determinable fair market values. As such, the Company’s investment in Reneo is adjusted each reporting period to its fair value based on its most recent closing price, which is considered a Level 1 fair value measurement under the fair value hierarchy.
There were no transfers into or out of level 3 instruments and/or between level 1 and level 2 instruments during the three and nine months ended September 30, 2022. Gains and losses recognized due to the change in fair value of the warrant liability, related party are recognized as a component of other (expense) income, related party in the Condensed Consolidated Statements of Operations.
The fair value of the Letter Agreement Warrants was determined using the Black-Scholes option pricing model or option pricing models based on the Company’s current capitalization. Expected volatility is based on the historical volatility of the Company’s common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation. Significant inputs utilized in the valuation of the Letter Agreement Warrants as of September 30, 2022, and December 31, 2021, were:
September 30, 2022December 31, 2021
RangeWeighted AverageRangeWeighted Average
Expected volatility
81.70% - 109.73%
95.51%
82.68% - 142.86%
128.13%
Risk-free interest rate
4.13% - 4.25%
4.20%
0.95% - 1.26%
1.15%
The fair value of the CinRx Warrants was determined using the Black-Scholes option pricing model. Expected volatility is based on the historical volatility of the Company’s common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation. Significant inputs utilized in the valuation of the CinRx Warrants as of September 30, 2022, were:
Expected volatility 85.2 %
Expected life of options in years3.1
Risk-free interest rate4.3 %
Expected dividend yield— %
The weighted average expected volatility and risk-free interest rate was based on the relative fair values of the warrants.
Changes in the unobservable inputs noted above would impact the amount of the liability for the Letter Agreement and CinRx Warrants. Increases (decreases) in the estimates of the Company’s annual volatility would increase (decrease) the liability and an increase (decrease) in the annual risk-free rate would increase (decrease) the liability.
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.22.2.2
Subsequent Events
 9 Months Ended
Sep. 30, 2022
Subsequent Events [Abstract]  
Subsequent Events Subsequent EventsThe Company evaluated subsequent events through November 10, 2022, and determined that there have been no events that have occurred that would require adjustments to our disclosures or the unaudited condensed consolidated financial statements.
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.22.2.2
Summary of Significant Accounting Policies (Policies)
 9 Months Ended
Sep. 30, 2022
Accounting Policies [Abstract]  
Unaudited Interim Financial Information
Unaudited Interim Financial Information
The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying Condensed Consolidated Balance Sheet as of September 30, 2022, Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2022, and 2021, Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders’ Deficit for the three and nine months ended September 30, 2022, and 2021 and Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2022, and 2021 are unaudited. These unaudited financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. These financial statements should be read in conjunction with the audited financial statements and the accompanying notes for the year ended December 31, 2021, contained in the Company’s Annual Report on Form 10-K. The unaudited interim financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company’s financial position as of September 30, 2022, the results of operations for the three and nine months ended September 30, 2022, and 2021 and cash flows for the nine months ended September 30, 2022, and 2021. The December 31, 2021 Condensed Consolidated Balance Sheet included herein was derived from the audited financial statements but does not include all disclosures or notes required by GAAP for complete financial statements.
The financial data and other information disclosed in these notes to the financial statements related to the three and nine months ended September 30, 2022, and 2021 are unaudited. Interim results are not necessarily indicative of results for an entire year.
The Company does not have any components of other comprehensive income recorded within its Condensed Consolidated Financial Statements, and, therefore, does not separately present a statement of comprehensive income in its Condensed Consolidated Financial Statements.
Use of Estimates
Use of Estimates
The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
On an ongoing basis, the Company evaluates its estimates, including those related to the grant date fair value of equity awards, the fair value of warrants to purchase shares of its Class A common stock, the fair value of the Class B common stock, the useful lives of property and equipment, the fair value of derivative liabilities, the fair value of the promissory note
receivable, and the fair value of the Company’s debt, among others. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable, the results of which form the basis for making judgments about the carrying value of assets and liabilities.
Concentration of Credit Risk
Concentration of Credit Risk
Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash on deposit with one financial institution. The balances of these cash accounts frequently exceed insured limits.
One customer represented 100% of the revenue earned during the nine months ended September 30, 2022, two customers represented 100% of the revenue earned during the three months ended September 30, 2021 and three customers represented 100% of the revenue earned during the nine months ended September 30, 2021.
Cash and Cash Equivalents
Cash and Cash Equivalents
The Company considers any highly liquid investments with an original maturity of three months or less to be cash and cash equivalents.
Investments
Investments
Investments in entities in which the Company has no control or significant influence, is not the primary beneficiary, and have a readily determinable fair value are classified as equity investments with readily determinable fair value. The investments are measured at fair value based on a quoted market price per unit in active markets multiplied by the number of units held without consideration of transaction costs (Level 1). Gains and losses are recorded in other income (expense), net on the Consolidated Statements of Operations.
Equity investments without readily determinable fair value include ownership rights that do not provide the Company with control or significant influence and these investments do not have readily determinable fair values. The Company has elected to measure its equity investments without readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment.
Revenue Recognition
Revenue Recognition
The Company uses the revenue recognition guidance established by ASC Topic 606, Revenue From Contracts With Customers (“ASC 606”). When an agreement falls under the scope of other standards, such as ASC Topic 808, Collaborative Arrangements (“ASC 808”), the Company will apply the recognition, measurement, presentation, and disclosure guidance in ASC 606 to the performance obligations in the agreements if those performance obligations are with a customer. Revenue recognized by analogizing to ASC 606, is recorded as collaboration revenue on the statements of operations.
The majority of the Company’s revenue results from its license and collaboration agreements associated with the development of investigational drug products. The Company accounts for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. For each contract meeting these criteria, the Company identifies the performance obligations included within the contract. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. The Company then recognizes revenue under each contract as the related performance obligations are satisfied.
The transaction price under the contract is determined based on the value of the consideration expected to be received in exchange for the transferred assets or services. Development, regulatory and sales milestones included in the Company’s collaboration agreements are considered to be variable consideration. The amount of variable consideration expected to be received is included in the transaction price when it becomes probable that the milestone will be met. For contracts with multiple performance obligations, the contract’s transaction price is allocated to each performance obligation using the Company’s best estimate of the standalone selling price of each distinct good or service in the contract. The primary method used to estimate standalone selling price is the expected cost-plus margin approach.
Research and Development
Research and Development
Major components of research and development costs include cash and share-based compensation, costs of preclinical studies, clinical trials and related clinical manufacturing, costs of drug development, costs of materials and supplies, regulatory and compliance costs, fees paid to consultants and other entities that conduct certain research and development
activities on the Company’s behalf, facilities costs, and overhead costs. Research and development costs are expensed as incurred.
The Company records accruals based on estimates of the services received, efforts expended, and amounts owed pursuant to contracts with numerous contract research organizations. In the normal course of business, the Company contracts with third parties to perform various clinical study activities in the ongoing development of potential products. The financial terms of these agreements are subject to negotiation and variation from contract to contract and may result in uneven payment flows. Payments under the contracts depend on factors such as the achievement of certain events and the completion of portions of the clinical study or similar conditions. The objective of the Company’s accrual policy is to match the recording of expenses in its financial statements to the actual services received and efforts expended. As such, expense accruals related to clinical studies are recognized based on the Company’s estimate of the degree of completion of the event or events specified in the specific clinical study.
The Company records nonrefundable advance payments it makes for future research and development activities as prepaid expenses. Prepaid expenses are recognized as expense in the Condensed Consolidated Statements of Operations as the Company receives the related goods or services.
Research and development costs that are reimbursed under a cost-sharing arrangement are reflected as a reduction of research and development expense.
Recently Issued Accounting Pronouncements
Recently Issued Accounting Pronouncements
Fair Value Measurements: In June 2022, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2022-03 “Fair Value Measurements (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions.” These amendments clarify that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. This guidance is effective for public business entities for fiscal years, including interim periods within those fiscal years, beginning after December 15, 2023. Early adoption is permitted. The Company has assessed ASU 2022-03 and early adopted the guidance during the second quarter of 2022. The adoption did not have a material impact on the Company's Condensed Consolidated Financial Statements.
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.22.2.2
Collaboration Agreements (Tables)
 9 Months Ended
Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Summary of Contract Liabilities Related to Company's Collaboration Agreements
Contract liabilities related to the Company’s collaboration agreements consisted of the following (in thousands):
September 30, 2022December 31, 2021
Current portion of contract liabilities$26 $35 
Contract liabilities, net of current portion18,669 — 
Total contract liabilities$18,695 $35 
Contract with Customer, Contract Asset, Contract Liability, and Receivable Changes Changes in short-term and long-term contract liabilities for the nine months ended September 30, 2022, were as follows:
Contract Liabilities
Balance on January 1, 2022$35 
Reclassification of the beginning contract liabilities to revenue, as the result of performance obligations satisfied(9)
Consideration received in advance and not recognized as revenue18,669 
Balance on September 30, 2022$18,695 
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.22.2.2
Share-Based Compensation (Tables)
 9 Months Ended
Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]  
Summary of Stock Award Activity for the Period
The following table summarizes the activity related to the stock option awards for the nine months ended September 30, 2022:
Number of Shares Weighted
Average Exercise Price
Awards outstanding at December 31, 20217,056,035 $3.19 
Granted4,047,333 0.78 
Forfeited(3,384,424)2.37 
Awards outstanding at September 30, 20227,718,944 $2.28 
Options exercisable at September 30, 20222,563,810 $4.75 
Weighted average remaining contractual term6.3 Years
Options vested and expected to vest at September 30, 20226,664,874 $2.49 
Weighted average remaining contractual term8.2 Years
Summary of Compensation Expense Related to Grants of Stock Options
Compensation expense related to the grants of stock options is included in research and development and general and administrative expense as follows (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Research and development$109 $186 $289 $542 
General and administrative229 288 692 820 
Total share-based compensation expense$338 $474 $981 $1,362 
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.22.2.2
Investments (Tables)
 9 Months Ended
Sep. 30, 2022
Investments, Debt and Equity Securities [Abstract]  
Schedule of Equity Investments with and without Readily Determinable Fair Values Assessed
The Company’s investments consist of the following:
September 30, 2022December 31, 2021
Equity investment with readily determinable fair value:
Reneo common stock$1,930 $4,928 
Equity investment without readily determinable fair values assessed under the measurement alternative:
Anteris preferred stock4,245 4,245 
Total$6,175 $9,173 
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.22.2.2
Leases (Tables)
 9 Months Ended
Sep. 30, 2022
Leases [Abstract]  
Schedule of Maturities of Lease Liabilities for Operating Leases
Maturities of lease liabilities for the Company’s operating leases as of September 30, 2022, were as follows (in thousands):
2022 (remaining three months)$65 
2023268 
2024275 
202523 
2026— 
Thereafter— 
Total lease payments631 
Less: imputed interest(90)
Present value of lease liabilities$541 
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.22.2.2
Redeemable Noncontrolling Interest (Tables)
 9 Months Ended
Sep. 30, 2022
Noncontrolling Interest [Abstract]  
Summary of Net Income Attributable to Vtv Therapeutics Inc The following is a summary of net income attributable to vTv Therapeutics Inc. and transfers to noncontrolling interest:
For the Three Months Ended September 30,For the Nine Months Ended September 30,
2022202120222021
Net loss attributable to vTv Therapeutics Inc. common shareholders$(4,261)$(1,087)$(14,419)$(5,936)
(Increase) in vTv Therapeutics Inc. accumulated deficit for purchase of LLC Units as a result of common stock issuances(1,174)(2,773)(103)(5,298)
Change from net loss attributable to vTv Therapeutics Inc. common shareholders and transfers to noncontrolling interest$(5,435)$(3,860)$(14,522)$(11,234)
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.22.2.2
Net Loss per Share (Tables)
 9 Months Ended
Sep. 30, 2022
Earnings Per Share [Abstract]  
Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Loss per Share of Class A Common Stock
A reconciliation of the numerator and denominator used in the calculation of basic and diluted net loss per share of Class A common stock is as follows (in thousands, except share and per share amounts):
For the Three Months Ended September 30,For the Nine Months Ended September 30,
2022202120222021
Numerator:
Net loss$(5,468)$(1,465)$(18,983)$(8,248)
Less: Net loss attributable to noncontrolling interests(1,207)(378)(4,564)(2,312)
Net loss attributable to common shareholders of vTv Therapeutics Inc., basic and diluted(4,261)(1,087)(14,419)(5,936)
Denominator:
Weighted average vTv Therapeutics Inc. Class A common stock, basic and diluted80,490,121 61,073,280 72,649,531 58,737,170 
Net loss per share of vTv Therapeutics Inc. Class A common stock, basic and diluted$(0.05)$(0.02)$(0.20)$(0.10)
Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss per Share
Potentially dilutive securities not included in the calculation of diluted net loss per share are as follows:
September 30, 2022September 30, 2021
Class B common stock (1)
23,093,860 23,093,860 
Common stock options granted under the Plan7,718,944 4,474,403 
Common stock warrants3,214,503 2,014,503 
Total34,027,307 29,582,766 
_____________________________
(1)Shares of Class B common stock do not share in the Company’s earnings and are not participating securities. Accordingly, separate presentation of loss per share of Class B common stock under the two-class method has not been provided. Each share of Class B common stock (together with a corresponding vTv Unit) is exchangeable for one share of Class A common stock.
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.22.2.2
Fair Value of Financial Instruments (Tables)
 9 Months Ended
Sep. 30, 2022
Fair Value Disclosures [Abstract]  
Summarizes the Conclusions Reached Regarding Fair Value Measurements The following table summarizes the conclusions reached regarding fair value measurements as of September 30, 2022, and December 31, 2021 (in thousands):
Balance at September 30, 2022Quoted Prices in Active
Markets for Identical Assets
(Level 1)		Significant Other Observable
Inputs
(Level 2)		Significant Unobservable Inputs
(Level 3)
Assets:
Equity securities with readily determinable fair value$1,930 $1,930 $— $— 
Total$1,930 $1,930 $— $— 
Liabilities:
Warrant liability, related party (1)
$1,409 $— $— $1,409 
Total$1,409 $— $— $1,409 
Balance at December 31, 2021Quoted Prices in Active
Markets for Identical Assets
(Level 1)		Significant Other Observable
Inputs
(Level 2)		Significant Unobservable Inputs
(Level 3)
Assets:
Equity securities with readily determinable fair value$4,928 $4,928 $— $— 
Total$4,928 $4,928 $— $— 
Liabilities:
Warrant liability, related party (1)
$1,262 $— $— $1,262 
Total$1,262 $— $— $1,262 
_____________________________
(1)Fair value determined using the Black-Scholes option pricing model. Expected volatility is based on the historical volatility of the Company’s common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation.
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
Changes in Level 3 instruments for the nine months ended September 30,
Balance at January 1Net Change in
fair value included in
earnings		Purchases /
Issuance		Sales /
Repurchases		Balance at September 30,
2022
Warrant liability, related party$1,262 $(221)$368 $— $1,409 
Total$1,262 $(221)$368 $— $1,409 
2021
Warrant liability, related party$2,871 $(611)$— $— $2,260 
Total$2,871 $(611)$— $— $2,260 
Fair Value Measurement Inputs and Valuation Techniques Significant inputs utilized in the valuation of the Letter Agreement Warrants as of September 30, 2022, and December 31, 2021, were:
September 30, 2022December 31, 2021
RangeWeighted AverageRangeWeighted Average
Expected volatility
81.70% - 109.73%
95.51%
82.68% - 142.86%
128.13%
Risk-free interest rate
4.13% - 4.25%
4.20%
0.95% - 1.26%
1.15%
The fair value of the CinRx Warrants was determined using the Black-Scholes option pricing model. Expected volatility is based on the historical volatility of the Company’s common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation. Significant inputs utilized in the valuation of the CinRx Warrants as of September 30, 2022, were:
Expected volatility 85.2 %
Expected life of options in years3.1
Risk-free interest rate4.3 %
Expected dividend yield— %
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.22.2.2
Description of Business, Basis of Presentation and Going Concern (Detail) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2022
Jul. 22, 2022
Dec. 31, 2021
Organization Consolidation And Presentation Of Financial Statements [Line Items]      
Accumulated deficit $ 267,062   $ 248,834
Cash and cash equivalents 15,339   $ 13,415
G2 Investment      
Organization Consolidation And Presentation Of Financial Statements [Line Items]      
Accounts and financing receivable, after allowance for credit loss 12,500    
CinRx Investment      
Organization Consolidation And Presentation Of Financial Statements [Line Items]      
Accounts and financing receivable, after allowance for credit loss 4,000 $ 4,000  
Class A Common Stock | Cantor Fitzgerald      
Organization Consolidation And Presentation Of Financial Statements [Line Items]      
Remaining available stock value $ 37,300    
Class A Common Stock | LPC Purchase Agreement      
Organization Consolidation And Presentation Of Financial Statements [Line Items]      
Common stock, capital shares reserved for future issuance (in shares) 9,437,376    
vTv Therapeutics LLC      
Organization Consolidation And Presentation Of Financial Statements [Line Items]      
Percentage of non-voting economic interest of vTv Therapeutics Holdings LLC in vTv LLC 22.10%    
Percentage of non-voting economic interest of vTv Therapeutics Inc in vTv LLC 77.90%    
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.22.2.2
Summary of Significant Accounting Policies - Additional Information (Detail) - Revenue - Customer
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Customer One        
Summary Of Significant Accounting Policies [Line Items]        
Concentration risk percentage 100.00%   100.00%  
Customers Two        
Summary Of Significant Accounting Policies [Line Items]        
Concentration risk percentage   100.00%    
Customer Three        
Summary Of Significant Accounting Policies [Line Items]        
Concentration risk percentage       100.00%
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.22.2.2
Collaboration Agreements - Additional Information (Detail) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended
May 31, 2022
Aug. 31, 2017
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Jan. 14, 2021
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                
Contract liabilities, net of current portion     $ 18,669,000   $ 18,669,000   $ 0  
Contract with customer, liability, revenue recognized         9,000      
Research and development     $ 3,055,000 $ 2,382,000 $ 8,393,000 $ 7,922,000    
Class A Common Stock                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                
Common stock par value (in usd per share)     $ 0.01   $ 0.01   $ 0.01  
G42 Investments                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                
Shares sold (in shares) 10,386,274              
Common stock par value (in usd per share) $ 0.01              
Sale of stock, price per share (in usd per shares) $ 2.41              
Sale of stock, consideration received on transaction, gross $ 25,000,000              
Sale of stock, consideration received on transaction 12,500,000              
Accounts and financing receivable, after allowance for credit loss 12,500,000              
G2 Investments Purchase Agreement And Cogna Collaborative And License Agreement | G42 Investments                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                
Sale of stock, consideration received on transaction, gross $ 25,000,000              
Accounts and financing receivable, after allowance for credit loss     $ 12,500,000   $ 12,500,000      
Consideration receivable, payment period 1 year              
Collaborative arrangement, contingent consideration $ 30,000,000              
Collaborate arrangement, contingent consideration transferred, cash 30,000,000              
Contract liabilities, net of current portion     18,700,000   18,700,000      
Discount on note receivable         600,000      
Receivables, fair value disclosure     11,900,000   11,900,000      
G2 Investments Purchase Agreement And Cogna Collaborative And License Agreement | G42 Investments | Class A Common Stock                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                
Common stock, value $ 5,700,000              
Share price (usd per share) $ 0.55              
G2 Investments Purchase Agreement And Cogna Collaborative And License Agreement | Cogna                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                
Royalties receivable, percent 8.00%              
Royalties receivable, period 10 years              
Collaborative Arrangements | Reneo                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                
Contract with customer, liability, revenue recognized     0 0 0 0    
Adjustments to transaction price for performance obligations     0   0      
Revenue recognized from change in estimated transaction prices       2,000,000        
Collaborative Arrangements | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Phase 2 MRCT                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                
Maximum contribution amount to clinical trial               $ 3,000,000
Potential development and regulatory milestone payments               $ 3,000,000
Unrecognized amount of transaction price allocated to performance obligation       1,000,000   1,000,000    
Collaborative Arrangements | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Phase 2 MRCT | License and Technology Transfer Services of Chemistry and Manufacturing Know-How                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                
Adjustments to transaction price for performance obligations         2,000,000 $ 1,000,000    
Collaborative Arrangements | Newsoara Biopharma Co Ltd                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                
Revenue recognized from change in estimated transaction prices     0 $ 1,000,000 0      
Collaborative Arrangements | Newsoara Biopharma Co Ltd | License And Technology Transfer Services                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                
Contract with customer, liability, revenue recognized     $ 0   0      
Collaborative Arrangements | JDRF                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                
Maximum research funding receivable achievement based on research and development milestones   $ 3,400,000            
Maximum funding percentage of research and development milestones   50.00%            
Funding received         3,400,000      
Research and development         $ 3,400,000      
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.22.2.2
Collaboration Agreements - Summary of Contract Liabilities Related to Company's Collaboration Agreements (Detail) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Deferred Revenue Disclosure [Abstract]    
Current portion of contract liabilities $ 26 $ 35
Contract liabilities, net of current portion 18,669 0
Total contract liabilities $ 18,695 $ 35
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.22.2.2
Collaboration Agreements - Contract with Customer, Contract Asset, Contract Liability, and Receivable Changes (Details)
$ in Thousands
 9 Months Ended
Sep. 30, 2022
USD ($)
Revenue from Contract with Customer [Roll Forward]  
Beginning balance $ 35
Reclassification of the beginning contract liabilities to revenue, as the result of performance obligations satisfied (9)
Consideration received in advance and not recognized as revenue 18,669
Ending balance $ 18,695
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.22.2.2
Share-Based Compensation - Additional Information (Detail) - USD ($)
$ / shares in Units, $ in Millions
 9 Months Ended
Mar. 29, 2022
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Award requisite service period 6 months      
Outstanding stock options (in shares)   7,718,944   7,056,035
Strategic Advisor        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Non-qualified stock option awards vesting period 15 months      
Non-qualified stock option awards expiration term 10 years      
Outstanding stock options (in shares) 624,659      
Stock options cancelled (in shares) 1,873,976      
Stock Option        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Non-qualified stock option awards vesting period   3 years    
Non-qualified stock option awards expiration term   10 years    
Unrecognized compensation cost related to non-vested share-based compensation arrangements   $ 2.6    
Weighted average period to recognize unrecognized share-based compensation cost   2 years 8 months 12 days    
Weighted average grant date fair value of options granted (in usd per share)   $ 0.68 $ 2.21  
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.22.2.2
Share-Based Compensation - Summary of Stock Award Activity for the Period (Detail)
 9 Months Ended
Sep. 30, 2022
$ / shares
shares
Number of Shares  
Awards outstanding, Beginning balance (in shares) | shares 7,056,035
Granted (in shares) | shares 4,047,333
Forfeited (in shares) | shares (3,384,424)
Awards outstanding, Ending balance (in shares) | shares 7,718,944
Options exercisable (in shares) | shares 2,563,810
Options exercisable, weighted average remaining contractual term 6 years 3 months 18 days
Options vested and expected to vest (in shares) | shares 6,664,874
Options vested and expected to vest, weighted average remaining contractual term 8 years 2 months 12 days
Weighted Average Exercise Price  
Awards outstanding, Beginning balance (in usd per share) | $ / shares $ 3.19
Granted (in usd per share) | $ / shares 0.78
Forfeited (in usd per share) | $ / shares 2.37
Awards outstanding, Ending balance (in usd per share) | $ / shares 2.28
Options exercisable (in usd per share) | $ / shares 4.75
Options vested and expected to vest (in usd per share) | $ / shares $ 2.49
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.22.2.2
Share-Based Compensation - Summary of Compensation Expense Related to Grants of Stock Options (Detail) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]        
Total share-based compensation expense $ 338 $ 474 $ 981 $ 1,362
Research and development        
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]        
Total share-based compensation expense 109 186 289 542
General and administrative        
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]        
Total share-based compensation expense $ 229 $ 288 $ 692 $ 820
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.22.2.2
Investments - Additional Information (Detail) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Change in fair value of investments     $ (2,998) $ 1,814
Reneo        
Equity method investments, ownership percentage 20.00%   20.00%  
Change in fair value of investments $ 400 $ (1,100) $ (3,000) $ 1,800
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.22.2.2
Investments - Schedule of Equity Investments with and without Readily Determinable Fair Values Assessed (Detail) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Equity Securities Without Readily Determinable Fair Value [Line Items]    
Equity investment without readily determinable fair values assessed under the measurement alternative: $ 6,175 $ 9,173
Reneo | Common Stock    
Equity Securities Without Readily Determinable Fair Value [Line Items]    
Equity investment with readily determinable fair value: 1,930 4,928
Anteris Bio Inc | Preferred Stock    
Equity Securities Without Readily Determinable Fair Value [Line Items]    
Equity investment without readily determinable fair values assessed under the measurement alternative: $ 4,245 $ 4,245
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.22.2.2
Commitments and Contingencies - Additional Information (Detail) - Novo License Agreement - USD ($)
$ in Millions
Dec. 31, 2021
Feb. 28, 2007
Developmental and Regulatory Milestone Payment | Other Indication | Maximum    
Commitments And Contingencies [Line Items]    
Potential milestone payment   $ 115.0
Developmental and Regulatory Milestone Payment | Type 1 Diabetes    
Commitments And Contingencies [Line Items]    
Potential milestone payment   9.0
Developmental and Regulatory Milestone Payment | Type 2 Diabetes | Maximum    
Commitments And Contingencies [Line Items]    
Potential milestone payment   50.5
Sales-based Milestones Payment    
Commitments And Contingencies [Line Items]    
Potential milestone payment   $ 75.0
Satisfaction of Milestone Payment    
Commitments And Contingencies [Line Items]    
Potential milestone payment $ 2.0  
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.22.2.2
Leases - (Details)
Sep. 30, 2022
Dec. 31, 2021
Leases [Abstract]    
Lessee, operating lease, renewal term 5 years  
Lessee, operating lease, termination period 3 years  
Weighted average incremental borrowing rate 13.10% 13.10%
Remaining operating lease term 2 years 3 months 18 days 3 years 1 month 6 days
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.22.2.2
Leases - Schedule of Maturities of Lease Liabilities for Operating Leases (Detail)
$ in Thousands
Sep. 30, 2022
USD ($)
Lessee, Operating Lease, Liability, to be Paid [Abstract]  
2022 (remaining three months) $ 65
2023 268
2024 275
2025 23
2026 0
Thereafter 0
Total lease payments 631
Less: imputed interest (90)
Present value of lease liabilities $ 541
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.22.2.2
Redeemable Noncontrolling Interest - Additional Information (Detail) - USD ($)
$ in Millions
 9 Months Ended
Sep. 30, 2022
Dec. 31, 2021
Noncontrolling Interest [Line Items]    
Redemption amount of noncontrolling interest $ 24.2 $ 25.0
Class A Common Stock    
Noncontrolling Interest [Line Items]    
Number of days used to determine exchange value based on weighted average price of Class A common stock 20 days  
Class A Common Stock | Exchange of Redeemable Non controlling Interest To Class A Common Stock    
Noncontrolling Interest [Line Items]    
Stock conversion ratio 1  
vTv Therapeutics LLC    
Noncontrolling Interest [Line Items]    
Noncontrolling interest ownership percentage 22.10%  
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.22.2.2
Redeemable Noncontrolling Interest - Summary of Net Income Attributable to Vtv Therapeutics Inc (Detail) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Noncontrolling Interest [Abstract]        
Net loss attributable to vTv Therapeutics Inc. common shareholders $ (4,261) $ (1,087) $ (14,419) $ (5,936)
(Increase) in vTv Therapeutics Inc. accumulated deficit for purchase of LLC Units as a result of common stock issuances (1,174) (2,773) (103) (5,298)
Change from net loss attributable to vTv Therapeutics Inc. common shareholders and transfers to noncontrolling interest $ (5,435) $ (3,860) $ (14,522) $ (11,234)
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stockholders' Deficit - Additional Information (Detail) - USD ($)
$ / shares in Units, $ in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended
Jul. 22, 2022
May 31, 2022
Jun. 25, 2021
May 04, 2021
Jan. 14, 2021
Nov. 24, 2020
Apr. 30, 2020
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Dec. 31, 2020
Class Of Stock [Line Items]                          
Capital stock, shares authorized (in shares)       350,000,000                 250,000,000
Stock issued during period                   $ 5,040 $ 17,024    
Net proceeds from issuance of common stock                   0 $ 26,111    
G42 Investments                          
Class Of Stock [Line Items]                          
Shares sold (in shares)   10,386,274                      
Common stock par value (in usd per share)   $ 0.01                      
Sale of stock, price per share (in usd per shares)   $ 2.41                      
Sale of stock, consideration received on transaction, gross   $ 25,000                      
Sale of stock, consideration received on transaction   12,500                      
Accounts and financing receivable, after allowance for credit loss   $ 12,500                      
Sale of stock, consideration, receivables, payment term   1 year                      
CinRx Investment                          
Class Of Stock [Line Items]                          
Shares sold (in shares) 4,154,549                        
Common stock par value (in usd per share) $ 0.01                        
Sale of stock, price per share (in usd per shares) $ 2.41                        
Sale of stock, consideration received on transaction, gross $ 10,000                        
Sale of stock, consideration received on transaction 6,000                        
Accounts and financing receivable, after allowance for credit loss $ 4,000             $ 4,000   $ 4,000      
Warrants, term 5 years                        
Sale of stock, consideration, receivables, payment term 4 months                        
Class A Common Stock                          
Class Of Stock [Line Items]                          
Common stock, shares authorized (in shares)       200,000,000       200,000,000   200,000,000   200,000,000 100,000,000
Increase in shares authorized (in shares)       100,000,000                  
Common stock par value (in usd per share)               $ 0.01   $ 0.01   $ 0.01  
Class A Common Stock | CinRx Investment                          
Class Of Stock [Line Items]                          
Sale of stock, price per share (in usd per shares) $ 0.72                        
Sale of stock, consideration received on transaction $ 3,000                        
Class A Common Stock | Cantor Fitzgerald | ATM Offering                          
Class Of Stock [Line Items]                          
Shares sold (in shares)               0 8,457,546 0 8,457,546    
Common stock par value (in usd per share)             $ 0.01            
Stock issued during period             $ 13,000            
Public float                   $ 75,000      
Aggregate offering price     $ 50,000   $ 5,500                
Net proceeds from issuance of common stock                 $ 17,000   $ 17,000    
Class A Common Stock | LPC Purchase Agreement                          
Class Of Stock [Line Items]                          
Shares sold (in shares)               0   0 3,941,726    
Net proceeds from issuance of common stock                     $ 9,100    
Class A Common Stock | LPC Purchase Agreement | Maximum                          
Class Of Stock [Line Items]                          
Stock issued during period           $ 47,000              
Common Stock                          
Class Of Stock [Line Items]                          
Common stock, shares authorized (in shares)       300,000,000                 200,000,000
Common Stock | CinRx Investment                          
Class Of Stock [Line Items]                          
Number of securities called by warrants or rights (in shares) 1,200,000                        
Exercise price of warrants or rights (in usd per share) $ 0.72                        
Warrants, fair value $ 400                        
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.22.2.2
Related-Party Transactions - Additional Information (Detail) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2022
Oct. 10, 2022
Class A Common Stock | CinRx Pharma, LLC    
Related Party Transaction [Line Items]    
Shares held by related party (in shares) 4,154,549  
MacAndrews & Forbes Incorporated    
Related Party Transaction [Line Items]    
Ownership percentage of majority owner 57.00%  
Amount of cash savings percentage 85.00%  
MacAndrews & Forbes Incorporated | Class B Common Stock    
Related Party Transaction [Line Items]    
Shares held by related party (in shares) 23,084,267  
MacAndrews & Forbes Incorporated | Class A Common Stock    
Related Party Transaction [Line Items]    
Shares held by related party (in shares) 36,519,212  
Affiliated Entity | Subsequent Event | Master Service Agreement    
Related Party Transaction [Line Items]    
Due To Related Parties, Monthly Amount   $ 200
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.22.2.2
Income Taxes - Additional Information (Detail) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Income Taxes [Line Items]        
Income tax provision $ 0 $ 100 $ 200 $ 115
M&F TTP Holdings LLC        
Income Taxes [Line Items]        
Amount of cash savings percentage 85.00%      
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.22.2.2
Net Loss per Share - Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Loss per Share of Class A Common Stock (Detail) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Numerator:        
Net loss $ (5,468) $ (1,465) $ (18,983) $ (8,248)
Less: Net loss attributable to noncontrolling interests (1,207) (378) (4,564) (2,312)
Net loss attributable to common shareholders of vTv Therapeutics Inc., diluted (4,261) (1,087) (14,419) (5,936)
Net loss attributable to common shareholders of vTv Therapeutics Inc., basic $ (4,261) $ (1,087) $ (14,419) $ (5,936)
Class A Common Stock        
Denominator:        
Weighted-average number of vTv Therapeutics Inc. Class A Common Stock, basic (in shares) 80,490,121 61,073,280 72,649,531 58,737,170
Weighted-average number of vTv Therapeutics Inc. Class A Common Stock, diluted (in shares) 80,490,121 61,073,280 72,649,531 58,737,170
Net loss per share of vTv Therapeutics Inc. Class A Common Stock, basic (in usd per share) $ (0.05) $ (0.02) $ (0.20) $ (0.10)
Net loss per share of vTv Therapeutics Inc. Class A Common Stock, diluted (in usd per share) $ (0.05) $ (0.02) $ (0.20) $ (0.10)
XML 59 R48.htm IDEA: XBRL DOCUMENT v3.22.2.2
Net Loss per Share - Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss per Share (Detail) - shares
 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Potentially dilutive securities not included in calculation of dilutive net loss per share (in shares) 34,027,307 29,582,766
Class B Common Stock    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Potentially dilutive securities not included in calculation of dilutive net loss per share (in shares) 23,093,860 23,093,860
Common stock options granted under the Plan    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Potentially dilutive securities not included in calculation of dilutive net loss per share (in shares) 7,718,944 4,474,403
Common stock warrants    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Potentially dilutive securities not included in calculation of dilutive net loss per share (in shares) 3,214,503 2,014,503
XML 60 R49.htm IDEA: XBRL DOCUMENT v3.22.2.2
Fair Value of Financial Instruments - Summarizes the Conclusions Reached Regarding Fair Value Measurements (Detail) - Fair Value, Measurements, Recurring - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]    
Assets: $ 1,930 $ 4,928
Equity securities with readily determinable fair value - Total 1,930 4,928
Liabilities: 1,409 1,262
Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]    
Assets: 1,930 4,928
Equity securities with readily determinable fair value - Total 1,930 4,928
Liabilities: 0 0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Warrant liability, related party    
Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]    
Liabilities: 0 0
Significant Other Observable Inputs (Level 2)    
Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]    
Assets: 0 0
Equity securities with readily determinable fair value - Total 0 0
Liabilities: 0 0
Significant Other Observable Inputs (Level 2) | Warrant liability, related party    
Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]    
Liabilities: 0 0
Significant Unobservable Inputs (Level 3)    
Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]    
Assets: 0 0
Equity securities with readily determinable fair value - Total 0 0
Liabilities: 1,409 1,262
Significant Unobservable Inputs (Level 3) | Warrant liability, related party    
Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]    
Liabilities: $ 1,409 $ 1,262
XML 61 R50.htm IDEA: XBRL DOCUMENT v3.22.2.2
Fair Value of Financial Instruments - Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation (Details) - Significant Unobservable Inputs (Level 3) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Beginning Balance $ 1,262 $ 2,871
Net Change in fair value included in earnings (221) (611)
Purchases / Issuance 368 0
Sales / Repurchases 0 0
Ending Balance 1,409 2,260
Warrant liability, related party    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Beginning Balance 1,262 2,871
Net Change in fair value included in earnings (221) (611)
Purchases / Issuance 368 0
Sales / Repurchases 0 0
Ending Balance $ 1,409 $ 2,260
XML 62 R51.htm IDEA: XBRL DOCUMENT v3.22.2.2
Fair Value of Financial Instruments - Fair Value Measurement Inputs and Valuation Techniques (Detail)
Sep. 30, 2022
Dec. 31, 2021
CinRx Warrants    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Expected life of options in years 3 years 1 month 6 days  
Expected volatility | CinRx Warrants    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Inputs utilized in the valuation of warrants 0.852  
Risk-free interest rate | CinRx Warrants    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Inputs utilized in the valuation of warrants 0.043  
Expected dividend yield | CinRx Warrants    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Inputs utilized in the valuation of warrants 0  
Minimum | Expected volatility | Letter Agreement Warrants    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Inputs utilized in the valuation of warrants 0.8170 0.8268
Minimum | Risk-free interest rate | Letter Agreement Warrants    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Inputs utilized in the valuation of warrants 0.0413 0.0095
Maximum | Expected volatility | Letter Agreement Warrants    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Inputs utilized in the valuation of warrants 1.0973 1.4286
Maximum | Risk-free interest rate | Letter Agreement Warrants    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Inputs utilized in the valuation of warrants 0.0425 0.0126
Weighted Average | Expected volatility | Letter Agreement Warrants    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Inputs utilized in the valuation of warrants 0.9551 1.2813
Weighted Average | Risk-free interest rate | Letter Agreement Warrants    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Inputs utilized in the valuation of warrants 0.0420 0.0115
XML 63 vtvt-20220930_htm.xml IDEA: XBRL DOCUMENT 0001641489 2022-01-01 2022-09-30 0001641489 us-gaap:CommonClassAMember 2022-11-10 0001641489 us-gaap:CommonClassBMember 2022-11-10 0001641489 2022-09-30 0001641489 2021-12-31 0001641489 us-gaap:CommonClassAMember 2022-09-30 0001641489 us-gaap:CommonClassAMember 2021-12-31 0001641489 us-gaap:CommonClassBMember 2022-09-30 0001641489 us-gaap:CommonClassBMember 2021-12-31 0001641489 2022-07-01 2022-09-30 0001641489 2021-07-01 2021-09-30 0001641489 2021-01-01 2021-09-30 0001641489 us-gaap:CommonClassAMember 2022-07-01 2022-09-30 0001641489 us-gaap:CommonClassAMember 2021-07-01 2021-09-30 0001641489 us-gaap:CommonClassAMember 2022-01-01 2022-09-30 0001641489 us-gaap:CommonClassAMember 2021-01-01 2021-09-30 0001641489 vtvt:RedeemableNoncontrollingInterestsMember us-gaap:NoncontrollingInterestMember 2022-06-30 0001641489 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-06-30 0001641489 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2022-06-30 0001641489 us-gaap:CommonClassAMember us-gaap:ReceivablesFromStockholderMember 2022-06-30 0001641489 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001641489 us-gaap:RetainedEarningsMember 2022-06-30 0001641489 2022-06-30 0001641489 vtvt:RedeemableNoncontrollingInterestsMember us-gaap:NoncontrollingInterestMember 2022-07-01 2022-09-30 0001641489 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001641489 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0001641489 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001641489 us-gaap:CommonClassAMember us-gaap:ReceivablesFromStockholderMember 2022-07-01 2022-09-30 0001641489 us-gaap:CommonClassAMember us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0001641489 vtvt:RedeemableNoncontrollingInterestsMember us-gaap:NoncontrollingInterestMember 2022-09-30 0001641489 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-09-30 0001641489 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2022-09-30 0001641489 us-gaap:CommonClassAMember us-gaap:ReceivablesFromStockholderMember 2022-09-30 0001641489 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001641489 us-gaap:RetainedEarningsMember 2022-09-30 0001641489 vtvt:RedeemableNoncontrollingInterestsMember us-gaap:NoncontrollingInterestMember 2021-06-30 0001641489 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2021-06-30 0001641489 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2021-06-30 0001641489 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001641489 us-gaap:RetainedEarningsMember 2021-06-30 0001641489 2021-06-30 0001641489 vtvt:RedeemableNoncontrollingInterestsMember us-gaap:NoncontrollingInterestMember 2021-07-01 2021-09-30 0001641489 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0001641489 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0001641489 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2021-07-01 2021-09-30 0001641489 vtvt:RedeemableNoncontrollingInterestsMember us-gaap:NoncontrollingInterestMember 2021-09-30 0001641489 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2021-09-30 0001641489 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2021-09-30 0001641489 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001641489 us-gaap:RetainedEarningsMember 2021-09-30 0001641489 2021-09-30 0001641489 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2021-12-31 0001641489 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2021-12-31 0001641489 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001641489 us-gaap:RetainedEarningsMember 2021-12-31 0001641489 us-gaap:RetainedEarningsMember 2022-01-01 2022-09-30 0001641489 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-09-30 0001641489 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-01-01 2022-09-30 0001641489 us-gaap:CommonClassAMember us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-09-30 0001641489 us-gaap:CommonClassAMember us-gaap:ReceivablesFromStockholderMember 2022-01-01 2022-09-30 0001641489 us-gaap:ReceivablesFromStockholderMember 2022-01-01 2022-09-30 0001641489 2020-12-31 0001641489 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2020-12-31 0001641489 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2020-12-31 0001641489 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001641489 us-gaap:RetainedEarningsMember 2020-12-31 0001641489 us-gaap:RetainedEarningsMember 2021-01-01 2021-09-30 0001641489 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-09-30 0001641489 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2021-01-01 2021-09-30 0001641489 us-gaap:CommonClassAMember us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-09-30 0001641489 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2021-01-01 2021-09-30 0001641489 vtvt:CollaborationPartnerMember 2022-01-01 2022-09-30 0001641489 vtvt:CollaborationPartnerMember 2021-01-01 2021-09-30 0001641489 vtvt:CinRxMember 2022-01-01 2022-09-30 0001641489 vtvt:CinRxMember 2021-01-01 2021-09-30 0001641489 vtvt:VTvLLCMember 2022-01-01 2022-09-30 0001641489 vtvt:G2InvestmentMember 2022-09-30 0001641489 vtvt:CinRxInvestmentMember 2022-09-30 0001641489 vtvt:CantorFitzgeraldMember us-gaap:CommonClassAMember 2022-01-01 2022-09-30 0001641489 us-gaap:CommonClassAMember vtvt:LPCPurchaseAgreementMember 2022-09-30 0001641489 vtvt:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-07-01 2022-09-30 0001641489 vtvt:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-09-30 0001641489 vtvt:TwoCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-07-01 2021-09-30 0001641489 vtvt:ThreeCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-09-30 0001641489 vtvt:G42InvestmentsMember 2022-05-31 2022-05-31 0001641489 vtvt:G42InvestmentsMember 2022-05-31 0001641489 vtvt:G42InvestmentsMember vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember 2022-05-31 2022-05-31 0001641489 vtvt:G42InvestmentsMember vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember 2022-09-30 0001641489 vtvt:G42InvestmentsMember vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember 2022-05-31 0001641489 vtvt:CognaMember vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember 2022-05-31 0001641489 vtvt:CognaMember vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember 2022-05-31 2022-05-31 0001641489 vtvt:G42InvestmentsMember us-gaap:CommonClassAMember vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember 2022-05-31 0001641489 vtvt:G42InvestmentsMember vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember 2022-01-01 2022-09-30 0001641489 us-gaap:CollaborativeArrangementMember vtvt:ReneoPharmaceuticalsIncMember 2021-01-01 2021-09-30 0001641489 us-gaap:CollaborativeArrangementMember vtvt:ReneoPharmaceuticalsIncMember 2022-01-01 2022-09-30 0001641489 us-gaap:CollaborativeArrangementMember vtvt:ReneoPharmaceuticalsIncMember 2022-07-01 2022-09-30 0001641489 us-gaap:CollaborativeArrangementMember vtvt:ReneoPharmaceuticalsIncMember 2021-07-01 2021-09-30 0001641489 vtvt:PhaseTwoMultiRegionalClinicalTrialMember us-gaap:CollaborativeArrangementMember vtvt:HangzhouZhongmeiHuadongPharmaceuticalCompanyLimitedMember 2021-01-14 0001641489 vtvt:PhaseTwoMultiRegionalClinicalTrialMember us-gaap:CollaborativeArrangementMember vtvt:HangzhouZhongmeiHuadongPharmaceuticalCompanyLimitedMember 2021-09-30 0001641489 vtvt:LicenseAndTechnologyTransferServicesOfChemistryAndManufacturingKnowHowMember vtvt:PhaseTwoMultiRegionalClinicalTrialMember us-gaap:CollaborativeArrangementMember vtvt:HangzhouZhongmeiHuadongPharmaceuticalCompanyLimitedMember 2021-01-01 2021-09-30 0001641489 vtvt:LicenseAndTechnologyTransferServicesOfChemistryAndManufacturingKnowHowMember vtvt:PhaseTwoMultiRegionalClinicalTrialMember us-gaap:CollaborativeArrangementMember vtvt:HangzhouZhongmeiHuadongPharmaceuticalCompanyLimitedMember 2022-01-01 2022-09-30 0001641489 us-gaap:CollaborativeArrangementMember vtvt:NewsoaraBiopharmaCoLtdMember 2021-07-01 2021-09-30 0001641489 vtvt:LicenseAndTechnologyTransferServicesMember us-gaap:CollaborativeArrangementMember vtvt:NewsoaraBiopharmaCoLtdMember 2022-07-01 2022-09-30 0001641489 vtvt:LicenseAndTechnologyTransferServicesMember us-gaap:CollaborativeArrangementMember vtvt:NewsoaraBiopharmaCoLtdMember 2022-01-01 2022-09-30 0001641489 us-gaap:CollaborativeArrangementMember vtvt:NewsoaraBiopharmaCoLtdMember 2022-01-01 2022-09-30 0001641489 us-gaap:CollaborativeArrangementMember vtvt:NewsoaraBiopharmaCoLtdMember 2022-07-01 2022-09-30 0001641489 us-gaap:CollaborativeArrangementMember vtvt:JDRFInternationalMember 2017-08-31 0001641489 us-gaap:CollaborativeArrangementMember vtvt:JDRFInternationalMember 2022-01-01 2022-09-30 0001641489 us-gaap:CollaborativeArrangementMember vtvt:JDRFInternationalMember 2017-08-01 2017-08-31 0001641489 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-09-30 0001641489 us-gaap:EmployeeStockOptionMember 2022-09-30 0001641489 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-09-30 0001641489 2022-03-29 2022-03-29 0001641489 vtvt:StrategicAdvisorMember 2022-03-29 0001641489 vtvt:StrategicAdvisorMember 2022-03-29 2022-03-29 0001641489 us-gaap:ResearchAndDevelopmentExpenseMember 2022-07-01 2022-09-30 0001641489 us-gaap:ResearchAndDevelopmentExpenseMember 2021-07-01 2021-09-30 0001641489 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-09-30 0001641489 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-09-30 0001641489 us-gaap:GeneralAndAdministrativeExpenseMember 2022-07-01 2022-09-30 0001641489 us-gaap:GeneralAndAdministrativeExpenseMember 2021-07-01 2021-09-30 0001641489 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-09-30 0001641489 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-09-30 0001641489 vtvt:ReneoPharmaceuticalsIncMember 2022-09-30 0001641489 us-gaap:CommonStockMember vtvt:ReneoPharmaceuticalsIncMember 2022-09-30 0001641489 us-gaap:CommonStockMember vtvt:ReneoPharmaceuticalsIncMember 2021-12-31 0001641489 us-gaap:PreferredStockMember vtvt:AnterisBioIncMember 2022-09-30 0001641489 us-gaap:PreferredStockMember vtvt:AnterisBioIncMember 2021-12-31 0001641489 vtvt:ReneoPharmaceuticalsIncMember 2022-07-01 2022-09-30 0001641489 vtvt:ReneoPharmaceuticalsIncMember 2022-01-01 2022-09-30 0001641489 vtvt:ReneoPharmaceuticalsIncMember 2021-07-01 2021-09-30 0001641489 vtvt:ReneoPharmaceuticalsIncMember 2021-01-01 2021-09-30 0001641489 vtvt:DevelopmentalAndRegulatoryMilestonePaymentMember vtvt:TypeOneDiabetesMember vtvt:NovoLicenseAgreementMember 2007-02-28 0001641489 srt:MaximumMember vtvt:DevelopmentalAndRegulatoryMilestonePaymentMember vtvt:TypeTwoDiabetesMember vtvt:NovoLicenseAgreementMember 2007-02-28 0001641489 srt:MaximumMember vtvt:DevelopmentalAndRegulatoryMilestonePaymentMember vtvt:OtherIndicationMember vtvt:NovoLicenseAgreementMember 2007-02-28 0001641489 vtvt:SalesBasedMilestonesPaymentMember vtvt:NovoLicenseAgreementMember 2007-02-28 0001641489 vtvt:SatisfactionOfMilestonePaymentMember vtvt:NovoLicenseAgreementMember 2021-12-31 0001641489 vtvt:ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember us-gaap:CommonClassAMember 2022-01-01 2022-09-30 0001641489 us-gaap:CommonClassAMember 2020-12-31 0001641489 us-gaap:CommonClassAMember 2021-05-04 0001641489 us-gaap:CommonClassAMember 2021-05-04 2021-05-04 0001641489 us-gaap:CommonStockMember 2020-12-31 0001641489 us-gaap:CommonStockMember 2021-05-04 0001641489 2021-05-04 0001641489 vtvt:CinRxInvestmentMember 2022-07-22 2022-07-22 0001641489 vtvt:CinRxInvestmentMember 2022-07-22 0001641489 vtvt:CinRxInvestmentMember us-gaap:CommonClassAMember 2022-07-22 2022-07-22 0001641489 vtvt:CinRxInvestmentMember us-gaap:CommonClassAMember 2022-07-22 0001641489 vtvt:CinRxInvestmentMember us-gaap:CommonStockMember 2022-07-22 0001641489 vtvt:CantorFitzgeraldMember us-gaap:CommonClassAMember vtvt:AtTheMarketOfferingMember 2020-04-30 0001641489 vtvt:CantorFitzgeraldMember us-gaap:CommonClassAMember vtvt:AtTheMarketOfferingMember 2020-04-01 2020-04-30 0001641489 vtvt:CantorFitzgeraldMember us-gaap:CommonClassAMember vtvt:AtTheMarketOfferingMember 2022-01-01 2022-09-30 0001641489 vtvt:CantorFitzgeraldMember us-gaap:CommonClassAMember vtvt:AtTheMarketOfferingMember 2021-01-14 2021-01-14 0001641489 vtvt:CantorFitzgeraldMember us-gaap:CommonClassAMember vtvt:AtTheMarketOfferingMember 2021-06-25 2021-06-25 0001641489 vtvt:CantorFitzgeraldMember us-gaap:CommonClassAMember vtvt:AtTheMarketOfferingMember 2021-01-01 2021-09-30 0001641489 vtvt:CantorFitzgeraldMember us-gaap:CommonClassAMember vtvt:AtTheMarketOfferingMember 2021-07-01 2021-09-30 0001641489 vtvt:CantorFitzgeraldMember us-gaap:CommonClassAMember vtvt:AtTheMarketOfferingMember 2022-07-01 2022-09-30 0001641489 srt:MaximumMember vtvt:LPCPurchaseAgreementMember us-gaap:CommonClassAMember 2020-11-24 2020-11-24 0001641489 vtvt:LPCPurchaseAgreementMember us-gaap:CommonClassAMember 2022-01-01 2022-09-30 0001641489 vtvt:LPCPurchaseAgreementMember us-gaap:CommonClassAMember 2022-07-01 2022-09-30 0001641489 vtvt:LPCPurchaseAgreementMember us-gaap:CommonClassAMember 2021-01-01 2021-09-30 0001641489 vtvt:MacAndrewsAndForbesIncorporatedMember us-gaap:CommonClassBMember 2022-09-30 0001641489 vtvt:MacAndrewsAndForbesIncorporatedMember us-gaap:CommonClassAMember 2022-09-30 0001641489 vtvt:MacAndrewsAndForbesIncorporatedMember 2022-01-01 2022-09-30 0001641489 vtvt:MasterServiceAgreementMember srt:AffiliatedEntityMember us-gaap:SubsequentEventMember 2022-10-10 0001641489 us-gaap:CommonClassAMember vtvt:CinRxPharmaLLCMember 2022-09-30 0001641489 vtvt:MFTTPHoldingsLLCMember 2022-07-01 2022-09-30 0001641489 us-gaap:CommonClassBMember 2022-01-01 2022-09-30 0001641489 us-gaap:CommonClassBMember 2021-01-01 2021-09-30 0001641489 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-09-30 0001641489 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-09-30 0001641489 us-gaap:WarrantMember 2022-01-01 2022-09-30 0001641489 us-gaap:WarrantMember 2021-01-01 2021-09-30 0001641489 us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001641489 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001641489 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001641489 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001641489 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember vtvt:WarrantLiabilityRelatedPartyMember 2022-09-30 0001641489 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember vtvt:WarrantLiabilityRelatedPartyMember 2022-09-30 0001641489 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember vtvt:WarrantLiabilityRelatedPartyMember 2022-09-30 0001641489 us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001641489 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001641489 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001641489 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001641489 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember vtvt:WarrantLiabilityRelatedPartyMember 2021-12-31 0001641489 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember vtvt:WarrantLiabilityRelatedPartyMember 2021-12-31 0001641489 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember vtvt:WarrantLiabilityRelatedPartyMember 2021-12-31 0001641489 us-gaap:FairValueInputsLevel3Member vtvt:WarrantLiabilityRelatedPartyMember 2021-12-31 0001641489 us-gaap:FairValueInputsLevel3Member vtvt:WarrantLiabilityRelatedPartyMember 2022-01-01 2022-09-30 0001641489 us-gaap:FairValueInputsLevel3Member vtvt:WarrantLiabilityRelatedPartyMember 2022-09-30 0001641489 us-gaap:FairValueInputsLevel3Member 2021-12-31 0001641489 us-gaap:FairValueInputsLevel3Member 2022-01-01 2022-09-30 0001641489 us-gaap:FairValueInputsLevel3Member 2022-09-30 0001641489 us-gaap:FairValueInputsLevel3Member vtvt:WarrantLiabilityRelatedPartyMember 2020-12-31 0001641489 us-gaap:FairValueInputsLevel3Member vtvt:WarrantLiabilityRelatedPartyMember 2021-01-01 2021-09-30 0001641489 us-gaap:FairValueInputsLevel3Member vtvt:WarrantLiabilityRelatedPartyMember 2021-09-30 0001641489 us-gaap:FairValueInputsLevel3Member 2020-12-31 0001641489 us-gaap:FairValueInputsLevel3Member 2021-01-01 2021-09-30 0001641489 us-gaap:FairValueInputsLevel3Member 2021-09-30 0001641489 srt:MinimumMember vtvt:LetterAgreementWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2022-09-30 0001641489 srt:MaximumMember vtvt:LetterAgreementWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2022-09-30 0001641489 srt:WeightedAverageMember vtvt:LetterAgreementWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2022-09-30 0001641489 srt:MinimumMember vtvt:LetterAgreementWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2021-12-31 0001641489 srt:MaximumMember vtvt:LetterAgreementWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2021-12-31 0001641489 srt:WeightedAverageMember vtvt:LetterAgreementWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2021-12-31 0001641489 srt:MinimumMember vtvt:LetterAgreementWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-09-30 0001641489 srt:MaximumMember vtvt:LetterAgreementWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-09-30 0001641489 srt:WeightedAverageMember vtvt:LetterAgreementWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-09-30 0001641489 srt:MinimumMember vtvt:LetterAgreementWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-12-31 0001641489 srt:MaximumMember vtvt:LetterAgreementWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-12-31 0001641489 srt:WeightedAverageMember vtvt:LetterAgreementWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-12-31 0001641489 vtvt:CinRxWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2022-09-30 0001641489 vtvt:CinRxWarrantsMember 2022-09-30 0001641489 vtvt:CinRxWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-09-30 0001641489 vtvt:CinRxWarrantsMember us-gaap:MeasurementInputExpectedDividendRateMember 2022-09-30 shares iso4217:USD iso4217:USD shares pure utr:Rate 0001641489 --12-31 2022 Q3 false 0.5 10-Q true 2022-09-30 false 001-37524 vTv Therapeutics Inc. DE 47-3916571 3980 Premier Dr Suite 310 High Point NC 27265 336 841-0300 Class A common stock, par value $0.01 per share VTVT NASDAQ Yes Yes Non-accelerated Filer true false false 81483600 23093860 15339000 13415000 57000 57000 12091000 0 1281000 2049000 15000 100000 28783000 15621000 230000 278000 328000 402000 6175000 9173000 35516000 25474000 6676000 8023000 208000 184000 26000 35000 557000 256000 7467000 8498000 18669000 0 333000 492000 1409000 1262000 27878000 10252000 24207000 24962000 0.01 0.01 200000000 200000000 81483600 66942777 815000 669000 0.01 0.01 100000000 100000000 23093860 23093860 232000 232000 4000000 0 253446000 238193000 -267062000 -248834000 -16569000 -9740000 35516000 25474000 0 3000000 2009000 3996000 3055000 2382000 8393000 7922000 2634000 2221000 9813000 6627000 5689000 4603000 18206000 14549000 -5689000 -1603000 -16197000 -10553000 403000 -1084000 -2998000 1814000 -324000 1328000 221000 611000 150000 0 200000 1000 8000 6000 9000 6000 -5468000 -1365000 -18783000 -8133000 0 100000 200000 115000 -5468000 -1465000 -18983000 -8248000 -1207000 -378000 -4564000 -2312000 -4261000 -1087000 -14419000 -5936000 -4261000 -1087000 -14419000 -5936000 -0.05 -0.05 -0.02 -0.02 -0.20 -0.20 -0.10 -0.10 80490121 80490121 61073280 61073280 72649531 72649531 58737170 58737170 15916000 77329051 773000 23093860 232000 0 243772000 -253303000 -8526000 -1207000 -4261000 -4261000 338000 338000 4154549 42000 -4000000 9336000 5378000 9498000 -9498000 -9498000 24207000 81483600 815000 23093860 232000 -4000000 253446000 -267062000 -16569000 60190000 60193967 602000 23093860 232000 224457000 -273114000 -47823000 -378000 -1087000 -1087000 474000 474000 6277209 63000 11626000 11689000 -15202000 15202000 15202000 44610000 66471176 665000 23093860 232000 236557000 -258999000 -21545000 24962000 66942777 669000 23093860 232000 238193000 -248834000 -9740000 -4564000 -14419000 -14419000 981000 981000 10386274 104000 4936000 5040000 4154549 42000 -4000000 9336000 5378000 3809000 -3809000 -3809000 24207000 81483600 815000 23093860 232000 -4000000 253446000 -267062000 -16569000 83895000 54050710 541000 23094221 232000 209161000 -290036000 -80102000 -2312000 -5936000 -5936000 1362000 1362000 8457546 85000 16939000 17024000 361 -361 20833 47000 47000 3941726 39000 9048000 9087000 -36973000 36973000 36973000 44610000 66471176 665000 23093860 232000 236557000 -258999000 -21545000 -18983000 -8248000 69000 67000 200000 0 9000 0 981000 1362000 -2998000 1814000 -221000 -611000 0 770000 -853000 367000 -1417000 -1514000 6769000 -996000 -9142000 -12891000 21000 0 -21000 0 5040000 0 5746000 0 0 26111000 0 47000 776000 887000 475000 335000 11087000 26710000 1924000 13819000 13415000 5747000 15339000 19566000 -3809000 36973000 11891000 0 4000000 0 Description of Business, Basis of Presentation and Going Concern<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Business</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vTv Therapeutics Inc. (the “Company,” the “Registrant,” “we” or “us”) was incorporated in the state of Delaware in April 2015. The Company is a clinical stage pharmaceutical company focused on treating metabolic diseases to minimize their long-term complications through end-organ protection.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vTv Therapeutics Inc. is a holding company, and its principal asset is a controlling equity interest in vTv Therapeutics LLC (“vTv LLC”), the Company’s principal operating subsidiary, which is a clinical stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has determined that vTv LLC is a variable-interest entity (“VIE”) for accounting purposes and that vTv Therapeutics Inc. is the primary beneficiary of vTv LLC because (through its managing member interest in vTv LLC and the fact that the senior management of vTv Therapeutics Inc. is also the senior management of vTv LLC) it has the power and benefits to direct all of the activities of vTv LLC, which include those that most significantly impact vTv LLC’s economic performance. vTv Therapeutics Inc. has therefore consolidated vTv LLC’s results pursuant to Accounting Standards Codification Topic 810, “Consolidation” in its Condensed Consolidated Financial Statements. As of September 30, 2022, various holders own non-voting interests in vTv LLC, representing a 22.1% economic interest in vTv LLC, effectively restricting vTv Therapeutics Inc.’s interest to 77.9% of vTv LLC’s economic results, subject to increase in the future, should vTv Therapeutics Inc. purchase additional non-voting common units (“vTv Units”) of vTv LLC, or should the holders of vTv Units decide to exchange such units (together with shares of Class B common stock) for shares of Class A common stock (or cash) pursuant to the Exchange Agreement (as defined in Note 9). vTv Therapeutics Inc. has provided financial and other support to vTv LLC in the form of its purchase of vTv Units with the net proceeds of the Company’s initial public offering (“IPO”) in 2015, its registered direct offering in March 2019, and its agreeing to be a co-borrower under the Venture Loan and Security Agreement (the “Loan Agreement”) with Horizon Technology Finance Corporation and Silicon Valley Bank (together, the “Lenders”) which was entered into in 2016. vTv Therapeutics Inc. entered into the letter agreements with MacAndrews and Forbes Group LLC (“M&amp;F Group”), a related party and an affiliate of MacAndrews &amp; Forbes Incorporated (together with its affiliates “MacAndrews”) in December 2017, July 2018, December 2018, March 2019, September 2019, and December 2019 (each a “Letter Agreement” and collectively, the “Letter Agreements”). In addition, vTv Therapeutics Inc. also entered into the Controlled Equity Offering</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald &amp; Co. (“Cantor Fitzgerald”) (the “ATM Offering”), the purchase agreement with Lincoln Park Capital Fund, LLC (“Lincoln Park”) (the “LPC Purchase Agreement”), the common stock purchase agreement with G42 Investments AI Holding RSC Ltd (“G42 Investments”) (the “G42 Purchase Agreement”) and the common stock and warrant purchase agreement with CinPax, LLC and CinRx, LLC, respectively (the “CinRx Purchase Agreement”). v</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tv Therapeutics Inc. will not be required to provide financial or other support for vTv LLC. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, vTv Therapeutics Inc. will control its business and other activities through its managing member interest in vTv LLC, and its management is the management of vTv LLC. Nevertheless, because vTv Therapeutics Inc. will have no material assets other than its interests in vTv LLC, any financial difficulties at vTv LLC could result in vTv Therapeutics Inc. recognizing a loss.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Going Concern and Liquidity</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Company has not generated any product revenue and has not achieved profitable operations. The continuing development of our drug candidates will require additional financing. From its inception through September 30, 2022, the Company has funded its operations primarily through a combination of private placements of common and preferred equity, research collaboration agreements, upfront and milestone payments for license agreements, debt and equity financings and the completion of its IPO in August 2015. As of September 30, 2022, the Company had an accumulated deficit of $267.1 million and has generated net losses in each year of its existence. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, the Company’s liquidity sources included cash and cash equivalents of $15.3 million. To meet our future funding requirements into the fourth quarter of 2023, including funding the on-going and future clinical trials of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TTP399,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> we are evaluating several financing strategies, including direct equity investments and the potential licensing and </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">monetization of other Company programs such as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">HPP737</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company also has promissory notes of $12.5 million and $4.0 million under the G42 Purchase Agreement and CinRx Purchase Agreement payable to the Company, respectively. The G42 promissory note is due on or before May 31, 2023, and the CinRx promissory note is due on or before November 22, 2022 (see Note 9).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may also use its remaining availability of $37.3 million under our Sales Agreement with Cantor Fitzgerald pursuant to which the Company may offer and sell, from time to time shares of the Company’s Class A common stock (the “ATM Offering”) and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the ability to sell an additional 9,437,376 shares of Class A common stock under the LPC Purchase Agreement based on the remaining number of registered shares. However, the ability to use these sources of capital is dependent on a number of factors, including the prevailing market price of and the volume of trading in the Company’s Class A common stock.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> See Note 9 for further details. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These conditions raise substantial doubt about the Company’s ability to continue as a going concern. If we are unable to raise additional capital as and when needed, or upon acceptable terms, such failure would have a significant negative </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">impact on our financial condition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. The</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Condensed Consolidated Financial Statements do not include adjustments to reflect the possible future effects on the recoverability and classification of recorded assets or the amounts of liabilities that might be necessary should the Company be unable to continue as a going concern.</span></div> 0.221 0.779 -267100000 15300000 12500000 4000000 37300000 9437376 Summary of Significant Accounting Policies<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Financial Information</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying Condensed Consolidated Balance Sheet as of September 30, 2022, Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2022, and 2021, Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders’ Deficit for the three and nine months ended September 30, 2022, and 2021 and Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2022, and 2021 are unaudited. These unaudited financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. These financial statements should be read in conjunction with the audited financial statements and the accompanying notes for the year ended December 31, 2021, contained in the Company’s Annual Report on Form 10-K. The unaudited interim financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company’s financial position as of September 30, 2022, the results of operations for the three and nine months ended September 30, 2022, and 2021 and cash flows for the nine months ended September 30, 2022, and 2021. The December 31, 2021 Condensed Consolidated Balance Sheet included herein was derived from the audited financial statements but does not include all disclosures or notes required by GAAP for complete financial statements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial data and other information disclosed in these notes to the financial statements related to the three and nine months ended September 30, 2022, and 2021 are unaudited. Interim results are not necessarily indicative of results for an entire year.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not have any components of other comprehensive income recorded within its Condensed Consolidated Financial Statements, and, therefore, does not separately present a statement of comprehensive income in its Condensed Consolidated Financial Statements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, the Company evaluates its estimates, including those related to the grant date fair value of equity awards, the fair value of warrants to purchase shares of its Class A common stock, the fair value of the Class B common stock, the useful lives of property and equipment, the fair value of derivative liabilities, the fair value of the promissory note </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">receivable, and the fair value of the Company’s debt, among others. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable, the results of which form the basis for making judgments about the carrying value of assets and liabilities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash on deposit with one financial institution. The balances of these cash accounts frequently exceed insured limits.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One customer represented 100% of the revenue earned during the nine months ended September 30, 2022, two customers represented 100% of the revenue earned during the three months ended September 30, 2021 and three customers represented 100% of the revenue earned during the nine months ended September 30, 2021. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers any highly liquid investments with an original maturity of three months or less to be cash and cash equivalents.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in entities in which the Company has no control or significant influence, is not the primary beneficiary, and have a readily determinable fair value are classified as equity investments with readily determinable fair value. The investments are measured at fair value based on a quoted market price per unit in active markets multiplied by the number of units held without consideration of transaction costs (Level 1). Gains and losses are recorded in other income (expense), net on the Consolidated Statements of Operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity investments without readily determinable fair value include ownership rights that do not provide the Company with control or significant influence and these investments do not have readily determinable fair values. The Company has elected to measure its equity investments without readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the revenue recognition guidance established by ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue From Contracts With Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (“ASC 606”). When an agreement falls under the scope of other standards, such as ASC Topic 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (“ASC 808”), the Company will apply the recognition, measurement, presentation, and disclosure guidance in ASC 606 to the performance obligations in the agreements if those performance obligations are with a customer. Revenue recognized by analogizing to ASC 606, is recorded as collaboration revenue on the statements of operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the Company’s revenue results from its license and collaboration agreements associated with the development of investigational drug products. The Company accounts for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. For each contract meeting these criteria, the Company identifies the performance obligations included within the contract. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. The Company then recognizes revenue under each contract as the related performance obligations are satisfied. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction price under the contract is determined based on the value of the consideration expected to be received in exchange for the transferred assets or services. Development, regulatory and sales milestones included in the Company’s collaboration agreements are considered to be variable consideration. The amount of variable consideration expected to be received is included in the transaction price when it becomes probable that the milestone will be met. For contracts with multiple performance obligations, the contract’s transaction price is allocated to each performance obligation using the Company’s best estimate of the standalone selling price of each distinct good or service in the contract. The primary method used to estimate standalone selling price is the expected cost-plus margin approach. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Major components of research and development costs include cash and share-based compensation, costs of preclinical studies, clinical trials and related clinical manufacturing, costs of drug development, costs of materials and supplies, regulatory and compliance costs, fees paid to consultants and other entities that conduct certain research and development </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">activities on the Company’s behalf, facilities costs, and overhead costs. Research and development costs are expensed as incurred.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records accruals based on estimates of the services received, efforts expended, and amounts owed pursuant to contracts with numerous contract research organizations. In the normal course of business, the Company contracts with third parties to perform various clinical study activities in the ongoing development of potential products. The financial terms of these agreements are subject to negotiation and variation from contract to contract and may result in uneven payment flows. Payments under the contracts depend on factors such as the achievement of certain events and the completion of portions of the clinical study or similar conditions. The objective of the Company’s accrual policy is to match the recording of expenses in its financial statements to the actual services received and efforts expended. As such, expense accruals related to clinical studies are recognized based on the Company’s estimate of the degree of completion of the event or events specified in the specific clinical study.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records nonrefundable advance payments it makes for future research and development activities as prepaid expenses. Prepaid expenses are recognized as expense in the Condensed Consolidated Statements of Operations as the Company receives the related goods or services.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs that are reimbursed under a cost-sharing arrangement are reflected as a reduction of research and development expense.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In June 2022, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2022-03 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">“Fair Value Measurements (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions.”</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> These amendments clarify that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. This guidance is effective for public business entities for fiscal years, including interim periods within those fiscal years, beginning after December 15, 2023. Early adoption is permitted. The Company has assessed ASU 2022-03 and early adopted the guidance during the second quarter of 2022. The adoption did not have a material impact on the Company's Condensed Consolidated Financial Statements.</span></div> <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Financial Information</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying Condensed Consolidated Balance Sheet as of September 30, 2022, Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2022, and 2021, Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders’ Deficit for the three and nine months ended September 30, 2022, and 2021 and Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2022, and 2021 are unaudited. These unaudited financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. These financial statements should be read in conjunction with the audited financial statements and the accompanying notes for the year ended December 31, 2021, contained in the Company’s Annual Report on Form 10-K. The unaudited interim financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company’s financial position as of September 30, 2022, the results of operations for the three and nine months ended September 30, 2022, and 2021 and cash flows for the nine months ended September 30, 2022, and 2021. The December 31, 2021 Condensed Consolidated Balance Sheet included herein was derived from the audited financial statements but does not include all disclosures or notes required by GAAP for complete financial statements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial data and other information disclosed in these notes to the financial statements related to the three and nine months ended September 30, 2022, and 2021 are unaudited. Interim results are not necessarily indicative of results for an entire year.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not have any components of other comprehensive income recorded within its Condensed Consolidated Financial Statements, and, therefore, does not separately present a statement of comprehensive income in its Condensed Consolidated Financial Statements.</span></div> <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, the Company evaluates its estimates, including those related to the grant date fair value of equity awards, the fair value of warrants to purchase shares of its Class A common stock, the fair value of the Class B common stock, the useful lives of property and equipment, the fair value of derivative liabilities, the fair value of the promissory note </span></div>receivable, and the fair value of the Company’s debt, among others. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable, the results of which form the basis for making judgments about the carrying value of assets and liabilities. <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash on deposit with one financial institution. The balances of these cash accounts frequently exceed insured limits.</span></div>One customer represented 100% of the revenue earned during the nine months ended September 30, 2022, two customers represented 100% of the revenue earned during the three months ended September 30, 2021 and three customers represented 100% of the revenue earned during the nine months ended September 30, 2021. 1 1 1 1 <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers any highly liquid investments with an original maturity of three months or less to be cash and cash equivalents.</span></div> <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in entities in which the Company has no control or significant influence, is not the primary beneficiary, and have a readily determinable fair value are classified as equity investments with readily determinable fair value. The investments are measured at fair value based on a quoted market price per unit in active markets multiplied by the number of units held without consideration of transaction costs (Level 1). Gains and losses are recorded in other income (expense), net on the Consolidated Statements of Operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity investments without readily determinable fair value include ownership rights that do not provide the Company with control or significant influence and these investments do not have readily determinable fair values. The Company has elected to measure its equity investments without readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div> <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the revenue recognition guidance established by ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue From Contracts With Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (“ASC 606”). When an agreement falls under the scope of other standards, such as ASC Topic 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (“ASC 808”), the Company will apply the recognition, measurement, presentation, and disclosure guidance in ASC 606 to the performance obligations in the agreements if those performance obligations are with a customer. Revenue recognized by analogizing to ASC 606, is recorded as collaboration revenue on the statements of operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the Company’s revenue results from its license and collaboration agreements associated with the development of investigational drug products. The Company accounts for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. For each contract meeting these criteria, the Company identifies the performance obligations included within the contract. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. The Company then recognizes revenue under each contract as the related performance obligations are satisfied. </span></div>The transaction price under the contract is determined based on the value of the consideration expected to be received in exchange for the transferred assets or services. Development, regulatory and sales milestones included in the Company’s collaboration agreements are considered to be variable consideration. The amount of variable consideration expected to be received is included in the transaction price when it becomes probable that the milestone will be met. For contracts with multiple performance obligations, the contract’s transaction price is allocated to each performance obligation using the Company’s best estimate of the standalone selling price of each distinct good or service in the contract. The primary method used to estimate standalone selling price is the expected cost-plus margin approach. <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Major components of research and development costs include cash and share-based compensation, costs of preclinical studies, clinical trials and related clinical manufacturing, costs of drug development, costs of materials and supplies, regulatory and compliance costs, fees paid to consultants and other entities that conduct certain research and development </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">activities on the Company’s behalf, facilities costs, and overhead costs. Research and development costs are expensed as incurred.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records accruals based on estimates of the services received, efforts expended, and amounts owed pursuant to contracts with numerous contract research organizations. In the normal course of business, the Company contracts with third parties to perform various clinical study activities in the ongoing development of potential products. The financial terms of these agreements are subject to negotiation and variation from contract to contract and may result in uneven payment flows. Payments under the contracts depend on factors such as the achievement of certain events and the completion of portions of the clinical study or similar conditions. The objective of the Company’s accrual policy is to match the recording of expenses in its financial statements to the actual services received and efforts expended. As such, expense accruals related to clinical studies are recognized based on the Company’s estimate of the degree of completion of the event or events specified in the specific clinical study.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records nonrefundable advance payments it makes for future research and development activities as prepaid expenses. Prepaid expenses are recognized as expense in the Condensed Consolidated Statements of Operations as the Company receives the related goods or services.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs that are reimbursed under a cost-sharing arrangement are reflected as a reduction of research and development expense.</span></div> <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In June 2022, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2022-03 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">“Fair Value Measurements (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions.”</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> These amendments clarify that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. This guidance is effective for public business entities for fiscal years, including interim periods within those fiscal years, beginning after December 15, 2023. Early adoption is permitted. The Company has assessed ASU 2022-03 and early adopted the guidance during the second quarter of 2022. The adoption did not have a material impact on the Company's Condensed Consolidated Financial Statements.</span></div> Collaboration Agreements<div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">G42 Purchase Agreement and Cogna Collaborative and License Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and G42 Investments AI Holding RSC Ltd, a private limited company (“G42 Investments”), entered into a Common Stock Purchase Agreement (the “G42 Purchase Agreement”), pursuant to which the Company sold to G42 Investments 10,386,274 shares of the Company’s Class A common stock, par value $0.01 per share (the “G42 Common Stock) at a price per share of approximately $2.41, for an aggregate purchase price of $25.0 million, which was paid (i) $12.5 million in cash at the closing and (ii) $12.5 million in the form of a promissory note of G42 Investments to be paid at the one-year anniversary of the execution of the G42 Purchase Agreement. As part of the G42 Purchase Agreement, G42 Investments put forward a director as appointee and the Company’s board of directors approved appointing the new director to the Company’s board.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">G42 Investments has agreed to certain transfer restrictions (including restrictions on short sales or similar transactions) and restrictions on further acquisitions of shares, in each case subject to specified exceptions. Following the expiration of a lock up period, from the period May 31, 2022 until December 31, 2024 (or if earlier, the date of receipt of U.S. Food and Drug Administration (“FDA”) approval in the U.S. for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TTP399 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(the “FDA Approval”) of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TTP399</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), the Company has granted to G42 Investments certain shelf and piggyback registration rights with respect to those shares of Class A common stock issued to G42 Investments pursuant to the G42 Purchase Agreement, including the ability to conduct an underwritten offering to resell such shares under certain circumstances. The registration rights include customary cooperation, cut-back, expense reimbursement, and indemnification provisions.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contemporaneously with the G42 Purchase Agreement, effective on May 31, 2022, the Company entered into a collaboration and license agreement (the “Cogna Agreement”) with Cogna Technology Solutions LLC, an affiliate of G42 Investments (“Cogna”) (“Collaboration Partner”), which requires Cogna to work with the Company in performing Phase 3 clinical trials for the Company’s </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TTP399</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> compound (the “Licensed Product”) as well as jointly creating a global development plan to develop, market, and commercialize </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TTP399</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in certain countries in the Middle East, Africa, and Central Asia (the “Partner Territory”). Under the terms of the Cogna Agreement, Cogna will obtain rights to the Company’s license of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TTP399</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for purposes of performing Phase 3 clinical trials in the Partner Territory, but will not have access to the various intellectual property (“IP”) related to the license and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TTP399</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Specifically, the Company will share various protocols with Cogna related to conducting the clinical trials and will provide the patient dosages and placebo of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TTP399 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">needed to conduct </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the trials. Separately, the Company will conduct its Phase 3 clinical trials for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TTP399</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the U.S. at its own cost that similarly will not be reimbursed. The results of each party’s Phase 3 clinical trials will be combined by the Company to seek FDA approval in the U.S. for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TTP399</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under the Cogna Agreement, Cogna has the right to develop and commercialize the Licensed Product in the Partner Territory at its own cost once restrictions on the use of the IP have been lifted by the Company. The Cogna Agreement determined which specific countries in the Partner Territory that Cogna may pursue development and commercialization and provides the Company with the ability to determine when Cogna can benefit from this IP through the powers granted to the Company to approve the global development plan. Further, the Company may supply at cost, or Cogna may manufacture, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">TTP399</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> for commercial sale under terms to be agreed upon by the parties at a later date.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The G42 Purchase Agreement also provides for, following the receipt of FDA approval of the Licensed Product, at the option of G42 Investments, either (a) the issuance of the Company’s Class A common stock (the “Milestone Shares”) having an aggregate value equal to $30.0 million or (b) the payment by the Company of $30.0 million in cash (the “Milestone Cash Payment”). The issuance of the Milestone Shares or the payment of the Milestone Cash Payment, as applicable, are conditioned upon receipt of the FDA Approval and subject to certain limitations and conditions set forth in the G42 Purchase Agreement. There can be no assurance that the FDA Approval will be granted or as to the timing thereof.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once commercialization takes place in the Partner Territories, the Company will receive royalties of 8% from Cogna on the sale of the Licensed Product for ten years after the first commercial sale of the Licensed Product.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock is generally recorded at fair value at the date of issuance. In determining the fair value of the Class A common stock issued to G42 Investments, the Company considered the closing price of the common stock on the effective date. The Company did not make an adjustment to the fair value for sale restrictions on the stock in accordance with guidance recently adopted in ASU 2022-03. See the “Recently Issued Accounting Guidance” in this 10-Q for details of the ASU. Accordingly, the Company determined that cash consideration of $5.7 million should be recorded as fair value of the Class A common stock at the effective date, utilizing the Class A common stock closing price of $0.55 at the effective date. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A premium was paid on the Class A common stock by G42 Investments of $18.7 million, net of a note receivable discount of $0.6 million. This premium is determined to be the transaction price for all remaining obligations under the agreements, which will be accounted for under ASC 808 or ASC 606 based on determination of the unit of account. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that certain commitments under the agreements are in the scope of ASC 808 as both the Company and Cogna are active participants in the clinical trials of the Licensed Product, and both are exposed to significant risks and rewards based on the success of the clinical trials and subsequent FDA approval. Cogna is determined to be a vendor of the Company during the clinical trial phase, working on the Company’s behalf to complete R&amp;D activities, and not in a customer capacity. The Company accounted for the commitments related to the clinical trials, which includes transfer of trial protocols, supply of clinical trial dosages, and collaboration on the joint development committee (“JDC”) as an ASC 808 unit of account, applying the recognition and measurement principles of ASC 606 by analogy. The Company will recognize collaboration revenue for its development activities under ASC 808 over time based on the estimated period of performance.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By applying the principals in ASC 606 by analogy, the Company identified the performance obligation and considered the timing of satisfaction of the obligation to account for the pattern of revenue recognition. In order to recognize collaboration revenue, generally, the Company would begin satisfying its performance obligation and Cogna would need to be able to use and benefit from delivery of the assets or services. The performance obligation under the agreements that fall within the 808 unit of account are concentrated in the Phase 3 clinical trials. As of September 30, 2022, the Phase 3 clinical trials had not commenced. Accordingly, no collaboration revenue was recognized for the ASC 808 unit of account during the three and nine months ended September 30, 2022. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company identified certain commitments that are in the scope of ASC 606 as Cogna’s relationship is that of a customer for these commitments. The significant performance obligations that are in the scope of ASC 606 are (1) the development, commercialization and manufacturing license of the IP once restrictions on the use of the IP have been lifted by the Company and (2) a potential material right to a commercial supply agreement. The Company will recognize revenue from the development, commercial and manufacturing license at a point in time when the Company releases the restrictions on the use of the IP, which is expected to be after the Licensed Product is approved by the FDA. The Company will recognize revenue from the material right related to Cogna’s ability to purchase the commercial supply at cost as Cogna purchases the commercial supply from the Company, which will occur after the completion of the initial clinical trials (if Cogna decides to purchase the clinical supply from the Company). As a result, the Company has not recognized any revenue under the ASC 606 unit of account during the three and nine months ended September 30, 2022. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, the Company has recognized the cash and a non-interest bearing promissory note receivable of with a principal balance of $12.5 million. The promissory note receivable was classified and accounted for under ASC 310 and was initially measured at its fair value of $11.9 million and will be subsequently remeasured at its amortized cost through its maturity date. The Company also recorded the $18.7 million as deferred revenue in the Consolidated Balance Sheets, as none of the underlying performance obligations had been satisfied as of and for the three and nine months ended September 30, 2022. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reneo License Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is party to a license agreement with Reneo Pharmaceuticals, Inc. (“Reneo”) (the “Reneo License Agreement”), under which Reneo obtained an exclusive, worldwide, sublicensable license to develop and commercialize the Company’s peroxisome proliferation activated receptor delta (PPAR-δ) agonist program, including the compound </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">HPP593</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for therapeutic, prophylactic or diagnostic application in humans.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has fully allocated the transaction price to the license and the technology transfer services, which represents a single combined performance obligation because they were not capable of being distinct on their own. The revenue related to this performance obligation was recognized on a straight-line basis over the technology transfer service period. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The revenue related to this performance obligation has been fully recognized and no revenue related to this performance obligation was recognized for the three and nine months ended September 30, 2022. There have been no adjustments to the transaction price for the performance obligations under the Reneo License Agreement during the three and nine months ended September 30, 2022. In the third quarter of 2021, the transaction price for this performance obligation was increased by $2.0 million due to the satisfaction of a development milestone under the Reneo License Agreement. This amount was fully recognized as revenue during the three and nine months ended September 30, 2021, as the related performance obligation was fully satisfied.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Huadong License Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is party to a license agreement with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (“Huadong”) (the “Huadong License Agreement”), under which Huadong obtained an exclusive and sublicensable license to develop and commercialize the Company’s glucagon-like peptide-1 receptor agonist (“GLP-1r”) program, including the compound</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> TTP273</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for therapeutic uses in humans or animals, in China and certain other pacific rim countries, including Australia and South Korea (collectively, the “Huadong License Territory”). Additionally, under the Huadong License Agreement, the Company obtained a non-exclusive, sublicensable, royalty-free license to develop and commercialize certain Huadong patent rights and know-how related to the Company’s GLP-1r program for therapeutic uses in humans or animals outside of the Huadong License Territory. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 14, 2021, the Company entered into the first amendment to the Huadong License Agreement ( the “First Huadong Amendment”) which eliminated the Company’s obligation to sponsor a multi-region clinical trial (the “Phase 2 MRCT”), and corresponding obligation to contribute up to $3.0 million in support of such trial. The amendment also reduced the total potential development and regulatory milestone payments by $3.0 million.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the First Amendment, the Company had allocated a portion of the transaction price to the obligation to sponsor and conduct a portion of the Phase 2 MRCT. Upon the removal of this performance obligation, the Company evaluated the impact of the modification under the provisions of ASC Topic 606 and performed a reallocation of the transaction price among the remaining performance obligations. This resulted in the recognition of approximately $1.0 million of revenue on a cumulative catch-up basis during the nine months ended September 30, 2021. The majority of the transaction price originally allocated to the Phase 2 MRCT performance obligation was reallocated to the license and technology transfer services combined performance obligation discussed below, which had already been completed. The reallocation of the purchase price in connection with the First Huadong Amendment was made based on the relative estimated selling prices of the remaining performance obligations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant performance obligations under the Huadong License Agreement, as amended, were determined to be (i) the exclusive license to develop and commercialize the Company’s GLP-1r program, (ii) technology transfer services related to the chemistry and manufacturing know-how for a defined period after the effective date, (iii) the Company’s obligation to participate on a joint development committee (the “JDC”), and (iv) other obligations considered to be de minimis in nature. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has determined that the license and technology transfer services related to the chemistry and manufacturing know-how represent a combined performance obligation because they were not capable of being distinct on </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">their own. The Company also determined that there was no discernible pattern in which the technology transfer services would be provided during the transfer service period. As such, the Company recognized the revenue related to this combined performance obligation using the straight-line method over the transfer service period. This combined performance obligation was considered complete as of September 30, 2021. The Company recognized $1.0 million of revenue related to this combined performance obligation during the nine months ended September 30, 2021. During the nine months ended September 30, 2022, the transaction price for this performance obligation was increased by $2.0 million due to the satisfaction of a development milestone under the Huadong License Agreement, as amended. This amount was fully recognized as revenue during the nine months ended September 30, 2022, as the related performance obligation was fully satisfied.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A portion of the transaction price allocated to the obligation to participate in the JDC to oversee the development of products and the Phase 2 MRCT in accordance with the development plan remained deferred as of September 30, 2022, and revenue will be recognized using the proportional performance model over the period of the Company’s participation on the JDC. The unrecognized amount of the transaction price allocated to this performance obligation as of September 30, 2022, was de minimis. An immaterial amount of revenue for this performance obligation has been recognized during nine months ended September 30, 2022, and 2021. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Newsoara License Agreement-</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is party to a license agreement with Newsoara Biopharma Co., Ltd., (“Newsoara”) (the “Newsoara License Agreement”) under which Newsoara obtained an exclusive and sublicensable license to develop and commercialize the Company’s phosphodiesterase type 4 inhibitors (“PDE4”) program, including the compound </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">HPP737</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in China, Hong Kong, Macau, Taiwan and other pacific rim countries (collectively, the “Newsoara License Territory”). Additionally, under the Newsoara License Agreement, the Company obtained a non-exclusive, sublicensable, royalty-free license to develop and commercialize certain Newsoara patent rights and know-how related to the Company’s PDE4 program for therapeutic uses in humans outside of the Newsoara License Territory.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company has fully allocated the transaction price to the license and the technology transfer services which represents a single performance obligation because they were not capable of being distinct on their own. The Company recognized revenue for this performance obligation using the straight-line method over the transfer service period. The revenue for this performance obligation has been fully recognized as of September 30, 2022. In the third quarter of 2021, the transaction price for this performance obligation was increased by $1.0 million due to the satisfaction of a development milestone under the Newsoara License Agreement. This amount was fully recognized as revenue during the three and nine months ended September 30, 2021, as the related performance obligation was fully satisfied. No revenue related to this performance obligation was recognized and there have been no changes to the transaction price during the three and nine months ended September 30, 2022.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">JDRF Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2017, the Company entered into a research and collaboration agreement with JDRF International (the “JDRF Agreement”) to support the funding of the Simplici-T1 Study, a Phase 2 study to explore the effects of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TTP399</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in patients with type 1 diabetes. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The JDRF Agreement was amended in June 2021 to provide additional funding for the Company’s mechanistic study exploring the effects of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TTP399</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on ketone body formation during a period of insulin withdrawal in people with type 1 diabetes. Consistent with</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the terms of the JDRF Agreement, JDRF provided research funding of $3.4 million based on the achievement of research and development milestones, with the total funding provided by JDRF not to exceed approximately one-half of the total cost of the project. Additionally, the Company has the obligation to make certain milestone payments to JDRF upon the commercialization, licensing, sale or transfer of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TTP399</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as a treatment for type 1 diabetes.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments that the Company receives from JDRF under this agreement were recorded as restricted cash and current liabilities and recognized as an offset to research and development expense, based on the progress of the project, and only to the extent that the restricted cash is utilized to fund such development activities. As of September 30, 2022, the Company had received funding under this agreement of $3.4 million. Research and development costs have been offset by the $3.4 million of cash received over the course of this agreement. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Liabilities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities related to the Company’s collaboration agreements consisted of the following (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.038%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of contract liabilities</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,669 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contract liabilities</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,695 </span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in short-term and long-term contract liabilities for the nine months ended September 30, 2022, were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.638%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.162%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract Liabilities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance on January 1, 2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification of the beginning contract liabilities to revenue, as the result of performance obligations satisfied</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consideration received in advance and not recognized as revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,669 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance on September 30, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,695 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 10386274 0.01 2.41 25000000 12500000 12500000 P1Y 30000000 30000000 0.08 P10Y 5700000 0.55 18700000 600000 12500000 11900000 18700000 0 0 0 0 0 0 2000000 3000000 3000000 1000000 1000000 2000000 1000000 0 0 0 0 3400000 3400000 3400000 <div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities related to the Company’s collaboration agreements consisted of the following (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.038%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of contract liabilities</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,669 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contract liabilities</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,695 </span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 26000 35000 18669000 0 18695000 35000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in short-term and long-term contract liabilities for the nine months ended September 30, 2022, were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.638%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.162%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract Liabilities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance on January 1, 2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification of the beginning contract liabilities to revenue, as the result of performance obligations satisfied</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consideration received in advance and not recognized as revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,669 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance on September 30, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,695 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 35000 9000 18669000 18695000 Share-Based Compensation<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has issued non-qualified stock option awards to management, other key employees, consultants, and non-employee directors. These option awards generally vest ratably over a three-year period and the option awards expire after a term of ten years from the date of grant. As of September 30, 2022, the Company had total unrecognized stock-based compensation expense for its outstanding stock option awards of approximately $2.6 million, which is expected to be recognized over a weighted average period of 2.7 years. The weighted average grant date fair value of options granted during the nine months ended September 30, 2022, and 2021 was $0.68 and $2.21 per option, respectively. The aggregate intrinsic value of the in-the-money awards outstanding at September 30, 2022, was de minimis.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 27, 2022, Ms. Deepa Prasad notified the Board of Directors (the “Board”) of the Company of her decision to resign from her positions as Chief Executive Officer, President, and Board member, effective as of March 29, 2022, and served in these roles through March 29, 2022 (the “Effective Date”). Ms. Prasad agreed to serve as a Strategic Advisor to the Company for six months after the Effective Date. Ms. Prasad will retain 624,659 of the outstanding options previously granted to her, which will vest at the end of the 15-month period following the Effective Date. As a result of the separation agreement, these options were modified to accelerate vesting at the Effective Date. These options will remain exercisable for the original ten-year period and the remaining 1,873,976 of her options were cancelled. The additional stock compensation expense for the modification during the nine months ended September 30, 2022, was de minimis.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to the stock option awards for the nine months ended September 30, 2022:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted <br/>Average Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awards outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,056,035 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.19 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,047,333 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.78 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,384,424)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.37 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awards outstanding at September 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,718,944 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.28 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable at September 30, 2022</span></td><td colspan="2" style="background-color:#cff0fc;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,563,810 </span></td><td style="background-color:#cff0fc;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.75 </span></td><td style="background-color:#cff0fc;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining contractual term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3 Years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest at September 30, 2022</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,664,874 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.49 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining contractual term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2 Years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation expense related to the grants of stock options is included in research and development and general and administrative expense as follows (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"/><td style="width:39.809%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.054%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">692 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">820 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">474 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">981 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,362 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> P3Y P10Y 2600000 P2Y8M12D 0.68 2.21 P6M 624659 P15M P10Y 1873976 <div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to the stock option awards for the nine months ended September 30, 2022:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted <br/>Average Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awards outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,056,035 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.19 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,047,333 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.78 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,384,424)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.37 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awards outstanding at September 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,718,944 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.28 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable at September 30, 2022</span></td><td colspan="2" style="background-color:#cff0fc;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,563,810 </span></td><td style="background-color:#cff0fc;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.75 </span></td><td style="background-color:#cff0fc;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining contractual term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3 Years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest at September 30, 2022</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,664,874 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.49 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining contractual term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2 Years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div> 7056035 3.19 4047333 0.78 3384424 2.37 7718944 2.28 2563810 4.75 P6Y3M18D 6664874 2.49 P8Y2M12D <div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation expense related to the grants of stock options is included in research and development and general and administrative expense as follows (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"/><td style="width:39.809%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.054%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">692 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">820 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">474 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">981 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,362 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 109000 186000 289000 542000 229000 288000 692000 820000 338000 474000 981000 1362000 Investments<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Reneo License Agreement and the Anteris License Agreement, the Company has received equity ownership interests of less than 20% of the voting equity of the investee. Further, the Company does not have the ability to exercise significant influence over the investees. The investments are classified as long-term investments in the Company’s Consolidated Balance Sheets.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reneo completed its initial public offering in April 2021. Prior to Reneo becoming a publicly traded company, the Company’s investment in Reneo did not have a readily determinable fair value and was measured at cost less impairment, adjusted for any changes in observable prices, under the measurement alternative. Subsequent to Reneo’s initial public offering, the Company’s investment in Reneo is considered to have a readily determinable fair value and, as such, is adjusted to its fair value each period with changes in fair value recognized as a component of net loss. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s investment in Anteris does not have a readily determinable fair value and is measured at cost less impairment, adjusted for any changes in observable prices.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s investments consist of the following:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"/><td style="width:68.705%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.296%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.102%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investment with readily determinable fair value:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reneo common stock</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,930 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,928 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investment without readily determinable fair values assessed under the measurement alternative:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anteris preferred stock</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,245 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,245 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,175 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,173 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No adjustments have been made to the value of the Company’s investment in Anteris since its initial measurement either due to impairment or based on observable price changes. The Company recognized an unrealized gain on its investment in Reneo of $0.4 million and an unrealized loss of $3.0 million for the three and nine months ended September 30, 2022, respectively. The Company recognized an unrealized loss on its investment in Reneo of $1.1 million and an unrealized gain of $1.8 million for the three months and nine months ended September 30, 2021, respectively. These adjustments were recognized as a component of other income/(expense) in the Company’s Condensed Consolidated Statements of Operations.</span></div> 0.20 <div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s investments consist of the following:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"/><td style="width:68.705%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.296%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.102%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investment with readily determinable fair value:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reneo common stock</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,930 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,928 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investment without readily determinable fair values assessed under the measurement alternative:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anteris preferred stock</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,245 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,245 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,175 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,173 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1930000 4928000 4245000 4245000 6175000 9173000 400000 -3000000 -1100000 1800000 Commitments and Contingencies<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Matters</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company is involved in various legal proceedings arising in the normal course of business. If a specific contingent liability is determined to be probable and can be reasonably estimated, the Company accrues and discloses the amount. The Company is not currently a party to any material legal proceedings.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Novo Nordisk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2007, the Company entered into an Agreement Concerning Glucokinase Activator Project with Novo Nordisk A/S (the “Novo License Agreement”) whereby the Company obtained an exclusive, worldwide, sublicensable license under certain Novo Nordisk intellectual property rights to discover, develop, manufacture, have manufactured, use and commercialize products for the prevention, treatment, control, mitigation or palliation of human or animal diseases or conditions. As part of this license grant, the Company obtained certain worldwide rights to Novo Nordisk’s GKA program, including rights to preclinical and clinical compounds such as</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> TTP399</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This agreement was amended in May 2019 to create </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">milestone payments applicable to certain specific and non-specific areas of therapeutic use. Under the terms of the amended Novo License Agreement, the Company has potential developmental and regulatory milestone payments totaling up to $9.0 million for approval of a product for the treatment of type 1 diabetes, $50.5 million for approval of a product for the treatment of type 2 diabetes, or $115.0 million for approval of a product in any other indication. The Company may also be obligated to pay an additional $75.0 million in potential sales-based milestones, as well as royalty payments, at mid-single digit royalty rates, based on tiered sales of commercialized licensed products. During the fourth quarter of 2021, the Company made a payment of $2.0 million related to the satisfaction of the milestone to complete the phase 2 trials for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TTP399</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under this agreement.</span> 9000000 50500000 115000000 75000000 2000000 Leases<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases office space for its headquarters location under an operating lease. This lease commenced in November 2019 after the completion of certain tenant improvements made by the lessor. The lease includes an option to renew for a five-year term as well as an option to terminate after three years, neither of which have been recognized as part of its related right of use assets or lease liabilities as their election was not considered reasonably certain. The Company has notified the lessor that it intends to exercise the early termination option and is negotiating an amendment to the lease. Further, this lease does not include any material residual value guarantee or restrictive covenants. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At each of September 30, 2022, and December 31, 2021, the weighted average incremental borrowing rate for the operating leases held by the Company was 13.1%. At September 30, 2022, and December 31, 2021, the weighted average remaining lease terms for the operating leases held by the Company were 2.3 years and 3.1 years, respectively.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities for the Company’s operating leases as of September 30, 2022, were as follows (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"/><td style="width:85.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (remaining three months)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">631 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost and the related operating cash flows for the nine months ended September 30, 2022, and 2021 were immaterial amounts.</span></div> P5Y P3Y 0.131 0.131 P2Y3M18D P3Y1M6D <div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities for the Company’s operating leases as of September 30, 2022, were as follows (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"/><td style="width:85.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (remaining three months)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">631 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 65000 268000 275000 23000 0 0 631000 90000 541000 Redeemable Noncontrolling Interest<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to the Exchange Agreement with respect to the vTv Units representing the 22.1% noncontrolling interest in vTv LLC outstanding as of September 30, 2022 (see Note 9). The Exchange Agreement requires the surrender of an equal number of vTv Units and Class B common stock for (i) shares of Class A common stock on a one-for-one basis or (ii) cash (based on the fair market value of the Class A common stock as determined pursuant to the Exchange Agreement), at the Company’s option (as the managing member of vTv LLC), subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications. The exchange value is determined based on a 20-day volume weighted average price of the Class A common stock as defined in the Exchange Agreement, subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The redeemable noncontrolling interest is recognized at the higher of (1) its initial fair value plus accumulated earnings/losses associated with the noncontrolling interest or (2) the redemption value as of the balance sheet date. At September 30, 2022, and December 31, 2021, the redeemable noncontrolling interest was recorded based on the redemption value as of the balance sheet date of $24.2 million and $25.0 million, respectively.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the Company’s ownership interest in vTv LLC while the Company retains its controlling interest in vTv LLC are accounted for as equity transactions, and the Company is required to adjust noncontrolling interest and equity for </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">such changes. The following is a summary of net income attributable to vTv Therapeutics Inc. and transfers to noncontrolling interest:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.757%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.741%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to vTv Therapeutics Inc. common shareholders</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,261)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,087)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,419)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,936)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Increase) in vTv Therapeutics Inc. accumulated deficit for purchase of LLC Units as a result of common stock issuances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,174)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,773)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,298)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change from net loss attributable to vTv Therapeutics Inc. common shareholders and transfers to noncontrolling interest</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,435)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,860)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,522)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,234)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 0.221 1 P20D 24200000 25000000 The following is a summary of net income attributable to vTv Therapeutics Inc. and transfers to noncontrolling interest:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.757%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.741%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to vTv Therapeutics Inc. common shareholders</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,261)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,087)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,419)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,936)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Increase) in vTv Therapeutics Inc. accumulated deficit for purchase of LLC Units as a result of common stock issuances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,174)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,773)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,298)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change from net loss attributable to vTv Therapeutics Inc. common shareholders and transfers to noncontrolling interest</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,435)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,860)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,522)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,234)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> -4261000 -1087000 -14419000 -5936000 -1174000 -2773000 -103000 -5298000 -5435000 -3860000 -14522000 -11234000 Stockholders’ Deficit<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amendment to Certificate of Incorporation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 4, 2021, the Company filed an amendment to its Amended and Restated Certificate of Incorporation (the “Charter Amendment”) to increase the number of shares of Class A common stock that the Company is authorized to issue from 100,000,000 shares of Class A common stock to 200,000,000 shares of Class A common stock, representing an increase of 100,000,000 shares of authorized Class A common stock, with a corresponding increase in the total authorized common stock, which includes Class A common stock and Class B common stock, from 200,000,000 to 300,000,000, and a corresponding increase in the total authorized capital stock, which includes common stock and preferred stock, from 250,000,000 shares to 350,000,000 shares.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">G42 Investments Transaction</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 31, 2022, the Company and G42 Investments entered in to the G42 Purchase Agreement (see Note 3), pursuant to which the Company agreed to sell to G42 Investments 10,386,274 shares of the Company's Class A common stock, par value $0.01 per share at a price per share of approximately $2.41, for an aggregate purchase price of $25.0 million, consisting of (i) $12.5 million in cash at the closing of the transaction and (ii) $12.5 million in the form of a promissory note of G42 Investments to be paid at the one-year anniversary of the execution of the G42 Purchase Agreement. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CinPax and CinRx Transaction</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 22, 2022 (the “Transaction Date”), the Company entered into the CinRx Purchase Agreement with CinPax and CinRx, pursuant to which the Company agreed to sell to CinPax 4,154,549 shares of the Company’s Class A common stock, par value $0.01 per share (the “Common Stock” and such shares, the “Closing Shares”) at a price per share of approximately $2.41, for an aggregate purchase price of $10.0 million, which was paid (i) $6.0 million in cash at the closing of the transaction and (ii) $4.0 million in the form of a non-interest-bearing promissory note with CinPax to be paid at the four-month anniversary of the execution of the CinRx Purchase Agreement. The promissory note receivable was classified and accounted for under ASC 505 as contra-equity. The CinRx Purchase Agreement provides CinPax the right to put forward a director to be approved to sit on vTv’s Board of Directors and a board observer, which was subsequently approved by the Company’s board.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock is generally recorded at fair value at the date of issuance. In determining the fair value of the Class A common stock issued to CinPax, the Company considered the closing price of the common stock on the Transaction Date. The Company did not make an adjustment to the fair value for sale restrictions on the stock in accordance with guidance recently adopted in ASU 2022-03. See the “Recently Issued Accounting Guidance” in this 10-Q for details of the ASU.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, the Company determined that cash consideration of $3.0 million should be recorded as fair value of the Class A common stock at the effective date, utilizing the Class A common stock closing price of $0.72 at the effective date. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CinRx Purchase Agreement also provides CinRx warrants to purchase up to 1,200,000 shares of Common Stock at an initial exercise of price of approximately $0.72 per share (the “CinRx Warrants”). The CinRx Warrants were initially measured at fair value of $0.4 million using the Black Scholes option model at the time of issuance and will be recorded in Warrant liability related party in the Condensed Consolidated Balance Sheets and will be subsequently remeasured at fair value through earnings on a recurring basis. (see Note 13)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CinRx Warrants will become exercisable by CinRx only if (i) the Company receives approval from the U.S. Food and Drug Administration (“FDA Approval”) to market and distribute the pharmaceutical product containing the Company’s proprietary candidate, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TTP399</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the “Product”), or (ii) the Company is acquired by a third party, sells all or substantially all of its assets related to the Product to a third party or grants a third party an exclusive license to develop, commercialize and manufacture the Product in the United States (an “Exit Event”). If neither of these events happen within five years of the date of the issuance of the CinRx Warrants, the CinRx Warrants will expire and not be exercisable by CinRx. The exercise price of the CinRx Warrants and the number of shares issuable upon exercise of the CinRx Warrants are subject to adjustments in accordance with the terms of the CinRx Warrants.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in conjunction with the CinRx Purchase Agreement the Company and CinRx entered into a Master Service Agreement (“CinRx MSA”) whereby CinRx provides the Company with consulting, pre-clinical and clinical trial services, as enumerated in project proposals negotiated between the Company and CinRx from time to time. (see Note 10)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not identify any other promises in the CinRx Purchase Agreement (aside from the issuance of common shares and the CinRx Warrants) and determined since there is no value ascribed to the CinRx MSA, the right to appoint a member and observer to the board of directors, that the remaining unallocated amount meets the definition of contributed equity and represents the amount in excess of par.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">ATM Offering</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, the Company entered into the Sales Agreement with Cantor Fitzgerald as the sales agent, pursuant to which the Company may offer and sell, from time to time, through Cantor, shares of its Class A common stock, par value $0.01 per share, having an aggregate offering price of up to $13.0 million by any method deemed to be an “at the market offering” as defined in Rule 415(a)(4) under the Securities Act (the “ATM Offering”). The shares are offered and sold pursuant to the Company’s shelf registration statement on Form S-3. In no event will the Company sell Class A common stock under this registration statement with a value exceeding more than one-third of the “public float” (the market value of our Class A common stock and any other equity securities that we may issue in the future that are held by non-affiliates) in any 12-calendar month period so long as our public float remains below $75 million.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 14, 2021, and June 25, 2021, the Company filed a prospectus supplement in connection with the ATM Offering to increase the size of the at-the-market offering pursuant to which the Company may offer and sell, from time to time, through or to Cantor, as sales agent or principal, shares of the Company’s Class A common stock, by an aggregate offering price of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $5.5 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and $50.0 million, respectively</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September 30, 2021, the Company sold 8,457,546 shares of its Class A common stock under the ATM Offering for net proceeds of $17.0 million.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September 30, 2022, the Company did not sell any shares under the ATM Offering. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lincoln Park Capital Transaction</span></div>On November 24, 2020, the Company entered into the LPC Purchase Agreement and a registration rights agreement (the “Registration Rights Agreement”), pursuant to which the Company has the right to sell to Lincoln Park shares of the Company’s Class A common stock having an aggregate value of up to $47.0 million, subject to certain limitations and conditions set forth in the LPC Purchase Agreement. The Company will control the timing and amount of any sales of shares to Lincoln Park. pursuant to the LPC Purchase Agreement. During the three and nine months ended September 30, 2022, the Company did not sell any shares under the LPC Purchase Agreement. During the nine months ended September 30, 2021, the Company sold 3,941,726 shares under the LPC Purchase Agreement for total proceeds of $9.1 million. 100000000 200000000 100000000 200000000 300000000 250000000 350000000 10386274 0.01 2.41 25000000 12500000 12500000 P1Y 4154549 0.01 2.41 10000000 6000000 4000000 P4M 3000000 0.72 1200000 0.72 400000 P5Y 0.01 13000000 75000000 5500000 50000000 8457546 8457546 17000000 17000000 0 0 47000000 0 0 3941726 9100000 Related-Party Transactions<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MacAndrews &amp; Forbes Incorporated</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, subsidiaries and affiliates of MacAndrews &amp; Forbes Incorporated (collectively “MacAndrews”) indirectly controlled 23,084,267 shares of the Company’s Class B common stock and 36,519,212 shares of the Company’s Class A common stock. As a result, MacAndrews’ holdings represent approximately 57.0% of the combined voting power of the Company’s outstanding common stock.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into several agreements with MacAndrews or its affiliates as further detailed below:</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Letter Agreements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has previously entered into the Letter Agreements with MacAndrews. Under the terms of the Letter Agreements, during the one year commitment period beginning on the date of each License Agreement, the Company had the right to sell to MacAndrews shares of its Class A common stock at a specified price per share, and MacAndrews had the right (exercisable up to three times) to require the Company to sell to it shares of Class A common stock at the same price. The commitment period of each of the Letter Agreements has now expired. In addition, in connection with and as a commitment fee for the entrance into certain of these Letter Agreements, the Company also issued MacAndrews warrants (the “Letter Agreement Warrants”) to purchase additional shares of the Company’s Class A common stock. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Letter Agreement Warrants have been recorded as warrant liability, related party within the Company’s Condensed Consolidated Balance Sheets based on their fair value. The issuance of the Letter Agreement Warrants was considered to be a cost of equity recorded as a reduction to additional paid-in capital. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exchange Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and MacAndrews are party to an exchange agreement (the “Exchange Agreement”) pursuant to which the vTv Units (along with a corresponding number of shares of the Class B common stock) are exchangeable for (i) shares of the Company’s Class A common stock on a one-for-one basis or (ii) cash (based on the fair market value of the Class A common stock as determined pursuant to the Exchange Agreement), at the Company’s option (as the managing member of vTv LLC), subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications. Any decision to require an exchange for cash rather than shares of Class A common stock will ultimately be determined by the entire board of directors of vTv Therapeutics Inc. (the “Board of Directors”). As of September 30, 2022, MacAndrews had not exchanged any shares under the provisions of the Exchange Agreement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tax Receivable Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and MacAndrews are party to a tax receivable agreement (the “Tax Receivable Agreement”), which provides for the payment by the Company to M&amp;F TTP Holdings Two LLC (“M&amp;F”), as successor in interest to vTv Therapeutics Holdings, LLC (“vTv Therapeutics Holdings”), and M&amp;F TTP Holdings LLC (or certain of its transferees or other assignees) of 85% of the amount of cash savings, if any, in U.S. federal, state and local income tax or franchise tax that the Company actually realizes (or, in some circumstances, the Company is deemed to realize) as a result of (a) the exchange of Class B commons stock, together with the corresponding number of vTv Units, for shares of the Company’s Class A common stock (or for cash), (b) tax benefits related to imputed interest deemed to be paid by the Company as a result of the Tax Receivable Agreement and (c) certain tax benefits attributable to payments under the Tax Receivable Agreement. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As no shares have been exchanged by MacAndrews pursuant to the Exchange Agreement (discussed above), the Company has not recognized any liability, nor has it made any payments pursuant to the Tax Receivable Agreement as of September 30, 2022.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investor Rights Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is party to an investor rights agreement with M&amp;F, as successor in interest to vTv Therapeutics Holdings (the “Investor Rights Agreement”). The Investor Rights Agreement provides M&amp;F with certain demand, shelf, and piggyback registration rights with respect to its shares of Class A common stock and also provides M&amp;F with certain governance rights, depending on the size of its holdings of Class A common stock. Under the Investor Rights Agreement, M&amp;F was initially entitled to nominate a majority of the members of the Board of Directors and designate the members of the committees of the Board of Directors.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CinRx Pharma, LLC</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Master Services Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 22, 2022, the Company entered into a Master Services Agreement with CinRx Pharma, LLC (“CinRx”) (the “CinRx MSA”). Under the CinRx MSA, CinRx provides the Company with consulting, pre-clinical and clinical trial services, as enumerated in project proposals negotiated between the Company and CinRx from time to time. As of October 10, 2022, the Company has agreed to pay CinRx fees of up to $0.2 million per month until approximately December 2024 in respect of ongoing agreed project proposals under the CinRx MSA, plus out-of-pocket expenses incurred by CinRx on the Company’s behalf. Dr. Jonathan Isaacsohn, who was appointed as chair of the Company’s board of directors on August 9, 2022, is the President and Chief Executive Officer of CinRx. CinPax, LLC, a subsidiary of CinRx, currently holds 4,154,549 shares of the Company’s Class A Common Stock.</span></div> 23084267 36519212 0.570 0.85 200000 4154549 Income Taxes<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to U.S. federal income taxes as well as state taxes. The Company did not record an income tax provision for the three months ended September 30, 2022. The Company’s income tax provision for the nine months ended September 30, 2022, was $0.2 million related to foreign withholding taxes. The Company’s income tax provision for the three and nine months ended September 30, 2021 was $0.1 million related to foreign withholding taxes.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management has evaluated the positive and negative evidence surrounding the realization of its deferred tax assets, including the Company’s history of losses, and under the applicable accounting standards determined that it is more-likely-than-not that the deferred tax assets will not be realized. The difference between the effective tax rate of the Company and the U.S. statutory tax rate of 21% on September 30, 2022, is due to the valuation allowance against the Company’s expected net operating losses.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 10, the Company is party to a tax receivable agreement with a related party which provides for the payment by the Company to M&amp;F (or certain of its transferees or other assignees) of 85% of the amount of cash savings, if any, in U.S. federal, state and local income tax or franchise tax that the Company actually realizes (or, in some circumstances, the Company is deemed to realize) as a result of certain transactions. As no transactions have occurred which would trigger a liability under this agreement, the Company has not recognized any liability related to this agreement as of September 30, 2022.</span></div> 0 200000 100000 100000 0.85 Net Loss per Share<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic loss per share is computed by dividing net loss attributable to vTv Therapeutics Inc. by the weighted average number of shares of Class A common stock outstanding during the period. Diluted loss per share is computed giving effect to all potentially dilutive shares. Diluted loss per share for all periods presented is the same as basic loss per share as the inclusion of potentially issuable shares would be antidilutive. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the numerator and denominator used in the calculation of basic and diluted net loss per share of Class A common stock is as follows (in thousands, except share and per share amounts):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.138%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.144%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.144%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.144%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.145%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,468)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,465)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,983)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,248)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net loss attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,207)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(378)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,564)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,312)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common shareholders of vTv Therapeutics Inc., basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,261)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,087)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,419)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,936)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average vTv Therapeutics Inc. Class A common stock, basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,490,121 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,073,280 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,649,531 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,737,170 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share of vTv Therapeutics Inc. Class A common stock, basic and diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.05)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.02)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.20)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.10)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities not included in the calculation of diluted net loss per share are as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:72.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.865%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.867%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class B common stock </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,093,860 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,093,860 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options granted under the Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,718,944 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,474,403 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,214,503 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,014,503 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,027,307 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,582,766 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"/><td style="width:2.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:90.720%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Shares of Class B common stock do not share in the Company’s earnings and are not participating securities. Accordingly, separate presentation of loss per share of Class B common stock under the two-class method has not been provided. Each share of Class B common stock (together with a corresponding vTv Unit) is exchangeable for one share of Class A common stock.</span></td></tr></table></div> <div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the numerator and denominator used in the calculation of basic and diluted net loss per share of Class A common stock is as follows (in thousands, except share and per share amounts):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.138%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.144%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.144%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.144%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.145%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,468)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,465)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,983)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,248)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net loss attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,207)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(378)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,564)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,312)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common shareholders of vTv Therapeutics Inc., basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,261)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,087)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,419)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,936)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average vTv Therapeutics Inc. Class A common stock, basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,490,121 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,073,280 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,649,531 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,737,170 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share of vTv Therapeutics Inc. Class A common stock, basic and diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.05)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.02)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.20)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.10)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> -5468000 -1465000 -18983000 -8248000 -1207000 -378000 -4564000 -2312000 -4261000 -4261000 -1087000 -1087000 -14419000 -14419000 -5936000 -5936000 80490121 80490121 61073280 61073280 72649531 72649531 58737170 58737170 -0.05 -0.05 -0.02 -0.02 -0.20 -0.20 -0.10 -0.10 <div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities not included in the calculation of diluted net loss per share are as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:72.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.865%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.867%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class B common stock </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,093,860 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,093,860 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options granted under the Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,718,944 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,474,403 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,214,503 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,014,503 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,027,307 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,582,766 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"/><td style="width:2.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:90.720%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Shares of Class B common stock do not share in the Company’s earnings and are not participating securities. Accordingly, separate presentation of loss per share of Class B common stock under the two-class method has not been provided. Each share of Class B common stock (together with a corresponding vTv Unit) is exchangeable for one share of Class A common stock.</span></td></tr></table></div> 23093860 23093860 7718944 4474403 3214503 2014503 34027307 29582766 Fair Value of Financial Instruments<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of certain of the Company’s financial instruments, including cash and cash equivalents, net accounts receivable, note receivable, accounts payable, and other accrued liabilities, approximate fair value due to their short-term nature.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level in which to classify them for each reporting period. This determination requires significant judgments. The Company determined that the promissory note receivable was level 2 and the fair value measurement was based on the market yield curves. The following table summarizes the conclusions reached regarding fair value measurements as of September 30, 2022, and December 31, 2021 (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.667%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.807%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active <br/>Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable <br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities with readily determinable fair value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,930 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,930 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,930 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,930 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability, related party </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,409 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,409 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,409 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,409 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.667%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.807%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active <br/>Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable <br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities with readily determinable fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,928 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,928 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,928 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,928 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability, related party </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"/><td style="width:3.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Fair value determined using the Black-Scholes option pricing model. Expected volatility is based on the historical volatility of the Company’s common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation.</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"/><td style="width:31.735%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.840%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.840%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.827%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Changes in Level 3 instruments for the nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at January 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Change in<br/>fair value included in <br/>earnings</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Purchases /<br/>Issuance</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Sales /<br/>Repurchases</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability, related party</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(221)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,409 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(221)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,409 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability, related party</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,871 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(611)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,260 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,871 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(611)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,260 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2021, Reneo completed its initial public offering. As a result, the fair value of the Company’s investment in Reneo’s common stock now has a readily determinable market value and is no longer eligible for the practical expedient for investments without readily determinable fair market values. As such, the Company’s investment in Reneo is adjusted each reporting period to its fair value based on its most recent closing price, which is considered a Level 1 fair value measurement under the fair value hierarchy. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers into or out of level 3 instruments and/or between level 1 and level 2 instruments during the three and nine months ended September 30, 2022. Gains and losses recognized due to the change in fair value of the warrant liability, related party are recognized as a component of other (expense) income, related party in the Condensed Consolidated Statements of Operations. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Letter Agreement Warrants was determined using the Black-Scholes option pricing model or option pricing models based on the Company’s current capitalization. Expected volatility is based on the historical volatility of the Company’s common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation. Significant inputs utilized in the valuation of the Letter Agreement Warrants as of September 30, 2022, and December 31, 2021, were:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"/><td style="width:30.738%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.790%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.790%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.790%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.795%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.70% - 109.73%</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.51%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.68% - 142.86%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128.13%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.13% - 4.25%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.20%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.95% - 1.26%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.15%</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the CinRx Warrants was determined using the Black-Scholes option pricing model. Expected volatility is based on the historical volatility of the Company’s common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation. Significant inputs utilized in the valuation of the CinRx Warrants as of September 30, 2022, were:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.471%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.329%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life of options in years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average expected volatility and risk-free interest rate was based on the relative fair values of the warrants.</span></div>Changes in the unobservable inputs noted above would impact the amount of the liability for the Letter Agreement and CinRx Warrants. Increases (decreases) in the estimates of the Company’s annual volatility would increase (decrease) the liability and an increase (decrease) in the annual risk-free rate would increase (decrease) the liability. The following table summarizes the conclusions reached regarding fair value measurements as of September 30, 2022, and December 31, 2021 (in thousands):<div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.667%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.807%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active <br/>Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable <br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities with readily determinable fair value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,930 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,930 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,930 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,930 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability, related party </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,409 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,409 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,409 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,409 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.667%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.807%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active <br/>Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable <br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities with readily determinable fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,928 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,928 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,928 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,928 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability, related party </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"/><td style="width:3.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Fair value determined using the Black-Scholes option pricing model. Expected volatility is based on the historical volatility of the Company’s common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation.</span></td></tr></table></div> 1930000 1930000 0 0 1930000 1930000 0 0 1409000 0 0 1409000 1409000 0 0 1409000 4928000 4928000 0 0 4928000 4928000 0 0 1262000 0 0 1262000 1262000 0 0 1262000 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"/><td style="width:31.735%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.840%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.840%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.827%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Changes in Level 3 instruments for the nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at January 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Change in<br/>fair value included in <br/>earnings</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Purchases /<br/>Issuance</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Sales /<br/>Repurchases</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability, related party</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(221)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,409 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(221)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,409 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability, related party</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,871 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(611)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,260 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,871 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(611)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,260 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 1262000 -221000 368000 0 1409000 1262000 -221000 368000 0 1409000 2871000 -611000 0 0 2260000 2871000 -611000 0 0 2260000 Significant inputs utilized in the valuation of the Letter Agreement Warrants as of September 30, 2022, and December 31, 2021, were:<div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"/><td style="width:30.738%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.790%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.790%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.790%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.795%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.70% - 109.73%</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.51%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.68% - 142.86%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128.13%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.13% - 4.25%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.20%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.95% - 1.26%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.15%</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the CinRx Warrants was determined using the Black-Scholes option pricing model. Expected volatility is based on the historical volatility of the Company’s common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation. Significant inputs utilized in the valuation of the CinRx Warrants as of September 30, 2022, were:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.471%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.329%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life of options in years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> 0.8170 1.0973 0.9551 0.8268 1.4286 1.2813 0.0413 0.0425 0.0420 0.0095 0.0126 0.0115 0.852 P3Y1M6D 0.043 0 Subsequent EventsThe Company evaluated subsequent events through November 10, 2022, and determined that there have been no events that have occurred that would require adjustments to our disclosures or the unaudited condensed consolidated financial statements. EXCEL 64 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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end XML 65 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 66 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 67 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 215 244 1 false 71 0 false 5 false false R1.htm 0000001 - Document - Cover Sheet http://vtvtherapeutics.com/role/Cover Cover Cover 1 false false R2.htm 0000002 - Statement - Condensed Consolidated Balance Sheets Sheet http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 0000004 - Statement - Condensed Consolidated Statements of Operations - Unaudited Sheet http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited Condensed Consolidated Statements of Operations - Unaudited Statements 4 false false R5.htm 0000005 - Statement - Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders' Deficit - Unaudited Sheet http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders' Deficit - Unaudited Statements 5 false false R6.htm 0000006 - Statement - Condensed Consolidated Statements of Cash Flows - Unaudited Sheet http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited Condensed Consolidated Statements of Cash Flows - Unaudited Statements 6 false false R7.htm 0000007 - Disclosure - Description of Business, Basis of Presentation and Going Concern Sheet http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcern Description of Business, Basis of Presentation and Going Concern Notes 7 false false R8.htm 0000008 - Disclosure - Summary of Significant Accounting Policies Sheet http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 0000009 - Disclosure - Collaboration Agreements Sheet http://vtvtherapeutics.com/role/CollaborationAgreements Collaboration Agreements Notes 9 false false R10.htm 0000010 - Disclosure - Share-Based Compensation Sheet http://vtvtherapeutics.com/role/ShareBasedCompensation Share-Based Compensation Notes 10 false false R11.htm 0000011 - Disclosure - Investments Sheet http://vtvtherapeutics.com/role/Investments Investments Notes 11 false false R12.htm 0000012 - Disclosure - Commitments and Contingencies Sheet http://vtvtherapeutics.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 12 false false R13.htm 0000013 - Disclosure - Leases Sheet http://vtvtherapeutics.com/role/Leases Leases Notes 13 false false R14.htm 0000014 - Disclosure - Redeemable Noncontrolling Interest Sheet http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterest Redeemable Noncontrolling Interest Notes 14 false false R15.htm 0000015 - Disclosure - Stockholders' Deficit Sheet http://vtvtherapeutics.com/role/StockholdersDeficit Stockholders' Deficit Notes 15 false false R16.htm 0000016 - Disclosure - Related-Party Transactions Sheet http://vtvtherapeutics.com/role/RelatedPartyTransactions Related-Party Transactions Notes 16 false false R17.htm 0000017 - Disclosure - Income Taxes Sheet http://vtvtherapeutics.com/role/IncomeTaxes Income Taxes Notes 17 false false R18.htm 0000018 - Disclosure - Net Loss per Share Sheet http://vtvtherapeutics.com/role/NetLossperShare Net Loss per Share Notes 18 false false R19.htm 0000019 - Disclosure - Fair Value of Financial Instruments Sheet http://vtvtherapeutics.com/role/FairValueofFinancialInstruments Fair Value of Financial Instruments Notes 19 false false R20.htm 0000020 - Disclosure - Subsequent Events Sheet http://vtvtherapeutics.com/role/SubsequentEvents Subsequent Events Notes 20 false false R21.htm 0000021 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPolicies 21 false false R22.htm 0000022 - Disclosure - Collaboration Agreements (Tables) Sheet http://vtvtherapeutics.com/role/CollaborationAgreementsTables Collaboration Agreements (Tables) Tables http://vtvtherapeutics.com/role/CollaborationAgreements 22 false false R23.htm 0000023 - Disclosure - Share-Based Compensation (Tables) Sheet http://vtvtherapeutics.com/role/ShareBasedCompensationTables Share-Based Compensation (Tables) Tables http://vtvtherapeutics.com/role/ShareBasedCompensation 23 false false R24.htm 0000024 - Disclosure - Investments (Tables) Sheet http://vtvtherapeutics.com/role/InvestmentsTables Investments (Tables) Tables http://vtvtherapeutics.com/role/Investments 24 false false R25.htm 0000025 - Disclosure - Leases (Tables) Sheet http://vtvtherapeutics.com/role/LeasesTables Leases (Tables) Tables http://vtvtherapeutics.com/role/Leases 25 false false R26.htm 0000026 - Disclosure - Redeemable Noncontrolling Interest (Tables) Sheet http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestTables Redeemable Noncontrolling Interest (Tables) Tables http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterest 26 false false R27.htm 0000027 - Disclosure - Net Loss per Share (Tables) Sheet http://vtvtherapeutics.com/role/NetLossperShareTables Net Loss per Share (Tables) Tables http://vtvtherapeutics.com/role/NetLossperShare 27 false false R28.htm 0000028 - Disclosure - Fair Value of Financial Instruments (Tables) Sheet http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsTables Fair Value of Financial Instruments (Tables) Tables http://vtvtherapeutics.com/role/FairValueofFinancialInstruments 28 false false R29.htm 0000029 - Disclosure - Description of Business, Basis of Presentation and Going Concern (Detail) Sheet http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail Description of Business, Basis of Presentation and Going Concern (Detail) Details http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcern 29 false false R30.htm 0000030 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) Sheet http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail Summary of Significant Accounting Policies - Additional Information (Detail) Details 30 false false R31.htm 0000031 - Disclosure - Collaboration Agreements - Additional Information (Detail) Sheet http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail Collaboration Agreements - Additional Information (Detail) Details 31 false false R32.htm 0000032 - Disclosure - Collaboration Agreements - Summary of Contract Liabilities Related to Company's Collaboration Agreements (Detail) Sheet http://vtvtherapeutics.com/role/CollaborationAgreementsSummaryofContractLiabilitiesRelatedtoCompanysCollaborationAgreementsDetail Collaboration Agreements - Summary of Contract Liabilities Related to Company's Collaboration Agreements (Detail) Details 32 false false R33.htm 0000033 - Disclosure - Collaboration Agreements - Contract with Customer, Contract Asset, Contract Liability, and Receivable Changes (Details) Sheet http://vtvtherapeutics.com/role/CollaborationAgreementsContractwithCustomerContractAssetContractLiabilityandReceivableChangesDetails Collaboration Agreements - Contract with Customer, Contract Asset, Contract Liability, and Receivable Changes (Details) Details 33 false false R34.htm 0000034 - Disclosure - Share-Based Compensation - Additional Information (Detail) Sheet http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail Share-Based Compensation - Additional Information (Detail) Details 34 false false R35.htm 0000035 - Disclosure - Share-Based Compensation - Summary of Stock Award Activity for the Period (Detail) Sheet http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail Share-Based Compensation - Summary of Stock Award Activity for the Period (Detail) Details 35 false false R36.htm 0000036 - Disclosure - Share-Based Compensation - Summary of Compensation Expense Related to Grants of Stock Options (Detail) Sheet http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofCompensationExpenseRelatedtoGrantsofStockOptionsDetail Share-Based Compensation - Summary of Compensation Expense Related to Grants of Stock Options (Detail) Details 36 false false R37.htm 0000037 - Disclosure - Investments - Additional Information (Detail) Sheet http://vtvtherapeutics.com/role/InvestmentsAdditionalInformationDetail Investments - Additional Information (Detail) Details 37 false false R38.htm 0000038 - Disclosure - Investments - Schedule of Equity Investments with and without Readily Determinable Fair Values Assessed (Detail) Sheet http://vtvtherapeutics.com/role/InvestmentsScheduleofEquityInvestmentswithandwithoutReadilyDeterminableFairValuesAssessedDetail Investments - Schedule of Equity Investments with and without Readily Determinable Fair Values Assessed (Detail) Details 38 false false R39.htm 0000039 - Disclosure - Commitments and Contingencies - Additional Information (Detail) Sheet http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail Commitments and Contingencies - Additional Information (Detail) Details 39 false false R40.htm 0000040 - Disclosure - Leases - (Details) Sheet http://vtvtherapeutics.com/role/LeasesDetails Leases - (Details) Details 40 false false R41.htm 0000041 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities for Operating Leases (Detail) Sheet http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail Leases - Schedule of Maturities of Lease Liabilities for Operating Leases (Detail) Details 41 false false R42.htm 0000042 - Disclosure - Redeemable Noncontrolling Interest - Additional Information (Detail) Sheet http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestAdditionalInformationDetail Redeemable Noncontrolling Interest - Additional Information (Detail) Details 42 false false R43.htm 0000043 - Disclosure - Redeemable Noncontrolling Interest - Summary of Net Income Attributable to Vtv Therapeutics Inc (Detail) Sheet http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestSummaryofNetIncomeAttributabletoVtvTherapeuticsIncDetail Redeemable Noncontrolling Interest - Summary of Net Income Attributable to Vtv Therapeutics Inc (Detail) Details 43 false false R44.htm 0000044 - Disclosure - Stockholders' Deficit - Additional Information (Detail) Sheet http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail Stockholders' Deficit - Additional Information (Detail) Details 44 false false R45.htm 0000045 - Disclosure - Related-Party Transactions - Additional Information (Detail) Sheet http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail Related-Party Transactions - Additional Information (Detail) Details 45 false false R46.htm 0000046 - Disclosure - Income Taxes - Additional Information (Detail) Sheet http://vtvtherapeutics.com/role/IncomeTaxesAdditionalInformationDetail Income Taxes - Additional Information (Detail) Details 46 false false R47.htm 0000047 - Disclosure - Net Loss per Share - Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Loss per Share of Class A Common Stock (Detail) Sheet http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail Net Loss per Share - Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Loss per Share of Class A Common Stock (Detail) Details 47 false false R48.htm 0000048 - Disclosure - Net Loss per Share - Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss per Share (Detail) Sheet http://vtvtherapeutics.com/role/NetLossperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetail Net Loss per Share - Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss per Share (Detail) Details 48 false false R49.htm 0000049 - Disclosure - Fair Value of Financial Instruments - Summarizes the Conclusions Reached Regarding Fair Value Measurements (Detail) Sheet http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail Fair Value of Financial Instruments - Summarizes the Conclusions Reached Regarding Fair Value Measurements (Detail) Details 49 false false R50.htm 0000050 - Disclosure - Fair Value of Financial Instruments - Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation (Details) Sheet http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails Fair Value of Financial Instruments - Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation (Details) Details 50 false false R51.htm 0000051 - Disclosure - Fair Value of Financial Instruments - Fair Value Measurement Inputs and Valuation Techniques (Detail) Sheet http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail Fair Value of Financial Instruments - Fair Value Measurement Inputs and Valuation Techniques (Detail) Details 51 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: vtvt:MaximumFundingPercentageOfResearchAndDevelopmentMilestones - vtvt-20220930.htm 4 vtvt-20220930.htm vtvt-20220930.xsd vtvt-20220930_cal.xml vtvt-20220930_def.xml vtvt-20220930_lab.xml vtvt-20220930_pre.xml vtvt-20220930xexx311.htm vtvt-20220930xexx312.htm vtvt-20220930xexx321.htm vtvt-20220930xexx322.htm vtvt-20220930_g1.jpg http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 70 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "vtvt-20220930.htm": { "axisCustom": 1, "axisStandard": 28, "contextCount": 215, "dts": { "calculationLink": { "local": [ "vtvt-20220930_cal.xml" ] }, "definitionLink": { "local": [ "vtvt-20220930_def.xml" ] }, "inline": { "local": [ "vtvt-20220930.htm" ] }, "labelLink": { "local": [ "vtvt-20220930_lab.xml" ] }, "presentationLink": { "local": [ "vtvt-20220930_pre.xml" ] }, "schema": { "local": [ "vtvt-20220930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 447, "entityCount": 1, "hidden": { "http://vtvtherapeutics.com/20220930": 1, "http://xbrl.sec.gov/dei/2022": 5, "total": 6 }, "keyCustom": 47, "keyStandard": 197, "memberCustom": 39, "memberStandard": 27, "nsprefix": "vtvt", "nsuri": "http://vtvtherapeutics.com/20220930", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "i68b502bf21134ced993cfa7c1f1a0ff8_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover", "role": "http://vtvtherapeutics.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "i68b502bf21134ced993cfa7c1f1a0ff8_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "i68b502bf21134ced993cfa7c1f1a0ff8_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000010 - Disclosure - Share-Based Compensation", "role": "http://vtvtherapeutics.com/role/ShareBasedCompensation", "shortName": "Share-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "i68b502bf21134ced993cfa7c1f1a0ff8_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "i68b502bf21134ced993cfa7c1f1a0ff8_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000011 - Disclosure - Investments", "role": "http://vtvtherapeutics.com/role/Investments", "shortName": "Investments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "i68b502bf21134ced993cfa7c1f1a0ff8_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "i68b502bf21134ced993cfa7c1f1a0ff8_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000012 - Disclosure - Commitments and Contingencies", "role": "http://vtvtherapeutics.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "i68b502bf21134ced993cfa7c1f1a0ff8_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "i68b502bf21134ced993cfa7c1f1a0ff8_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000013 - Disclosure - Leases", "role": "http://vtvtherapeutics.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "i68b502bf21134ced993cfa7c1f1a0ff8_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "i68b502bf21134ced993cfa7c1f1a0ff8_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MinorityInterestDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000014 - Disclosure - Redeemable Noncontrolling Interest", "role": "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterest", "shortName": "Redeemable Noncontrolling Interest", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "i68b502bf21134ced993cfa7c1f1a0ff8_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MinorityInterestDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "i68b502bf21134ced993cfa7c1f1a0ff8_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000015 - Disclosure - Stockholders' Deficit", "role": "http://vtvtherapeutics.com/role/StockholdersDeficit", "shortName": "Stockholders' Deficit", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "i68b502bf21134ced993cfa7c1f1a0ff8_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "i68b502bf21134ced993cfa7c1f1a0ff8_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000016 - Disclosure - Related-Party Transactions", "role": "http://vtvtherapeutics.com/role/RelatedPartyTransactions", "shortName": "Related-Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "i68b502bf21134ced993cfa7c1f1a0ff8_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "i68b502bf21134ced993cfa7c1f1a0ff8_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000017 - Disclosure - Income Taxes", "role": "http://vtvtherapeutics.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "i68b502bf21134ced993cfa7c1f1a0ff8_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "i68b502bf21134ced993cfa7c1f1a0ff8_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000018 - Disclosure - Net Loss per Share", "role": "http://vtvtherapeutics.com/role/NetLossperShare", "shortName": "Net Loss per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "i68b502bf21134ced993cfa7c1f1a0ff8_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "i68b502bf21134ced993cfa7c1f1a0ff8_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000019 - Disclosure - Fair Value of Financial Instruments", "role": "http://vtvtherapeutics.com/role/FairValueofFinancialInstruments", "shortName": "Fair Value of Financial Instruments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "i68b502bf21134ced993cfa7c1f1a0ff8_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "ia2928b4e55ad4b71a771f309dac1b23c_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000002 - Statement - Condensed Consolidated Balance Sheets", "role": "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "ia2928b4e55ad4b71a771f309dac1b23c_I20220930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "i68b502bf21134ced993cfa7c1f1a0ff8_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000020 - Disclosure - Subsequent Events", "role": "http://vtvtherapeutics.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "i68b502bf21134ced993cfa7c1f1a0ff8_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "i68b502bf21134ced993cfa7c1f1a0ff8_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "vtvt:UnauditedInterimFinancialInformationPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000021 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "i68b502bf21134ced993cfa7c1f1a0ff8_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "vtvt:UnauditedInterimFinancialInformationPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "i68b502bf21134ced993cfa7c1f1a0ff8_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000022 - Disclosure - Collaboration Agreements (Tables)", "role": "http://vtvtherapeutics.com/role/CollaborationAgreementsTables", "shortName": "Collaboration Agreements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "i68b502bf21134ced993cfa7c1f1a0ff8_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "i68b502bf21134ced993cfa7c1f1a0ff8_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000023 - Disclosure - Share-Based Compensation (Tables)", "role": "http://vtvtherapeutics.com/role/ShareBasedCompensationTables", "shortName": "Share-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "i68b502bf21134ced993cfa7c1f1a0ff8_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "i68b502bf21134ced993cfa7c1f1a0ff8_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "vtvt:EquitySecuritiesWithAndWithoutReadilyDeterminableFairValueTableTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000024 - Disclosure - Investments (Tables)", "role": "http://vtvtherapeutics.com/role/InvestmentsTables", "shortName": "Investments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "i68b502bf21134ced993cfa7c1f1a0ff8_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "vtvt:EquitySecuritiesWithAndWithoutReadilyDeterminableFairValueTableTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "i68b502bf21134ced993cfa7c1f1a0ff8_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000025 - Disclosure - Leases (Tables)", "role": "http://vtvtherapeutics.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "i68b502bf21134ced993cfa7c1f1a0ff8_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "i68b502bf21134ced993cfa7c1f1a0ff8_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000026 - Disclosure - Redeemable Noncontrolling Interest (Tables)", "role": "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestTables", "shortName": "Redeemable Noncontrolling Interest (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "i68b502bf21134ced993cfa7c1f1a0ff8_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "i68b502bf21134ced993cfa7c1f1a0ff8_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000027 - Disclosure - Net Loss per Share (Tables)", "role": "http://vtvtherapeutics.com/role/NetLossperShareTables", "shortName": "Net Loss per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "i68b502bf21134ced993cfa7c1f1a0ff8_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "i68b502bf21134ced993cfa7c1f1a0ff8_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000028 - Disclosure - Fair Value of Financial Instruments (Tables)", "role": "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsTables", "shortName": "Fair Value of Financial Instruments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "i68b502bf21134ced993cfa7c1f1a0ff8_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "ia2928b4e55ad4b71a771f309dac1b23c_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000029 - Disclosure - Description of Business, Basis of Presentation and Going Concern (Detail)", "role": "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail", "shortName": "Description of Business, Basis of Presentation and Going Concern (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "i0a93e7c8e64f4606a46c1ee93744f5ac_I20220930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:AccountsNotesAndLoansReceivableNetCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "i99ef27b8975547cf9b2b841d1f62fec6_I20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "role": "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "i5aa7323b5a8b43e69ad858017b8642be_I20220930", "decimals": "INF", "lang": "en-US", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "i6a3fadaca8a64969a5ffd48cc836ae13_D20220701-20220930", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000030 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)", "role": "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail", "shortName": "Summary of Significant Accounting Policies - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "i6a3fadaca8a64969a5ffd48cc836ae13_D20220701-20220930", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "ia2928b4e55ad4b71a771f309dac1b23c_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerLiabilityNoncurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000031 - Disclosure - Collaboration Agreements - Additional Information (Detail)", "role": "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail", "shortName": "Collaboration Agreements - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "if572b987582a48249e7dd1a18fb1b131_D20220531-20220531", "decimals": "-5", "lang": "en-US", "name": "vtvt:SaleOfStockConsiderationReceivedOnTransactionGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "ia2928b4e55ad4b71a771f309dac1b23c_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerLiabilityCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000032 - Disclosure - Collaboration Agreements - Summary of Contract Liabilities Related to Company's Collaboration Agreements (Detail)", "role": "http://vtvtherapeutics.com/role/CollaborationAgreementsSummaryofContractLiabilitiesRelatedtoCompanysCollaborationAgreementsDetail", "shortName": "Collaboration Agreements - Summary of Contract Liabilities Related to Company's Collaboration Agreements (Detail)", "subGroupType": "details", "uniqueAnchor": null }, "R33": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "ibc9dc42485754eedbe1f63553a384301_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerLiability", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000033 - Disclosure - Collaboration Agreements - Contract with Customer, Contract Asset, Contract Liability, and Receivable Changes (Details)", "role": "http://vtvtherapeutics.com/role/CollaborationAgreementsContractwithCustomerContractAssetContractLiabilityandReceivableChangesDetails", "shortName": "Collaboration Agreements - Contract with Customer, Contract Asset, Contract Liability, and Receivable Changes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "vtvt:ContractWithCustomerContractAssetContractLiabilityAndReceivableChangesTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "i68b502bf21134ced993cfa7c1f1a0ff8_D20220101-20220930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "i793b4516620a4a6a90e3c529f2f5c990_D20220329-20220329", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000034 - Disclosure - Share-Based Compensation - Additional Information (Detail)", "role": "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail", "shortName": "Share-Based Compensation - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "i793b4516620a4a6a90e3c529f2f5c990_D20220329-20220329", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "ibc9dc42485754eedbe1f63553a384301_I20211231", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000035 - Disclosure - Share-Based Compensation - Summary of Stock Award Activity for the Period (Detail)", "role": "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail", "shortName": "Share-Based Compensation - Summary of Stock Award Activity for the Period (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "i68b502bf21134ced993cfa7c1f1a0ff8_D20220101-20220930", "decimals": "0", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "if3a85249d4ed417ba30a9329f0821656_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000036 - Disclosure - Share-Based Compensation - Summary of Compensation Expense Related to Grants of Stock Options (Detail)", "role": "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofCompensationExpenseRelatedtoGrantsofStockOptionsDetail", "shortName": "Share-Based Compensation - Summary of Compensation Expense Related to Grants of Stock Options (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "if3a85249d4ed417ba30a9329f0821656_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "i68b502bf21134ced993cfa7c1f1a0ff8_D20220101-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:UnrealizedGainLossOnInvestments", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000037 - Disclosure - Investments - Additional Information (Detail)", "role": "http://vtvtherapeutics.com/role/InvestmentsAdditionalInformationDetail", "shortName": "Investments - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "ic87186a0f5804bf9ab0e87b6e41897eb_D20220701-20220930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:UnrealizedGainLossOnInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "vtvt:EquitySecuritiesWithAndWithoutReadilyDeterminableFairValueTableTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "ia2928b4e55ad4b71a771f309dac1b23c_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000038 - Disclosure - Investments - Schedule of Equity Investments with and without Readily Determinable Fair Values Assessed (Detail)", "role": "http://vtvtherapeutics.com/role/InvestmentsScheduleofEquityInvestmentswithandwithoutReadilyDeterminableFairValuesAssessedDetail", "shortName": "Investments - Schedule of Equity Investments with and without Readily Determinable Fair Values Assessed (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "vtvt:EquitySecuritiesWithAndWithoutReadilyDeterminableFairValueTableTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "ia2928b4e55ad4b71a771f309dac1b23c_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "ix:continuation", "div", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "i4949550c27a842fea4d0c21881bb774a_I20070228", "decimals": "-5", "first": true, "lang": "en-US", "name": "vtvt:PotentialMilestonePayment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000039 - Disclosure - Commitments and Contingencies - Additional Information (Detail)", "role": "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail", "shortName": "Commitments and Contingencies - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "ix:continuation", "div", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "i4949550c27a842fea4d0c21881bb774a_I20070228", "decimals": "-5", "first": true, "lang": "en-US", "name": "vtvt:PotentialMilestonePayment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "if3a85249d4ed417ba30a9329f0821656_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000004 - Statement - Condensed Consolidated Statements of Operations - Unaudited", "role": "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "shortName": "Condensed Consolidated Statements of Operations - Unaudited", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "if3a85249d4ed417ba30a9329f0821656_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "ia2928b4e55ad4b71a771f309dac1b23c_I20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseRenewalTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000040 - Disclosure - Leases - (Details)", "role": "http://vtvtherapeutics.com/role/LeasesDetails", "shortName": "Leases - (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "ia2928b4e55ad4b71a771f309dac1b23c_I20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseRenewalTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "ia2928b4e55ad4b71a771f309dac1b23c_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000041 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities for Operating Leases (Detail)", "role": "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail", "shortName": "Leases - Schedule of Maturities of Lease Liabilities for Operating Leases (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "ia2928b4e55ad4b71a771f309dac1b23c_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "ia2928b4e55ad4b71a771f309dac1b23c_I20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "vtvt:RedeemableNoncontrollingInterestTemporaryEquityRedemptionValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000042 - Disclosure - Redeemable Noncontrolling Interest - Additional Information (Detail)", "role": "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestAdditionalInformationDetail", "shortName": "Redeemable Noncontrolling Interest - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "ia2928b4e55ad4b71a771f309dac1b23c_I20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "vtvt:RedeemableNoncontrollingInterestTemporaryEquityRedemptionValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted", "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "if3a85249d4ed417ba30a9329f0821656_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000043 - Disclosure - Redeemable Noncontrolling Interest - Summary of Net Income Attributable to Vtv Therapeutics Inc (Detail)", "role": "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestSummaryofNetIncomeAttributabletoVtvTherapeuticsIncDetail", "shortName": "Redeemable Noncontrolling Interest - Summary of Net Income Attributable to Vtv Therapeutics Inc (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "if3a85249d4ed417ba30a9329f0821656_D20220701-20220930", "decimals": "-3", "lang": "en-US", "name": "vtvt:ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "i30cdbed6f75b4d94b8fcbeae0031407d_I20210504", "decimals": "INF", "first": true, "lang": "en-US", "name": "vtvt:CommonStockAndPreferredStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000044 - Disclosure - Stockholders' Deficit - Additional Information (Detail)", "role": "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail", "shortName": "Stockholders' Deficit - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "i30cdbed6f75b4d94b8fcbeae0031407d_I20210504", "decimals": "INF", "first": true, "lang": "en-US", "name": "vtvt:CommonStockAndPreferredStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "i40728201e950413b91585aba53dea209_I20220930", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInAndAdvancesToAffiliatesBalanceShares", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000045 - Disclosure - Related-Party Transactions - Additional Information (Detail)", "role": "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "shortName": "Related-Party Transactions - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "i40728201e950413b91585aba53dea209_I20220930", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInAndAdvancesToAffiliatesBalanceShares", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "if3a85249d4ed417ba30a9329f0821656_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000046 - Disclosure - Income Taxes - Additional Information (Detail)", "role": "http://vtvtherapeutics.com/role/IncomeTaxesAdditionalInformationDetail", "shortName": "Income Taxes - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "ia2659ed9810142cdad63d7a054843d18_D20220701-20220930", "decimals": "2", "lang": "en-US", "name": "vtvt:PercentageOfAmountOfCashSavings", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "if3a85249d4ed417ba30a9329f0821656_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000047 - Disclosure - Net Loss per Share - Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Loss per Share of Class A Common Stock (Detail)", "role": "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail", "shortName": "Net Loss per Share - Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Loss per Share of Class A Common Stock (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "if3a85249d4ed417ba30a9329f0821656_D20220701-20220930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "i68b502bf21134ced993cfa7c1f1a0ff8_D20220101-20220930", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000048 - Disclosure - Net Loss per Share - Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss per Share (Detail)", "role": "http://vtvtherapeutics.com/role/NetLossperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetail", "shortName": "Net Loss per Share - Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss per Share (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "i68b502bf21134ced993cfa7c1f1a0ff8_D20220101-20220930", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "i9704f5c2b19f4754866b26292b42e37f_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:EquitySecuritiesFvNi", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000049 - Disclosure - Fair Value of Financial Instruments - Summarizes the Conclusions Reached Regarding Fair Value Measurements (Detail)", "role": "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail", "shortName": "Fair Value of Financial Instruments - Summarizes the Conclusions Reached Regarding Fair Value Measurements (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "i9704f5c2b19f4754866b26292b42e37f_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:EquitySecuritiesFvNi", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "i7ec6dd4ddd3d422a87026b6e5f9deb2d_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000005 - Statement - Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders' Deficit - Unaudited", "role": "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited", "shortName": "Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders' Deficit - Unaudited", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "i7ec6dd4ddd3d422a87026b6e5f9deb2d_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "i20d31812c5e8471596f1f7ca175a3233_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000050 - Disclosure - Fair Value of Financial Instruments - Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation (Details)", "role": "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails", "shortName": "Fair Value of Financial Instruments - Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "i20d31812c5e8471596f1f7ca175a3233_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "i2b7ef5dcdcca445eb3f27b3cdbf64681_I20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:WarrantsAndRightsOutstandingTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000051 - Disclosure - Fair Value of Financial Instruments - Fair Value Measurement Inputs and Valuation Techniques (Detail)", "role": "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail", "shortName": "Fair Value of Financial Instruments - Fair Value Measurement Inputs and Valuation Techniques (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "i2b7ef5dcdcca445eb3f27b3cdbf64681_I20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:WarrantsAndRightsOutstandingTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "i68b502bf21134ced993cfa7c1f1a0ff8_D20220101-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000006 - Statement - Condensed Consolidated Statements of Cash Flows - Unaudited", "role": "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "shortName": "Condensed Consolidated Statements of Cash Flows - Unaudited", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "i68b502bf21134ced993cfa7c1f1a0ff8_D20220101-20220930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "i68b502bf21134ced993cfa7c1f1a0ff8_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000007 - Disclosure - Description of Business, Basis of Presentation and Going Concern", "role": "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcern", "shortName": "Description of Business, Basis of Presentation and Going Concern", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "i68b502bf21134ced993cfa7c1f1a0ff8_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "i68b502bf21134ced993cfa7c1f1a0ff8_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000008 - Disclosure - Summary of Significant Accounting Policies", "role": "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "i68b502bf21134ced993cfa7c1f1a0ff8_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "i68b502bf21134ced993cfa7c1f1a0ff8_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000009 - Disclosure - Collaboration Agreements", "role": "http://vtvtherapeutics.com/role/CollaborationAgreements", "shortName": "Collaboration Agreements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vtvt-20220930.htm", "contextRef": "i68b502bf21134ced993cfa7c1f1a0ff8_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 71, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]", "terseLabel": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]", "terseLabel": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r504" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r505" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "verboseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r502" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail", "http://vtvtherapeutics.com/role/IncomeTaxesAdditionalInformationDetail", "http://vtvtherapeutics.com/role/InvestmentsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/InvestmentsScheduleofEquityInvestmentswithandwithoutReadilyDeterminableFairValuesAssessedDetail", "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestAdditionalInformationDetail", "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r502" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r502" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r514" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r502" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r502" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r502" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r502" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail", "http://vtvtherapeutics.com/role/IncomeTaxesAdditionalInformationDetail", "http://vtvtherapeutics.com/role/InvestmentsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/InvestmentsScheduleofEquityInvestmentswithandwithoutReadilyDeterminableFairValuesAssessedDetail", "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestAdditionalInformationDetail", "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r501" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r503" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "srt_AffiliatedEntityMember": { "auth_ref": [ "r265", "r397", "r398", "r401", "r497" ], "lang": { "en-us": { "role": { "label": "Affiliated Entity [Member]", "terseLabel": "Affiliated Entity" } } }, "localname": "AffiliatedEntityMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r30", "r32", "r72", "r73", "r194", "r212" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail", "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_EquityMethodInvesteeNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investment, Name [Domain]", "terseLabel": "Investment, Name [Domain]" } } }, "localname": "EquityMethodInvesteeNameDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r143", "r251", "r255", "r485" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]", "terseLabel": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r175", "r176", "r177", "r178", "r193", "r211", "r267", "r268", "r416", "r417", "r418", "r419", "r420", "r421", "r440", "r483", "r486", "r498", "r499" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail", "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail", "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r175", "r176", "r177", "r178", "r193", "r211", "r267", "r268", "r416", "r417", "r418", "r419", "r420", "r421", "r440", "r483", "r486", "r498", "r499" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r143", "r251", "r255", "r485" ], "lang": { "en-us": { "role": { "label": "Customer [Domain]", "terseLabel": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r141", "r176", "r177", "r251", "r254", "r443", "r482", "r484" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r141", "r176", "r177", "r251", "r254", "r443", "r482", "r484" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r170", "r175", "r176", "r177", "r178", "r193", "r211", "r257", "r267", "r268", "r299", "r300", "r301", "r416", "r417", "r418", "r419", "r420", "r421", "r440", "r483", "r486", "r498", "r499" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail", "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail", "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r170", "r175", "r176", "r177", "r178", "r193", "r211", "r257", "r267", "r268", "r299", "r300", "r301", "r416", "r417", "r418", "r419", "r420", "r421", "r440", "r483", "r486", "r498", "r499" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail", "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail", "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r31", "r32", "r72", "r73", "r194", "r212" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail", "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "auth_ref": [ "r154" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Axis]", "terseLabel": "Investment, Name [Axis]" } } }, "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r144", "r400" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]", "terseLabel": "Title of Individual" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]", "terseLabel": "Title of Individual" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_WeightedAverageMember": { "auth_ref": [ "r416", "r418", "r421", "r498", "r499" ], "lang": { "en-us": { "role": { "label": "Weighted Average [Member]", "terseLabel": "Weighted Average" } } }, "localname": "WeightedAverageMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsNotesAndLoansReceivableNetCurrent": { "auth_ref": [ "r145", "r146", "r470" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of accounts and financing receivables, classified as current. Includes, but is not limited to, notes and loan receivable.", "label": "Accounts and Financing Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts and financing receivable, after allowance for credit loss" } } }, "localname": "AccountsNotesAndLoansReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail", "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r21" ], "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts Payable and Accrued Liabilities, Current", "terseLabel": "Accounts payable and accrued expenses" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r145", "r146" ], "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r14" ], "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r75", "r76", "r77", "r311", "r312", "r313", "r356" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r270", "r315", "r316" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Share-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss before noncontrolling interest to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r304" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-Based Payment Arrangement, Expense", "verboseLabel": "Total share-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofCompensationExpenseRelatedtoGrantsofStockOptionsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r103" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Potentially dilutive securities not included in calculation of dilutive net loss per share (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/NetLossperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r103" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/NetLossperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/NetLossperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r103" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/NetLossperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r9", "r68", "r130", "r133", "r139", "r156", "r180", "r181", "r182", "r184", "r185", "r186", "r187", "r188", "r189", "r191", "r192", "r341", "r348", "r375", "r404", "r406", "r458", "r471" ], "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r5", "r20", "r68", "r156", "r180", "r181", "r182", "r184", "r185", "r186", "r187", "r188", "r189", "r191", "r192", "r341", "r348", "r375", "r404", "r406" ], "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r359" ], "calculation": { "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Equity securities with readily determinable fair value - Total" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r274", "r275", "r276", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r293", "r294", "r296", "r297", "r298", "r299", "r300", "r301", "r302" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r2", "r74", "r124" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Business Description and Basis of Presentation [Text Block]", "terseLabel": "Description of Business, Basis of Presentation and Going Concern" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcern" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r3", "r7", "r58" ], "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets", "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r59" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r53", "r58", "r63" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Total cash, cash equivalents and restricted cash and cash equivalents, end of period", "periodStartLabel": "Total cash, cash equivalents and restricted cash and cash equivalents, beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r53", "r376" ], "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "terseLabel": "Non-cash activities:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r11", "r12", "r13", "r66", "r68", "r91", "r92", "r97", "r100", "r102", "r110", "r111", "r112", "r156", "r180", "r185", "r186", "r187", "r191", "r192", "r209", "r210", "r214", "r218", "r225", "r375", "r506" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets", "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited", "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://vtvtherapeutics.com/role/Cover", "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail", "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail", "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestAdditionalInformationDetail", "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Class Of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r234", "r272" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]", "terseLabel": "Class of Warrant or Right [Axis]" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.", "label": "Class of Warrant or Right [Domain]", "terseLabel": "Class of Warrant or Right [Domain]" } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r226" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Exercise price of warrants or rights (in usd per share)" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r226" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "terseLabel": "Number of securities called by warrants or rights (in shares)" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "auth_ref": [ "r334", "r335", "r337" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.", "label": "Collaborative Arrangement Disclosure [Text Block]", "terseLabel": "Collaboration Agreements" } } }, "localname": "CollaborativeArrangementDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreements" ], "xbrltype": "textBlockItemType" }, "us-gaap_CollaborativeArrangementMember": { "auth_ref": [ "r336" ], "lang": { "en-us": { "role": { "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.", "label": "Collaborative Arrangement [Member]", "terseLabel": "Collaborative Arrangements" } } }, "localname": "CollaborativeArrangementMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r25", "r461", "r476" ], "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r172", "r173", "r174", "r179", "r496" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonClassAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Classification of common stock representing ownership interest in a corporation.", "label": "Common Class A [Member]", "terseLabel": "Class A Common Stock" } } }, "localname": "CommonClassAMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets", "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited", "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://vtvtherapeutics.com/role/Cover", "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail", "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail", "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestAdditionalInformationDetail", "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CommonClassBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation.", "label": "Common Class B [Member]", "terseLabel": "Class B Common Stock" } } }, "localname": "CommonClassBMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets", "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited", "http://vtvtherapeutics.com/role/Cover", "http://vtvtherapeutics.com/role/NetLossperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetail", "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Common stock, capital shares reserved for future issuance (in shares)" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r75", "r76", "r356" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited", "http://vtvtherapeutics.com/role/InvestmentsScheduleofEquityInvestmentswithandwithoutReadilyDeterminableFairValuesAssessedDetail", "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock par value (in usd per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r13", "r225" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Ending balance, shares (in shares)", "periodStartLabel": "Beginning balance, shares (in shares)", "terseLabel": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r13", "r406" ], "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock value" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockValueOutstanding": { "auth_ref": [ "r13" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.", "label": "Common Stock, Value, Outstanding", "terseLabel": "Common stock, value" } } }, "localname": "CommonStockValueOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r119", "r120", "r143", "r373", "r374", "r495" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r119", "r120", "r143", "r373", "r374", "r492", "r495" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r119", "r120", "r143", "r373", "r374", "r492", "r495" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r115", "r469" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentration of Credit Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r119", "r120", "r143", "r373", "r374" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Concentration risk percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r119", "r120", "r143", "r373", "r374", "r495" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet": { "auth_ref": [ "r233", "r346", "r352" ], "calculation": { "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestSummaryofNetIncomeAttributabletoVtvTherapeuticsIncDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "This element represents the total net income attributable to the parent for the period and the effect of net changes during the period impacting the parent's ownership interest in a subsidiary as it relates to the total (consolidated) equity attributable to the parent. The changes to the parent's ownership interest in a subsidiary represented by this element did not result in a deconsolidation of the subsidiary from the consolidated financial statements.", "label": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Change Due to Net Income Attributable to Parent and Effects of Changes, Net", "totalLabel": "Change from net loss attributable to vTv Therapeutics Inc. common shareholders and transfers to noncontrolling interest" } } }, "localname": "ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestSummaryofNetIncomeAttributabletoVtvTherapeuticsIncDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock": { "auth_ref": [ "r346", "r352" ], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of the effects of any changes in a parent's ownership interest in a subsidiary on the equity attributable to the parent if the ownership interests in a subsidiary changes during the period. The changes represented by this element did not result in the deconsolidation of the subsidiary.", "label": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table Text Block]", "terseLabel": "Summary of Net Income Attributable to Vtv Therapeutics Inc" } } }, "localname": "ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "auth_ref": [ "r240" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.", "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]", "terseLabel": "Summary of Contract Liabilities Related to Company's Collaboration Agreements" } } }, "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r236", "r237", "r252" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract with Customer, Liability", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "verboseLabel": "Total contract liabilities" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsContractwithCustomerContractAssetContractLiabilityandReceivableChangesDetails", "http://vtvtherapeutics.com/role/CollaborationAgreementsSummaryofContractLiabilitiesRelatedtoCompanysCollaborationAgreementsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice": { "auth_ref": [ "r239" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained.", "label": "Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price", "terseLabel": "Revenue recognized from change in estimated transaction prices" } } }, "localname": "ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r236", "r237", "r252" ], "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "terseLabel": "Current portion of contract liabilities" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsSummaryofContractLiabilitiesRelatedtoCompanysCollaborationAgreementsDetail", "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination": { "auth_ref": [ "r238" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration from customer has been received or is due, from business combination.", "label": "Contract with Customer, Liability, Increase (Decrease) for Contract Acquired in Business Combination", "terseLabel": "Consideration received in advance and not recognized as revenue" } } }, "localname": "ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsContractwithCustomerContractAssetContractLiabilityandReceivableChangesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "auth_ref": [ "r236", "r237", "r252" ], "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.", "label": "Contract with Customer, Liability, Noncurrent", "terseLabel": "Contract liabilities, net of current portion" } } }, "localname": "ContractWithCustomerLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/CollaborationAgreementsSummaryofContractLiabilitiesRelatedtoCompanysCollaborationAgreementsDetail", "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r253" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Contract with Customer, Liability, Revenue Recognized", "negatedLabel": "Reclassification of the beginning contract liabilities to revenue, as the result of performance obligations satisfied", "terseLabel": "Contract with customer, liability, revenue recognized" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/CollaborationAgreementsContractwithCustomerContractAssetContractLiabilityandReceivableChangesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConversionOfStockByUniqueDescriptionAxis": { "auth_ref": [ "r60", "r61", "r62" ], "lang": { "en-us": { "role": { "documentation": "Information by description of stock conversions.", "label": "Stock Conversion Description [Axis]", "terseLabel": "Stock Conversion Description" } } }, "localname": "ConversionOfStockByUniqueDescriptionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ConversionOfStockNameDomain": { "auth_ref": [ "r60", "r61", "r62" ], "lang": { "en-us": { "role": { "documentation": "The unique name of a noncash or part noncash stock conversion.", "label": "Conversion of Stock, Name [Domain]", "terseLabel": "Conversion of Stock, Name" } } }, "localname": "ConversionOfStockNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r118", "r143" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredRevenueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Revenue Disclosure [Abstract]", "terseLabel": "Deferred Revenue Disclosure [Abstract]" } } }, "localname": "DeferredRevenueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DepositsAssetsCurrent": { "auth_ref": [ "r19" ], "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.", "label": "Deposits Assets, Current", "terseLabel": "Current deposits" } } }, "localname": "DepositsAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r56", "r167" ], "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r273", "r274", "r305", "r306", "r308", "r317" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "Share-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]", "terseLabel": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DueToRelatedPartiesNoncurrent": { "auth_ref": [ "r24", "r71", "r183", "r185", "r186", "r190", "r191", "r192", "r398" ], "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Portion of the carrying amount as of the balance sheet date of obligations due all related parties that is payable after one year or beyond the normal operating cycle if longer.", "label": "Due to Related Parties, Noncurrent", "terseLabel": "Warrant liability, related party" } } }, "localname": "DueToRelatedPartiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r41", "r80", "r81", "r82", "r83", "r84", "r88", "r91", "r100", "r101", "r102", "r106", "r107", "r357", "r358", "r464", "r478" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Net loss per share of vTv Therapeutics Inc. Class A Common Stock, basic (in usd per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r41", "r80", "r81", "r82", "r83", "r84", "r91", "r100", "r101", "r102", "r106", "r107", "r357", "r358", "r464", "r478" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Net loss per share of vTv Therapeutics Inc. Class A Common Stock, diluted (in usd per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r103", "r104", "r105", "r108" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Loss per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/NetLossperShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofCompensationExpenseRelatedtoGrantsofStockOptionsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r307" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Weighted average period to recognize unrecognized share-based compensation cost" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r307" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized compensation cost related to non-vested share-based compensation arrangements" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-Based Payment Arrangement, Option [Member]", "terseLabel": "Stock Option", "verboseLabel": "Common stock options granted under the Plan" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/NetLossperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetail", "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]", "terseLabel": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r35", "r36", "r37", "r75", "r76", "r77", "r79", "r85", "r87", "r109", "r157", "r225", "r232", "r311", "r312", "r313", "r325", "r326", "r356", "r377", "r378", "r379", "r380", "r381", "r382", "r394", "r487", "r488", "r489" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited", "http://vtvtherapeutics.com/role/InvestmentsScheduleofEquityInvestmentswithandwithoutReadilyDeterminableFairValuesAssessedDetail" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesFvNi": { "auth_ref": [ "r4", "r10", "r371" ], "calculation": { "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.", "label": "Equity Securities, FV-NI, Current", "terseLabel": "Assets:" } } }, "localname": "EquitySecuritiesFvNi", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": { "auth_ref": [ "r151" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity security without readily determinable fair value.", "label": "Equity Securities without Readily Determinable Fair Value, Amount", "terseLabel": "Equity investment without readily determinable fair values assessed under the measurement alternative:" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/InvestmentsScheduleofEquityInvestmentswithandwithoutReadilyDeterminableFairValuesAssessedDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Equity Securities without Readily Determinable Fair Value [Line Items]", "terseLabel": "Equity Securities Without Readily Determinable Fair Value [Line Items]" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/InvestmentsScheduleofEquityInvestmentswithandwithoutReadilyDeterminableFairValuesAssessedDetail" ], "xbrltype": "stringItemType" }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueTable": { "auth_ref": [ "r151", "r152", "r153" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment in equity security without readily determinable fair value.", "label": "Equity Securities without Readily Determinable Fair Value [Table]", "terseLabel": "Equity Securities Without Readily Determinable Fair Value [Table]" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/InvestmentsScheduleofEquityInvestmentswithandwithoutReadilyDeterminableFairValuesAssessedDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r195", "r198", "r199", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r266", "r360", "r413", "r414", "r415" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails", "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByLiabilityClassAxis": { "auth_ref": [ "r367", "r369" ], "lang": { "en-us": { "role": { "documentation": "Information by class of liability.", "label": "Liability Class [Axis]", "terseLabel": "Liability Class [Axis]" } } }, "localname": "FairValueByLiabilityClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r359", "r360", "r362", "r363", "r370" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r367" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstruments" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r195", "r258", "r259", "r264", "r266", "r360", "r413" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Quoted Prices in Active Markets for Identical Assets (Level 1)" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r195", "r198", "r199", "r258", "r259", "r264", "r266", "r360", "r414" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Significant Other Observable Inputs (Level 2)" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r195", "r198", "r199", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r266", "r360", "r415" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Significant Unobservable Inputs (Level 3)" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails", "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "auth_ref": [ "r364" ], "lang": { "en-us": { "role": { "documentation": "Represents classes of liabilities measured and disclosed at fair value.", "label": "Fair Value by Liability Class [Domain]", "terseLabel": "Fair Value by Liability Class [Domain]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r364", "r369" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases": { "auth_ref": [ "r366" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases", "terseLabel": "Purchases / Issuance" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales": { "auth_ref": [ "r366" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of sales of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Sales", "terseLabel": "Sales / Repurchases" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r364" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r195", "r198", "r199", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r266", "r413", "r414", "r415" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails", "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r367", "r370" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Fair Value, Measurements, Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings": { "auth_ref": [ "r365", "r368" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in income from derivative asset (liability) after deduction of derivative liability (asset), measured at fair value on recurring basis using unobservable input (level 3).", "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Gain (Loss) Included in Earnings", "terseLabel": "Net Change in fair value included in earnings" } } }, "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r148", "r149", "r151", "r152", "r153", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r197", "r223", "r354", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r506", "r507", "r508", "r509", "r510", "r511", "r512" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r45" ], "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r42" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofCompensationExpenseRelatedtoGrantsofStockOptionsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r39", "r130", "r132", "r135", "r138", "r140", "r456", "r462", "r466", "r480" ], "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Loss before income taxes and noncontrolling interest" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r169", "r171" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofCompensationExpenseRelatedtoGrantsofStockOptionsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r171" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofCompensationExpenseRelatedtoGrantsofStockOptionsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r69", "r322", "r323", "r324", "r327", "r329", "r331", "r332", "r333" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r70", "r86", "r87", "r129", "r321", "r328", "r330", "r481" ], "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Income tax provision" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://vtvtherapeutics.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r55" ], "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable and accrued expenses" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r55" ], "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r55", "r441" ], "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Contract with Customer, Liability", "terseLabel": "Contract liabilities" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r55" ], "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Temporary Equity [Roll Forward]", "terseLabel": "Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]" } } }, "localname": "IncreaseDecreaseInTemporaryEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r38", "r128", "r384", "r385", "r465" ], "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseOther": { "auth_ref": [], "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense classified as other.", "label": "Interest Expense, Other", "terseLabel": "Interest expense" } } }, "localname": "InterestExpenseOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeOperating": { "auth_ref": [ "r43" ], "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities.", "label": "Interest Income, Operating", "negatedTerseLabel": "Non-cash interest income" } } }, "localname": "InterestIncomeOperating", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r46", "r127" ], "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Investment Income, Interest", "terseLabel": "Interest income" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentPolicyTextBlock": { "auth_ref": [ "r155", "r479" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment in financial asset.", "label": "Investment, Policy [Policy Text Block]", "terseLabel": "Investments" } } }, "localname": "InvestmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]", "terseLabel": "Investments, Debt and Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares": { "auth_ref": [ "r493" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of affiliates held for management investment companies.", "label": "Investments in and Advances to Affiliates, Balance, Shares", "terseLabel": "Shares held by related party (in shares)" } } }, "localname": "InvestmentsInAndAdvancesToAffiliatesBalanceShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "auth_ref": [ "r150", "r457", "r467", "r494", "r513" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investments in certain debt and equity securities.", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "terseLabel": "Investments" } } }, "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/Investments" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]", "terseLabel": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r391" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Schedule of Maturities of Lease Liabilities for Operating Leases" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r391" ], "calculation": { "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r391" ], "calculation": { "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail_1": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r391" ], "calculation": { "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail_1": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r391" ], "calculation": { "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail_1": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r391" ], "calculation": { "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail_1": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r391" ], "calculation": { "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail_1": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "2022 (remaining three months)" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "auth_ref": [ "r388" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Renewal Term", "terseLabel": "Lessee, operating lease, renewal term" } } }, "localname": "LesseeOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/LeasesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r393" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r22", "r68", "r134", "r156", "r180", "r181", "r182", "r185", "r186", "r187", "r188", "r189", "r191", "r192", "r342", "r348", "r349", "r375", "r404", "r405" ], "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r18", "r68", "r156", "r375", "r406", "r459", "r473" ], "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities, redeemable noncontrolling interest and stockholders\u2019 deficit" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities, Redeemable Noncontrolling Interest and Stockholders\u2019 Deficit" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r6", "r23", "r68", "r156", "r180", "r181", "r182", "r185", "r186", "r187", "r188", "r189", "r191", "r192", "r342", "r348", "r349", "r375", "r404", "r405", "r406" ], "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r359" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Liabilities, Fair Value Disclosure", "terseLabel": "Liabilities:" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermInvestments": { "auth_ref": [ "r8" ], "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).", "label": "Long-Term Investments", "terseLabel": "Long-term investments" } } }, "localname": "LongTermInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MeasurementInputExpectedDividendRateMember": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.", "label": "Measurement Input, Expected Dividend Rate [Member]", "terseLabel": "Expected dividend yield" } } }, "localname": "MeasurementInputExpectedDividendRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputPriceVolatilityMember": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.", "label": "Measurement Input, Price Volatility [Member]", "terseLabel": "Expected volatility" } } }, "localname": "MeasurementInputPriceVolatilityMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.", "label": "Measurement Input, Risk Free Interest Rate [Member]", "terseLabel": "Risk-free interest rate" } } }, "localname": "MeasurementInputRiskFreeInterestRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]", "terseLabel": "Measurement Input Type" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Domain]", "terseLabel": "Measurement Input Type" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_MinorityInterestChangeInRedemptionValue": { "auth_ref": [ "r204", "r205", "r206", "r233" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Change in noncontrolling interest during the period as a result of a change in the redemption value of redeemable noncontrolling interest.", "label": "Noncontrolling Interest, Change in Redemption Value", "terseLabel": "Change in redemption value of noncontrolling interest" } } }, "localname": "MinorityInterestChangeInRedemptionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited", "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestDisclosureTextBlock": { "auth_ref": [ "r353" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.", "label": "Noncontrolling Interest Disclosure [Text Block]", "terseLabel": "Redeemable Noncontrolling Interest" } } }, "localname": "MinorityInterestDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterest" ], "xbrltype": "textBlockItemType" }, "us-gaap_MinorityInterestLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Noncontrolling Interest [Line Items]", "terseLabel": "Noncontrolling Interest [Line Items]" } } }, "localname": "MinorityInterestLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_MinorityInterestTable": { "auth_ref": [ "r29", "r44", "r339", "r347" ], "lang": { "en-us": { "role": { "documentation": "Schedule of noncontrolling interest disclosure which includes the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.", "label": "Noncontrolling Interest [Table]", "terseLabel": "Minority Interest [Table]" } } }, "localname": "MinorityInterestTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r53" ], "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r53" ], "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r53", "r54", "r57" ], "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r33", "r34", "r37", "r40", "r57", "r68", "r78", "r80", "r81", "r82", "r83", "r86", "r87", "r98", "r130", "r132", "r135", "r138", "r140", "r156", "r180", "r181", "r182", "r185", "r186", "r187", "r188", "r189", "r191", "r192", "r358", "r375", "r463", "r477" ], "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss", "totalLabel": "Net loss attributable to vTv Therapeutics Inc." } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited", "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Attributable to Parent [Abstract]", "terseLabel": "Numerator:" } } }, "localname": "NetIncomeLossAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r33", "r34", "r37", "r86", "r87", "r344", "r350" ], "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 }, "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "terseLabel": "Less: net loss attributable to noncontrolling interest", "verboseLabel": "Less: Net loss attributable to noncontrolling interests" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r80", "r81", "r82", "r83", "r88", "r89", "r99", "r102", "r130", "r132", "r135", "r138", "r140" ], "calculation": { "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestSummaryofNetIncomeAttributabletoVtvTherapeuticsIncDetail": { "order": 1.0, "parentTag": "us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "terseLabel": "Net loss attributable to vTv Therapeutics Inc. common shareholders", "totalLabel": "Net loss attributable to common shareholders of vTv Therapeutics Inc., basic" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail", "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestSummaryofNetIncomeAttributabletoVtvTherapeuticsIncDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "auth_ref": [ "r90", "r93", "r94", "r95", "r96", "r99", "r102" ], "calculation": { "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "totalLabel": "Net loss attributable to common shareholders of vTv Therapeutics Inc., diluted" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest": { "auth_ref": [ "r203", "r344", "r345" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after income tax of income (loss) including the portion attributable to nonredeemable noncontrolling interest. Excludes the portion attributable to redeemable noncontrolling interest recognized as temporary equity.", "label": "Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest", "terseLabel": "Net loss" } } }, "localname": "NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Issued Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncontrollingInterestAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncontrolling Interest [Abstract]", "terseLabel": "Noncontrolling Interest [Abstract]" } } }, "localname": "NoncontrollingInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r75", "r76", "r77", "r232", "r338" ], "lang": { "en-us": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]", "terseLabel": "Redeemable Noncontrolling Interest" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_NotesAssumed1": { "auth_ref": [ "r60", "r61", "r62" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value of notes assumed in noncash investing or financing activities.", "label": "Notes Assumed", "terseLabel": "Notes receivable recorded at fair value" } } }, "localname": "NotesAssumed1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableCurrent": { "auth_ref": [ "r21" ], "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.", "label": "Notes Payable, Current", "terseLabel": "Current portion of notes payable" } } }, "localname": "NotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r130", "r132", "r135", "r138", "r140" ], "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Operating loss" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid [Abstract]", "terseLabel": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]" } } }, "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r387" ], "calculation": { "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Present value of lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r387" ], "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Current portion of operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r387" ], "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liabilities, net of current portion" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r386" ], "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r390", "r392" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted average incremental borrowing rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/LeasesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r389", "r392" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Remaining operating lease term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/LeasesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OtherCommitmentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of other commitment.", "label": "Other Commitments [Axis]", "terseLabel": "Other Commitments" } } }, "localname": "OtherCommitmentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_OtherCommitmentsDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other future obligation.", "label": "Other Commitments [Domain]", "terseLabel": "Other Commitments" } } }, "localname": "OtherCommitmentsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r47" ], "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 5.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other income (expense)" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r48" ], "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedTerseLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]", "terseLabel": "Preferred Stock" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/InvestmentsScheduleofEquityInvestmentswithandwithoutReadilyDeterminableFairValuesAssessedDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r20" ], "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r49" ], "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from sale of Class A common stock, net of offering costs", "verboseLabel": "Net proceeds from issuance of common stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfDebt": { "auth_ref": [ "r50" ], "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.", "label": "Proceeds from Issuance of Debt", "terseLabel": "Proceeds from debt issuance" } } }, "localname": "ProceedsFromIssuanceOfDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants": { "auth_ref": [ "r49" ], "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholder, which takes precedence over common stockholders in the event of liquidation and from issuance of rights to purchase common shares at a predetermined price.", "label": "Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants", "terseLabel": "Proceeds from sale of Class A common stock and warrants, net of offering costs" } } }, "localname": "ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r49", "r310" ], "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercise of stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r1", "r33", "r34", "r37", "r52", "r68", "r78", "r86", "r87", "r130", "r132", "r135", "r138", "r140", "r156", "r180", "r181", "r182", "r185", "r186", "r187", "r188", "r189", "r191", "r192", "r340", "r343", "r345", "r350", "r351", "r358", "r375", "r466" ], "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 }, "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss before noncontrolling interest", "totalLabel": "Net loss before noncontrolling interest", "verboseLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r168", "r406", "r468", "r475" ], "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReceivablesFairValueDisclosure": { "auth_ref": [ "r372", "r460", "r474" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of receivables, including, but not limited to, trade account receivables, note receivables, and loan receivables.", "label": "Receivables, Fair Value Disclosure", "terseLabel": "Receivables, fair value disclosure" } } }, "localname": "ReceivablesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReceivablesFromStockholderMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Category of equity that is due from owners or affiliates of the reporting entity (including due from officers or directors) resulting from the sale of stock before the cash payment is received.", "label": "Receivables from Stockholder [Member]", "terseLabel": "Receivables from Stockholder" } } }, "localname": "ReceivablesFromStockholderMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount": { "auth_ref": [ "r201", "r202", "r204", "r205" ], "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.", "label": "Redeemable Noncontrolling Interest, Equity, Carrying Amount", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "terseLabel": "Redeemable noncontrolling interest" } } }, "localname": "RedeemableNoncontrollingInterestEquityCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets", "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r265", "r397", "r398" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail", "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r265", "r397", "r398", "r401" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]", "terseLabel": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r265" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]", "terseLabel": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]", "terseLabel": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r265", "r397", "r401", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]", "terseLabel": "Related Party" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail", "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r395", "r396", "r398", "r402", "r403" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related-Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfNotesPayable": { "auth_ref": [ "r51" ], "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.", "label": "Repayments of Notes Payable", "negatedLabel": "Repayment of notes payable" } } }, "localname": "RepaymentsOfNotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": { "auth_ref": [ "r319", "r320" ], "lang": { "en-us": { "role": { "documentation": "Information by form of arrangement related to research and development.", "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]", "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": { "auth_ref": [ "r319", "r320" ], "lang": { "en-us": { "role": { "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.", "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]", "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r318", "r442", "r500" ], "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofCompensationExpenseRelatedtoGrantsofStockOptionsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r318" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and Development" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r15", "r232", "r406", "r472", "r490", "r491" ], "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "negatedTerseLabel": "Accumulated deficit", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets", "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r75", "r76", "r77", "r79", "r85", "r87", "r157", "r311", "r312", "r313", "r325", "r326", "r356", "r487", "r489" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r125", "r126", "r131", "r136", "r137", "r141", "r142", "r143", "r250", "r251", "r443" ], "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r65", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r256" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRemainingPerformanceObligation": { "auth_ref": [ "r241" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.", "label": "Revenue, Remaining Performance Obligation, Amount", "terseLabel": "Unrecognized amount of transaction price allocated to performance obligation" } } }, "localname": "RevenueRemainingPerformanceObligation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received on stock transaction after deduction of issuance costs.", "label": "Sale of Stock, Consideration Received on Transaction", "terseLabel": "Sale of stock, consideration received on transaction" } } }, "localname": "SaleOfStockConsiderationReceivedOnTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale of Stock, Number of Shares Issued in Transaction", "terseLabel": "Shares sold (in shares)" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Sale of Stock, Price Per Share", "terseLabel": "Sale of stock, price per share (in usd per shares)" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r119", "r143" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]", "terseLabel": "Revenue" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r103" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/NetLossperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r103" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss per Share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/NetLossperShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r336" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r102" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Loss per Share of Class A Common Stock" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/NetLossperShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r303", "r314" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofCompensationExpenseRelatedtoGrantsofStockOptionsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r303" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Summary of Compensation Expense Related to Grants of Stock Options" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r359", "r360" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Summarizes the Conclusions Reached Regarding Fair Value Measurements" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r399", "r401" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r269", "r271", "r274", "r275", "r276", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r293", "r294", "r296", "r297", "r298", "r299", "r300", "r301", "r302" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r277", "r292", "r295" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Summary of Stock Award Activity for the Period" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r11", "r12", "r13", "r66", "r110", "r111", "r200", "r207", "r208", "r209", "r210", "r211", "r212", "r214", "r218", "r223", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule Of Stock By Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Disclosure [Abstract]", "terseLabel": "Share-based Payment Arrangement, Disclosure [Abstract]" } } }, "localname": "ShareBasedArrangementsToObtainGoodsAndServicesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r55" ], "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Share-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Noncash Expense [Abstract]", "terseLabel": "Share-based Payment Arrangement, Noncash Expense [Abstract]" } } }, "localname": "ShareBasedCompensationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": { "auth_ref": [ "r274" ], "lang": { "en-us": { "role": { "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period", "terseLabel": "Award requisite service period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r274" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "terseLabel": "Non-qualified stock option awards vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r280" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "terseLabel": "Options exercisable (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r280" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Options exercisable (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r284" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r282" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r293" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average grant date fair value of options granted (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r278", "r279" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Awards outstanding, Ending balance (in shares)", "periodStartLabel": "Awards outstanding, Beginning balance (in shares)", "terseLabel": "Outstanding stock options (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Number of Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r278", "r279" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Awards outstanding, Ending balance (in usd per share)", "periodStartLabel": "Awards outstanding, Beginning balance (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "auth_ref": [ "r297" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number", "terseLabel": "Options vested and expected to vest (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r297" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price", "terseLabel": "Options vested and expected to vest (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r274", "r275", "r276", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r293", "r294", "r296", "r297", "r298", "r299", "r300", "r301", "r302" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r284" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Forfeited (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r282" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Granted (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Share price (usd per share)" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r275" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "terseLabel": "Non-qualified stock option awards expiration term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r309" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Options exercisable, weighted average remaining contractual term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r297" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Options vested and expected to vest, weighted average remaining contractual term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r64", "r74" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r11", "r12", "r13", "r66", "r68", "r91", "r92", "r97", "r100", "r102", "r110", "r111", "r112", "r156", "r180", "r185", "r186", "r187", "r191", "r192", "r209", "r210", "r214", "r218", "r225", "r375", "r506" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets", "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited", "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://vtvtherapeutics.com/role/Cover", "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail", "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail", "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestAdditionalInformationDetail", "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r28", "r35", "r36", "r37", "r75", "r76", "r77", "r79", "r85", "r87", "r109", "r157", "r225", "r232", "r311", "r312", "r313", "r325", "r326", "r356", "r377", "r378", "r379", "r380", "r381", "r382", "r394", "r487", "r488", "r489" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited", "http://vtvtherapeutics.com/role/InvestmentsScheduleofEquityInvestmentswithandwithoutReadilyDeterminableFairValuesAssessedDetail" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets", "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited", "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://vtvtherapeutics.com/role/InvestmentsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r75", "r76", "r77", "r109", "r443" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets", "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited", "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://vtvtherapeutics.com/role/InvestmentsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r27", "r196", "r225", "r226", "r232" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities", "terseLabel": "Exchange of Class B common stock for class A common stock, shares (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r12", "r13", "r225", "r232" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of Class A Common Stock to Collaboration Partner (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r12", "r13", "r225", "r232", "r283" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "terseLabel": "Exercise of stock options, shares (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r12", "r13", "r225", "r232" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of Class A common stock to collaboration partner, net of offering cost", "verboseLabel": "Stock issued during period" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited", "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r28", "r225", "r232" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Exercise of stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r13", "r16", "r17", "r68", "r147", "r156", "r375", "r406" ], "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total stockholders\u2019 deficit attributable to vTv Therapeutics Inc." } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets", "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 deficit:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r67", "r210", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r224", "r232", "r235", "r355" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Stockholders' Deficit" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/StockholdersDeficit" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityNoteSubscriptionsReceivable": { "auth_ref": [ "r12", "r13", "r16", "r207" ], "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Note received instead of cash as contribution to equity. The transaction may be a sale of capital stock or a contribution to paid-in capital.", "label": "Stockholders' Equity Note, Subscriptions Receivable", "negatedTerseLabel": "Promissory note receivable for common stock" } } }, "localname": "StockholdersEquityNoteSubscriptionsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r383", "r408" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r383", "r408" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r383", "r408" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]", "terseLabel": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r407", "r409" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_TransactionDomain": { "auth_ref": [ "r32" ], "lang": { "en-us": { "role": { "documentation": "Agreement between buyer and seller for the exchange of financial instruments.", "label": "Transaction [Domain]", "terseLabel": "Transaction" } } }, "localname": "TransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_TransactionTypeAxis": { "auth_ref": [ "r32" ], "lang": { "en-us": { "role": { "documentation": "Information by type of agreement between buyer and seller for the exchange of financial instruments.", "label": "Transaction Type [Axis]", "terseLabel": "Transaction Type" } } }, "localname": "TransactionTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r148", "r149", "r151", "r152", "r153", "r197", "r223", "r354", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r506", "r507", "r508", "r509", "r510", "r511", "r512" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r336" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_UnrealizedGainLossOnInvestments": { "auth_ref": [ "r56" ], "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment.", "label": "Unrealized Gain (Loss) on Investments", "negatedLabel": "Change in fair value of investments", "terseLabel": "Change in fair value of investments" } } }, "localname": "UnrealizedGainLossOnInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://vtvtherapeutics.com/role/InvestmentsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r113", "r114", "r116", "r117", "r121", "r122", "r123" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]", "verboseLabel": "Common stock warrants" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/NetLossperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetail" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstanding": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.", "label": "Warrants and Rights Outstanding", "terseLabel": "Warrants, fair value" } } }, "localname": "WarrantsAndRightsOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.", "label": "Warrants and Rights Outstanding, Measurement Input", "verboseLabel": "Inputs utilized in the valuation of warrants" } } }, "localname": "WarrantsAndRightsOutstandingMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail" ], "xbrltype": "decimalItemType" }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Warrants and Rights Outstanding, Term", "terseLabel": "Expected life of options in years", "verboseLabel": "Warrants, term" } } }, "localname": "WarrantsAndRightsOutstandingTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail", "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r90", "r102" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted-average number of vTv Therapeutics Inc. Class A Common Stock, diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Denominator:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r88", "r102" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted-average number of vTv Therapeutics Inc. Class A Common Stock, basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail" ], "xbrltype": "sharesItemType" }, "vtvt_AdjustmentsToTransactionPriceForPerformanceObligations": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Adjustments to transaction price for performance obligations.", "label": "Adjustments To Transaction Price For Performance Obligations", "terseLabel": "Adjustments to transaction price for performance obligations" } } }, "localname": "AdjustmentsToTransactionPriceForPerformanceObligations", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "vtvt_AggregateOfferingPriceOfShares": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Aggregate offering price of shares.", "label": "Aggregate Offering Price Of Shares", "terseLabel": "Aggregate offering price" } } }, "localname": "AggregateOfferingPriceOfShares", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "vtvt_AnterisBioIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Anteris Bio, Inc.", "label": "Anteris Bio Inc [Member]", "terseLabel": "Anteris Bio Inc" } } }, "localname": "AnterisBioIncMember", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/InvestmentsScheduleofEquityInvestmentswithandwithoutReadilyDeterminableFairValuesAssessedDetail" ], "xbrltype": "domainItemType" }, "vtvt_AtTheMarketOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "At the market offering.", "label": "At The Market Offering [Member]", "terseLabel": "ATM Offering" } } }, "localname": "AtTheMarketOfferingMember", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "vtvt_CantorFitzgeraldMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cantor fitzgerald member.", "label": "Cantor Fitzgerald [Member]", "terseLabel": "Cantor Fitzgerald" } } }, "localname": "CantorFitzgeraldMember", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail", "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "vtvt_ChangeInContractWithCustomerLiabilityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Change in Contract with Customer, Liability", "label": "Change in Contract with Customer, Liability [Roll Forward]", "terseLabel": "Revenue from Contract with Customer [Roll Forward]" } } }, "localname": "ChangeInContractWithCustomerLiabilityRollForward", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsContractwithCustomerContractAssetContractLiabilityandReceivableChangesDetails" ], "xbrltype": "stringItemType" }, "vtvt_ChangeInFairValueOfWarrantsRelatedParty": { "auth_ref": [], "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Change in fair value of warrants related party.", "label": "Change In Fair Value Of Warrants Related Party", "terseLabel": "Change in fair value of warrants, related party" } } }, "localname": "ChangeInFairValueOfWarrantsRelatedParty", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "vtvt_CinRxInvestmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "CinRx Investment", "label": "CinRx Investment [Member]", "terseLabel": "CinRx Investment" } } }, "localname": "CinRxInvestmentMember", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail", "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "vtvt_CinRxMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "CinRx", "label": "CinRx [Member]", "terseLabel": "CinRx" } } }, "localname": "CinRxMember", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "domainItemType" }, "vtvt_CinRxPharmaLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "CinRx Pharma, LLC", "label": "CinRx Pharma, LLC [Member]", "terseLabel": "CinRx Pharma, LLC" } } }, "localname": "CinRxPharmaLLCMember", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "vtvt_CinRxWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "CinRx Warrants", "label": "CinRx Warrants [Member]", "terseLabel": "CinRx Warrants" } } }, "localname": "CinRxWarrantsMember", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail" ], "xbrltype": "domainItemType" }, "vtvt_CognaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cogna", "label": "Cogna [Member]", "terseLabel": "Cogna" } } }, "localname": "CognaMember", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "vtvt_CollaborateArrangementContingentConsiderationTransferredCash": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Collaborate Arrangement, Contingent Consideration Transferred, Cash", "label": "Collaborate Arrangement, Contingent Consideration Transferred, Cash", "terseLabel": "Collaborate arrangement, contingent consideration transferred, cash" } } }, "localname": "CollaborateArrangementContingentConsiderationTransferredCash", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "vtvt_CollaborationPartnerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaboration Partner", "label": "Collaboration Partner [Member]", "terseLabel": "Collaboration Partner" } } }, "localname": "CollaborationPartnerMember", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "domainItemType" }, "vtvt_CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Contingent Consideration Transferred, Aggregate Share Value", "label": "Collaborative Arrangement, Contingent Consideration Transferred, Aggregate Share Value", "terseLabel": "Collaborative arrangement, contingent consideration" } } }, "localname": "CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "vtvt_CollaborativeArrangementNoteReceivableDiscountPaid": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Note Receivable, Discount Paid", "label": "Collaborative Arrangement, Note Receivable, Discount Paid", "terseLabel": "Discount on note receivable" } } }, "localname": "CollaborativeArrangementNoteReceivableDiscountPaid", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "vtvt_CollaborativeArrangementRoyaltiesReceivablePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Royalties Receivable, Percentage", "label": "Collaborative Arrangement, Royalties Receivable, Percentage", "terseLabel": "Royalties receivable, percent" } } }, "localname": "CollaborativeArrangementRoyaltiesReceivablePercentage", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "vtvt_CollaborativeArrangementRoyaltiesReceivablePeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Royalties Receivable, Period", "label": "Collaborative Arrangement, Royalties Receivable, Period", "terseLabel": "Royalties receivable, period" } } }, "localname": "CollaborativeArrangementRoyaltiesReceivablePeriod", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "vtvt_CommitmentContingencyAndRelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commitment, Contingency And Related Party Transactions [Abstract]", "label": "Commitment Contingency And Related Party Transactions [Abstract]", "terseLabel": "Commitment Contingency And Related Party Transactions [Abstract]" } } }, "localname": "CommitmentContingencyAndRelatedPartyTransactionsAbstract", "nsuri": "http://vtvtherapeutics.com/20220930", "xbrltype": "stringItemType" }, "vtvt_CommitmentsAndContingenciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commitments and Contingencies.", "label": "Commitments And Contingencies [Line Items]", "terseLabel": "Commitments And Contingencies [Line Items]" } } }, "localname": "CommitmentsAndContingenciesLineItems", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "vtvt_CommitmentsAndContingenciesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commitments And Contingencies [Table]", "label": "Commitments And Contingencies [Table]", "terseLabel": "Commitments And Contingencies [Table]" } } }, "localname": "CommitmentsAndContingenciesTable", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "vtvt_CommonStockAndPreferredStockSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock and preferred stock shares authorized.", "label": "Common Stock And Preferred Stock Shares Authorized", "terseLabel": "Capital stock, shares authorized (in shares)" } } }, "localname": "CommonStockAndPreferredStockSharesAuthorized", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "vtvt_ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent": { "auth_ref": [], "calculation": { "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestSummaryofNetIncomeAttributabletoVtvTherapeuticsIncDetail": { "order": 2.0, "parentTag": "us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Consolidation changes wholly owned subsidiary parent ownership interest changes purchase of interest by parent.", "label": "Consolidation Changes Wholly Owned Subsidiary Parent Ownership Interest Changes Purchase Of Interest By Parent", "terseLabel": "(Increase) in vTv Therapeutics Inc. accumulated deficit for purchase of LLC Units as a result of common stock issuances" } } }, "localname": "ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestSummaryofNetIncomeAttributabletoVtvTherapeuticsIncDetail" ], "xbrltype": "monetaryItemType" }, "vtvt_ContractWithCustomerContractAssetContractLiabilityAndReceivableChangesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contract with Customer, Contract Asset, Contract Liability, and Receivable Changes", "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable Changes [Table Text Block]", "terseLabel": "Contract with Customer, Contract Asset, Contract Liability, and Receivable Changes" } } }, "localname": "ContractWithCustomerContractAssetContractLiabilityAndReceivableChangesTableTextBlock", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsTables" ], "xbrltype": "textBlockItemType" }, "vtvt_CustomerOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer One", "label": "Customer One [Member]", "terseLabel": "Customer One" } } }, "localname": "CustomerOneMember", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Developmental and regulatory milestone payment.", "label": "Developmental And Regulatory Milestone Payment [Member]", "terseLabel": "Developmental and Regulatory Milestone Payment" } } }, "localname": "DevelopmentalAndRegulatoryMilestonePaymentMember", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "vtvt_DueToRelatedPartiesMonthlyAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Due To Related Parties, Monthly Amount", "label": "Due To Related Parties, Monthly Amount", "terseLabel": "Due To Related Parties, Monthly Amount" } } }, "localname": "DueToRelatedPartiesMonthlyAmount", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "vtvt_EquityInvestmentsWithReadilyDeterminableFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity investments with readily determinable fair value.", "label": "Equity Investments With Readily Determinable Fair Value", "terseLabel": "Equity investment with readily determinable fair value:" } } }, "localname": "EquityInvestmentsWithReadilyDeterminableFairValue", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/InvestmentsScheduleofEquityInvestmentswithandwithoutReadilyDeterminableFairValuesAssessedDetail" ], "xbrltype": "monetaryItemType" }, "vtvt_EquitySecuritiesWithAndWithoutReadilyDeterminableFairValueTableTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of investment in equity security with and without readily determinable fair value.", "label": "Equity Securities With And Without Readily Determinable Fair Value Table [Table Text Block]", "terseLabel": "Schedule of Equity Investments with and without Readily Determinable Fair Values Assessed" } } }, "localname": "EquitySecuritiesWithAndWithoutReadilyDeterminableFairValueTableTableTextBlock", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/InvestmentsTables" ], "xbrltype": "textBlockItemType" }, "vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exchange of redeemable non controlling interest to class A common stock.", "label": "Exchange Of Redeemable Non Controlling Interest To Class A Common Stock [Member]", "terseLabel": "Exchange of Redeemable Non controlling Interest To Class A Common Stock" } } }, "localname": "ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fair value of assets and liabilities measured on recurring basis.", "label": "Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]", "terseLabel": "Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]" } } }, "localname": "FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails", "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail" ], "xbrltype": "stringItemType" }, "vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fair value of assets and liabilities measured on recurring basis table.", "label": "Fair Value Of Assets And Liabilities Measured On Recurring Basis [Table]", "terseLabel": "Fair Value Of Assets And Liabilities Measured On Recurring Basis [Table]" } } }, "localname": "FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails", "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail" ], "xbrltype": "stringItemType" }, "vtvt_FundingReceived": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Funding received.", "label": "Funding Received", "terseLabel": "Funding received" } } }, "localname": "FundingReceived", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "vtvt_G2InvestmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "G2 Investment", "label": "G2 Investment [Member]", "terseLabel": "G2 Investment" } } }, "localname": "G2InvestmentMember", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail" ], "xbrltype": "domainItemType" }, "vtvt_G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "G2 Investments Purchase Agreement And Cogna Collaborative And License Agreement", "label": "G2 Investments Purchase Agreement And Cogna Collaborative And License Agreement [Member]", "terseLabel": "G2 Investments Purchase Agreement And Cogna Collaborative And License Agreement" } } }, "localname": "G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "vtvt_G42InvestmentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "G42 Investments", "label": "G42 Investments [Member]", "terseLabel": "G42 Investments" } } }, "localname": "G42InvestmentsMember", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "vtvt_HangzhouZhongmeiHuadongPharmaceuticalCompanyLimitedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Hangzhou Zhongmei Huadong Pharmaceutical Company Limited.", "label": "Hangzhou Zhongmei Huadong Pharmaceutical Company Limited [Member]", "terseLabel": "Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd." } } }, "localname": "HangzhouZhongmeiHuadongPharmaceuticalCompanyLimitedMember", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "vtvt_IncomeTaxesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Income taxes.", "label": "Income Taxes [Line Items]", "terseLabel": "Income Taxes [Line Items]" } } }, "localname": "IncomeTaxesLineItems", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "vtvt_IncomeTaxesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Income taxes.", "label": "Income Taxes [Table]", "terseLabel": "Income Taxes [Table]" } } }, "localname": "IncomeTaxesTable", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "vtvt_IncreaseInCommonStockSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Increase in common stock shares authorized.", "label": "Increase In Common Stock Shares Authorized", "terseLabel": "Increase in shares authorized (in shares)" } } }, "localname": "IncreaseInCommonStockSharesAuthorized", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "vtvt_InvestmentOwnershipPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Investment ownership percentage.", "label": "Investment Ownership Percentage", "terseLabel": "Equity method investments, ownership percentage" } } }, "localname": "InvestmentOwnershipPercentage", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/InvestmentsAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "vtvt_IssuanceOfClassACommonStockUnderATMOffering": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issuance Of Class A Common Stock Under ATM Offering", "label": "Issuance Of Class A Common Stock Under ATM Offering", "terseLabel": "Issuance Of Class A Common Stock Under ATM Offering (in shares)" } } }, "localname": "IssuanceOfClassACommonStockUnderATMOffering", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited" ], "xbrltype": "sharesItemType" }, "vtvt_IssuanceOfClassACommonStockUnderATMOfferingValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Issuance Of Class A Common Stock Under ATM Offering Value", "label": "Issuance Of Class A Common Stock Under ATM Offering Value", "terseLabel": "Issuance of Class A common stock under ATM offering" } } }, "localname": "IssuanceOfClassACommonStockUnderATMOfferingValue", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited" ], "xbrltype": "monetaryItemType" }, "vtvt_JDRFInternationalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "JDRF international.", "label": "J D R F International [Member]", "terseLabel": "JDRF" } } }, "localname": "JDRFInternationalMember", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "vtvt_LPCPurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "LPC purchase agreement.", "label": "L P C Purchase Agreement [Member]", "terseLabel": "LPC Purchase Agreement" } } }, "localname": "LPCPurchaseAgreementMember", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail", "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "vtvt_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": { "auth_ref": [], "calculation": { "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail_1": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Liability, to be Paid, After Year Four", "label": "Lessee, Operating Lease, Liability, to be Paid, After Year Four", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail" ], "xbrltype": "monetaryItemType" }, "vtvt_LesseeOperatingLeaseTerminationPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Termination Period", "label": "Lessee, Operating Lease, Termination Period", "terseLabel": "Lessee, operating lease, termination period" } } }, "localname": "LesseeOperatingLeaseTerminationPeriod", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/LeasesDetails" ], "xbrltype": "durationItemType" }, "vtvt_LetterAgreementWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Letter agreement warrants.", "label": "Letter Agreement Warrants [Member]", "terseLabel": "Letter Agreement Warrants" } } }, "localname": "LetterAgreementWarrantsMember", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail" ], "xbrltype": "domainItemType" }, "vtvt_LicenseAgreementObligationsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License agreement obligations.", "label": "License Agreement Obligations [Axis]", "terseLabel": "License Agreement Obligations" } } }, "localname": "LicenseAgreementObligationsAxis", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail" ], "xbrltype": "stringItemType" }, "vtvt_LicenseAgreementObligationsDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License agreement obligations.", "label": "License Agreement Obligations [Domain]", "terseLabel": "License Agreement Obligations" } } }, "localname": "LicenseAgreementObligationsDomain", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail" ], "xbrltype": "domainItemType" }, "vtvt_LicenseAndTechnologyTransferServicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License and technology transfer services.", "label": "License And Technology Transfer Services [Member]", "terseLabel": "License And Technology Transfer Services" } } }, "localname": "LicenseAndTechnologyTransferServicesMember", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "vtvt_LicenseAndTechnologyTransferServicesOfChemistryAndManufacturingKnowHowMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License and technology transfer services of chemistry and manufacturing know-how.", "label": "License And Technology Transfer Services Of Chemistry And Manufacturing Know How [Member]", "terseLabel": "License and Technology Transfer Services of Chemistry and Manufacturing Know-How" } } }, "localname": "LicenseAndTechnologyTransferServicesOfChemistryAndManufacturingKnowHowMember", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "vtvt_MFTTPHoldingsLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "M&F TTP Holdings LLC.", "label": "M F T T P Holdings L L C [Member]", "terseLabel": "M&F TTP Holdings LLC" } } }, "localname": "MFTTPHoldingsLLCMember", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "vtvt_MacAndrewsAndForbesIncorporatedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "MacAndrews and Forbes Incorporated.", "label": "Mac Andrews And Forbes Incorporated [Member]", "terseLabel": "MacAndrews & Forbes Incorporated" } } }, "localname": "MacAndrewsAndForbesIncorporatedMember", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "vtvt_MasterServiceAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Master Service Agreement", "label": "Master Service Agreement [Member]", "terseLabel": "Master Service Agreement" } } }, "localname": "MasterServiceAgreementMember", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "vtvt_MaximumFundingPercentageOfResearchAndDevelopmentMilestones": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum funding percentage of research and development milestones.", "label": "Maximum Funding Percentage Of Research And Development Milestones", "terseLabel": "Maximum funding percentage of research and development milestones" } } }, "localname": "MaximumFundingPercentageOfResearchAndDevelopmentMilestones", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "vtvt_MaximumResearchFundingReceivableBasedOnAchievementOfResearchAndDevelopmentMilestones": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Maximum research funding receivable based on achievement of research and development milestones.", "label": "Maximum Research Funding Receivable Based On Achievement Of Research And Development Milestones", "terseLabel": "Maximum research funding receivable achievement based on research and development milestones" } } }, "localname": "MaximumResearchFundingReceivableBasedOnAchievementOfResearchAndDevelopmentMilestones", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "vtvt_MaximumSponsoringContributionAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum sponsoring contribution amount.", "label": "Maximum Sponsoring Contribution Amount", "terseLabel": "Maximum contribution amount to clinical trial" } } }, "localname": "MaximumSponsoringContributionAmount", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "vtvt_NewsoaraBiopharmaCoLtdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Newsoara Biopharma Co Ltd.", "label": "Newsoara Biopharma Co Ltd [Member]", "terseLabel": "Newsoara Biopharma Co Ltd" } } }, "localname": "NewsoaraBiopharmaCoLtdMember", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "vtvt_NotesReceivableCurrent": { "auth_ref": [], "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Notes Receivable, Current", "label": "Notes Receivable, Current", "terseLabel": "Promissory note receivable" } } }, "localname": "NotesReceivableCurrent", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "vtvt_NovoLicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Novo license agreement.", "label": "Novo License Agreement [Member]", "terseLabel": "Novo License Agreement" } } }, "localname": "NovoLicenseAgreementMember", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "vtvt_OperatingLeasesImputedInterest": { "auth_ref": [], "calculation": { "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating leases imputed interest.", "label": "Operating Leases Imputed Interest", "negatedLabel": "Less: imputed interest" } } }, "localname": "OperatingLeasesImputedInterest", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail" ], "xbrltype": "monetaryItemType" }, "vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Organization consolidation and presentation of financial statements.", "label": "Organization Consolidation And Presentation Of Financial Statements [Line Items]", "terseLabel": "Organization Consolidation And Presentation Of Financial Statements [Line Items]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail" ], "xbrltype": "stringItemType" }, "vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Organization Consolidation And Presentation Of Financial Statements [Table]", "label": "Organization Consolidation And Presentation Of Financial Statements [Table]", "terseLabel": "Organization Consolidation And Presentation Of Financial Statements [Table]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsTable", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail" ], "xbrltype": "stringItemType" }, "vtvt_OtherIncomeExpensesRelatedParty": { "auth_ref": [], "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of other related party income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items.", "label": "Other Income Expenses Related Party", "terseLabel": "Other income (expense) \u2013 related party" } } }, "localname": "OtherIncomeExpensesRelatedParty", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "vtvt_OtherIndicationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other indication.", "label": "Other Indication [Member]", "terseLabel": "Other Indication" } } }, "localname": "OtherIndicationMember", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "vtvt_OwnershipPercentageOfMajorityOwner": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ownership percentage of majority owner.", "label": "Ownership Percentage Of Majority Owner", "terseLabel": "Ownership percentage of majority owner" } } }, "localname": "OwnershipPercentageOfMajorityOwner", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "vtvt_PercentageOfAmountOfCashSavings": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of amount of cash savings.", "label": "Percentage Of Amount Of Cash Savings", "terseLabel": "Amount of cash savings percentage" } } }, "localname": "PercentageOfAmountOfCashSavings", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/IncomeTaxesAdditionalInformationDetail", "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "vtvt_PercentageOfNonVotingEconomicInterest": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of non voting economic interest.", "label": "Percentage Of Non Voting Economic Interest", "terseLabel": "Percentage of non-voting economic interest of vTv Therapeutics Holdings LLC in vTv LLC", "verboseLabel": "Noncontrolling interest ownership percentage" } } }, "localname": "PercentageOfNonVotingEconomicInterest", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail", "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "vtvt_PercentageOfNonVotingEconomicInterestByParent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of non voting economic interest by parent.", "label": "Percentage Of Non Voting Economic Interest By Parent", "terseLabel": "Percentage of non-voting economic interest of vTv Therapeutics Inc in vTv LLC" } } }, "localname": "PercentageOfNonVotingEconomicInterestByParent", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail" ], "xbrltype": "percentItemType" }, "vtvt_PeriodUsedToDetermineExchangeValueBasedOnWeightedAveragePriceOfClassCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period used to determine exchange value based on weighted average price of Class A common stock.", "label": "Period Used To Determine Exchange Value Based On Weighted Average Price Of Class Common Stock", "terseLabel": "Number of days used to determine exchange value based on weighted average price of Class A common stock" } } }, "localname": "PeriodUsedToDetermineExchangeValueBasedOnWeightedAveragePriceOfClassCommonStock", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "vtvt_PhaseTwoMultiRegionalClinicalTrialMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Phase two multi-regional clinical trial.", "label": "Phase Two Multi Regional Clinical Trial [Member]", "terseLabel": "Phase 2 MRCT" } } }, "localname": "PhaseTwoMultiRegionalClinicalTrialMember", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Potential development and regulatory milestone payments receivable.", "label": "Potential Development And Regulatory Milestone Payments Receivable", "terseLabel": "Potential development and regulatory milestone payments" } } }, "localname": "PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "vtvt_PotentialMilestonePayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Potential milestone payment.", "label": "Potential Milestone Payment", "terseLabel": "Potential milestone payment" } } }, "localname": "PotentialMilestonePayment", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "vtvt_ProceedsFromSaleOfCommonStock": { "auth_ref": [], "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds From Sale Of Common Stock", "label": "Proceeds From Sale Of Common Stock", "terseLabel": "Proceeds from sale of Class A common stock to collaboration partner, net of offering costs" } } }, "localname": "ProceedsFromSaleOfCommonStock", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "vtvt_PublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Public float.", "label": "Public Float", "terseLabel": "Public float" } } }, "localname": "PublicFloat", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Redeemable non controlling interest exchange agreement stock conversion ratio.", "label": "Redeemable Non Controlling Interest Exchange Agreement Stock Conversion Ratio", "terseLabel": "Stock conversion ratio" } } }, "localname": "RedeemableNonControllingInterestExchangeAgreementStockConversionRatio", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestAdditionalInformationDetail" ], "xbrltype": "pureItemType" }, "vtvt_RedeemableNoncontrollingInterestTemporaryEquityRedemptionValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Redeemable noncontrolling interest temporary equity redemption value.", "label": "Redeemable Noncontrolling Interest Temporary Equity Redemption Value", "terseLabel": "Redemption amount of noncontrolling interest" } } }, "localname": "RedeemableNoncontrollingInterestTemporaryEquityRedemptionValue", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "vtvt_RedeemableNoncontrollingInterestsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Redeemable noncontrolling interests.", "label": "Redeemable Noncontrolling Interests [Member]", "terseLabel": "Redeemable Noncontrolling Interest" } } }, "localname": "RedeemableNoncontrollingInterestsMember", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited" ], "xbrltype": "domainItemType" }, "vtvt_RemainingAvailabilityStockIssuedDuringPeriodValueNewIssues": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Remaining availability under our controlled equity offering sales agreement", "label": "Remaining Availability Stock Issued During Period Value New Issues", "terseLabel": "Remaining available stock value" } } }, "localname": "RemainingAvailabilityStockIssuedDuringPeriodValueNewIssues", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail" ], "xbrltype": "monetaryItemType" }, "vtvt_ReneoPharmaceuticalsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Reneo Pharmaceuticals Inc.", "label": "Reneo Pharmaceuticals Inc [Member]", "terseLabel": "Reneo" } } }, "localname": "ReneoPharmaceuticalsIncMember", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/InvestmentsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/InvestmentsScheduleofEquityInvestmentswithandwithoutReadilyDeterminableFairValuesAssessedDetail" ], "xbrltype": "domainItemType" }, "vtvt_SaleOfStockConsiderationReceivablePaymentPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale Of Stock, Consideration Receivable, Payment Period", "label": "Sale Of Stock, Consideration Receivable, Payment Period", "terseLabel": "Consideration receivable, payment period" } } }, "localname": "SaleOfStockConsiderationReceivablePaymentPeriod", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "vtvt_SaleOfStockConsiderationReceivableTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale Of Stock, Consideration, Receivable, Term", "label": "Sale Of Stock, Consideration, Receivable, Term", "terseLabel": "Sale of stock, consideration, receivables, payment term" } } }, "localname": "SaleOfStockConsiderationReceivableTerm", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "vtvt_SaleOfStockConsiderationReceivedOnTransactionGross": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sale of Stock, Consideration Received on Transaction, Gross", "label": "Sale of Stock, Consideration Received on Transaction, Gross", "terseLabel": "Sale of stock, consideration received on transaction, gross" } } }, "localname": "SaleOfStockConsiderationReceivedOnTransactionGross", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "vtvt_SalesBasedMilestonesPaymentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sales-based milestones payment.", "label": "Sales Based Milestones Payment [Member]", "terseLabel": "Sales-based Milestones Payment" } } }, "localname": "SalesBasedMilestonesPaymentMember", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "vtvt_SatisfactionOfMilestonePaymentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Satisfaction of milestone payment.", "label": "Satisfaction Of Milestone Payment [Member]", "terseLabel": "Satisfaction of Milestone Payment" } } }, "localname": "SatisfactionOfMilestonePaymentMember", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "vtvt_ScheduleOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule Of Earnings Per Share [Line Items]", "label": "Schedule Of Earnings Per Share [Line Items]", "terseLabel": "Schedule Of Earnings Per Share [Line Items]" } } }, "localname": "ScheduleOfEarningsPerShareLineItems", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail" ], "xbrltype": "stringItemType" }, "vtvt_ScheduleOfEarningsPerShareTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule Of Earnings Per Share [Table]", "label": "Schedule Of Earnings Per Share [Table]", "terseLabel": "Schedule Of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfEarningsPerShareTable", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail" ], "xbrltype": "stringItemType" }, "vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelled": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled", "terseLabel": "Stock options cancelled (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelled", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]", "terseLabel": "Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollForward", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail" ], "xbrltype": "stringItemType" }, "vtvt_StockIssuedDuringPeriodSharesPurchaseAgreement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issuance of Class A Common Stock under LPC agreement shares..", "label": "Stock Issued During Period, Shares, Purchase Agreement", "terseLabel": "Issuance of class A common stock under LPC agreement, shares (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesPurchaseAgreement", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited" ], "xbrltype": "sharesItemType" }, "vtvt_StockIssuedDuringPeriodValuePurchaseAgreement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock Issued During Period, Value, Purchase Agreement", "label": "Stock Issued During Period, Value, Purchase Agreement", "terseLabel": "Issuance of Class A Common Stock under LPC Agreement" } } }, "localname": "StockIssuedDuringPeriodValuePurchaseAgreement", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited" ], "xbrltype": "monetaryItemType" }, "vtvt_StrategicAdvisorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Strategic advisor.", "label": "Strategic Advisor [Member]", "terseLabel": "Strategic Advisor" } } }, "localname": "StrategicAdvisorMember", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "vtvt_SummaryOfSignificantAccountingPoliciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of significant accounting policies.", "label": "Summary Of Significant Accounting Policies [Line Items]", "terseLabel": "Summary Of Significant Accounting Policies [Line Items]" } } }, "localname": "SummaryOfSignificantAccountingPoliciesLineItems", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "vtvt_SummaryOfSignificantAccountingPoliciesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary Of Significant Accounting Policies [Table]", "label": "Summary Of Significant Accounting Policies [Table]", "terseLabel": "Summary Of Significant Accounting Policies [Table]" } } }, "localname": "SummaryOfSignificantAccountingPoliciesTable", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "vtvt_TemporaryEquityChangeInRedemptionValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Temporary Equity, Change In Redemption Value", "label": "Temporary Equity, Change In Redemption Value", "terseLabel": "Change in redemption value of noncontrolling interest" } } }, "localname": "TemporaryEquityChangeInRedemptionValue", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited" ], "xbrltype": "monetaryItemType" }, "vtvt_ThreeCustomersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Three Customers", "label": "Three Customers [Member]", "terseLabel": "Customer Three" } } }, "localname": "ThreeCustomersMember", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "vtvt_TwoCustomersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Customers", "label": "Two Customers [Member]", "terseLabel": "Customers Two" } } }, "localname": "TwoCustomersMember", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "vtvt_TypeOneDiabetesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type 1 diabetes.", "label": "Type One Diabetes [Member]", "terseLabel": "Type 1 Diabetes" } } }, "localname": "TypeOneDiabetesMember", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "vtvt_TypeTwoDiabetesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type 2 diabetes.", "label": "Type Two Diabetes [Member]", "terseLabel": "Type 2 Diabetes" } } }, "localname": "TypeTwoDiabetesMember", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "vtvt_UnauditedInterimFinancialInformationPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Unaudited interim financial information policy.", "label": "Unaudited Interim Financial Information Policy [Policy Text Block]", "terseLabel": "Unaudited Interim Financial Information" } } }, "localname": "UnauditedInterimFinancialInformationPolicyPolicyTextBlock", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "vtvt_VTvLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "vTv LLC.", "label": "V Tv L L C [Member]", "terseLabel": "vTv Therapeutics LLC" } } }, "localname": "VTvLLCMember", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail", "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "vtvt_VariableInterestsAndEquityMethodInvestmentsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Variable Interests And Equity Method Investments Disclosure [Abstract]", "label": "Variable Interests And Equity Method Investments Disclosure [Abstract]", "terseLabel": "Variable Interests And Equity Method Investments Disclosure [Abstract]" } } }, "localname": "VariableInterestsAndEquityMethodInvestmentsDisclosureAbstract", "nsuri": "http://vtvtherapeutics.com/20220930", "xbrltype": "stringItemType" }, "vtvt_WarrantLiabilityRelatedPartyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrant liability, related party.", "label": "Warrant Liability Related Party [Member]", "terseLabel": "Warrant liability, related party" } } }, "localname": "WarrantLiabilityRelatedPartyMember", "nsuri": "http://vtvtherapeutics.com/20220930", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails", "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail" ], "xbrltype": "domainItemType" } }, "unitCount": 5 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258" }, "r108": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r124": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "https://asc.fasb.org/topic&trid=2196928" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r174": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r179": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r2": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(12)(c)", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(16)(c)", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(3)", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "14", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "15", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "16(c)", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r235": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.23)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r256": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org/topic&trid=49130388" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907" }, "r317": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r333": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r337": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "808", "URI": "https://asc.fasb.org/topic&trid=5833765" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "4M", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591554-111686" }, "r353": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r393": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/subtopic&trid=77888251" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r403": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r409": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1(e))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.19)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953" }, "r457": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "940", "URI": "https://asc.fasb.org/subtopic&trid=2176304" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(7))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r467": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "942", "URI": "https://asc.fasb.org/subtopic&trid=2209399" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(5))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(5))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(b))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14.Column B)", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611322-123010" }, "r494": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "https://asc.fasb.org/subtopic&trid=2324412" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r501": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r502": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r503": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r504": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r505": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r506": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r507": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r508": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r509": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r510": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r511": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r512": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r513": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1403" }, "r514": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r74": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(12))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" } }, "version": "2.1" } ZIP 71 0001641489-22-000015-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001641489-22-000015-xbrl.zip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̟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

'1M6K@:PQN@SS.)5]/7Y/TR% 7W5%3\ MJ_J/*C50C,/-X,I:TAL,ON(],ZT,;8(1[F$:%?;EM W;JOU!IX_&%;-+!]N-,@T2AAV;YAGH,4KIO3P<'RSZYO@H(:RI$NOA?8/ MSD)/+IN$BBB_$L>_8=&TWKUKM_8"5?J[Z=A7(:EWT-P6VVZWK;O)6+;YO M+A_\NH4STXF],BY442VG8P!S&0!^6$X$&E'CT3C0NJ\0V78KP^0_5X#PCM#U M/,I=.6VS]U22A.4$RND^':#J0-$Z&@[.4*Q/<2 P!IN[N>M5581+K\^V"HW$ MX1AD$LGS!Z?!FW<>^CHJ+484CJ*T5X/?'I+YPE>1HMZ-\C*'[P8C"$*V)-4Z M5 8S:T@;:J5:0"?85ECN!T@.T>Q.&^AR5P6><"DOVKZ >ARDY^&M5#/:74I MK(1ORY\'05W\L'#NZ]*=TV6V>"'$M98^QF!6WRY]?*+/%S\J)W;QPWJ:EBZ MV9^O>-_I<'"\JATE,"Y^>I;WEIXT @/TXP89&!^ZUA?CT_"PZ[I;U7>!5@R&\U]#55>$ M]MX:VJ=+I0;W*]O0#BYH*_I/W_?T"NJA50GM M.1KJ$TQ\K^=\,]R'_?V_19K>TQ5DN<#/'MA>&O1VF<@BO M03L69^RH-S:(-QAMQXW";R@TK5\JI?3V_]NN5-*ODWV'(',G5563 $*4J/;+FB9!HM/Z#K=&W4-(BP:B\,[5ZY MF?9Z#Q]0.-Q#[3#^T"!TH:[<'QBP MK?<"RMC(.2SI GI^V=FN*LFAY!YA4*.^Q 2+3IP;!7"<$V>0 ME;EC5)EL9GVAD<\5, MH$H89R$T4 X_2%H9B2T I##DA+$ /.TY'.>(#2,<;AQ*4,'#P??@'X-"8VUH MZ%280\1VA&9Q@<'IR6G7N8=F+EQ"11BNU^NB?#_*P%0%UWN?]4%1[&0SH2LF M%-"YV@]&T^+\='#4.S?N)->M<++X9- OT7T2M?V[BZ8UGRBH?5(IJ%"4M%I" M,,,G3N.J\^/2)0I%7C&U9Y* !9H&$.@3KHLR1C()[4X*=%:+ M-SRXF='Y%I"P+F"8,6?O%&>MS*-=FM]RVI^ >@AGR:?64SAR[K!X*CB-8% 6 M03C1^<^Q*FN]QX)%@D/6M0G;",4X!+;#M^%372'(1/<&L&MD;0$] BYC]'62 MX3:J#O:7O@Z:)3 %7]UHH$UN![@A5]LH.S.^.$CIO&$S42M6C_0L#I7S4F[( MP0>@+F#R]%'X9AW __CVKWVLV-O-LSRX6H@3;__Z&U]'U>_LPS;X.97 ]AN![E+-964^-X;3"2SO"+78P<>M%@1CF!N 5 MSR'8&#>#C!F?C'ME9#L 6C7:C02O'%JT%8>##$-C4S?X4J1!LS$,]IMQV Q& M;5^; Z$:? @L%=VI";M9 [Y3.^][F2OJ7//=:O^C./FI,W$\& _[(>]D.0$& M1U)Q:.MV2-V%UDUZLET4 Y.7<:B/)B^WVDWK8[WO.\!@+;AR<1WX_.&YA?!5= 'IY5)$[:B@Z,X$X>^*8\7IO>?'+6*H?F_ M+[Z-OHTF9TN^'+&MX].C%RW=&UUV:1Z+A)*GW^_"XQ4GT>EW7).WW9-4_)H] MR8?.:KUREQ*WR??+\/9$K_Q=[9B'Q!OV^T]3Y*M;/&\Y/>YX2A,_?[CX^20^ MZOI'@$UV?E^CBI8B(=())LW,#3)@&.[X%77LM)A$3^\4E+^/F'R=XU?OZY99 M-DTD>/,BP9@#5::?ML#<=0159K#;064.1_"$D$\3$G_++*=24F#:$ F.Y2E M&%9 ,0W>#'#ON(P&A80^S*9J_6]Y, %;!.I2_(@CL"GHN6K7' !T@-FK=N5V MOUX1KFZP3,N2B-F.[,+;3K!_,NIF&@&',,?(+ M$-]#:[F8TB; @J[!UXZ'(=^H8O<-,FWP>$8= <;AMT-]AH8#QGA-&0J;>9%= M&6C>0H^FP-R_>@?F=.B^Y8-Q,9M:&@"F7<<];A(&K3J R.7= M&2S/&0PT]29H"!B5Q :;&B_: &F95RS5] ?B#.>^SMD!50B_/*>S0AY:8-;/ M& O=L.F,%#:)R!LRSLZET4#X>FPSMNEM%1G:HHI%_7,>160M^+6NU0A MO6FK!9^&DR0ACQHO,^]B!T@,->X2A"4![M M^89GHLI#2B%SSV(!@E7G>'Y^-.J6T9ZWDK?>A?X]G0SZ77W>$FQE OUD)4,K MAZAF0]I%1=54U%D9U:',UG_S:(NVH)&]P( R&28\R+8P<%NM3^'0;9#E< ZS MBC-,G[[0E#)V@#D[#B!XX7%(AR)4W.:);!5=/;R<#.K/<(QG>[YH!1X?A087 MQ3B$)4R(>OPWWY(,C=ORB95Q\=^,;T63/I[JO#PGKHLN/@494F 93 ^Y#MV) MSD,<;4J$M?B(\S*0/S<1HK2.9L9:]XI!O:8G,#!=M=CX\O CO$#0N7F8S7Z: MCL[*D8#Q71S:7_#P-?8/'M3+W3@<)L"Q'$6 M%$OM#7WJ!Z*?CZ/R.-N"X[#'R!2A1ZA?1W9? EN$PE[0B&;H;(X8,'42X3[\:JN3+ZC^YKV))" M\]\-AQ@*/&^CG=Y']@D\=6+*>'%@T2E%?3>W%@#YM2Y&[=:VQTRU$K70D8'! MWRYR_13\T9(I]^_QT(2U/:'1?1*.:7FT.UJ'9\HN\TMA /_6W]O(+3:)_I:? MU0%@M*R1D#.W.6Y7HXXO!STLYZ5O?IA\\48^;ODN,,8KSA?99I%L1S)=X:G] M67IJ'\M"BSX0I*UT7>\+$C9UPE.*DE9F>-_%E9SU8 MUN:4AL."-2DW0FLY[CC1IJ8IO;%?B_)0\LP ;",F%Z&YX41V%5L(42L,P0_S MHR/DH/MEJEFGGFN90M$ ]7P+?EUBLBMW?NJEMKAZ:X[OX)&%/3> MY4;EW77B''X#:;Y&Y].*!2!CJR@OVW6V5/6TBMD/*3\F6FG*9+3(!%VQ:Y9O M_Z9!R 'VR.2=&#V$-M3+ZY]WK^>8B5@S*;W96Y MOO.YJ55GW1R XD#L^$M-9H$C%CC62AZHH#\61P:_6"LD7Q88J$*/%5')E*2M M?M?J24/U<^77X$V_0I/"SG099STKV4Q+0I- 0%@K\VEZU/3+[E#,T- M=9&+:9UB4-!5N809(M00J@9MU1]@E@),>"!+ ^6X=4FOJH8.G1\$8I<9$N[% MQ]8Y2..)<0*S/CO3H4YTV-DLG9-K^;SO"&7J)A4+-B8S^XW5-1L]<4)=U&) M7]!00-1A'A*,\'OC4P)_APR7@0&C$0P%Z U@%&[UU]3"3H,[UO+.U8ML&ONJ M"8CK@,'4*'X:J0!3UL8P%2?Z?#(+\Q. JO DR_N34NSU'D^8E/9D@' 49\88 M_8P9PN7!N>X%Z*UH*5WY]9GG34BKD'XI3$;UY GG$FJ9'FZ9C,N@#*#MZ'PV M+;:DEYV1(.C8I%,A(<3WT-#!?X9VU/FMH"_J7P.[3Y4S4BD.L /KC:^I3W59 MMP.E;R DK@=@ZIM5WP[_+)\9. [/9SSA0")E'(:J)AQ4]6Y;X!VN!JM=6^X@ M4.6>_WD@=2S&!HSBPH_+:,M,5,N"X>_Q^5[GO3+.BQQ1%;GH NG3BI,\980G M)!25Y?J@3=/YF3"F%Q.5QB[ ML,97D7Z'S, )MM?;3),\]QGJ4VT!^ MLIPX'I*'O-UFS#Z[&;JT#*L#"D9BA M!VQAH4)<*(\?F#[F(:X0%CNR[(9,NEI33(A(2Q&!O_"H/()2^<%T<.:R829F MWVP OLK."_;R#!OHY$3#DL.)BUSWQVC-EOF4*\BSRY4^8V?6//,@\S,+!#=A MD$8!U\>*A180#;,)P?*\<)=WS%6S7FT3E^L?>AAJQ93*LC*"KW]$%9>=4::P M]A!:PO%B,RAFZ#N"N@QQJ)#N5*<0#89%N_;@=8 ]4X5P*XTZ&(8YF!O:2C$SR"2YOJJT/BT+=RL<'J&IV?5JQ0@<(? MR0'K!E3TOLCD4L4(9I:>-L-! =X@QFR06.'2EU94NI4,E:-5T\##>P>FGJ0R M%E63D=21G*=@V,!V*9P5*IV9QTJ[U!#84+X6?O='^%;P=LN*ZR(25FI M&A[KI;\85(ZIFLEBNDHV:G&Z?+B??6Y(TN2&-+DACQ* ]JXRDB:*)#N?A,\G M&G/;T^7M\*EA4+'Y37)MF247GJ9;K%+KUWU6,:VE(SO]-BKKXDT>N:-%5N) MNOSR!C96WNBQH3IU);V3NO5BPGU15]^F6'M[YGF36].E6U?4L"\U],/4Z%;7 MA81I29F $+9;(M?K>>1J 6@M5BE_1D/304R_XS?W,0R+3YBN>.^Y94+33&.3#^K^@UEC=]F#Y?;RO3DO/O1G&SES>0 MBTO'H[)70^#Y=-0*>[>MNFNWD*9K!_Q'GM$T\NW M6J$+KUQL&^L+>+HY\G5O/88V3]+R#/=L7KIM>E,3=?.D+KHM:F^> MX_#$9RB0[[M?JA%=ULE>\.4R^J,EX#QMX,QGABK M.W2CG,RGF/"P_@':^"4V6I1 M;9'>,5+6K)9FM3RSU9*T4_YH=4MPQ7X+!!*O'C$3R&A":HX0)+,MG M\'!6IG\9JO3,O6"89W$1J]OMNU)5-" R'XV'8NM7V M6^#8OX2=]VKB12PW,*7AKVK// %FK5!A?$)[ MN6JPYGCD9^G^EB@NBU87GHQ$:%CU%YDMMUK;H[*"+U)?!K8M@S4M<'7H H8R M@[N1 N]$5U2:?5VRJI84G^U6H/,J1I.B$A598,7W6;%7]@/S%W)O+S)SE@4= MD ^U^OY"!Y'Y<[&?@^&5W:QK$H9RX*$0N$6_R$^4[T!_&O_\\8)H?+BZV(AP+G)WI M_)W7TEF8P2D(_["J,A:8_T"R2T:H2F],0*Q_-"B+EZ"NZ/7*PKKG,S#57BJ! M->77O0'CY^^-0#RL0$S+G-;,E1-LFH$?+'Y9SF%9.+F9J8>=J04ZYK*V:WN> M+KKFLNWFL++^__:NO:EM)F7%IF$ T'S^F;*]2R;?QY_P@\T1O>X1\5AU1 X+ M8W>4,HR8XXY=W\2H"IF5PT4QTR+.Q1=U()Y )9&ZCO& MU+4)-%2+..5?+@:%9W 9-3Q$,CSRKVL99V!WN+]L]*I-'>*>;!CI3637.$TF M883RF(;7TO!^AC%,8Q$T8Y#[@FLR=."D,)@ <[D)O H!*5%8#")13)T MY7,=%4<3GK] 6LD<^.7TI!B#1^ >R)61ASYXCJZ.Z]MS4B:L7^A)".A1$CR0 M4_3OY3GI"T4-A8SOY!ZOQY440H-(L6V.7>YI K M-02/O%QC4!U/855X"G>:=18A;3!4! IB#*KED#?"T2B%XQ_-);B$@'% ;#H2 M+O$\3MSI4W 5-N9BG4OLP?, -=7V7Z*;#)E400%F,)#"ZL#HZE3&:7?J&$\+ MQ7[-.;H-[D;GJ,'=:' WMM3T8QN"U9.Q)^3;>Q->F&R_E+L4+C-N[H.4:IEM M)ZP]2@.D 5Q-@B(T;L&7N25.IQ*PFG*QEKU$A[2?@=DXL6%O&7X] MOJ@4PUZN1%JO,SO";-3* +P#Z[>';\"+GW\E**'$:KQ46(TUV7IC;BBIZ4-T.HO*@8R&P=%QVL\ '$9G=G-L MQE^38Y(-4[G M.%=>$,.%">^#-P+TTS]J'1VNAANS.]@Y6[?8H^?$SMFL^M1R4(<]!^],%!LY M,*[*)F:KOVG8%37WN0SW1TGQ52!NMN&0KQ,P/E3A5":?'3NQZR!7;-=1[RQ, M2_W][R9*3\W]GY A_Q)(-=QQT'WXMD\]Q_'=-1767PD,]16KZI^Q\V*M9%CH MO'C,")C:M#BLW4"P5F*(H7A/02EZ8L=/PU8[R%9=$Y[?,%7#5,\Z'9NXZOW3 M%/B2L1L;K\!%]"RX56GAU>#EZ@YK:9[QS!;B8,,9[*JJ7^(Y1+DN:>I,]%FW M NOW7T*![3SE:#1$0[E54*(.NR^GVS9=]"RI"WL.';=5C- Q#[J]3='L6T:Y M3JT85T.YA5F^UA.%SQ*[I]/?<.'#P^7"!?/Z27;/H]VOC>>1OGEPM("W^]JJ M???(VC,/VMV&K"\PWO;HH D6W%(!U5-TXNZQQAY)LNIL]BL9"CM(6 ME64/8 MYR=L#Z79$V.?VYR\5,7_7KZ'XZT$!ZS^B^13=IYN+YC@W'G:%7GN3=E/YX4^ MG#<7A=H[6KL>WTZZ+6+X-G2K0[?.&S9O]!X9$X?JO3D#YW#MD:6M)%NGMUJF MX*W3;<\ZZ+_A4I*+,,9I)#B45T@=([%_N4V)G"Y9VGVY[UIFMSO[D) M)=JD416$ 0(;X"0US,')J2Z-?=785Z]C7_4:^^J%\G!OVKZZ<./XHV$H<5<< MR_*<$Z)N"YL/GYU8V]*=V#,[!]:+F%P-8S:,^21+I'VTHB72,&;# MF"]HYIG68:_$7%D=/W-CQ@6*62O;/[P3K28<Z3]BTLB?J=:<0Z4# .[<@V/GOA;&+#(XR3L&4:%XD#_[U'."?M3_)3 M]$_KTWMC#Q]9^*-Q(5YQ+%^A/HX-CU=NX(;&=WK'B"Q4@E= (U6]ASZ3?SI_ M[:*X>O5H#5DQADW'8T$HQ"/1FKN!:\!##P,W;AFK,^P&73VMB?V+ML_= 5&H M[--7C6L$2_*NV[+P='T\=/SHNTZKIW[Q^$N(Y:GJ^XF3@Q\ M&!;822.:*8H@H#P&%-GR7;MUJ!8(Z^L0T>O5JC>+Z37-/43;^8C M8O1(?,-!!)TX29TY,?)FG?D?W[\?=@_-M1ZZ/.,DUB&#X*#Q_C+:AWX8Q ,@ MV;P(@7OQ6)6]AG=91ZV"Y)LND,3^DK_8)RV%<(/%FD\1H\?.99N<[ MNV0'2P5T42C,[#GA32J$\MS:-!LSG.,<]D]Q:NBZ;@O>DL3H$&U]5 ZE1"Z@SRI&D@=1I(G:V3T#L#%E9L2'RB^?,( M.;@]I\YM5 I R?BP,Y!_O#-Y]'AXH%*M)YO"^*#,"H5M%1"8=$6->"X9FA(: M>1R S,,GE3E+:[=B)(@4[&:=/KD>T\CC&"\B2X5I$BDK41@^G2>G1.JR<^2<5TO+^C+D+_\YC#[\9?%!-2&_>K]MM:Q> M1-0*X#,O":A5?2C==NM%P<8:E*U54+8&@U:_WT4'8060K8/!BX!L#=J]E1[[ M$&[58;/8=@.RM:,@6]]0L#<86PW&5G%3.XUG.R&<@M(&X?6R^FV31<]#<)61HN!>62M)GQ>0!MN%>4.S(/. M84.YE3PVZZEX- W&UNZC%AV9G?:+./9OG*X]L]];^XCIW:-KUSSH'S8!@P9E MJW3$MFD-7F;RQ%NG;-OL]QNL&-(_/PJ ENO,1T<-/J-H1]F7C<0?^I\#?; M;%TUL%M-[&CU*(C5&%0KE=#UWZXMU>!MK6A:#1K3ZF5,JTZO03)[&=/JL/M4 MJ.9M-JT:Q*W: "S]@UX3U%HQ(-BU.@WM5J1=I_^6PUH-ZM;Z&Q*?G5A;T['8 M,WO6R^11&\YL./-)V8Y!]V42U0UC-HSY)%>U5XP!-+!;&S;NM8B6]8C1B (L M"\PQ1$MH:R@" MV@"CIK!>0L>\J+J4#0^B.UG1#!6JJ!J.QR**I%O+"Z%"!D M!QS4&6>X!+;OAR-;OE*BF(D_J[4'CI&XHTD 1WP[9_*,$?NDE K&U'9HMBCX MWH'+VZ$]XR//O"A.U.Z/D4BT/6UBZ,"2Y,OX,VFA&S$/$A/**\:R=RF.6Q_R>\88HW_ZAC'7Z*\7GRL&9PP @J M(93B?.8:'?B[/71!,YMYF*$"$%PGPQ=K@.!>& C.5$APFT6X]5)L"28>8REF M^%>9KM%8-0^9]3B(+'C!KJ!D-WA[NAJ6Q,3& M @XWJ(>)IW]38>(UZ%T5K-!MYTG3H'!H9YIV-A\GJLW'H0@\XG8_D!NX7%7T-'S),P>WG MBA(HP4XA@K8"CWC50()+L-WP100$%LQ5%.EAC$$-SF^]D'IE6'D=+8Z^@FBM MB!Y<17 )8RKU'7@1%\66N!NZBD)!2 &&/3.RZY#2.TR2-7%Y5 M]DV\P/D,"[SR+(U0OM&>46&,DOQ[ ]=%?\JA2 GF9 2KPS+T)8U3]%I00BC\ MJY;Q )7QX[[B,G%S9'&#PR1#WJ,?7/@^MQ4I\V32(S MV+^E"X)O$L0O4!H7O5FQ4,Y%KC,*+RM9*,G#(7@\(6"&3*?%JJPARU%QM82D M-RA=-_'^5,4?' X06A)]H]O(GL9&G&(".MZP0^#TT3H/@>.WDEP33@?F'4J^ MZQC?I765U9K,[+FL$==L%G1805R)AKZO]MSH6B0-NFP5E;^Y MIX5[LA>?>,'5K\>]^AO<! B-8W**/4QO(5E5WCB,6A-DU5B MXDWYT#P0;, M]$S M6,\51K$N53DZY.+!XC^!D7^ZB:@%Q-(\(5KO0C^=L@,0V0[WF%72G00&1AKX M=49D>[C6=(A> \EG+*]-4*VF2?$DE,U =X>O?'1QE:I$->&I53V3Y)OO<+(! "XG7 M9Z*K0+"6\4/]"4@[55*D\#E3&>B@[DH(;-.60),*HXA7V_TW^;AL9R 41V#C M"[^$BT,Y[R36BH<1N=YT"&?F*JQR3LV.7:1E)&PN,*GI0V2W/6C^2R8U6^8M (F&O""VBB0% M(L$ Z"P@:X8%%BX+R\03U\=*Y%N1AZ+E*Z#@P#@+HZEQO=\EYR4(#2Q93OA( M[UUFF*6[I]1 Z;"WP[X >$;)]XD2.Y 1?=:7^:I<"S M(W13[81^97TR]J@HB_6&"A-57ATRXM#8X@ D&_.Q"Z8(>;C*M<2K3B$W%F BDYUN=_1'Z<8X=<=!-EHW&(?C%>'EC6J2^ M(V'I8#D"^.'&N\/LWNZTYLG9+HN&R XKHW++RRS7/O0(,HCQT4IH%XV_3'^4 M7?K:^D1=):%&>H>9DU-;4/XG65E M@2Q=1/:UXO!2$=G4Y535Y5A-74Y3E[.5LO3R3IA6W8-]5JQHA2YW9!I5#U> M/I+-R&4O9XM/[]SK'/;+=N/QXD9^&.?\D,H5B^(0D/9@)Q#/*K(YJ(+ @,0# M$M90KP6OQ'?1:SE'B2L;+[S"?FZ%'/,'4W!$)Z%SB-+&4QNT M7#K5>_K8>B9/#-;HEYP-9SW"1%C.QCL$=Z?]\F&J)68=E0_'CX;9]\BLS3&T M6%/%4N"K8$=SQH43X_<<[MF#>T-,R10H!*)L!R4+1] =%RZ5-R33:,D]?O\1 MGOE>O21.V!/,=XZN=)#(37N>>+8-OL!D"G=\!&8%>*NWBDG LW?5NR4;L2M? MZ):[D6F,OM@"TU(XDRH;]80MK MT]RK]S(>/M88=]%,X:BCNH!>-$JG&,\?B0"@1Y408>10:;9J@U_M'A:KL>#A MJNVO;)FQW%ML3W/"? <$]LT29O#C$!WWB3?$UKY4A&B9J$B!2KIJD6;1\5G* M,62PA>H(G3.RKN!Z\ MF?*"\'3@ ^2'![X@8RK9V^A=43SQ9B96TFL6WBSTN#2.O0U8?18)';0&@TS8 MX?I9XNDU< _L&F[WR/9'HD1(E[G78FB$U=USE'-QG05#3W^),KSC$=4468-N MC[(78N8&Z\>K%/9@=9W]+GX_QE[$ M[#_Q8A&6:5%8IC#%B?]V:+4&W>H_MUM6Y=^6/=;JM-I'U5]=]MCE?^NU#UYF ML=U:CWU@ON*#LR@'"Q\MF7/%4<+BJ?.!/_<].7JHKI0G+6(9\5PX*_TCX MC&$*CW+B6M/ZGH,_GI65<@]Y_&CL\;@]'I5/GFVOZPP?,7F62G?3F,-79873 MM0?.EE"B]OS#M9)A8?[AH[;XX+3"M>YM;V!:O<7)U*NP\R-V^KCAU?E7UI[6 MV?#;)O*;U3&/!M9:&.Y9IX9OG>SFJO[ELOLQ@UT?O%<;R'R=1S#>DL-_*4E7 M%ZED-T^',H>=3UQOLXYC>INV'>').1PIS'JMGB@CZNK>S>-"RS+;1X>/9,+- MLXIV_)0Z!^:AU5[?*3VK*3'8 E&A3Y2M;.M\5NR1ZL'P.VW2/R=I-OL.6^:@ MTUM-VS\'==9LS#5WH[D;2^Y&USRR!MMW.;8/Z**B$E<%.H\7#>&GECNT#H_6 M5O%PML)8M)1;NQZ,!&L#I\&7>-?5)O*I]K;:DWI:I;,"UCYFCAK3LA%=U%)+ MH&Q956,VWB>CF%8=B6,&:0+16DV.-.HO/Q%S7S"(0;:R(GMJJZH&@PG8VV-^%@0'66! MR)+A=P1MZ/(TY2!H;MU.BXUW33<]R;-]]_V,F3IND_ M;/H/-T^3E%>%GO$@@+-4=BG\*_4BGBBQ \7>(97G9PV3V.?!@\NI^R"8*^@Z M+O76<9A(H-*($2>D+_X,PGLJV29P+&^=@02GTWPGIMH!I/BF"U0$\>8<4U M$@B'AR1:Q3\5;F<#"O$+"NM"'RK$'E N4%S [J,1A0'/'W'HGVAR MX_*O%'B6.YQPFIZ:D82?2&,ULZ5Z&B;^B^3D(?*,Z&%%EU0I"BE0)J94H-:S0D.DZG,WXZ:4!<#>IM.57G M/@JE]M2&=-($16V@,0=)(SEJW(C#,* #AXN!I@H+;S!=6--O[+(^NTS?K)'9 M!:45&Y$7_Y2&I> A"B_ .L.1E_4E4K.K;L(5[,M,VE580L@W:2 Y1]*$FY2G M82HF34MKTE%[#-/$QT$"-&A4J4BRE,!P23'8 98*6,=V-,_Q9''%E;:O,H#\ MN>JEC7!8DV#3XFC3&B&68C/XPLC4;1U36G<,U[,S\/:;F9= 6F*J>UG_C:; MYWR.!N&A@[A?/+V/=0DALKO[F/[G8-(#I-E?(VVH-?[@T_K,CCRY.MU6'VEQ MPW!/<#UC. ,!;,9MTS%S>*:=:0 B&.[8@RTL;)1S;+R[&V;E;0 R]C(DY!OK MRZ>&SU^/SU&JH_B!/P1:9O?LR[' Z $9/I.#SH5^Y>&LDN.5@#Y0;T27OG#15.20S%E7 MMR%+KB6A<&HW7[.]FV-^Y6/6<"7*3BH)E5FC@I=EYX9^/;I6XQ1\H^807_$0 MN0:/ZZ7 Y(H&S(9PC'_THQ*YKL/$*,@(77,Z,A7=Y\ROJD,#?3=,X?^%Q: :QS$+YC'E?.RYB/%P0&SHRM"/(R=E$F_I0S]%P:U9 MEHVE*8L95XXID$<Q*#)MV 0,^E>\U+2AC=3\*)E.^56@ :AEV+ MZB?NS#AWXF'F)%BJ:IV*/ M9$<+5[MY;.%I=1V(S'WK9@4@- Q?+PXOVHG\KMSWJ(PH!\!&=$#"?#[@0=.H3/2!DD"DXE!"J&D]QADI7\ZJ7@"Z7?BW8* MFR$Y2P6>(,N&1UC>YQ'P@"G0/\HL'JIJRTIRJ+Z-$$\3C'?",0H+F6IYJ.H( M&"W6<>RT"FF]%LI"A7H*DQ_^P&N2(X*NH 5+67J,E4 M*"!4N"E'ZB<%<%VL8@9R"MY,V!@,6.K FF.L M2;#9PU8X:,O6UC*^Y*Z1+%2 9Z-U)VBB_DQ20/&O*99Y%_IWB.8KV$DL2"Y_ M%((\L-6OA*IC4)D#U\$6*PL3M"T%BLO(4%6TLDBX>C [9#PR7%JN MGU^OC"1'!,2_;T=&A)PS MXJTY8![.L9[,24<<_W6130*"E%F6[%,M!&%4UD0T1NP;/GM.W",$,1T4%KG; M/DEK0NK*ND-CC MTOOM873@%Y>_Y1V3H+GV/]L^J?3KB>LFQK'&V-NO7QX&PX7[0_>"K =NH59 M9;P_%.2)B3QYBP0KE4'(NHY0YM>G)T:44F/DZNS2W5QV^>+%HU3API^@TL/( M[_%HA$$'I-KW$.3/@:J?&AQR"!YUA<"*LX4T'9$PEV MQV@_7,J+'[E4O2@2E$X I1X' 6;$KBB2JZ#DK?;^7]7T$9KPP^,3OK@C_=Y8 M]X1*7LS <84;:3^7*0)I"$9*V2XL2"!+T@0*Q*0!25"C5/7#D2RF2*/ MKD--HIJ1[=OWJ-AOX5FLU,$ZOI71\ D[EY*2\<-[KPH#$0_NN]G=A*^T_'&8^QK3[C:C@@C,GZZ284?';KS4!1X MT7BQT*?9,55'+_T-#[/Z4U$T%.)V EF:.0M!$%+,)N*.,]?)+&,E\[*-Y1I? M";]VIDXQ9]T)BW%.$BU/]7"<$!0I+^X^C)RLQU5(;3"I32E>Q:_02RK^CL^\ M^%MBNSNW^&MFPN)OL6L,**>P0B6TJ.J*+WZ!^'SAGD9:BR3)2R)7 M+$Z%VT*QK'L6816<%JO)P5NV## PYW"OP2W#T$")I[^+>TV/(PN0W)F5$ MI;D>\!0X79<[XX $=#=(0D22Y^E,,C\>)WH$HO61?Z9F2#,O&D0C<'98^:H? M%#T9XG.VZXG+/7,2LAR>;)PQ[23C\(?)L+&.<=5L[-0P/'C-I=\^9S4 =/V; MHNOB(_X&Y^ C3-/M1#]$C<1+5$^!C[%?,V0O.$CESI6)=VMFTO M,4WI&&?NL,UU5%DU@!*[4;D$%@VU^!A67N()\L,8+_ P:JKL1EB+F$$6QDHH M+%&GVV\U40=E-5^2W$0[&Z,PD9"C8DT:6+> P7Y;"&L9Z0K1 Y6J#LFJ.L\"GSX?XK1;5Q'V'@GT5G M&/%D:%(56DQQ3G19.%=#MV)[8]YZ(DZ!3@DGY&MF<4]=+42 M#W8]Q\%WI&%L"CAB [CV9C%Y0'ZQ[+Q7]YL&F^LWG:JZ,RPW@./2@PU@KX:H MWG;$C[IVW4+ (>(]Z[YS;L_(##1?HZ.,PNMT.D7>P;B7-IZI)$:CS$DUR@,I M@)H0?J+)VM0 D(4;KG6KG9DP4\%-,4%5,4&ONIC@$9?4ZOS6E" T)0A*'A?* M@0XWI7JJ7(R?WYQ^-;HM#B0N_O???AQ_NSF_.;XY__NI?WCZO3:./Y\^>/&^'I\]=?3&^/J_/JO-:7^NK8M\LS&%5I2:.EOOY;* M1CX6:BC0[%)A8)EA-ZC0! R@, 8_O);9OD9KXRO7K^_&05VRJ4V$YX)/VAR& M!7#(#B7Q.7>[=+Y?(1HH@CJ)C,:BWQ>(K &FR,'.Y5%?MZ&8R\>]1W+BG JZ MD66,=K$;W:EZ(9'WQ\RW/_9\7S;Y<#$%5A=PP1%%.#TG!;LDFLLXHQKOST7M MV4Q^&B'IQR'/TB12_(+=_XF^!R[ZI- ME<<[8\I%JP@X 04P-DY_4;,J7*!+3)6)L23\-\WY%G\T=<&.4T'E:"VN,.1N M.X1#T 88.2XJ('UTH#:C,#N?D7X^,W4^QIY6K@)R_ KK5 RK:^];_3WW/>IN MJ^_(?_ ;K[.DZ^DO$8T[YFB,->CVWHM09$5]#:BB+*Y.JL15/,49VI5(1]E! MS,IQ$L5/'&*$DJA MX09LZL')"6M =F]CV:'6$C9+A[XWTJ@2YV8\8AF31K$L2+PK8?>,F,4I0*O= M92=TX]P0?&3VNGR'A;4SJO"D\;2&&T68DJ0\'=;<1G:*06MEY'+OI2F*;K#C M;H*S_#%E2GESPK7*A 0R$Q;]"P@63B%D62Z3UBUC:R89NQ%E&F7Z#,[_GWPI ME"3*+X73$RY"Q'!]L*F+*^Q$*WYAFJ)C*/(#C+HEJ48I -&K)BKP\3*!S^ % M:EH7CEH#T3CV..^D2$O/'>8J,F2@400YO8B'8BR8R5Z +Z;Z67"+U*1T.H+\ MZF,BO9M3CVH%.J4E48LTU1]).&*R"U <5ZF LD'2LO;*<1/* M=,L4?<5&N(Z!(0AL'L?"J_EGZMRJF*[CCDCK[:LR[( KAE-?"A/\#D4S&$/T0?F&1T_08],PM I*8<2]S)RY5G"'2GR M/:Q'K(Z$'O4I\Q+8B:8Q-$G,:2]'!! XF8UW)ANO*0?/JFQ@R[B\0]N-.IXR M<<,5^.3A@X?M@-^-P2B-466Q(D\E$0_C&>JJZ K6C"T2AHK=^O*&Y--^9H@4Q3XV$65Y&*P>0\U/-PW^C^0&O9PO)9=H MJ=)_)2RVS],^R>I*S^40@Q,9]\'#S_)45W).P4[9,HQ-U>I.87,@GJIV4D8S4@4&+_C_KF-\CSS*':" M5Y5](N.?,;>$@GT[P2#K<9'40/D&Z-E]+K]Q24-ODR5*Z.RN)SB)4C M%*) B!.JPN+?%3Y\C(/-R*&3GP3RRTGSV+(DQX@FV/PG'W^<8G#U1+2'PJ>^ MA=34))ON2I>I/BX^,D4@)#86U9_RP"!Y>LE'MDS+A0IF5 O.*317R1C+RY'*W,C^&*)Z5[\?GB MB_"CJO(6-#(F23+[^.$#4BIV1RU8+A-]))*NTAV6GY?5EU3(9+-=5*_^L"E^ MJ"I^Z#]/\<-14_S0%#^L.R3^_?CJ!LMH2=!8GXS+FS].KXSS;V>75U^/;\XO MOZV<$^E8#^1$%L;E;$5*Q*I,B5R<_GY\P;F0TR_GWWZOFPS98//G'YD"R0HC M6(N0=9S+J_GN+0^F1 \8]>/J^;1.;S=YY[B2>;#NQS@[/KFYO-H!OL& --5D MR&84ZO%R$S1!P+<7IJHN/12AJ&=;Y.JWZ7 G;U.G M\C+]^'9U^OOY]D7X_KXXO3:N#PS3O_VX_SF?]&J_G%U?G-^RKGK']>G M^$^O%":4@LM;5 MVG!7FTNQ\\#X[Q2N[2(AP$%QC)YI]7MFOS?0<.7JHJP1/J- ;@/GE)] @6SL MQ/M%;8KPYG>=5@^N^9A2"X9]>XO-(PG!>O" )(7]]LYJ9]B6JXN$[D,#/+93 M)%17XWXY/3O^<7%S;?SX?OD-9,"W\\LK311L/Q-_"X,G%#!U'YK0L9W\4%V_ M]/7\VRFHAK-3T A:,?:6E;D]\= ?FBVQG8?>KSST&L[M2L<]M$<_;Z,0+-5] ML=,Q_>?3EO!!::\?SFR>H M@7 M=U&JD&<$KLL^#6F;Q>Y'^<,G\ ]FOCW_Z 6T2OJ2)*V(D_;A#33Y;V3[XBWT M0OZSB/@-CEH=JX=!OR2"_W?DBT4\L$7QP ^)4_(W^&/'JOQSN[7JWWKM@Y6^ MN6RQ1PSIZ; M5X\>8E4*XI[^FGA#+_G/8?3A+]\($$YQI:# DLVU<6N_U?IH"1TXM%ZD!+/= M>HCQ)1MWDJ."..MB6H+V7KYM<2$IY3I+#"IG-'#]GU:@78V//O)]&\^\#VLC M.K"NU;+^X]48MFSOBETU\;T)V8]VW>Q'3OFZ+ T^K7V!(B6"*=I]=);;@V[[ ME_OK5Q?4R20!>I_@,6 WD2PB_ [^LN?(R;]5E:AJG.AP3C7<7,+=V[/??Z#Z M;?Q)"QH^4,)-U=/VE.(=_+,3SB@[K-<#"[2F;KNC*L/M:&@';KQ_^9((R6> M24ITGF9SZ'?9.C)^M*Y;)RUUJZUNO_W@U1^T#YJKO^E7O[$=WI94>+3MT B" M-R (K+;5.O]VO1FB8!T$.*=0L_$_GZ\NC'/1E6=\"4MDTHOCSPV35C#IA3UT_4:( MKI4_OU^=-OQ9P9\81@3!V>CZ=;-I[^VRZ F-%?ANW[H\(,+F^1E?[,0VSCS? M-?:XUQX#4X1!FG$THU5H _9%39$!]_[](AM_H"*T]52Q_E_U?^H6XVUH(6+Y M?JFSJ?=)_4_%A,4P&%,:PV-<()LGB^*$"QJ')4 F8@EC30,G!*(0M7>+8&WM M&4!;1T'S]+9WFO&^C>=[16C;5Z)O\LK MP*_/?_]V?//H/H^-[/?YKN6A> 0>ESJ(YQM'-KJ8"<P3@2')"8:L=(?[Q$;&%;=C1A_B#\=U.?>._L83EYR3RUG^!'^Z"V0;* M;AI5MXIV=2HR&VFYX:>XF]+RLQU%<^-S%-Z7=A&N),=[)W)QZ9,ZDXL+_L'?X^F"/,-\1+O?''_:^#"XZ[_?^\?&GGW[[ M6Z?SK[.[*W(NG'#*_(#T)*,!<\D##R;DF\O4=S*28DJ^"?F=SVFG\U$#]<1L M(?EX$I"C@Z.CU5_EZ?')FW?LX-#IL'='QYWC@W=.Y_WAT4''>7MTY#HG;YSA M._9J?/KKT:%S\G;XON,X1X>=XQ/VKG-R,J*=]T?'P^&OHW?'(_I6(WU4I\J9 ML"DEP)BO3A_5A[U)$,Q.]_/[QY+>1X_^C@X'#_7]=7][KI7MS6X_[W MI=:/0^DE[=_LX\]#JEC2?![,@[0Y?I@P26A_V=(/3[BS 55\!@*>ZF!\7- Y9@%-W3*U(PZK-Y@ M?/R)$!03G\Z$#(B?@QY1-=14*QEHL#T2B?1*.#30>HHM53(DN?;[S L4?NK@ MI]>/RMW;K]]KJ#IC2F>->C9AHM[C;YI08.CGXHD5NH/ MCPY? R5)DUP'RZJ'/^\#"/.N,DX26)3^AST% O!8-#9M9GPF65/& 43!*J$% M_1_/OT.]IOP#B!-Z_QWLNVS4E'T X3Y?@WN$'L#OA+L?]GH"O- ]@M]]N;NL M="5TKU'[!&&",J/EXX'^YY!T,I^U0S34;_NK;5>PA(JY??^C_GM5N6/@N$D% MX(I6U(9;'LY"L/C+9/PJ1]5WF0_ \(<2'G?19S^C'B[3]Q/& M5HR*W(K/(X M B'NQ&^(_P T "Z\:4?,!@!"*< 3#C?)\)SF500 MA'.'!]M7CRV29%6IMPU5"C4JIHYPGV3TD64"24(A 1*)2>//)*;R11V+34./ MJLF%)QZ>QO 48+(38S.0IC-3*DSJCA(X=;@ M#";(9P%3!L;28=)O(.QU>[ *_%=TU+ER/*%"R?!#UA/*-NGK%=&]X5=F?WK. MZQY)W.4.B?T^G$ZI7(C1/1_['"P=]8.NXXC0#V! ;F&V.!#_-9!R3816H;Y? M%6J,&*5GH"89;I(@WR'Q]6#]HD,1N4S=L62116MD@HLQ6 5TLBJ@)4PD0[5# MXKB?0(0"1@87M.D,%AU-3Y/94XS )HS#@]QL040=C8F8J'9(&)?^'#RZIO/! MA+(.^^'JL!O0.S32H&!3'G$-:RDLHFB.F=]PY:C"8I7$4=X:I=CT K^$;X=D M<\7 !C010PQ@'?$WJR,> >[0T-K"W0:#;D5E%X.B:H@[=!D52Z MM@KD;6Y)+DHK[) ,[IB'@?&E5'XR(F MLAT2R278A2D;T,=&*X0)91WX7' >01,-OD-#?<."*Z'4C$GMFC<8[E5(ZY#G M0F? 0! % 1Q19+!# W]!N?Q*O9")T07W*?A_U+OT52##IJ&!#9-5,+F0&3$2 MC1+3&BE28F#=(4G=AT/%_@R!@4_SAJ+)@=ID<92/F%,4),*Q4R-?)VGW9-G MVEG!HUS 73\K2'Y)_MJMG>/"]-X XX(MI EC/%:Y%83GQ7"^;(,XBY*R$CK-19+'M8JBUPL;^#8Q>&/,DN-1WX)S#KHN7@] M M_%\;9EHQI+HB9"JXP*HGAK1<<.RF\E8FPLKF)XJW1RH7X^[MQ%:5C"QL;2 MJ8?/*JU[I OUPMFN MZ^H.<5J.A)QJHAOKP^9]V73B34$.I'8TW2%9U\3H>Q?5HB0XWHX>K('<*OA< M&J4T''\1LU7,Z43%$@-)G>"*TR'W.!Z9 H$1-/47J@3'MK1BB[18E:A^ M3F?)L"24$8.T9#>.!(+$U/VL*G)$+[H7#T4RF'B50B]4@9@RF7S758H%JWJP M@'7\CCF,S]&1BVOCH^'<0CIPN^18-3"7LZK0P%3M]*T3"7&OLN\U?:_RZKEX MI7V?C,KT1$&LACOE#1,LF%NR6Q-^O-J@CY:IQR13"]8.RUHU"">$66&WI,C#[]&8+A-'Y")PR\ M*OR?"(,[1EWN+6"PF)QR'YVL-,FIT"^#?YNO*T]-B55GAYQJ21F#9B$F;F9S/XX_,%* AV^J$FK MJDRVLVYOTHM5(7(I\!KU*"\K>'T52"/Z&Q9$YT:Z\QU+>4Q\@I87A.?IC%IPI0"4$5,LK#=+BI8P6JFR&V*D,^ M45UR"=&+\;"=)]S6NM$QHOF9V'JK0B *TX];Z%' MDL_9/7/BV-$7Z&YZH8O*M*1)Q1JTJ7X_+5E6+:YQ9GDES#;() F=)".4 *4D M(14U>46+*W1W!W744E,>!1W\+PA!P*P)'%5\]47=,8H2N6-C*O'=EQ3--:,H MQ_5JVWX ,59]7.>H=AJ=(6V1YG/<$_/7/J:;Q?\>-ILVODVMR513SNS5J^6,I() MN43@';DQP=$Y@%?$I)EHHE>=B5W9K^K8J7RX W53S3TD7:%.URIC21C*C_Q!A$%0$(%U6E[1$Z5+J0]B'KX<@>^WX.;,[6@?8Z5M/B" M!X@1G_W !\A.9_K7@7Z8(WJR"1\8"J$G'H0(_EF*^\GQV6N[YI'LOK9S,_NLJXD1X"G9)%+P7H@$QUPV BT*LN-VO-D#R-=5.Z MGSH8IJ&YW#.9I#,+4ZJO%7*']6^VEP?18T1H'4#Z=VJ3O M,F@A\ZGA^::Y=;VL+Z+_#MAC<.:!!2@=N TP/J%Z!4DO-<8DGOCI:273 %2O M$W4@V[ ^=(/!A%U3^9T%_1%H+2AT-6,5 &W@9^F0&HZVSV0U0U40;> H\3@2 M?ZH_]/A8]ZG.-0Z;JU(!V ;^M!=QJ53(W/,0U2F*DK2UO VE,Z$&#Z6VIB&6 M#=;NI[7"]<(JB(6UF M:-NZ6 \>1'+*UA*P%+5LP[3OP: )><&#O\;@.'FNQ4B7M&X#)U>WO9R%L021 M%1!MX*CK_CM,;M431MW,K80EY4)(L*W:@0-%-Q:5TDFX+KK6&FFCP,5JB8O; M/K>Y3?9Z^Z-/5/H HV[C/67[TE(']+GYBU9_K+,8B.1(%_OTZ.C87MMV?:ZT M[W]C?#P!Q[P[![LR9EHE^U&]B)'UJ(J6M]O/$PU<@]SPC0CP.I/TVHA0RBK' MJZSY^BOGTR9'T.C"FG@=>@&_8V-=/M8#EP!?O1U("$ZK37=]^#88\AOVH 25 M](R+&V)J\"RU%;#M($K=//U8I&OZ_KBNTQV!]=):%JJMHUP/)4UJYO2 M+-I62C,+ W'&;BEWNR,P/__+J+P0H6RT0V5#U58GN"PQAR8ILTBXHXIQ#S+6 M.,=7A:JU[LD=PXD$TNW.*?=BV58%R##E]2_E+MPF*/^C\^1GB^A=],WRY1F6 M5N3-ZVQB@6&-M\HJ]]'&Y:=:_K(I^'T M?H:;NS*Z)#0Z&(2;O%,T#*5:4@NVK7:VW..OKA"P@;5GM_N>(IG:GBWMY62F M'ZLXRI./-<&?W[DW-C7UE6P*YEU!:5U_I;3.&A1NCO>Y(T;\&?SZ+_H//7'R(A[L<)GZT(N&74DWX+%FJ8I D/]4? MU5X)?T#/K76YOE((_73=:40RZG^44KYFP42XQMTS685?-Q[',BW;$.ESSZCK MB\'@]G?A83FVNKKJ68J'2EJW84YM5-IEM9W;PO[<\D[/C%QS#_02)L\M751N MVE5 M-47ZG'_[C&I![+L610U;8,ZEUP%FD6]9XNL22P1?4MC?'=>#P?:\RH* MQK;8PW/G7BY]4"@@\](W4D2U*^=J0C\WDRN7MEQ.9V%2ME-5*V8#:^LDOJ8. MV%;)'G!%O1!RR/!J"2%Q*Q@8L%6YU@)NPT3OB;%/;=4O1I,VT)QLGO1'2WOW MO8*]>Y%+W5;SNA74;1BC?Y[?76A2HV,%MCV+TN9MX.7S4>;&5K-1U+(-' PF MDK&ZU1B%;=O A9G'C!)2_5&/JLD]G:-'7BO_60C7BHSG[S#O_YJ(\/\FPA]/ M&?\]I"[\=:LWN!Q]_HMZ\>,(5WS*K:O !@C;(.VDR#VYD/^;\:9 5K,*1A$6 M./3+2I>/QGB>.TJY"'T,,:/47(7GEFO7VMS#C9B+U5I/RQ9O!40;M+-D8RGR MFS>N"2U%\]Q>>'4:&;.G1O$4=*K*K?(ZJ-JZ3X<_]WU6/S-;T+@-6FW38FB.J!_OJ&# MY>.-2;:N[NG)NN"M73[OF,_$Q&CV8W;>".0XWB_G60ME:YXYKB.Z88EV5RO+!; M+K9KC.?Y2YUSCQ&B^U_U!&$I\VM@:JEBQSD)/)$R VIU84 ^3A,9,K)[*:V!Z_LFATHILPV'3R; Q7MXKY&*U M4MNP%O8R[[60MG0IK=B1K=04.UQ[M"%R?+)G']#O :*_V9]SCI*E]=*S6^ZE M)7E9LUHQ7VRB13_VZ?)BC#:C21W/=OMH@VTV+ 3U*FU$]<@TQ],&[HV[@BIM M2+Y=>VQ&06JI/[JF_Q8PN?5!P/*[*>J MJ*:]!XZ4*.HP (H;*29]6#;H(W- M @5;\G%-;&U(2MI."R3G"E*+FN1)YJ#.F"1!0=6[HG!][$\4H\W ;:T;W]0( M:]JDWW%*,TYEFC9GTRSI6BA;8=F^#N;6^'2YS0^5I'[%0SD3F"\??_I_4$L# M!!0 ( -.(:E5>^U8-"18 #G* 5 =G1V="TR,#(R,#DS,%]C86PN M>&ULY5U;3T=XWY);;+E2[+E*B=VV?"\2ZLCG"\/GBTP+#$? M?)PN#P_^R-C_>5 6W='!']WBS^F' /#3^DO/NN.3Q?3]X?) ,"&N?KKX07EI MD/$$:(0"Q4P"QP6#I(7(R"$BM$6HTK0 MZYO.IO,_?Z@_8NCQ@!HW[]__#X\<>/'[__%!>S[[O%^\>",?GX M[.I'IY=_^N+ZCW)]-??>/UY_>GYI/[WN0KHM?_RO7U^^38=X%& Z[Y=AGNH# M^ND/_?K-EUT*R[7,OXGKX*M7U%=P=AG4MX +D/S[3WU^]--W!P<;<2RZ&;[! M?,2U8!_?<6=WW\ M&70*L[2:K67TDEZ?WKO":X\?/RV1OK&1V1F 69O)R&.)U-EU/LGZT6"^HED\Q=\0DU.+0%5*F\9;R LXGK@MH5EB_+ MK;:MI\:M-5U"']?J/GW$XRK0QSA;]F?OK$6\%N_746S$NGN[GJ34K>;+_G4X M"7&&3^:9WEFL,%_3X"2L:['5VI3%Q;D:T#5?$P^1*0U4THP>9ZN4BI.4?Y$\\6_7+[@@77R#+C"M, M64.QV8$R*I('X ,Y!+X(S50.P38FR3:XMJ&*?)A4::Z69H3YK5OBF;4[!Q*I M74%SR-$27[FR$%&25X36Q(!.,QX;\^,:&-O003U,.NPK]&;:?]+WY,9-N/0L M!9^ 645Q@68)HC$*(@^))RP)DVSM;JR?W ;_F0A%*3I2OZ$>HR4H81V0J?6@ M.8W$,4=1M!ZD&2/TBW;0[!>^T,[";<;/UXN.!MGER6L*.I;DC/W\[]7TN ;. MO^%R8CC*Y"*'$JCS*1<4^%*-)@7#-A@NG7.-U7T3GC%Y.@VTWTST [F^;ZH8 M7Y7?>UPW=J)U"LDA!UEXY2?+X&TB2,'Z;*56EJ=!/=\K@,;DS32@0SOA-^/# MRV[^_ATNCE[,/V"_K-3L)U&IS$5D8%EUM84U$%1(57?42">CD*T#YVM@C,EU M::#[?07=3N.?W3"R2&^77?KSL)N1./MJG98GD\A3EJ5$2*XD4%(B!$P&- 8I M2R)LOO60\"U,#=L\2:3!PK,!IW0$"@@HI P,P3B7F4.CHQBP>6-R;YHRX0N^ M[RCRAE'\T=%TT]&H=35X),.+\U0!":%4%%H 65;J>#XB1"D\F"040\&*CZ%Y M\/Y5.&-R>@;E1"N5-./(&\R(1S6"_*V;ISJ_T,WHVOM/E96"Q. MZ-TG1W5:77".R7<:E%6#*[$9 MW:YIN,A)&2$9!.T\T3XI""PP(&\OLA!4":'U:/2MX74TLT3MJ;*G H;PP2;) MTH 8LP"1,SF5T3J(@JR?LPZ=X,72P'E7_LCM6_)\A>^Z-SBKRYJOPZ+>LO;" MT_D.98J3IC PV3)RF LYN&3G(0164 92(VL]"7HCH)%Z7[?BP%5.M]/ T.MK M%V"5[(J.48%5U.&4R!%\B0DH&A(Y('IG^-TLL=V.'/?@ANU%CK::&,+^G4V- MHA48G0G42BO(#CL%Y @ZR)PIS5T10MQU>L)H?*:]*+"GK.]F5?4"(9/#H&T* MH$S,FT# )<. !>$-+TE)UYH(6T(;J9NT%SN&T,J0_K*WB,X8!\X58@^ M&K!&,)$@ M%:1Q.]@$464++',EZ;V$KODRW#=1C/84\4+13(+BVD)(-)@C&BECPD!@TG*8:9S*=1PD9&=-%0&*%_#Y+44*42D%6 M.AOA.)?-([(;,H%VF)K"XZZ?+OO+K9+TSQBD>->;2,XR#>7.\P))6:.9\<8V M3^Z]%LB8?*G=]?[%9-3>,F^8]H3'Y,K]_.FX[K]X,L^OZ@Z-R\""TA:32^"M MU=2?A02OD"QX9#D;SXQ4K>>\UR!!U#HB@X1 BASIYH^B!9(G)J/4V_%; Q^5SMR-)>)^T& MR=/=+9\'Z]]P>6[I7) %"4*Q6&=3BE0PY!1,*IF"OSN!\N4_QAOMO MHUK]8%3;2I!7-/JWQU>E\Y)>M]Z.^G9)/]=9+5TY77"A3W^?AU4FN5V9%MUC M@^JWGC/DEM5;M;'1)M;7BZY,ER^[OI\DQ84*(H!F% FID@T$;@OPJ )Y!HRB MZ_:.VMG3]QTQ7LQ)MECO] MUG4W:TXH&L<]R?(JE6^#FNG?A$_8_?UHN O7B MZ3PL3EZ0Y/OKML\:_ M N66\=.PLTA-:;2?U!M38!A.&\5#$MR#];I.N#L&43$/QB.Z*'VTKO46E#LS M:'MDTGS&.(DQ:1U-@;H'&A33L?I7$9RQ1;*HC&2M8XQK8(S)5(^%CU_-OME1 M>VWBD_4\RP;!J?'H+Z2+G4QX%(4'"J #&0TR(8R1]:"_LO/)U$5^&D:V"E2^ M\: Q36N-C3'-%=70UI_M5]H@.V^FREY%70HXZ>M<7:$P+T<%QC+KBV.68K[F MAOIZ+&.: QL;LYKJL2&K3G/S-SR?:%L4HM+ " JY1DZ2&^,9%,Q.&_K3Y?9D MN@1A5$N/XR71[FIKEUU["3ZQ)15%I3G#)05'!S' #1, M1"=UU%:UWN7V!8A1S0JUYL9^(A]0\]FB-:)(\*66./!&@Q=24>"B!>?19 HB M[U;SNYC+'DDX=4'Z.?7!6;F]9K))< -"@E=K:8D5EDT09;:]=4EYR3DFJ]O4+JJAFJD35/ M0/_:BNS]VKC=-7Q-M;!=I#L,5Y\LEXMI7"UK)L:[[BLAGRU6&5\^CJ9E_O\RZCP.GT5SSF+O*HOE6 M"QLET=3'7$FC)#^*Z)+HB:=IEI??N'#E:UQ,NTP\6]3MX\]Q\YM>;R)-"CD/ MP_P]OJ%6_5P*IN4D>U+F97S%DJY2LA"]DZ P>G Z2P@N M88CD7Q73>J/7]NC&M&+]\.FYK_J'IN=UUCVA#0Q%AI@\X3.$U-OBZJ8G,O=6 M6*U:SPSM.KCO-$^0$/-ZD?%%WZ_J:4>ORFMJ!BX6N*GJMGF%]1RD^I)(]D=8 M+$*MBULS$6+2#&)@KE(D@HLF NDT6H^1%]&ZR,=^B,?D# W$P6LF*^Y*Q0WK M*AR'DW7X]:I0$@I@TL\1!I9N&I>E>?K:,;D0]RK MT;FU:@:FRL6B0<@R#]HA6,4IB.,R@<_& AD_$:3W4C6O@/E-4&/:%7JOQ-E5 M46WRLB]B>DO>]&4\-@43K=9 8R'A23[5A:H,4AIO);J4]17_\"M9V3<^9DRY M:0-3H;',![$A:QBO-L5@?OZ$BS0E$4P"!DPU?X?5LGD&5('C'0&JC>%0$4@^P7+?3 MC-U>:],46SCD18&ROLY/:02?)$+RG&FA^#�O7MQ%]FV'T MV7J"B;I[F"[694%>E;,H\]+NF1RBRP8%\"QLS0_2$"0F$-S)J#ER(=E6 ^J6 M#QS3#/3 /!A,#^W*Y!V&!3X-Z^78HYH.M);:Q#/"X*,#QG*H5=84!*=K2E 0 M6ONDVN?N78_D <1RK8U& Y6TW-!\9?YZFS.L)Q)14RL)G)$9E P%G$X:A+>N M%$-QIV^]&V WI \@XFM-KSM0:3/Z/*,J3M3I)19H>W/YL@_26T>*]3&H/;X":Z_0.QK\+)6F-M++8@B"%$X2, M)X@.-904!->*Y]R\ N(VN+;AEOW+A/0=3BV88K[:PUM>ZNC&3%^GQ-39]/_8/Y'F,[K7,&K^<6S M<*WAW">"XN@GJ$B.EU>.[%Y2 KT7,C>O\/8-2-O0Q?_%#$M++0TX.MUX:LTD MJQ X>@G$9UXK6F0(AH+)X&+=HR[1-C_A]Y80MYHC9'\U4S2<%IL/7YNM%>0N.V]<;NWX[)J#NL."RVG.SKON2?KW:KI >B9I9GGR M>A;F2PIK:IKH>HONA%-4PWQ)X&J]0V4Y Y^W2T7;.ZE M0^U+KB]6;(;1W=#;QM:G6/9OTR'FU0R[\FM8KA9K:73ET@F7]$[I%I=/O^R? MUS-\9I>Q;K>/K,ES&VTL:R^#1CO-7M:J(WCY>>?#^1GAGJ]P(I4VV7H-GH5, MC(H1HHT:DK%*)Z&B2JVSZ+;%-M#)MY-@1 Z)!_)CZ@\A(OB:R&B2]L';>H!C MZP33KT 9T_+T((S9\@C<6ZFD42'.RUWQQ='Q:EF-^UDU9R5,%-9 9DG4PZ40 MG&8*!!GRZ#0Y-KI\RU!M\9PQK4L/2H#6,G\(@]N$W]?P1D\>T0!W50YW/<0A M+SIZBD2*)5=)2:\H,$D<),4HI9Z#(6WK>/&NAKAMG_._&!:_=*O%Q$ER%X-B MD!%)%G73AX\D%6-U]JZ(&@#>DRS.,#[(0?$V'/OB4/ AE=CNF/AM4+[!HS"E MOKUX57Z9]J2[BGG"1.+&DDA0UV/M(U?@!%GWH!D)+2HG^;UTP&O1/L@A>7#Z M[:_8NR7B:7=Y][&;9"V0>1, UUDDWHI::J4 =RR*[(7.^;[,_RG$,262YGEME+90U3M4<6^MK><\$,10!W##!C ]HTG8Y MK;=_]IA2R@8ET%WHYGX,%3$":6#/J*SR(&6LI]IC I=2 2:%-#+$;'.X3U-5 M08XI)VU\QNK6:KQSMOU&X=>[CSC[@+]V\^5AG;H66I<@0-<"C,K% )YS VA5 M"#926T+K0WYVQ3JFC4ZCXMY>2AUZ+N4-4IQRM#X:]-IB>&^KQ!Q MA-ZR^^?RP[L+-Z9+=E\\& Q+H_F6NY%5JW)VY]7T:E.)JN\.P_R/0T)\\NKC M'//;5>RG>4IX7X=Z>FA]<]$?3H_/6K/9ID+\?===VYYWW>:+=0UL7;"F?U4V MW^GI^HE-Q28M&21J"]G93'&P-0F2I@ XRX*1-3\&^GZ;W+:JZ M4EO(CO9/0S]-D\BL$8(70/I' 5Y4X(778(S5GJ'3H?E1,+>$.*;9HH?4'VXN M8=J6&8WV%EZ4[FFK;R_<_O5JD0YI&'U5SCYX>OJ-";H<"]><&L$TJ.)IT(Q9 M@\N)ADWA6(AQJPAN<*ACFJ1ZB*P?(:&&]L)(5+5KDRNYWNSW!LF[2.1'KN_= M%?K2;ZNCZF=VBU!K^L^[H^F\OJI)+U-R*O'99RQ=65N!>N%T5A?QKMR]*\]F M@>S(!>NQN\\V$N2-/+R1M&8(?_"V8PAGPAJ993TRF8.REN)DLD" R7!GE QX MM:S*_7H7>]5!,$(5$:T!PUPMM<@Y!*41G'5!VB!L;'XD\VCK( S&DAN*(=Q& M_O=8Q;^8*'G0"0IC-)HQ9^J2BH>20[0L\LQP@"S5OTH5_X'I-*PZ!V+=32(Y M'34F+D3NG2[@?#V.1>52U_ X2 )LA1/9LM99@+<&V= 6Q\"8\$%3^Y(#E:0G ME]$%L#HKY&B8*JT[V4.WQ;LPY09K?!L-W*,UEL9E11T80N'KUM;Z43F"S2HG M IUX\QJ3_U^L<0M"#:O0H2.R\^(\73DMCQ9F+^;]X/M0#X)]?WZ;7S'TJ\7F2)/=HZT[0-4HDKIK^36*DC:U M!PE*PS(AS"Y6"U"\U+;7P6SKZVM>U:6 M)V\QG::+_O+AM^E$I,2E9@P"N6"@./4^9W.MZXD&0\ST:>M4G.MPC&D$;L.& MJX9Q;^EO:?M.WZ\_8NCQI^_^#U!+ P04 " #3B&I5(/MN)?1RG>^_]PE$ "C)72Z0723EV__I3X$47BI1(34Q*IGHD462) MGOA07TV@"JC+O_^/K^=G/WS!R70X'OWE1_$G_N,/.$KC/!R=_N7'WS_^S/R/ M_^,__NW?_OW_8NQ_O?CP]H=7XW1QCJ/9#R\G"#/,/_PQG'WZX>\9I__XH4S& MYS_\?3SYQ_ +,/8?\[_T=__,N/GV:SSW_^Z:<__OCC3U_CY.Q/X\GI3Y)S]=/JTS\N/_[U MUN?_4/-/BQ#"3_/?7GYT.MST07JL^.E__?+VM_0)SX$-1],9C-+5 #1\GEW^ MQ>MHS$^+7])'I\,_3^=__^TXP6Q.S[U3^&'K)^J?V.ICK/Z("U\>4P9Q#Q;/[30<;A8+7+O!F5\>03R9#4#S:)V73"KZH@N7+$B#3&B#6@I1I$U-^%P;^(BH[2+2VRR+%BR_ MQ\EPG%^/\BLR=@<^1RF4+XRK:&B"V9 5JCBS.?H8A=+9Z"8ZU5FV5Y;>0C8KF3 M4&\3K;H0_7HT&\Z^_3P\PU\OJC@&)@F;,4D6DR4LT6A:5%Q@PI YYX(K6=E. M!*^/> 3$=A+B;4)U=T(_X.EP.B,]F_T*YS@H$:$ T/IAC&?:%,.B\9G99 /G M'E.QO &I-T<]&F(["/,VN:8[N6]&:3RAA6,^R=]FM%6\'%^,9I-O+\>9;+_D M?.9(&@>\,)TT 2V>,P_:QE0R"@T-N+X3Q-%0WT[4MS7!=M>$C_#U3::9#\MP M<0:V7'^$4!@-&0VVPM'.!^:S=,SJ+)+/7D?9S06\<_BC8;^%>&_S[KKS?I+S M!*?3Y?_J=,4 HD)EHV+%ET#*&"(+27G&'9@$(3E,L0'G&X8^&KZ[BO4VU[X/ MKN4@*I4XD%5AJVFADZ6%)R$Y"MDI%\C4X"+WPK4\8J[W$^MMKD,SKE_2M^\F M'\=_C :I7D68J%FT0,:&-8F^0W+YG2>!1BS;5C^FK@8^/Y@2+=<&S2Z73L M!J:Y/?%N\GXR_C(<)1SD%(-+,C'@+E5@@D'0@2FG D;.G=+=CD_N&OW8".\B MW VL=SHMNP'L_7@Z@[/_,_P\-R$M!A5!(P/O%=,H,_/).)9<,-Y:#>10M./\ MQMC'QOC#!;N![TZG9W6Q.9D@S(%$D$5[<@UT$,"T4)8%)1++)1?M@G(TO4X, M7Q_M"#A]L/ VL-CI:*S&%9R]_S0>K4YU8A92.+(,0) B:8Y CG\RS/.0L:/P]D9#EPJ*<4(S'E%QCW4$W;O M#:/Y<)D=]YR\FRZ,KH]X!(QV$N(&1CL=B'V<0 W%^NW;>1R?#8S 0D:Z84HZ M6BV4]RS(!,R4PB4B>*&['7O<&.X(N'RX^#80V>D\:Z55K[^F3S ZQ?E)JPN@ M 0QG'J-@VDG.(M)N[LE\,]Y+'7RWK7/3J$= :V=A;F"WP:G5RXO)A*:ZN/2J M:DX/SJ MS6B&$TBSX1=\!3-8XAQ8'H4Q4K Z-;(#3&0!H+!Z.<:US-) FVN*3:,?#>L- MA+N!]08G6?4R=/*27/#3\>3;@'RM$#E:YJPB9TQD5 M-P8]&HX?+LH-02$-3J]^.X>SLQ<74YK>=#IP6 PFL(P;^J*#DLP76[]HU#IH M'D2+U?O&H$=#[<-%N8':!D=4K\]Q>+T";T#QQL&/ANKNHMU >:=3JJ4*?L*SLQ4<)R./Z!S+ M]:14)Z<9^>N.)1L%&?\E2-GB#O'ZF$=#\(,%N8'7!B%=A.2\ABR,TS]^^P03 MG+Z[F-4TF^KO#:Q4)1G0+#F<6X6*9BH$L^3ND4T(W+LF)O<=&(Z&]V:"WJ ' M#2+!7M*L)W#V9I3QZ__$;X- ;GQ&+Y@LL=Y^U1-RB8HA9LUSEKQ BU=\;=CC M8;N#.#<0W.GP:VGM_SR<)CC[WPB35>!PX=8' X[%$I&TCKX$VE:82XF,1"E4 M\-TV[&TC'P'-382Z@>E.IV.KF5ZA^IE^,AU$3&0R&&"<>UI>2LWX%+DP5-IY M43>AU(WH+0,? <\M1+J!YD['9#J8VN1TW1KZZ*A^J%@WD-WI=.R$(.4YK#,XI=6E2,]SS=@NA 1+9,$$PR1Z M!U$&6F"Z;"\ M2QIE,(UR9=9';DCOM/7#\6B& M7V>OS["._9'>=N)BR4X#/@WD$4GW0RS.83M^5N8MP\G4X'20M MBQ6TQY04@&E#@O+.>8:%&R%2#"'>=?9=8!KG9"U'6F@'GLVFJY][5G0?0/.Y#W WS)%? KN-Y-5\M=T(T6"MQT$@1;J-IN1ELJ\]PQ7]C MNL:]R/HP6A",*?2?(,/#/2/X^(NZ# M]/G9T!S7R2]S"VG $QB#SM#<','RJ3!"89D!3V:*2@[<77GP#R+]%HK#V7^M MN%FGNIM@&]8\V(#HQ0J1\%[Y+!D(T#1+1;N9(7^R*.#.%$R9R_ZH?G%\5#]$ ML%O?ZG__:4TB9+[^HU-MFE&FY0\S?3,=GPUS+?_U LYJ9:O?/B'.IC.]G9ERBZ+BPGTRD)YR36#.0T(]W/PM)4 M&"^AU&4NLV YN;M([T0N.FMU5T+00^9T$\'A%Y2.S*XO*!T$VL.^L4"S/'6^ M!%6X B]D8E2W:V'Y;7@!R>["[L;"2ZBVC[, EA^NED ME.O_7O_WQ? +G!&XZLO",MCIDV@K!HN/ 3,YH MLO(@77/381=@CZ4/G4A<-RB:,]"#FIRD5 L-3#]@0H(8S_!7G*W"^W15>YT+ MRQP=O11(EA!PP4 51(SZ/MORCN=_SY2V$EO#2DNK2;Z?X&<8YM=? M/U=3F!:A=]48OS'U@=2"O*&DF#,0JL,4R(\UGEF1(%J($E+KI7\'6-^S0O0E M_8:5FU807^'G\71(N]$-4#D%@>@$A20#$Z'H4*+B=V<,=S;^CX'FATNT8:&F MJX5G_!DGLV_OSX"F-\K5[/Q<'5JR,0;%VJ0"&=JO M]]OQ?-<>7S-!-[3B5MC>$3*HF5EO$:;XH=;\?U=^IWVH3G^0@30SDEY*9: & M##OFN2@L8M;1)Z>2:6W2WPGHNU:#=J+NP09\.QZ=?L3)^9O1%YS.JG).R=DT M5EA2R")K4@\OD47"PKCQ-AO.M8UW1?\\A/T-,+YKSKN*M0=C;C&[ 62/*93 MN$N69F5(WQ(FQG-0H+P!>V<)IX=OY]\UGP\07@^&V=LAQ.$920VGM)W,K[0^ MC<_HV=.ZM>Z*4O::HNB34:XP,F4%8+Y.%^3P+D 2?OF-U';T1Q>(?IA M<+N:=!%_CX>Y[^%;/8PB$=!/)A>8;T,>Q&A4<8CD]- R1U SH_\D"UE& 3YP MKYH[?[O#>U35Z<3JEO/>UI3TH#TWK=D5OE7!AX%74B==$O.Y(-.8/9FSDK;) M3 NN,]):6WKU'-81'8V.-!1\#_[DR_%H/L6_#V>?7EY,9^-SG-S":)/D6?#" M)%E-M)[JPD#):A GF7,4)LC6J\DNN(Y&19J3T(/#.;\*6:YSEY DCS+%R+Q- M9(Y!!.:U(\N\1&=M$ G+787/'J(7&V &?4Q9%;@+BBF1:88I M1])#8YA5-J-R3J=R5SY*&R/T:#CO*. >G-4[%Z-?QZ.T.@VGF;G$-7-9!J9U M(B/;U*0+(Z(C_ZPDWOI 8D=H1^J9]$%,[R?4FP!&KB5&5 QLCQ-8]>9]J2T8-9\>H"/XX_X%F-XWT/DRJ-Z^ 0%?(*KM0.2)9\ M)B"+F&7-R>A!;G-I?9]Q)Z CU9)V)/1K@@QTIMV/:\&PN%KHR)$-'! 8>FY4 MR@3-MLYUNC;\D;+_4 'W8GN#Z/J:2UJ=I"XS/Z[.F\>"5. M9PLIK,)O3\[KP=Q .)HOAEH9K>1:FH%LZ>*1.0S%6&>*P-9&ZD-P'JDV]4Y9 MP[985[=.6T612 S XU*V M#3\;TS,?*-P>;DMN3[,>SOUV$:=I,OQ<17PM++QFDEITJ!E@Y$R#@5IK@A-8 M,HYU2E[KUIP$\&C7ICY8>#D).PS"_&;V$S\,9G%U3]8%WIO84 MJG>"]:@OJLB"#('Q%)VI34"C:UW"Y7Y41Z,MC0GHX?3C \Y(/IA?PV1$%M#T M)*6+\XNY'_Z*Y)Z&,_+(#'!;FT8&/X\^*RP6J:O5[2*W(<.=158?9L'>A^IH M5*0Q 3T^$ $S#$ZQ[06Y*2;)%A41C&3C'9*2=+B]H6?UE$\&_MS+W$W M[.>YZ[0' I0I$#SSH K32M"&ETE?;99HK5&%7HX#!PT>J7(TI:)E4]!;(9.+ M0FA)Q)036A91T.Y6)-9T@QJ=?-C HM$#K M&7.^T)IF568Q 6]^F4.!FT/5:1>TH% _?BYOZ"@?L(]C % [U/ MPCLGF,JRIBE[S3RWFF&V &3[NBA:6WU/M&!@(ZH?(M@G5##P/=0PCD](?P_. M;N)K53WPYA"'*B5XQ\36Z@J".UDE<3U;C(?(<\O=-[C M9-[7:* %]SX+Q4*I%SL1"_G?A59.319W/8S5L7W8Z+VPGD1VXSXZ<,<%6A/1 M][9576MQ=7(Q^S2>#/^)>1"E,48GQ1)YYTP[SEF4(3-$[I))OO#86OWO@'-, MVM!)U+W9IEL:G4FO+"W,@:E0"%N*4$/?+:M=#%-PA52V?:+14^@N=R@]>*BP M>[@>73N#*3*CLA:8]3PPS6MCK!IO"K7H<];@08>0C1<"42:L'*@X^:C MR_M&;'Y^*8HC)\5J5COOT=)B P-?-".K5$B;MC4(543YU\M2X5<5#8,4N2C4S!?C:*T7A8$.A$ZGPIT* M-OG69^!;P7SWFM%&S#U8MA]PBO3 VB7D%6GOV7A>0WB)*PK:,T[H%T+&K14O)]%DU939HT M5;H@" &/8)D613'R^P5SA1M9"B+9@GWO$<="?C?I]I#W!=@)O^/+/.TK-H=V M,[U6>.?;P-+6$U,L3.58CX$0F(^!H(().D$,<;TVUI:.7/<,]-URW%R*/>3L M774/6&! 796)(7Q!D1-J$FG-^ \(14/UPD?90B>C*LE@= M1PU'%[3+7!VTOL RGN#BD$>Z-P +;0 MQ6MAXLMZ%B]@.DP##8*V)%)&#,K6,U=@ 9-FT@%Z'KQ5N?4]Y9X0CTM!&E.R M084ZGV6N"B6MDHH6J,B]3@(T,J5]=@N MW@VD=[ZN6$?U:GAV,<,\2$7'5!/FD\B:Z6P"\XXTTF>/T9(S$YNW@-@"Y>B( M?XB(-U#?^2CS[UC[WF(^^4(.[RG^>E&E\J[P'\[M6D/SHV*$_GH] M:)>Z?3LC+7BC3-*))44JKM%G MPELSTJ0"3-R+X%H'?N\)\5@5J DE&U2H\UGK6O:30 &EE,A*KNVP:FU@\$G4 M\ITY955">Z_UR60)=J&]@QB??I9@SBI83_90H?VQIL1%YFN51FN2% +0R-0Z M:NJI9PGN1?#.68+["/HP^6&[('JV68)[T75_HMA#9'T8+;"D[E9"9B4H0I8S M9P$<9TKQ1$9/%L&W;A/UY+,$&Y._CX@/DR6HA%=)T=PXCYXL$X?,@T!61* ) MAA(]M+XI?:)9@GMQDM35$V;Z45W!0 MD%=CB]Y)C4$Q'W-A4A650RU EI]^*:\WHS2I+2-?X>+_;T8?\?SS> *3;XM: MUQ](RC^/)W_ ) \$1*,#+RQ81TXB*& ^",L$K1V0:Q^7V-H WP??DW#:]]&* M#7$$_9#10];;@WI^88Y>9QU9C8NHC18R P>>62$45N=6\]:Q[]]'F[;^F&_1 MJFT?VGHP"F_?S%E:+!FC".6LBT'ZA M:Q?O9 N+@==H$(/DT2EI);_/,-UCO"/4G;ZDW4L?J >LODX)8[,HS"4K:AT@ MP2"8S&1V(7IR_Y5N;6=VWS1;6**W&Z]<5Q4?N !M A/>TZ8D@V91",EXMMYG M6XC2UGV"]X1XA/9H.TH.77(4O+*J3CR&4.@M$H&146-(&);3BZ\40C_5TI]* MR=%>R=RG'ND^3!RDY><@BN#(D-4L1*B=Y9# )!<9B@RT$$9I57M/_O%[:1U2 M(SI*O8=LW9LAFSZZ@F =LUIIIFG'91'(4DR6,"'F9'3KJX5'CH ])/L/EW4/ M1MA)_J^+14+A].-X2^_0^:H587XL>5YS.N9)0!^0I#(=SO WG'P9IEIQ?3C. M'S"-3Q=L+8Q,KPM82^ZR-(%\YN(C\X)6N2)B"EX5ZUSK8[*^YW3 M";SSDDO MVU=WWP'8L]2@#MPTS*:>'\]4"+7'SKNRN(*^YB#\/J+GGWS\Y5TI6+$/> XA M&%/KG6?R6*,C13=.L,)KY2:=>,QKY[-;3L3V&/0X]:-7T3=,5=X7YV)3)4=1 MA>B @0@U?@%K*J81S"LM(0MT'&1K/3EB8ZA_$GI(<;YS[WPY'GTA\1 S-)WY M][-A/"-3+=%':W/G@<640A&>UD!->ZJ"R$):9%D9J[P!85K7[.B&^#A5[Q'8 M["$W^T[T\U^^F]]$3%]_Q4D:DB4YPQB4,\)ZB*W; M'NR/\AGK7'?6^NG^OMW1U$=IRJU"<_?22LWWG%;(!'2?_0C&-FVA,X#ZDP"!:02RVQ M>76]W2_[&UU92PV*6V:"H-Z%I M$U,Y6[)S !F@MDR2P4,KDY8JMI_3$TGZ[1*FTT&,3R[I=QE9-C[_/![5^[A% MCIL2,1A/*EY;IFJ.R((NDH62(%K'L7TYW3L!/9'DW[V(WJ8SG07>0XC.&J95 M7NH.H'K* =X(Z)'3@+L3MUZ:IIG4#Z827D5E= K,F"S)T(%:^E\JEJ+7J(3F MKGE)_0.JPJXYP0?2A'V$W4<6R,9(Y%4;1"53C1QBVD(]^LVU5RIA \% M+ZU#%^["3=6X?1N4&Z!&0C)@##:0$%LH=YK5]CDV$II1R+ M+,;GY@V$UT$< ^O=)-M+=[6$PR_5WIF7YK[FA"SQD=GC>&WP4?L!D#Z*>F>M M"BM"1^FDL=ZV/MN^#],Q*$)3N?<0OKLE3&\)#FQPHM9!(_.X+E*8&7A7!<'! MZB21_.?F(9AW #H&C6@G\5XRJV8T/\RK^HI+5+X4GQ-&%D,]" K1T#Z5%.EL MT9AL0"G;YTYM0G(,"M! QKT$MVXKC0.%.V.,)OM$D$I"01:Y\XQ#+E%Y:;UN MW5KOJ=<+:W)DT$G0/6P%&TKE[(+HV=8+VXNN^TM&/436AZD7AN@4#5Q8=+79 M9RB<>8F>T:+D:E]UHV7KXX$G7R^L,?G[B/@P]<*<@(361"8A.Z:-\#6[*#.E M?%#!)ZUYZXO#)UHO;"]N[J\7MH]@>_/YYXA>7%8P*S();IBLS1:T-XETF0-S MWGH!103Z?7]4OS@^JA\BV(9O]3R>Y/J5E/NL$4!I^/R$J:??CX;_S'ML;[?YF$.4:IO MAPFN5=VS1KL8 Q1:JC7WQ7-1,'M>N /[KZJ>YL';%Y 3ZM4C(B."4UNJ!:^ MAJE8PQRWD5L(Q=GV^8:M"^C]BK,JJ_>3\9CR_;4)VDV_#*/ M3[]L<8X80$4LS!NHJZN+# QDYG)*7@E./G@/[7;V1/DDBI?LHR$;CQ&1TWHJ.'M6[E:BQD<3GC <_)\8""\5+K0?EL&5@T3 2-J22N MDFE]3+\%RK\4I@E)/2PK:YWAWU4W:B CCZ5BTB949]AZ+-@SR :3"(86@1-,1558E'%Q)('CB5SGD/S6.*- M2/ZE-BTHZN%"^??1!.%L^$_,?R6I5JF\&[T9?<&EZ,AE<*HDGU@1&)C6-?T7 M0ZTQK++/TH,/K2\8[H'T+U5J2EK#ZDGSL]=5"M7/,)S,DZ?>E;_#9 *$ZP.> MU9.W]S"9?1O8Z)ST*3/C?/5% U]4"=,1=58V>)76#*$M)]H[#OB,U:8W7AH6 M3KK:7->S_RZEL0S!NA0%SX5;+(H!FGEX1V+@R,*7ON0@O);M[SYW1W?T_GQ/ M1/5@&]U&>I)2+>(]O0K[' 03@@#EF2N"MF%9BT&AUBS+A,YZY-"\Z_,NN)Y" M^FT;7N]5GXZD].+#KV-\/\'/,,ROL.!D@GGI 9R,\MP).)E.D79?6SRYB);$ M4@,.-7I'%IV1C'XVCSNQUK6.SG\8TF>D7,V)Z\7MW_9*O(=O]7T@N/23R07F MMT.(P[-%(:A,?B9AK7T2.&URY[D+ZC-2M.7$' MV19?UD@)$L;?A[-/+\ET)2-UL@+\;2"X=SXFR1*9!368&IE73C+E?8XAJA)Y MZ^CR/2$^(P5K1U4/9PJ[6Z(#H906G@0B/0^UW8MGPOBM^G_[X83I"PD\+/OKT_@]&,MNJ:2_1Y7C[*%GJ%%.&+ NJ: M;02+01:6[HGLSJU(SK]<"5?HCJIV?CCH(92)D$>:Z&28B% M:+<**\NA@9.6)FEXRQA38V!C R4\DSE@DJ;Y)QL M[9YU0WRTJO8(A/:PJVU&?^-]<8"I!D&$VLE8!Q\8>) L"R,3[?!)-H]8N1?4 M,U6JA]+2PUGEC35V8P%Q'R46)SAS$6L8C5 L1*S'%:3NVB7DN75XW+V@GI7> M=*>EAV.CS8K]"N-L$(Q#%4JA]:_&>,:@F47G.\*[\.I[AZLYFH),R)D?+8C21G 3EF'<:F-,"@\Y>RN9%UK9A M.7KU:$)"#]%(NXMA(+4/F,$SD$A(4486,[?,%1M<[5EH=.O*;+NC.WH%ZHFH MAFW?5D@KS/I?/;S\0N[B/.*%)#!,,\SU%V2NW_S!M4\NFAWU]/KK MKVD>Y?CJP?KO M!CX4SIV=Q\\;MPB$!J,5$\((H*F$H%K?'S?4M8=)JQ;!J"53Z-NK.Y%1WK"- MOAI.:\N$BPE>[M]1V60U6>XI1L$TCYR%#(+%(G+DOI %U[K"15?,1_%^'HRT M'@SL71OPU L'HR PDW0MN&HE@X22<9>#54GQP$MCW7JR#9(.R_D#.R;M0U@O M]?/)B3R93B_.,8M!$JRT700XV.W79I. M9H/?TB?,%_5R=E$I^A>5&"AM59-*E&JB=,@-N M28S!RUR2$2KNY'40D&OZ0G^ZTI6N&)](Q>6]U&+\"/0TW&HJ[FVXE@4,=T&V M3V'F>Q3H;C2'+4U3 MQDV+'ZX@#4N+V+I.[RN$,'+%<#)Z5?N*G-U$NUO%WFX#MJG=VW#2 M:U5\1=;%2'(4#3JM0HJZ9&E%%K2TAP)NT&WH#N_KN\DIC(;_G#_\JH)P?:%& M^?K [\K2M8:SJ^+"5]Z7$M$$\KQ8U+30Z"QKL6E5F#4VTMR##,[O]*JWP=,M MJI@\A#K,*=;[^M'?QO5LX37Y;>/S85H=#0ULB&@B2(:R1'IMZ]Q=CO3N.F.] M-,8&N=.,=QKN<,O>8VG%S;#CYA2TWN=V0OCB&VW,-85'&EKCLY(,M*D'3@IJ MH'1BR40%*?)DU\_HNBC+:MA_*4TC2GIIAGBS ]=)2A?G%_-21:^(J#2<#1(O MSBN!K& T-17%A9"!%,LD^ M@?3D1P8M&4=- O$E:VR=[K 3L.>G4>WYZB&6957E M8W'?,G7/WPUC" 9=G$I@JSWM-](0=F6=IC'F5? ZAI9;V8T"\7 6#SU^%7_&/^ MF^D@."[)70:6BJM-*@O!#EPPU(E[[7+@;K?:B@_'\'RTZI!D]1#_?BW+9UFR M9EZHM@8>X>0+YI_'DY\O9A<37(7M#Q22B+2SS =-@"'E>HHF6.+<2F^!1VS= MKF-OD,]'_0[#8\/0G^X"6]PU.BFE MGL+9Z]&,UO+Y/9--J)U*OF:CU)ZB&9C7.9$4 M;4C26BO"74F&4TQ_.AU_^8D>O5CTZ)NKM6[#@(>^U7\4GL=MY-WP *)"6:!8 M7F+L@F.'>_S[^;\^ZF'OZSN+?]Q0=GURJ3@4F;,B_'%M&3F/B3G@*:// MX-8/I9\ P;P17)7R%B1R+1)G $D8$Z8 MK$$0'+?;EG_]J8?=L94C#.#3-!DJDABF+>Y%)SP<&& M[)15K1V%K6">TU;:EID^3F-O]_K=!=$^H7+[.)<'ZF*_;>MM3-?];>P?(NL^ MVMG?1@916JZ"924956/%:\&1@,R*I'6(0LGF11D.Q?Z63?O@Y.\CXCY(O^J_ M?K+JPIW)$ F@62B)]B]14PVL ,8Q%UE2S*9YBZ';*)Y$P_.]N-G>V/XA@FU] M^?]VF.85]D\G.%?K=_%L>#K?[*9SK38A>(NWU[BG;DOH-\6[MT]Z/,4BA; M0HTT2;)6C1+,.P-$KQ7"&$@9RE-F?\M>_]CD[R/6YJ2_?_G^8I(^P36$RVW* M:K"UC!Q3.N.BRT_ (IB!&*/#D"#PW=C>.L:!KX,:4S%N+\<>S@&N=Y'[.('1 M%-)\QB^^7?_-7,>SREYR89GW9,UJI6J/N>!9!B>,@OIOZTK%NZ-[3A9#S]SU M4-/C.I[5N[0#HIZ.#FZC>9RC@[[XNT--.@B_EUC16\BB$U$GK9CEFOQF1^NL M#]XS06X/N448LV]=CN10ZG#/6<+C:<,^,F^>,0UL@\ MG'RNL[O,[S0E)F538481"JU#(>N8;)P47+9%) FP4VW%>U)B-XW]G*R!)O)O M&*)6\7S S^OF[CK$E6N[ \B&R?8[ SM\WGUW#L>'(J!Q:OWN8%V(-B5REC(! MI8V/?*^89606I+)6>.[%3MT,G[:6W)%P_TA*LH_<6UL(?Y57]016/C.6+(3C MS,EY'CA-'3!S%KR6P3KM(^P6*7W[V8=-P^Z)@7$[\?621G\+$1FN66IO69') M,[)AR&KAA?8] (U.>5?B;O<*&Q]_=)QV%^+!\NU_NS@_A\FW#H:EF&J M3> 6F1PUM)YLI%2K2><\'PS.WHS*>'(^MY,>GG/??= V>?>-)[^6>R\5+TKS M6FR?ZX3"&P"42"I@R'5 ''0?OL.+OAS\W=V#O[V,<)8HM-%!L6(027MYC7#' MVJLD@"Q ^QB*G9: /0?N?C4^JLFYBW(E'X;3?UQEZPJ:E%9%8V$RH:ZUVR+S MB=[0F+FG]YU66M?^DGP[G@,?J/>I K@=),59PW3HQS&]*8(]ZT[70CI)7)K'=\* MW=((W05?7R&<]V![G%N9MHS>JRX-Z'@,M;$0/((6#'PF']+0.^-#%BSP(DN, M/ K>O.C"HZC+/;N6'\B141$7>)U:W5J-A M4=7./=[RF+021K16C8U 'B$XM"E?ZWD!G87=0_C(!O7_2']U<2Q)>Z1 -?62-K$.KP%9W#SM .Y3M<07K MR9@=#Z/P/M7H*/]#&!O7( :-R>.\W(%33%ORVGT!SE(QTGBNN>&]GZ#TK1K[ MFQB]:\8^8N]#(RZFL_$Y3FY!O$R>#%X8 I5 <::5IQTUJ\ D8HD\")-EZU#$ M>R ] 6/CH?2MJT5#V3<.,_D%_FL\6>%;!%XK[@*0]43#.U%[%TCF8RF,HRP) M@C6X6V>0>VZ$;X]\E/9$ R$WS#ZI:.IUV;MR ]-E&O;]H!I&CFP%8^$(F1947S#E"(,' MC-?U9.1RP"]X,IG4KIV+(4>Y-HG<\NOKZ2-O+R_5D988M*(PH:0AIU!RYKT" MI@+:Y$4$8=H?I;3#W^*R8EFXX=>+^LK2'^:U-A>U7M^,KHTZX/5 GI[! *-F MM8H#"UH \QA12LC6E-:EG_?!]QBG#8^DB9NN07JAL9?;D@>:)=R,0 J9 UWUK3=H#UC!6L-6D]W;LN MWX'WDV&ZPB4R:;>,AN7H2XTHCBS0)L:R VTQ657 ][=LW<#RC#6H"3T-K^(6 M1X=7H&IRVI >N3C9G5?0Q_SN^L+YU\EX2C*(&*V;-Y+FF6GG);DEOMK+/"'I MN)3KE0"WA2/N/?8SU)Y#L-1#.XV]$ ^$!V&5CB03TC)EY*S/CFBL5P*&, M.^6$/FR!NA_@,]2[_HGLH:#$'LU BL"L3"W$9^D=B1H8&.$8_4SQ')4MO/66 M^ 2;N#PY;>N'P(9IS#LLQQ7H>_A6!;3H$3)PT5JE5&1%A#G6P&(VF5F.F%&0 MTU%V:PR[Y\#/4)%ZYZ=U\XQM$B/@]?)V\=W5%.:2*DCO0#XY/9W@*7DA@E\-Q>UM+72,MW6\> MM>?;P!C+99[W+:U+=9&*>9?(%)56)HF@4.W6++<+BG_I8,_,W58YW\O"^&'\ M#>]"L9VS&]L1WV0MT')NA7QWR:M>OYVM;N^&D[GQW+O89@'WN5@ MI3,L6:B5JH38=@:8-6-2CMO((U_1F&D_E& M6P&>C:<7$UI9.-_PR5ZU!L;="P!Y^I[_1"O+PXOSB;R^TE MS-*GWS]?3?+C>/FVO/Q4!?IF]'HZ&Y[##-^5]32T>HOF6^T!IO4,%?VI*LV&%Z/;R?\O\'5X?G'^V^=:+7TR')W.9SR, M%W."SZN-.PCHK#&%S)!JY&K)+:,?$=2DM;*6UVZ\.ZVS.PSV#'6M%QXV*$JW M0_SWY/^,9D,X>T6*?3;^7&5 $OJ I_4=&$^^_3(DHW8V'JWN^Z^=& \*6;(@ MK:_95;6H/H\,1,KD(44M1#20O-Y)@[J@>*ZJ=3#F-L3+-FB.M;14J\!K@OTF MXV( 0BE'6!BMHY*64.M8-$HP*R.X9 *6W4H0[.7B[@#L&:I9?+ M-?<#3I&>^NGGB_F]Q)7ROX!IC;D\29^&-)EY/[JR^C")\]KK=/D&30?L-"K2@>BLHV@+ @=LO;[ /=,]3'I\'T!MWMEDNPG-%R)E<7_3O@ M-ERA5\4SU#$P;7QB-!/.T'LO; RY^-W.9ZV#=K&[2MV]7%C1<&\T#Y M# IU9D9Q$H!3ED4NR1+5M?Q]UO33W>XEUA[\7/6BBWPWD-W@1F&3-K[^^KEV M9QT(-%!J.+@H\V[KMI\G?!;^H3Y MHL:'-Q#8HJ16D1ADR8[)(FA*CCP3GS+)#H2W+CIM3>N*INUGT7?!_R>GIH^L M"$^E=4 M#_BN7)O6O(J45U[%4 I#>DV9YEFR&&FQYS2GX$$4V_S0>".00Y?3 M>RK*,6Y-4@_IYK>% 9OGORR%LPOXI$/SX^K0/,7WVAYR^7V^]1^A? MCD]'<'-U'^6WPU2MU,O/K8A,;5.D(&'-F+X&F6*54%IG], M">CS7;O:%-.?3L=??J)'+W2"OKE2A0T#/G-3NRL%#0OS5"@+%*ON3SO@V,%R MOE\EKH]Z6".XL_C'#677^,V^@4=)K;,SL?:;)!2![LC<)]1-;:C/R (QR__P23.&I63(F,:L673* M,(P*O0B.=@V^DUUXYS"'VY&[B7[?8?3M[?!\.,.\1$V^47:E-HA5@NP.&3P#X(6ID))67$0KTDYL M/QC"]Z@)AY%WZ_?^5_QC.H8)O!B./\^1OAR_G:V 296BX>1,)*@I6RAJ*%+V MS*3HDH.@XWJYLBV*<-?WU1,(UB4T5[Y:(6< MLY0Y4S'-;0I:%C@Y:K)>1ZL 5IK=.D!L&>![Y*Z%K'JHQ_>N%FBO^?;#Q5'. MW":T.:=0J\@ 1EK6E26=,@J9<$($Y3//L77IO4TXGKF_VXRB'HJ'KF-:M4G= M 55/%TB;$3W./5%WQNY1@0[B[N$V: NZ>G#K=**M2-:>N3P%%HJ(C"N1$&)V MM&9^QTIPS]W.H71@'RFW-L'?UT/_CW^,?R']&G[ T_F^]I(^6AV&CY/AY29G MLBPENKW^*'_$]&DT/AN??EO5 M*UW!I"7R$YX/I[/)-_K<+S"Z*+3N7=35D3W''R&2:S;[5=Y**]KC8: MI8X,-?!Z0E>;J0?-,@ (2]:36J\O_*"=9=/8_[(_NU/2L!-$Q?,!/Z\'IZU# M7)WL[@"RH3VZ,[##VZ?=.1P?BH#&"\KN8(,QRF9RZ8.4GFD5(O/<)U:*%0FB M2QQ;K#*/K"5WV+./I"3[R+UYP+*^'O2Z"I3(!HI)@M&B2!NKIR4SB)B8 LZ# M1?@;6">N5'8EJR&O9TNX\VOX5D=VN^ J*=KS-MH'N<*LQ%= MZ['];63=PUJR 9D167EM G,\%J93+=(":)DS-B0-*8%MWG;]0.S??UB3REOXX_\7\YW7&'[#\4/__^X2SK M]$]I?/[37#KS3A+S,DXUO)7>CGELUDG.PT6,UIO1O/I8_<,KG,'P[";"Z?#\ M\]F]=;GV'^2GJRG=G.IRI!O4]S4Y_#K#4<;\XP_#_)KCRQK%)[\ 9/\]JHX!48NA,C5/ZVK M62'[M43!O+)1F%S(:=WIJGH?,[$SZB8-;!Z"8/[E;^2[+8I0#<=9#(K/"9VU M+#M/%J$7P,"20Q! F1RRDB:$IR+!#?@/O] >6&LWMLYY#/)[2-N= XWWSR6N MS^7UU\_#13?%95,R0Y.0@3OFZ@V)=H6S2&L=*^"*QM\0E_=IF\5*_GD]+L/%"SC].)XM4G%6OW\YGM8F,_\;9U=M&>96 MW+O/BP+Z,MD@=&T+*F6]^*,O/M%+ZC#;Q+/B,K0V: \RL6>G]T]/71JF /4^ MR<4K__-XLOQ1_9P8!!40.7B6,$;:P9)B06M@Z&A= %&XQ]9U:0X[PW^])4]' M@7I(PWBPL)>O^U_I@[/IF^6&^'<HAWZV; _0!__MB.!W.5LO+ MRA.*PO+$@V$R.62:^WJ;ICESJG"5@N':-Z\OVL=$_J7]!U>'AO%.K5[I:^V6 M?[U8Y/DK)XO0F:&(O*:^&A9U F:E<1J,S7F]CK_NW)O$OW3ZH&C2\J9W' M'72=S:U)KZO*=R!)0?9:H72V-WB@9M!>C:J^8A, MWM;'SKT!KR(L[IW2=-N<%H$5F*+Q BSC/A?RNFOX-*];1S+<*5E/HDSK];45 M^$.5)7_LU?11R'XJ-<@7\.G#BS#/:,A2S\"DKB'_2B.+,6F6$B\^QI!B;.T& MW@#P^"%5!]6!]1J_#^:BCQB\!POB:AJC_/X,1M84T_Q5WW,YW$BN#JH MR;Z&Y*$X_E[T5ZC(4ZE)_]Q:5M.C& 0?6$15/.HL8FX>?OK=Z.T]L6=/7&WW MH;;/.\.K.YM59P">:Z8?9YF,WGJN9AE8EVHQSPQD$!MM M]Q"=B&I5IR;;AH>/VZ$5#M7OX!S^;RF'X:?OXXOE$);Q>H#?,E]X1W M^*S)!H3>I1X]L-$X>7)OR )02"EI^=.*:>XT\_,[(9V5+Q*D"3MYD=^#XMR1 M2/G(>K,'":WS*7^;36"&I\-TDK\,I^/)XK3 ?.>S^MXOSR;?#.FIP3[7&E9FP!"!5EIK4BW$I +SR7K2&ZLD[LV/ M:C.%SF>]BY$P;P:R:A,KN8>8C*]-?40M 518#"J1'1R\LBB+;1XTO1NRPWN? MCZF#MTZ'V[/71^S^I?_51G;+_&0?BU9*L9 ";7:I;G8"Z8MTD$ +!:IU3]1> M)G*H*[6GI+>/KQ%/Y:[MS8AL +S,P7V[G.?<+4A">Z%<83:IVOTL*@;9!)9, M0AX*F7;-FZC? >?Q3V\>35?&_7#6PY'Q%FA+?V,7<#U=M=T)[''NS)K1N)MZ M=.#@X(H"!IQ&D"S:FK_MR"?UMAZ&*P7<^ PNM]Y;'T%![KF<>AS]V$?T/>C% M!YPB/?#3R2B_PB]X-OY<,2X-R>4Q@XMD06KO6$"1F(9B&=1&0IR63IXMCP9: M9YGM .OPGD!#(L?]LM"#4?]7'.$$S@CA23XG44]GBYI"-T%ZI;QW%IF5/-![ M4@M!U)=%<0RVN&QD;!TKOQ.P8U*6]DQL75=:GPU>*P_7N ['CD]NAY8@V6L_1D%V*0.Z5E!A5$+)P:08[CM&HR-J5F^=YBC%HQ:(.A6DA/0N& MO+Z$)@@H(MK8O.C#+12=;AZN)/?N#WI3ZCD\N0.)_@RG./#&F.AI0E7>3$M! M+D'6FDE!JE3?C>S+?C:R_+@$"H8AQMD2K%VMQ4TH[I%9.NV.*#M#:TMF7O@?3=*D,?(N^S5.3" MU?D?&>C 67^EK!#ALTWY;E#F)\[-.U3;VO9;"U MEAEGUDM!FND- X/ T ,/VFKI[XQCO[_3]]J CW9>UH&V<1OQ]=FP?1<<.YQA M/87&[=L.J#J+?UOG]H?(KD\N0S8JSZO+2IX)CRHL)%Z8B:'4*N*)%JPGSN&6 M,Z3>*-Q'9*U#>.YN(A\ N% 8:7E)-0\ZT/1< MIJN!4F>YG1[&1(WSG,(W8# MWDOTXU[D=K"@G6O6W.K^95Q>__<%2>/:K_X8SC[!*-?_C2]F'\AI'9Y](T<4 M)^?#4=U]+BM!3$^F4Z1_2%6O(*RN>^A'B,\YE!K=6./[Y:2'8Y,'B.GDO+:7&,1YDPYR[*% J.<]@<6:V,*! M>PD MI9R<;DEF&2_EKOC_I\#A'@=032C<1V2'/8#*EF=NA&:FUH;2JI9G3?3%9RZ4 MRKHHH7=RHM_] &H?N;7NR'=2V]4-IR^&XRL\3JH0LPP,39CW20<& M6A8&+F!PT8OD[$X\;GCX]\A>5QGU><.ZL IJ_/5X- ]-J>N,E4IXE3@34M$Z M4U2LC4$EH_ESH!5'A="\P\)=@)Z%R=2>FCXJOM_$M'PS=@'54UCZ1D"/W(2O M.W$;?;,64N_-^U\'9Z+-PH-@GLR4VFV&WH $CID,!8#6.VE:!^T<4!5V[:;YPHO=S>#VJ5: *&$NKL!H:))!2:MJF56P'C3O!GC.HC'.CGL M1,[&SGP/E6P/A\[OB2R<3)9M2%;V9PY%R()DO-3J%S[86K4 61+1Q>BXBZKU MU&?Y'BSRNZKF<'%3 J/\CF7E< &G@QR;FD. MG!?)-()AX,ESQN24H3=)!@T[S6'K$(=;A?IA[H;GVD:0K<\<[ICSPOT"!2:( MVK7$I4";I**U6-8:^,XEZ2W'6TE+^VOJ06Z%#D!Q4V$^]OW.:AM]5Q?SZS.; MIWR:E$2UNZ7VP+1PBGE1:@/!B!#)9;?-4]DVX3CT848/+(\;2[L'GV0=TRIY M>P=4/9U4;$;T.$<5W1F[1P4ZB/MPRE# !L1ZENLA,4T:7JNW"1944")8+E+S M)/E#*L$]AQ2'TH%]I-SZONE:[O4\O_8#GEZ7J:;]D2$:[2UQZ,'PGRV'?D0_OO+:@:WPH6;ML]/6JU32;IIP[U#?/_5MI=F\<"DYR=,":5%2:(LR M"HO%H2Q,B%H..JK HA2D,0Y)+GY'NN\?[1@8;RS3'NZJ:IGX=^5:;?#Y M#A? E) RH;#9DJ$K20D1:,,KIAC!K=&E=1/AC4".SPWH+N\>E.!Z:7B:\J_C M$5S]Y"-]-UTH\?0RF>=^N#TY"'M"?1S/H0')ZR4P#\!0#S[%OK"Y,,9G6UA6 MDBQK(VBIA1)8X<:3U0U@[Q0AY?G_8AIK5I\NOXR_CM,-4J/R>G M$\1KFR>"0^&R82XD0>LOQ'KI0R8RQBQ-TN21[5;69/L8AS=#>N5FW%ZP/=R@ M;JX,=DTP=5>>D!@^CM_CI-[Q_#R>S,VWZ8MOEYV6K"\T^]H6T5FRW@I-QSM) M!H QX ,:X7;KQM"Y@MN>P(_/ZCD\G[>54CVB4M8IK *2=IA$3[93DPD\CD7U M" K43H4[LG^P^I?[3B;R()4QM-/,>V?G7!M[J,@<+0M6!1 \M\(J?(\- M=RP:O _IK2W!.9C:=V9157)5\]%BL&0,,V\L+(_-3+&,1X2LBDUFO;[*%B-P MX^,/;_\] D_CID)N?0X]=W]&^&I(/Y_ARNPM)4E-YBG+7),]XDVIE?D5<]'[ MHJ5(V>UV&+GQ\<^.]NY";OVV5T0?_QBO(4+C>,A6;N+?:CS7C3*+0!.B,!LMKQ&="(+10/+6JOB4RQ& MJUW,BWN:Z5T.>#QNU\/E>)M,W9G,I4[M J-A<\UK0Q^^<>8#A;].7P?)-5R, M;\'))21;!$-:",@4("T'M,@B1Y.*M$+"7;4 G@R!=S2P;,S?'@)KS-LO\'5X M?G&^NF"6)3LE'1EQIE:L)?LMQE28$Z%FWED.8:?@OGN8NS'H87M3/ECLXQ8R M.UCAN@^8$<_K_O#K>%3#0^FG]*33-S6)%J>SQLD%789KDV'0;,)K:0;"H%;T MZ%B-&A=X\&0I66N")GJ=2H,N W<[H_EE.!I/YM6V%B.]O0QC%A&R-@9)IVOA M:5LD Z%]+:R%P:#7:=WSZ7SNLA5,MQ2$R_+J[PJ)]V_C:OR\)BF/SX=I-=0@ M)AN+#8:LSY!KGC"P(+'VHRDF\"1"R&$GBW^GX0[O ;0A^F9*0G/!MO;I;[Q7 M+V^_5Z^_ID_S37AU,37/]:(/?B''A^CX4%^T@089N #.@I&&C&,=23;U,E2 M T4.JA*[Q9\U@7,4JG-X8EJ?&RRZX/T^Q?QQO"H_@"O8\_H#\RB\=Z._X_#T MTPSS"4&G5^7]9)CH?7EY!M/IM9S2 :+@FO8#EC(W]37QK ;Y,LSD=1M30*3= MSA<; SL*=7M,LAJ>7-Q^=3;8"A_Q_/-X I-OBY38^O'S>=OH1:E,9TM)U=($ M6SN,F L:F69!\<#)FE QOT7L[UQ'(5:'9"*'FZ:UP6R. FR41NM"8JMK2XT M!E'KI=#NK7GF7F3@T#HU:R.00U5Y;*L6[63[V/E[FXJ>@0@6K \BC:?C1@[X[BB_M(L<^"?;O@.,+BBWN)?UOEOH?(KD\N#8)- MGF<&LM[8(R86)7>,NV!%($0L;38Q^J) )[];,8?K3WW$XGQ["7;<0BH]Q(9>UHV: MV_[ORMSNGRN?289,_*R8-;J>8I 7 -P(XB.""MQ"RJWC/;>"^?XWR+;R[B%K MY3J>E8+O@*BGX,K;:!ZYP%XWNM9K;+61=1]UU6XCRXI;4Q!JFZ%$/H+G+ CP M##F"=$%&U,T+JQV(_5UKZO5-_CXB[JV8WAS7R6I7XLEA*+J>SGA$3!T1/!D+ M5 EPM6O'NF)[.LY $S8:G*#=P?G&?;[)E>L"K963;R%-GR>4IJ!9#0Q M*,JXC[4[=XZN)R?\BK.K21\.:A\)W-Q& MO6\VY'6OR'U&OTO$QI\ E@M%6>YVAU@!S!FS<(BN65Z-;L/H10R"@>1T,A+TW[. MB*.,$B.DY-[EJ&FW\_).KWO,?#<2:FW79P?7LUG\L>_Z':!H2(71'BVY5V5\ M>"Y'!J7%KI$S>4+CK6Q^]$C03<8,3]]+"[L:#NRY2PM^L(;Y:+J]3 M?#7;Z4XRR0QR%$(355),(87U,8,E(K(<,W5&A]KG,7WP/6;%:YD\< M@_44-*6V]"O6"1Y0YG5RYW=[_,O!K6:WH#" 7T[QD>L [7T*:?JUY/_N;&5_6\R7RPDH6V;%***B M 92!Y\06@PC*6P%\S K4GI&[ZJ,'-Z(,87X]6RW?S%>I%-J_GB.T M#=+UN6%:O;A&MWNVFD!,3*-<4+%Q*P3N@7B?*9$J>RE55$:&RJK3&=Q34)LV M3-Q5&5,IL>3OZ^:+J[>+]Z7^Y-;-OAUW^L)=7:7X_-OV[RVW?W$YL9XK1F-" M?]MH7$-)MG,* S;KA$N:@N&U%6D@Y*>@7F.R=E?I[%"EN\%31@.L ;V]7BU7 M;A:GLX\?TN+S!+P4RBA&A).XCW)IB!$Z$FX49":#LKYVCN,I3$]!;:K*_< I MW/ TF$-Z_?M?:1&FRYMBN'UE9I.DK%5*" SR49'!.%]:PVJ"H9ZB-@3O((ZQ M!YT"^A14J#U#!_1J<.+#?8H_D5$$IG)"-"QA1!@CL=H8$DQV4D.T--6^P[H/ MSU/0DFKR/J ,PZI7[_?GBV^VW@A%9$:#EHBQU!!P9HA/7!-ME$S2B>A3MU/^ M;N][S)RW$NL!Z@9.%/R2T4P(C$F#:T>5WTFV+]:W\U#2^OYFXUR1X@ M>R^)IJI<)T1.7)",J"A99%KGS+KU8=QYZ&.F<9" #C U[#SUV<>/B_31K7#K MR6FM3!L'9',]-,&P!CA%1];[,E4,+(;6W%N"?VPB&)DLTYW(N_\]CY[/BF(\ M0/'@0]%WBWE(*2Y?HAS*_N!FZYX8.^TPE.>,.0]$K+M'1E$:&3!%LE.*9@%@ M]HFN,'7^!*C'K!5M)'] -P:?>/X9/J5X?>M[//^V%L*F D#DD+0TF8A45FY3 M(E9Z3A0:$2-=]++Z(<(]<,;J)]' 9%>2\;D[2IPN'XL>>>%1$IHCNJ<"(G'2 M%KTV$HRFS.K:!PD75UI;C>W.!;9]I#Y2:64'1#]M@6TONCK46#Y UN-H06"> MZ=(*-X,QJ.U*$TMS(DQ9Q:GR3G7K 'R![#^XP+8R^7U$/$Z!K8B1I5SN;:5% M1-)3='NU*6FIZ-P(PY)JDYQU<06VO;@Y76#;1[!-"FSWJV(X2Q!E!J*"0@76 M:-:,\)DXGBU720OAJW_>%U"DU(+HAXJUR M9EQ2&N-7DIPOS0)$(,:B&"1$%;73G$/M6OKNZ)Z:^]>(EP;IW[MXME](%T3- MIMGMHSG7:+HV_-VC)@.$WWACV2+C0&W6T1"K(90^%)RXLGLR)G,NI<&@:K>J M'$L=3HYY.YNHWH.OS\5V9U:[R>_WNQ;OK1?CD[@X$UBEJ'Q0076Z; M(-I(?(Z>A(1J#) S8ZH3EH _ >&JNW%!)-RB[VH&TU? N@!JY;'? G,=C&TS3<=H' MR+CME[\%EH,/6E#K;Z\"G]X1;_EU8W-]4W[D3,VGG#2/:J7%&+4CT.N$L*GY5(ULO4;:C T5>, M;[8'RGY>77 5_; ?I\_Q%(2)@1'CO=A<3CHOT"VD&"%(SF*2G28]7>H(S%8& M^>%2;#@ LPN,IS< LY?PCPQ0?(CD&@[ S"CGS*TF/(>2L\T$<2X"82*7\>PI M*NA4V7-N CL-P*S!7Q^!-1V R3@W/J?2]( : LIGXAEC99IGS,*'F'RG@^W' M,0"SE]B/#L#L([/*AO!%J11,BR\E/B\MX]8*J17E&$\GXJ",]92X-)>M)(G) M !X-?@HU.#ST[J=D'@?+MF(+@+7BIB_[QR?[$+?.7A>0->UH5V#C6]GA',[' M(J"V.>X,5EIK#&69)%F^#PVX"4+I9ITH\P*H"*E3KN-E:\D]IOQ,2M)'[K7# MX;\!?S7[FI:K@F^YM6-41*N8XD3;T1>2LAB1D)$D%#/QU*9\,@1+#@!O*4;E-M[ZZ!Q__ MY%@=+L2CGVK]$>>'+U*KCS;O_YI:(\T'+G"O*:X#SA0U,494 ?1JNEUGW"-O?/T]^1YYT"6DI,E$C"UH:1S.+.XO/#LF,4)QM7MDG,(T M],Q]9]=\-7LVB\_BUU(S@Z7<]$55H(=G:?NPN MJF>?BR_P-K]PRT]_NJ_3V&<>M-38KRJ5!ND:'P_W>N6/+@]]XM:!Z$E6B#O"8@@"FA- M)%B?K6=.[_?AJ%C#V0/H6-6=3?V%]A1=2@EHC_Q5KS$&E=(3*DNKM. 9,9Q* M8AU:2>F45+%V7]['5"703%,>7C_0A[%Q$L6[(/I5/_ @_DYGC#]$^..HA9;" M".G0ZP*P)0G:H#'.0&P(@F,4EA/D1ZH.]>H'*FM#'YG7#G3^< &C\$7Z9^F+ M]G*^\ GC\C!??)DO"LSM.67QTD D36Q,JK2@-L1K!219GV@40!D3G;S?3J^[ MB'3T7J3,FTJT\MW^[4%+W(RHOYG(ICB3%./K$$K^O9216!DS\2*K8(V.*JHN M7_Z)Z[K#;W^TE%<2:(/-_7C!?. Q4>D#D9&6\B=N<><2%'/!L6EA\JO.R#Z:9N-]**K0[^)!\AZG&8CU%-4:*-(-*4IJJ*> M."XT\8:'3%W0D.@C9?_!S48JD]]'Q&V;C3S?6JW(CL=H>RNR@NH@=%+VZ.-QMYB&";-1OYH?T)MZ72%@ M[V(U%0A%" 6AY"O<]SDO4_CWC_.O_X&/WM"+__.=U0,O?/K^W% I5[S'*% V M*&X:EW7 T<%O.\WZ[EO']<\&BW]>47:5/]X?\#C@8#,W)#E3A@Z7H7"*,30: M"7>0;!+=/W.Y. Z/>%G-*.PCLNJ-.$J"W[M/;O'9O7[]XB9M4RE+;9(D&W09 MP0E3IG!I0H54%HU$E&POR^J^),F]IX]G.8<)^DX:Y! I-?",_KSVR_2/:_3V M?_^*O]P6*6L%*3+IB*4A%BLNB$^HEXJIE)P+/NU?^0\_)CD,Y>D;U9IA?6;47&:6"-3DJ.@CK3@4D-ZDZKPP"YMSAD/0J02Q>4+IN:3X) &6SFF >B MHHK16=PH6?6!'>,JQ*DSE%'UH8^XV^O!UK !!:VS";C_<56&QJ-AB[CHQ%/* M$)0UK'9^\4$@X\?8E8BZG_X'2+F!^W#$-*YUW64M3%"!:$T3 :/0*(*GN%BT MCUG*Y&CMYNWWP/EYW(A:G%2LM#T![<:Q[@!NA*R<"VD758W&;NHQ@(/QN@;? M%*(YQ861C!A63BQSBOAU"$FXS9'*&&W2(]7O7%[*3F/]Z"/Z^NDZRU5:_)D6 M7Z?A3K=#!5Y$J@R)*I2T))I+S8PB6:HH!1S=(Z_Y6+RTQ_"QKR% M*(_Z%+4+,TL:T>?TP?V5:M=B=GQRG?++ARQCK^*211:EM1DDU:;G8[) M,Q4!F)]T?,> +W'G#:]O,]T9_J58!@J $QC;",N)M18(%PERX(*#ZU;I?NCI MP^LCM\_\_:\ON,&FYVF&)*XF5''/C57H,$-&T-$3[Q4C.2)@I4!#]-P"=4^N[]?[>?W+K@J(& MQ T2SKDK@P[=DSE0AB=C24ZB')]02PQ-BOBL-5QO$$[^E[B?_X)6]_V;7D,AKI4#<5L2$C'FLI<3F77HV2R0PA8TQR MX1SVN*>O0F$?D56/H%]^^/#NO^97L1CNG3MHEEC I1$9.)J95 +*,N);A@A< M"'#>=FOC5U)C18:OTFKU_/E$@W,NFO(^X2F.*R+,O#9\XS_ MZ,WU9_R'J!AN%G]+L_GGZ:S\[K_1BJ.$/Z47[BI<7VW__G.WG(;R%Z=7UZL4 M]YX^SYMLOYU!8P\/O2\$>9W0_D(6<]_1 540G8HYQ03@-'@:F"Z=!FBV%O]W M/VH#&84@J#?&2F\1M9"%U MZV?1X65##RY09AN/L$CNF5^N%BZL)M)$Q2UN9"F4K@* @9?Q 0V3T2S3!(Z[ MVFT8#@(9.;"M3>[^&<9P83>X8WVWF.?I^L.9>*Z%Q%B0"(LV#8)$WX,[3A2E M'J1*E.?:>17?WS[^X7<%.N959-G@ANO'M:U6BZF_7I5X[\/\#>ZY&$RCI/ ? M?WQ56C&FY6J"N[0T.G@BT6\A8/ 7&Y0C44DI +=T1VLWON@-\BGH2%MF&M0P M_@CX*QK0#=H=N_H)/=FT6&[M\$1$"HJ62; &R@B:DKW*5"+2!4@,4:MNSE0<+PW]/TXR=4YF=?,5+X6"(&E-?;O&EI^?9ZM5QA2(#[YZUL M&,O,:(-:3LND0L<$L2)SD@5SX!W#/ZU]"=<7XQ-S=)M2U,!;ZHIWH_]*9E_. M:5#A'7YKC(:RB7HBL@F":>VDKAT=]0(X_I[4EN\'*E=_LL;3K*T]OH-Y HIS MQ[@E,6A N-FCJ6::,-Q@P9ELM1])MXY!_#FUJPIA#9SS_?U[H_3 (Z!')XFT MU!%(UA)32K^2\BJ!2EJIVK'<02!/7%>&"[^!C[T/ZL;UYTE'S2+"XH(1D*K< M51A-0A >- *.N;8O?03*3Z85#R&@HMM\PN';) 'H"+@TM))&E,DY#E=N,_6H MLY8!M4S"?M_=WD?6XZ6YM/)NJTORW$DPIUOR),.%I%Z0G$M+GM)!W*08B9-4 M6F NJ^IM3"ZFG5E]NCMW+>LC]G'Z575!]--V+>M%U^G&50^1]4A=RW2@B("B MS4J!H'YS8J7B1 B@QI4*0UF[,N;BNY95)K^/B-MV+;OIN.19@D2=(E%**,VU M,(*6H F7(E)N333FOF8I3ZF551]N3K>RZB/87XW7Z'Z3]'M^K;V M:*=?TY\I7"^F9?3$;%Z.D*^N8TG3^"%'XW!N1K6O >K+>3:9R6UL _=[ ?BV Z:D]15^IV[!LX'(V41PU M$53 -7 ?T1+;$LK2^$-;&>HV73 M2@$-D+0:9_MLK6DG3LP>K:+U(7"ITU,$^HBY04SS^^"&YLPXH3$; -R!=Z/:Q M&+TNEVE5QBV^GCH_O5I_A=N7Q;>S]^7+7&R3;7>:RJ3$DZ0<=TLO2MMYBQ\G M]1B]1J6-U(:%?2?X2#[14"2#C?(_KJ>K;]\WH)=?WTPGCG(!RFEB3"Z.@DW$ M"J,($]IP#UII6[M.\A".D8L&1E6*.W9Z* \-'+:-%&[%\MMT68X 4083&:,3 M*EK"J!($P&3B/5=$L2QS1&OCJ^=:'@7S,VE)'48:>',[$CB$+CD68_%@HD_H M@5B=B&?@"<,XUC*/H8BKG5=S/Z*?26DJ):2*CTT(J_,_0EC9XO(3?LZC/N 1=RL73[8*??]MQ.5\NUJ,#PJ:/E<;H M.-@LB#?LS;\M3 )AZ*76X!W@3Y M'2 VNK[I .\\-SC5J3VF.I5Y.9,*>73]&,L8&D#)-(@)B%/)$9Y]< !24E'[ M\/1LJG/B2N82-*"&9&DPL^$NW1VX-@6)EZPX@V,2AE.:W? M"J<+KO$/8:L3VD%A!K'1(,K?^6AN__>_IFF!+_GT[77ZFJ[6WXW$R( YI0CG M)4Q0,1$3 *.&(%2F5(:PWQFZIM-S#[*?UN^IQ5:#JNV#>G\7[\T8C@Y@1W2" MC@(]NSM4C?$NVU15NL:R=$=!@U I@&5$9"]Q%_= C"^ESTKC]JO 6E/[!.H" M=*N[OW09JM6'I98J]6KVY7JU7$N W;0N%B% ]HY$03D!3D,I@U,$(!NM?&E2 M5_O(^QXXE^$J52+RF,H,9*&EK[0#C6^A&25LLE#*J)%3H3:9APVGCN M>>UYC?? ^=D4Y"$LC+2#B"TTZ07WU'@2I,8E9V.(XT(0 RX(BA&&#K5S7.Z! M\[,IR$-8:.$9WTV&6-M89D+6I8,7@S*(5CE!+$6 2(PQDO*$L4%MY3@,Y2>+ MIRKPT:#)T7I684Z+(H?-F$%<\MN#J31E/O+R\(^VGU*7M32*KVJNXTSA5PT% MF5\8NPTL7]4U>4Z-L#27-C.X2:-3AQ&'I22($$/**?%0.UJ[?$T]%,6( 2XDQHE749#2Y5ZQ8)P5>TEO1]() M3K]K?-_K?$3.V[$P6L^0$\FLMS\^X+',]SR6_Y[-_1()*([+VCO]<4;,)K5U MV2!UN0'(43*96PMW+['9!V6\=PY8C!"L]-8%!2*8'*CG*9]*;&X ]YQYSBX M"YQ&PB5^A* B(T:"0-3$+%C*8;'.K\+[5HAY;FF0?=3UZ:' 1&M+R M\'+G_.7OT]6G.XM9_KB:Y;ZTM]9[_:R)AD0U[IK$!X/NI1")6"T8$6!SEEDI M&9N=B]=J^Y!=J9@KV%_PTY M+UW ;EJ%O9K=E'Q/I!'4<%7.HV4L8S1C2;&F1)82*BX9HZ&9:1AUI;\^HD>G M;R-E?W39.H[L'.^N%^&36R9@=&E#P(0H% JHZ(B@E,7G%(0JG=B:[66 M7U_*!>I,@X/\RNOZTUWAFGCT4G&EB: \E+OO,D-;EG*.*++.5@<<5]Y+DQ%&@ M5''B2L4I.JO9TJ"MHLT289Y8*GDO+7E8*GD?MLZ>YML%[*]4\IJ,#\KW?0A= M9]+<>P!A+C;7RX.#IZ5:=5/+Q5*L/2R,G@@8FHP:9 M2++K&($EXB$GXJQ+7#N,5T/M]CJ/.!&T%Y$]$D'[L-"V[.XV)MA,3UDW #4: M#/J7!&,T59KS48+&/!!>LE_!.^>K]\.[%]!/ZQD-Y*;EZ>KP,XS]Y=VD7G=8 M8&LGJM7BSNYX#56H=K?6%;6AI4%MME"M538LH2W(/A(HTU$]SP%_:Q582"P' M]4O=^_F"CT[;^RC!&9)4;2[5EEH2%*(CP%(DAC(TYGV05LXQ* M$6V*U'C)G3<\$XIQCQ:91\UKMVCI@^^,!N42-/9(C_;ZU#8XK+@/ZX>T^#P) ME*&Q,X%("(8 -898-'RE0I])ES5'7V]$U2N8?JE;.PI;QG=UA;?T>.P+*-.0[QHA;X8A3GW[?MRL9J\=[./:1U> M^Q@H2)&)A8#($QH)'U0B KAPEE.M F&.2DB!D21 HXTK MW=.8E2112L&#S")V2M8]P=P/+QW/]QTD]GD-F54,=]9 W%\[0#Q#3R3P1'SV M: VL9,1P!007Z;WS46I?A;S=ESY"\AXLL\I?WM]3"6U2?/8U+=SMLHS4C',7 M"<^E',8@*@M6$*:9E+C1)+G?V>%!)!Y\^>,C<[@,&UQZ[Q^(E"85:U,1L@.C M;"21:50V"+A*+P5J'%4^V1@8U$[&.H;EER<\;T#:2,JTO2#J@JQ1ZL-Q5.?) M6:C#7@>5&"#Z!N=0]R#,N(DZE25QKC0?39Z7;P']$]P:/7,\9E'[%&ELI3AQ MLS^V3O21^ BZ\&XQ#>E_YJ7J:U.YNS:- FV?SD$3M(\.]TGKB5$AX&]Y=$*[ MJ%SM=,Y.P,8_ *_%Y D%&4Y#@RN2?9#OI\O_>[E(Z=5LE19IN7KO5C>^5 1F M$G!/>%"E(QL:5EO:LJ64&L1'\>O%2XQ09/$O=EAE^40;16G>/HGJSJ5"*D@2N[3FYZ MF[>7>V\7ZZN]K46FS'NP1&<9T'&/BMC T&--EEDSF+U&O&C8'Y%1O,6M#5H M5W 0V*V#?AI:H]CH'ECG"8XJ$=A%+09(OX&MN@^B3\)FI1U)H'$OS-P0FVT@ M(6%4$)6.3-5N^9GRGHQH;\R:BK!C;K)&]F,[>_[6' M)X'A23I.F-(9G2N#_H^0DN3@_D0('2JVH]_JD13Q[1^7 M7[Q;IO_\M_\'4$L#!!0 ( -.(:E4KT.G3P$_U!C-0-X@*!R,Z1 M_;Y _[K(SIPE/W<>,(F2"KBAG@XP_^S9,X"QY\C)@6]#@>]!Y/3G&*Y+J)QG M-+*GX/9EDOPC*>\"S]WJ#F;C413O+8?'X1 7$!22DKXM(RLG MKZJFKJ&II:USW\34S-S"TLK1R=G%U0<6(PMZ7D5ORCPM,=Y/RJCLN\MPR1C$[/!ZEO,PKMI$ MRYL4%)V7Y#68E/0OO5^OE^W!-G(=6:F7+40_56R0&A?5=]]$8F(BCE?;6'VN MH(Q[]]Z#?DVKM_(F/, ]@JR2:IO&"6D,ISUE-,5%.Q#3N$.W$L0VC?F7"OV^ M)"D?ZG*JY3XK2BC)2^+UEU;EU#>VYS;!30(WQ2L?:N4^RWOWDY?3PVGS7D*] MY).\/:IANIH*D93_-LX(K MZPH22\L8]P$7&/=-^H\\F'[W^;7_S\[*. !;A)RV[R6D2?J7!;_[>55^HG\L M[]0\K?X]9?G,O(3B,A<&7@ $HXFDIV7B3F5''P#32Y;*4HKXJV,7DN1-HH\\ MI #G%\N"WVBE/BD#\*#;-.XA"!D$,?"?WG8W]UFQ0=J-AR%_@N'W)=4?,,C$ ML1(P+D7 M*#OR$-@RP=6+^>6HU0.NJAOW31B+!S/0 *B6_AZN6D$&?IV0)]V;A@D &N)_ M(UO+\$]D"WO^Q*)4[CN3D3IY!)/1G7/_:%SQ!T;J8:^AA63J3/?(U)D7\,R$ M=WA+-.Y>.A?-YM*3R]VB/0O#W(V-O$[G'2=P OPY;];S_>)XAF2<'B-]9T(X MV1PD[M][&> U*Y8EZR'\ [>/Y=OHMM:])00)-%O[/)+"_+UCI''H F2J/7CZ MB2Z,>CLCTW_'3GTO5V'>1O.33 :WA)E-N$H'Q6M?R]'NL7*\G,VOF@2^@5^: M?!G3\9J<8\]@2<8Q I4C#__[2=_FNM*X8XZ$)UC);UEYI55&9O#3VWE(OG', M>L?P7%B!]M&GHXHMTPC97R9/-7/?NGQ2;$Z>"._;;LO M%V5@^(I(,LS19RZK77>?#!A=O:S+;7^9B,K*]^-%)G OUN=GDX<%B_L@"A M4&I79U\U0[N^89S3(4BL)!#?=RW[ SW'=VK7:S2:2KX;5L1HW]7*IT<&+?\@;,@\!83Q/H5&OK_@?*:P?VB5"4!' MJM\H!?*?_T^UJ]E"1F/Y!FD"FRIQT8RG/,*T>Y_?*M+O2^#V?7Z=E_[ Y.>Y MCIZ8I/:7YKG(8)+TM'3K=UP;G<[V"Z?W:% GG9*1VFE/17N.W$!4GX9L[ D0 M5:>Q:=AFW&<$1)%CV0\G;4[]>P SO=%*^TTC![+G&;;=YU\L_&J'1)9]8-WRR&AZ>1IH M8IM&-&DBD+&D$6Z5OXQ+=^4&J&Y">ZRH3.Z[+I?1Z>N06T)JN F _\10+62 MCG]V=DI%.F_E)WB* "SL-A2C$OX=B\:2_V8ORY?1IR'HSVO[08]-" AJ>1/! M4TK1WG$XXC4 J'0N_C>E "S']P^62\E1B_Z;>;2SN/X$X]U//DX/P!;6[5/V M_-3*H/F>*N=O]-3B(#:M%CN9P2\O>1 !IZ?R,KTOU/9,LD_H4% M31! 'BK7?W/&WXT"&;W,'@\LK@3>\WN MTF+'O5]7FSI<'M!R"26D'2]"\I8X/,7F73$B[.KU.Q*>5*Z76H_!Z-W@\V,M M?;P\J<-!"C;()+O;/B30S04BC1<4UHH/[JG+P/C;6+5?ELZHW_42A0K[A6*4 M15'3NPI($H@RL!SG,-_S;'SIUOYK&YLZM/ZPEMM"&@\*V2 \#G?)G66 S'E< MA_0W< ER7TJO#PVA&'HW3$>VB'LC+_]E5!XG"N M6JQA!-?#C/%%#:]):.OMY*$=T$B5\&;N"[LS39-@1RXFO$)UYGDT3>1)5;0L M^?MD1ZF*EQOD(J^VPX/9+;Z:RM[%/JW:R3(;9?/-95J;T>/.H)TJ8:]-DS5X MM.;-M$A8G\I48L:TIX_F0 )PY(%UGO0ZBSS MCO'+DKP_\R88X+:75Z]C959)():M=L&Z3]\JO>=XM7PH4C^KK+_E>_!,;*A# MZ0ZO;_@SVMD"FT8T>*<)V:;SC;E^0IK38YU.0SRQ*2,QC[G'FL6* _5R+\4L MK(TV?EBV5K93DR6\ VEK85RN?A?6O-Q>N'9YK*YB>H7 J24DI=SYS?(<7+E[6M$DT#DVU@_))QV*RG0KW>N MN*AB\^'4N%YR!U^=#,A).+]XQW64$(2H)X%6WN3^],D1(H$^5L!/])E-2*#P M>] O20@2Z(3X@@12KV M!=$\N_JI:AS#U!@\\D*1N99>-58DFL 3";"E?8RHZ,)E15A74PU8GY!)8 MZK@H$Y4-=C5I&K-5_M6E3$$<63H[*=IZ%S +[Z8H$?!^B[:D(9=Z M5.0GT^IB (7+E1JXD&]CV3!%H0?X8]3S,)Z0JQ.*^JCYGLS>4HR[L"9F,5+. M3J(IW_EGP1,'B;B$%>3Y%E@DUWE%3F2V6!\7L[20>I/XXY3M)E M,I;/KP@IU[XQ-'N-@/YC^P?TC#^,#OMB1;DQ",%%91$HKYVY5E$W;^U3N]/P MD]%3GO'U6N/&]<"S?VCP0X?JZX7/K@_VL#R;JB[:RM!7/F)0>[AJ ML>XL>+V8%S]_PR7I\^;B9<9P-I@7,9&_L\#S"L,.' 0^> ME) R"]=/^HB;:KS^HO1$&> SKW-.T Y#Q5#:*#QX%0+:+')H#)<(5M2:F66G M%3IW[2D)9/$(VEQ?Z(E0KCXT6^X))H&>'(H?KX>*$![5;>MF2B\L', _&JT; M'<-Z$UL_6H;I>$A>W'!N=:9A_3TOG"*:>\MG#"14A3]XA[V%FJ_ M*X<-]156<+."5R/YV[$&5> 9@>@+O=]T$[)3.+<1(Y%7I:!18/H#T:"SC1AU MO,S#F* DHRY)XC5Z[/1";D-4ASO84^SETE4T5_CW*-/F\:Z1A]'7(/4= K9; M%Z]1&,=V]&EP>H:$I@NE?L"SGT!.JO=\=TK'$'%5[>X^'VZ&$ID5%/R>+&>$ MC>2[)I% '7)0-Z7 D >&%SV>%:WG%7O>T_FFZ2>L\R!'2M+Y(K^;0&+2-_0R M+!A :V:Z(Y<)Z@FAVYP^:DY/$25F^,#4?1Z@-3=8TK5*?-Y>P8Y:H*?N>G)A M* BO\=HKM*_V@=G [$X"S=)O3OU4=R9?TQOAJ9I* 65_H/NXD=(RUK3/&39I MQ@!8<4<*1C=C>U%*]-;@-^=/9H2%;]6^/+C\UHK/1S,7MFTFQ11-EI@)V59[ M(4O.([&(AUYVE\L&!Z..B@P6JO(#=+8UOB?;$F]^[< :X1CGL'!,,1H2[J^; M;:S$V.7V,RLK()[_B4/D L.7P71-\E7H2R3S:* YYBQJ/TZ9.[!!ZW!1UQ E M$W'S4JSMD(BQS:(AAWT5#2KF55*R279)FG(4EWF(^J>Q=AJW'#'T;(3Z!L9# MN@-YM'XN90!2)NF%+Q\ ._A318L649:1EM_%IUSKZIU*VLE.45!LVUBSR^I3 M^ERUO4K1 XFYM\V2:1@5=A$;W+G%.S01.5DW[_"9[N)#@=?HY^8!1C/K=>U4 MVP'BT ZY^J&["^VY_AA.AR?BC&R-CB(;:SQ)"4MO*CT<).@3A3+FS"9E*H^J M-]=M5+HM'DJ5JC*7P]3OVAQLZ6MX/#-,TR.[M77RK#5C$?D;'-'HV#OO\,%1YI9PKKQK2+$RC3=, M$M50G-@R973E4NMZ49!!<_)>XDTV^CYF5#Z=XS+OA#]U08K-( MC/TW"(*B6TFLRTX"O9?HF&?;4RS5P%XA43\>Y#0(IT,*X%(?.#WX-13$LK.( M8TM,E#^*EN8T-_LT'B*=9S?HR3=L6G73R:8V9.AGU:30UVXHW>?M1"> H*RV M4K9S.- ]NQ.1GN5M!H+KKP^39FW?Y);=:$Z<*;=K1/-_'KG\ W-OUM;C65AY M:8]HT;?S@E^+,L'B 1K#XSN5EI/=9@5"94KF0O!!OY&A3[&R Y[K3WY,>C\Z M:>78J8)Q/0OP+#>;]MQT[-N%VY- (+P+-NB#!YRJU;S"PWS.NM6%4]VD8KC@ MNFS";=NNO88+!-\T-!=&&(6)P/'WH,^JM4_OU3-Z>@6)MG6IKW57#=24F=Z9 MO=N'_33G.=;.@#?$YMHCK(?XNY;)0^16 US/_+1WF_.O91X>&P-=UG-">N^W M]5G]@-H;LFJB75?Y8_ 2E=9W4]R;ZP<6+,O/5*L_WK\YNL/[ZSD)]/1#8)RZ MU,:0_^6QBF)=25RS7[-'MZ<5W339KV# GK@ M6/ZJ%!0.X_D)K52/:92)KB,H4PVV!#F_FHL\IEXUT;A"29643KSJF87=QUW' M.JYD[ P6!.:LDT V)-#+(-O"ZZL0OWIB"'\Y9!HVZJXO'@H^2@F+ 81Q*HO7QM!"L4U4W;&(CL:F>) M>!6K6^>YF>KH?6PPR65J,;)R\-&B0MUJM$AF:G]L6FLD'%O^RD]D_E(:8DO; MSJ N]YDW?2H/\3()=%"P!F2$[6^(Z?])-/^3:/ZO2S3-CKI(H.BE:UCS"A+( M+3#8K&W,^U67%&U$JE]7V;&-W^@?S"_4]?(+*T7CRK\5V64560D9!1=7Y7YP MK?* -+KVA)IU5*ZA0SM[D>1=KE[4N2\*[:-6/.-08KW+ET.DT:+#U?G;C?UQVC7_3A^ M--^%(C&3M-RO!Y!7N?6YW88QS8R;F1O1>U45?"20)?F]GH?)B9H_DP)H'9-, M\?0X?2QRM>^/$M12?"4A4;WIE^*\3_5\?\M75NC;;XT\W]!SGX0$3MINVMF9 M^JA4<0T@5;?*+QG.+F=E)"LV[GM:$8.SI[MHY\Q[X>=;E?R+ GVLB$,?VU)' MI"".X5Y[)H)R2:P)3#2T'CZ=T#F%7NC9'1_15C$ +._/"'Y8FNOT7,_ M;@F.JY-=H_K?BO<#*P/&'V]]#_(R-3+MZK0;&PYX";EE+>>^;UVT[[@W@N5/ MC,X;& M%@M5_07A2U2.0CD?K'C-A(+C5A+JUZ7,I17/R4ZF65HN8F:.6VO_$)=].,CX MUH&'O::<3^"7BETV/*V%L#7/TX0UQVD'+J\4YRJ51/IO'LQ;1RM./^]B0F=\ M/A?^I8+L,QL/V^?*24)CN^#+-C.TU]?H4FJ]FCGK+Y_F&RG9)>D<:Y#3E4'Z MS*T?)YR.BYB6\Y5.\'*IT^5"AZBZ-3GO!>[Y0R_;[*DHG YVNBN7^@;**[W^ M.]8[L"A<%US]>3[9N%>E-2],EPN!5'1(C.*J@\6',00:[*NB,/6$W*)EG5\C M%#,K&<'-0A(+/[Y*EA:\F/MD)91-Z26%J)]VU/YN^1 I:TA[ON2F._^%.6.B M:W'-KV>Y#L3>.=HNR!_R3LI*<&QT,:<&3I->OTBZ6U>Z0,(L2<^C5U/N#I/7 MU4_\K,=]F%AL,PG$$2:^K,2W@P1L3"3 M9#NKMB>'3;:Y76)S++VY% Z!K7*(*[NW*;QZR1HL_+;7/CF/E/5)]QK9&K]T M:7*J2BSL64%A/Q@D"&6^X]+FG5XX4.+I@]9/=T.CY14SPV"(\LV*]2M.D1<0 M]9::!4$Z+5'5B-:E&,&[[ZY5GO-15:2Q?MFA.OM@4^-=L(:0\)[VU6ADXAP< M$"N)Y#)1TC"ZMKW$:W%*3;6-B8%QD7K-O1PKI4I!?=+#(?+80H)\QFB!*&"^ MO&R67#OK,W-HR$"F1DIR[HG7EV8#%%\7.2 -=&86:6[W"+_.+[$N+G)E]U.P- MHR0SGTP*!5IY")99WKV];JTSM?@D^#U,#=VW"T&?16B&7^G*G'YE=Z3Y6N/J MPNQ\7ZN&Z@U;1YI')E=;D9F_FH6U[[_,?&S>T.?-?[/3P97R4XS1N[*6G@'! M3^UH+[<#JZH^7U0N)@&=^QEW9="':AL\^VCY2XT!W"G<1R+U <>7.$V*>N? M6XB-:.6K@?E>KFI3-P\6==;>%J7[/:+R86 M^PA^;C+)*J":;%18,\]N6!]?:M1=./2A"YM?9L+K%RL53OU^C875*,[7@HLN[/HVF EOZ5?E.5U9ZI%A MKU;+9'%T[MZ',^\I0: G9ZK=/IB\SY74P84D9,K94<;[5!@5L(ZD:;Y5YQ]H MB!^#"]74S-\Y+8NW_F=O[3][:__K]M8@#7"45R.>01@31&B'V\.9 _L0TUW[ M6%U%S6+LUKY&0PMQ<:)"L45M_& S62E]FOYZ=\I +/H+T=9$&WW!V(2?&4$ M?*P!30#OE$!(H,UR;=@0WK3/X=%;ZG)[(9UW3045UK&XR;<_UE[';<_I;/4! M*T:W-*1:DT#O@V\YW"?J5U$A&_'LY3@!O"&J M/.-*IHA)HVX1&';%KM3J(T MSL:C[5H[QI7N"(6R>:XG8A4@F!QL&DX!;XWE5>;"WT6/_!%!3/N@_411"6;K MGNONG#XC"+T^[4OVYLPS;^7Z'2C*LP_/A$1D[,ZC]A&&+XD"6XF(K.4H_1)] M>YB-4.S@*V_B6+O:VAV:>_/.-OB^8&]^T#0RIRO&S4D<817TW^KG MW6*LMI]&Q$0S,3S5*O1*YM963;"TY(27Y$8MHS1R9R&=< JI9G?YG=S<_40\\&7"5EEI9XAPW)S;O@J""*\+K!Y9F^5?-7A741 M]=DRO?'%\[9,5YW,CB[+,.BR/G2EQGQ+OA7W_H#Y,_XZ8)55GQ$NNH==>^%%^"YWV6._>PTNF.F< >N%9O])PQ\UVMVZ S*V00]:SU M^E_XV+/QL/@$=O_'-O9 M=Z%P- OQDC"A5/%R"U18)1!FB+[U&:'M5-R8=C)2Z:TXYWI0YS&N1;].2 M/=]0-E?1+4C(HN^V=+'>07W"ZSG*,$W?SK#V"YES3>)0TLE(YMH*U M)E*W3E;AE;QNU.-4-^?"/HR^\/5R7"EI;8Q&29;=6NH>OO6.D3U9[O,FY"(P MM*;PE9_DXE'U23-^58U"G0?/EB^ F42@K%* M)-!YM\#Q[K!+]SQKV;CM5KR[X4FO>HR].$5M.3T'>?A1F#/9:R4+F*YPQ"TZ FG;@W(QUNE&,87YVIY MB=;9ZOBS(A:IQS6%_8^MU/BY;B+N3J^+?;["5C-6_OHW6NLHWSQ++4Q3=\3= M1,.ZH#38LRLCT:O?ZBZQJ$5(!7^NGK'H>5B.R_A!?P>V=D2\M$1()7(19[A0 M]PUIL)X(];2JZO?N<[9[M9<3GZQ8;[.("QT_THIZ2W?>7<]Q_\*CS\4H:-E( M'.2G5NM]$NA!,)S <(@/!$;T=MB9$ U",0GD!3N#%5L5BQ%M94$S&F>N(]6G MJL3V1!P_)L^-!9@=$@AEPX7E<]U9*X%VW&KGQ^9J8R&HH]4]^$H;7WT\ MOSD*$^M>8'#3T7F6JDX@W/1-KK#C7O]KKZY=GN-(V/0(5H1KAQ$7&'@6(S*E M:(_^A=Q_&1* ^M5Y9!;OE[]I5;\2_-:E*>;"NRX,56#1S$]A%\WC.WQ!*_A8 M@'J&@(#GQY_N/)4'*O2P+W)\>ZKPC,/?1B[S:?3?VK]S/.7>"7JE6A?B$'B9D?D\4E:#L#B>:8M=:TDY+Z>EG?T32K ?&([ 9E MI7RX02L7,/\*B*.9C;OB(13E'NT7Q@\4E&XNF\'1_A73 >PV[E(UO:)Y#"I, M*8NT?(L%(.XR_;&;AQ0_*OV(U,T3E0=R3N-0MZPK;5J:;]XWH52M/^\GQ LM M*PB,^+*=/(5!&1$REU;76"=ZA.M#F8K@82:[OZI'..#THOEAG*-V:3@;8G_[ M;<(KL-LEZ"JLFU/ZR3)#X+-[-4'&00U'2;*7F+L9'OC$J%U/7:%_)VYF9K0+ M1NE!L#RN/W/ER#B(<\L.OC).^CNV05ALN>9[#46 M=[(RP-K1P^(6(5S3VZ8Q14['L )#SP"XKK=?;^J:LEJ]LEX^W(^'!'HA6G); M(0OS^J7-[DBZ(KF.]\$BH>!=\"Y>^-<1D3(*&(4[6#CPV8!3KD88[BPS!U(9 M-5U.#[LQ>G0L*+A@+/SF'46XF2DO[5O:.SLJ9SL'/OVZ_K6\XB8M79%,C8<1 MO$32/$QKJ>I\F^PO WDN]E%UYL.-:W\=VO@?; =_23]J)ZWL#X!P*O%X*S]Q M*T>U[R^!R$;[I[1BU4HNC*W7!%3'^X[DOXL_XD[18T6<0KRG/8GYL3$ 2DD- M-\D!&2LT;-/:2 )T3KI\]*F(-%3EUMKRB)3/+.Q4 U07_4^%V0^5.KX>HI?RNG&PY'_RH3M7T]K84! MRO'5J5A+30CZIV22 R13>KY!FJCV"#<@O(#7:?ZN=0$NG(JYO0G!WWV^3?FS M,^-36TSZI_).1:3QD=QWQ=-RT]U3\Y)2%OZE^+[^):2-'_3?!U3HV._RD(ZA M(TL3]Y,RQKT)=\#Y%N,C\22!W\KQ^EA1[(G)N].*'W#;J4K+%M*;P?X)QD:2 MP&E]J[3/"C#NQH/^O\6O7N'?2 P#7J4!JO!4(Q\RWZ!U^&>-+N6T1G=_;\+H M5$3:;2A&>P"NQA0EEA8^P/PMS*8- MXH5JU#B1LA&Q3.$!IPM11V:S$.D&K;.L+5J5_#PIQ>]R[!.=,Z#ZB]0LH':D3RY*JTN8E>WZ> M.6BNX 9< ;JR#L<*T?898OGAW3XO&[@N*/J20!?B8=%UBQK(^X8[7H":VQ5C M^BCB*G-/QYQL?N\U3= (,W89IP&\Q@7L03L'[QQW"Y/%]B/*=]DW+6\^?((^ MG^3S-(ZR1B_=M[,FCWR-@QF#@$M\D65\Y=>:$Q[XJ8]R;\)'5)0?8V+\;+'\ MRT$YTLVH7"Q@:2^TF@2B,#G=.I7&&>/-4",=,-!60^9&5#N'S1"TRL,L6:1A MVJHV[CSZH)#.$4.T)X%6DL _/[J&@W>"IL 'IKMA)P!" ? U.A*(DP3: ML26!YE]YX T[NYB[V<+82[ID[\C3L>N*/-HM0=5VLI^K.'J6TX@(OI#D8*QG5+'U<\ W_+)LVG?'I @- M.02\!AJG+/H11=MIR+3=7-EIY?[L9E( -$CA]656AXC%A93/9":YG9]"]+Y\ M9+OA^")(+8C?<_;V8:Q-S61C *PR7G+K5Z5!V+1)&"#6.G+ -34+-H'3^M-26O6Q2H^P[S=]#7HM'9+/&5;K46DX&L^$($R^ ML+$-EY]EHG.KYC0+FC-N2A MB<"#S XN$KA;DH$U%#(F4B[F'(>;1&$:H9 MMQHXFME[12$XV_20=M)J;%6<^\2B*:N-M6+ Y M)X2RU*B,K8195JJJ*EE'?Z]NW% U@SFZ0)Z2/N.6V8^1S64D"SY9C(D$FKD* M6*G6!A7E0GF9XXOA*XV$/O!!5^GTH1@ZEJC-$@/=H0T@@?+MX.F)V-OEQ/L0 ME#41F7MB/^'Y&;5,U%[8(+:!"=QYHV^@5Q-A6XD+7%BY+N*]/K0FL?T 0E"P M,A\$HUP"\%G+O2,X5B"L"3>2VP%]^N(=>(T:R@3=WEYC8OTXK\& M?:$&X5< 4X>AWZOP%"301V7@^8)*ST7H"J!)CR7A,;D8!3'B:^O15ZLAS1EG MNF['@:&"_$,!^+W;MJ(^W3S1I>BJ-,(REN(K'!4(?IX')S2%T2]L-@?K5FTO M,1!'?'@9^98&-U\*-N9YC"52;7EZJ MBPF^=$M/M^7MTUM!OIIE44\[PPV8&)]?/( MZ9MAK&W9UQ%C9,&*C^I>W^6= MX7]0^&&OH]?@_*-GT[3,B')EM@'QHR/V4H)5LNZ>_HE-JXCYE,=@5=0*L04 MWA, /EX7YP:. \;R.93-?%7Q614W2A%.M7]FL)CBFO "E:-XLP2^5T70B%]= MX#;7'->>BN;+*OH*TG?Z><,AR_-LC9O3+/=W M9SOQ8',D!L"8(G,1"S5K_@@GO/$6@544!P=G>29RL:XU)ETTTS0;)S,CIU-A M(V?/Z@*C@FZ4(&V?+NN.PIW+=ZWOM_ ]J*M!CX\H=I_1,M$7J7UT<>7)^;:X MC1?8*&8AYH]!#\7W,BQ,2BHKQL.(6\N7]TYJA61;%;U+C 8(XR00#ZK$>M2[ M5:;2=G/Z6UO][LM]+U\JPH]"#:&!T [R,&:SAG:>P!8B(PGTRFJO#0.M@7IM MR; 0-=^N!RD_C+\Q-'.ENH7M\[ \90]L1!L0J0(22=Q/RU(J[_Y6NL-!M']IHT*G/VN#A?;_M2UH__B9>R%11:3ZQ7E3[=(\6>"?KYI_*NN1O65KW M-O;?FO/H=RGUWUK2^)^2V?CK=ZUL(:MH>9-Z?L5HQZW?\OMWJ?3%^7_NA4Z= M[H6>=@:H\FN;]_FM7CX!L-!=V'B-_GO+VM#WSRUM7?$D/@"$!$ C:K_@^UNW M"BK%V7V//I6W1B6 \[NZ"YUJ!44 'J?;KV*;QK\+QH!V/2W+/BF[]:_]TI0< MM8+3\FC!Z7[NQ-L7_Q"EDDE_(:'[6WP#\I9NT[AOPN2-4O0_2[QZ_8D)1:B7)WT<6\^N$^ -H1/V%;-&;?R); M?T/D3RQ41J[EQPCP_M>Z.MXG/T;XX 7AVF_5^]]5.=?78XZ])59ANSM-:\3Q MV<628#^O-?_C; L]S8]ENZ)^F!8BK1P)E-R"XB)^/H$3$^IA/>P"5>VL_>#J MGP.6/F P'V';ZLAK-\ +EQ1=N>LAGU[?"?]$^P+^4ZM5]+1J84A@2,.#1R$* M?2&7B#4:<:'P&DS(LFLF?HIXX.49E,TJXC,Y_[1MI!W\7S09U#A'&85Y<:JG MV2$Q(G79NG M6.X/I,T8Z8T\H1S84[ 8M,+1=D:GMTD@4"**BB658IH$453A ]K]UQ M='V\T.I-D3I/SGG7>H:XPI2O9]4ZM&?BCJ\/((^/\MO'^5#IZ5?$(^W?((I> MI;*[2WN937L;>]V<"YWC\*_5%/+.EOVY0- !EB<7Z$IE#@?A99@8]L4JK+O2 M2,HG"DY?'+D^;?;I04/SY=(7@[02??W4H[N:K]]IV+]ZS=0"V^?:+0+2>1(( M*P.0^BVL9;$[F/Y &,*PB8FH.O RZ_W1Y>_@9-2TN\C M^1.LR]*%+6;HYU?5/&O=_7*=:7VI\8;$)T3<,(N$R29.**D97)(XF_6[_ 5U MAEZ>Q\9TK>("?1K# FPM4JS'A\F=1&! Y8"[ M-;]N=?C,5_$W1V_6W\R:Y8KDIU?RB=T&X,HHK6:=>QQ56T3%@WN.[3E-5GK M& I@^HR*008U\5=,22!!&!:8W+XC!/$M:50]LXW,*AQC8!O_.=0Q=UMB#<[7 M%#JK@5D/P,*:9R38HNK++OZ<3SLZ74I-(2B_*'Q>(B*1$/H#?O*T#I8.7?FZ M?RP#C\_%2+@#B:<^'Q3\Q,S"A[HMD6;RBW(MU%TY+$R_G5,NJ!X; +>-$NG% M1D RG#TA1#(MY*:;E^Z-P40.[RH;]*VUMA'(@65L"S\9B.K!#4.0R'?:^V2A>O4)O6KXBDZ88([Z5(B,J4FW_ M6JN/[^V9= ==!FWI'V!*J*/A+)1X40D%L9IX4DG; :7&*V.&:"H1E^QVKK2\ M6>9QRL@0&?O(][$ZLM>:LA4!3R\7PPHV[O(5SQ4"/M=Q]6*OQ]GS)/99Y7^@ MO4..9=Z ,!,5L$CD,.P2"900XHR LRW/1UI4^2]:(8TRK\U\,7\[$[?B2O$1 M]B8QHFGQF6^G8ZV@/#U.^.V/!C/OI8RV%D[PW!.'XU7#)7%IG+"MC%U;8W4K M>WPJ"X.FSU-NMX@)^U>6MV6^MCRGH$AZQUZBSHS+'+5 GXD1*/Z?5!7_41;_ M41;_E\HB@\D!K@4>(Q,HZF%]3W[ZYW.&&!NC&)".H*^&P-EJ0BX1C&W$6&%[ M\K DT.?,1@Q+;(C,+1OW1B WB]S>&?XRFK+V-?%*2%77NK'<(J>6J MV]@U7!'5[5R2Q[; MI4YIQQ^^M3]V*U\6+DW_LBKJ@&MP>JLTG$ >X/6$ YO M-P^'6^@ M>NUK7(IXP<; ?UK3!B9 J5RIZ[_.+=Y9+U;IX;D!Q&9^G,E,H?WU0U[;LC=E MW)Q"U/\Z9TCCX<3Q5W&;P^2]K_&11)+([[*V7ISCSS*ZD(F$(-K?9SC?'W^P MZ#%4_7=O0T#@ ?,K^J@L1@ZX#8C0?\4!Q\07V;\.2'"H'D]D_W6.<\+7N%O> MA%4KZ7=!-U_EE\D792N]GCWYWUVV>?Q]2(*"64KUV/C?E6D*:4F:?Y^2N(8H M[M$>X=;ZL\P-S,WWQZ7BCN._9SH?E[3>B[6*KV]^;'G$2!@?%OI]>7T:I'>! M[APS,YK^=6"$3J[LM>^?)R5^O_;/ YWW)8S5Y$W>_#X7^J0T-612B.8?T?H> M4:32)>N_WD"X\^*=Z%*S"E3% '$$Q_$S&O[P3+V-_4LEJ;ZG4;][X.=O*QE M;G(S1NI,%_YKT!(C@$\B&#SY$0AIT'_:_V@[$Q6C>+\XD*M+/J&^TN.VO')\ MP=Q@,!0:_"@=,V6&OAYT(UWSNK&4NLC7;A 9[XJY#,H5DX -PFEL-C;":4." M5D:N6F[65+#X80.L&R9YZI,BU[39*1Y5:%[CX##/ 33>/1)HC0V0*H:$%"X& M()O[L X7!K32!#S.RG4'#6BW8T(Q'EJI$NI?$,C^'1M)O,*KV92Y-*Z?CE"/ MMDW3B^"YKBH9KM5_-O-DH3$2&=LOP?;.Z7ASF-[HQW$FI&SP/AW22NI$:GDA M##$*R0 2K(X%:,V$,GGC9&\*VEOW>*^P,93YB;!AX^<8INBW\3.-/^=]02(] M/^/3C,+#6K&W@)1#'RN,AF,$X(3W3T@@)A+(->3V:+K1A\6MV[N7>M-$'G[X MILNPI^SM%"=4O$OT\%K\Y!I[I?-M+XU0X#LI1.&QZ?B4H?.OS>6\1SW&675. MB?;8#G1Y)[AVX[F/XGUD+L./' ;4VA^FGR;J/;OK&J*SP_,S'I]?=P!Q:E\C MLZE*PGF%7)]2)MM<9NKKAIV;QC/$F@'60 3MT-3E^?2,G%ZO&TV1ZE ME[Y=-@=I+ZIJ;L*I57<[B/=(-@1PU-A#H\,:HJ+J!5<$$+6%RY9;F2X%E#9S=E9Z MM2K^C,\'>;T+RX7/7+CV6J6\_B=%)VP^ !-"B("NI,&IE:\1X"8HS]X6%F=>$STKYJA),"'!\!U^;N@M';71#: M)T/\B/2(#UBX293FV,W#4$HRUR _J7S65"D6R2]Y[TH7OIS9&V0F>W6LA6IW MM30M?YDG=[_X>]8:T79_O;EP,2&W8MS,.+D%K%X*BR"!'HIA9557?':\T$,VC[J#/U1M_%A M'3JIAYS19#P,>JR;/CP7/*?Y?:]B*0YJ630T^+4JM,_&Y2U.(T1IBBAJBSTS MTA=VJ06]^-+%$T:C6FFM76Y]C2Q6J10JK<%FH(,D?S;]:Y($.K\"[3!QQ%+@ MC ,S]+&YOFAP'WM4C_8!A&:S.4[/WZ*NS&I+37*Q7W$+W4F]I7O-+P*:NG+V M2&SGJ(SXI09 M-N.OPZU$:$L-D_\5@WQJ/0-#A(M0]4%0.Q?+X[0,;[]Q2LJ M0);BYD[#',BS66L *D]'5+.&J+Y+D_?V376HV$G;#W)G6LR:/.:80 \4.@K, MFWL93LD+KR;.IQ!IV @ #=ASQ65PT1Y&*SHBH2R;?2XE)5A5@\B#36W]5):6R=2@\&:X[N#!>]*M[X M4E1V8,M\'%#T)R],Y:T,:9ID:&,;G8,RK,1KSP][GL?8(:U MERFNWPZ,U$../_V?'A@P%T/[(:'A1%"@J?_RU4!X)_'BZ%7_>EM5R.2#<2\K M%VHS"9&O9:T1#BQR"H9%_LS'H4"F[4,"#0@?D$"XJW7+!/Y6F&O4XT_KEMG4 MY&L#'[2%JS(DNDV>;#9512V$40%,$AYR#IM2V5,<&( ,Z!2%&F>':[J7!/89 M-.=H*(+H;XAHGYC#S'_IHC>(%W&HLUU@E'= %RQ^U\=K=20^,[VG+EM:L'6$ ML<5C3$5$WWOXWO'3#S^]U8P5$PRE,7UXQG$BE;TC[@*T@X5(A1U!#N5V@R]# M.U7+/7(XO^U+M00'#[;$ZLK9:(S5]W3+J9'EF0URW"7;S,3I+3_G_DA<%GBW M)6UE8N/,E)5ZWZNG>-Q*>?F%G*!CKHRH27I&$^Z<>H@UCA_:$0Q0]LB\#'(D M.N3BRJYA]T42Z (L7S\1'0ICCF3)6&CNA,\0^ M9 ,,&2\=QK;U3?-F5EDG[):'X8W==%1WP5?W?LWS2BVO>W&8EP[*QEA&8+RT MPX9RKQ*E?BA?K!UK%W)KM..?0(Q)+:K>__8 QSS472-B5/KSIG/J^:X5MEJJ5BREPJ[+/O:)-+FSC] N^RIH@N4S?H%RX+NGK,+R#1<:',KCKZ/\X-(MI.(%_62N) M2\UIP%82@G(K_#DG)YZ:C>E+13-)" ;Q/J4L?>^4; @B@V2U2Y! +TI(()?$ MJ!Q9]'24]) "(B&K''N9B-0+A*@U9. < ET#G:S-$M8B)2-JY5YY\;Q#VQ7A M!* =]NUDI]MNRF?QQK%=J,!*+T7I5=S;$.W578=A!7T=6WDM9TMV,2'7^!<" M3P8&*--M=AR&T0^+'[17O^H:ECIHK2QN:-S8#*6)B"GB'V03SC7&7R.\ MQY_#J6QF9+23H>$O%7U<2_0QGDUX<,7\EI'58-SQ8ZF;'=8<*RO3$$@&"83R MUHP%.WM"(Y?9_ UG?VECS;_>N=_HP+8>H?*J]7\W='*C8$.X:[Q =]LTR MR_WX6(1B$(HPQ'-"<:*!M'T9SZ0CX-W++'.66HX9EJ-2LE<,/S^*Z,A!".HX MQ8DG4O"P?:GZZDJ!+'HSU>%R:QVI'G M66)VY/[J@AQ,AI .7OD.GL5A"@COZR"1D-END3X+,V!O$;Q6RYH:52 MFVS21CX<+L\'K')%DD!NP6(O&Z'TBD*YC-(4%@C4&$0D\[5+U(AI8(8HFSCB M#I?WO7(:5L8M?RP+6I5H+MM GUL?TL"E::UA9V8FS,Z2=5\L>?3,;";BQ-2 M.'C<'MO/&%6U);=.A<*9V$IT5@<)1(;G!D@\0=%\%7[>35#HSEQZ M2UE'B95(8F=>NHO)PHPL6W]5.OPV?&4;?*R64$X".6JDD4 %5]M"7H@FV+^] M]WEHUB0Y?EJW5NB04][;,P_#?[KKN0Q2#*W0+'&#<+33>EJ]+"2O_XC.R?:[ ME?Q(/%J"/YG"X' 2'T(H##F+$\$R!68AP'&*2BN5Y_;,AA46'0Y%'7.>FCE' M*G6SO/Z@0&[3,.$7)\ASO("FQ3/^6CD#[:@CTF&W/UA; W2M/C%=7K(E7*;' MAV8J0U#%&M9>MZ;!<.!.T8)(%JH3NU..X0-JPU0B",V]8CAP/5 M$_FVW.-96#13YM-<>37RF)X-[7>"*V\0CWQ[/??WYU\0*8]1CIAS6+\50\; MKGO3_IY(M MU*-RX8("[A6IT!4/?/W,3DELD8"?GZB,\OO\=BI"$G0%L?\<4K^\>[$8+]8X M3N0)I.J5G^B<-ZQ#A\5?>M.:G2JOQLZV?F&/=H!W_M/*V?1[3\%>B5@Q^&<2 M:"8*>9!+57^%]I6R$GHQGV?9W>[2* *>82#*E7E95>1;&52D/.UNCRHU\IV? M,N/P9?XM'UHQ=V]/ZQT22!K3F+W[F%BOF9'[U@+W..:X ,,,+, ?0_B SS]" MN- !\:U\RBWO?Q#/."C>5=1U:@[>O*,V5JO5L:3TX57/*[]&'UE85JL*L&3< M(PXU:S2%8I0HD)=;5KWD#T5N*EJ78%UNCW(GU3:*\77J2))=8VVDDR0K*^AL M:O.8%#] _?0K\7;V@M6$^>1O?[LJE*QCH/.5(%!U%@G>M46U8!ZU?'R!X.K. M!6%I0DVOZ@K@U1%7]$7WF2_0C$9_O[NJ>U-GXTKDLREX!R3^*BLAOYWIAYT, MRJ[:$X:%=#>4!P$CSV <.*RI&EY105GSD;JBHO#,!5@7&*NX3=09^>R#(_?D M.I$?:Y'5C+KL]4Y5N%N&ZA=$_WZ,]U281S>B^NI ;#FGX3*5PI=Z*JV2<(N- M\"<,FKP/V7B-)5GI.\B?2//YP2] OZ<$0H@=ET_/7N7#TM\%.2%G?EB51S 9 M&8O_.Z.M@+R"T..54(D=C4O<:+NV@D#'KA.'J-9):<^9G8I=IH]WG#(U3.Y8 MII[16GN^;VV*SL5S\)! H^P2!+HP2"8(#LWG9>Z@HSK,^K4GC5YYQBV,"0V M$5/[_46&4_!5($&Z*T:DC-HP&?RRS"/YVJ&(.6FSZ])N']V2EG\O]A[SVC MFNK";M'8 $%!0$!J4$!4FE(5D-CH+R J(#4B(DV(] A$1%06@0$I$8$1*5$ MN@(2(12E2I<@) $!*8$=P!!(._&[]YYQOG/O..,[/^Z/>\?[([^R]LY::\YG M/L_<:ZULYC*R"P+8$!^!Q7$D(CJ1 SJ&0,'\BY@F0%=IA48"\U+HZ5=9LPL" MEN%UU1OA.S>>W0^4TQ5GK5T^5@5M XLC?*A"[,,Y]&@[FG$58J M;6]&ZFE^;*&7M0=+(XQ]JW DS#"Q#9L\(\$J,I)<_UZA M?GQ,73M:3O+!UG;4M_GK_:I4 V;Z:1;A_ KT#;@>S!0K)F%7,QAGZ)9SRD__ M])M>!TQ3F6BZZ>*P]I+Z_&C?=^W?14A;R8VA9R(U=][Q/C=&6(>V?2H4D && MBO0DK6W?4"J& Z9"_:!680:G[RX-R Q8^B/0I=[8 0XHA@@$PU8IU.RYL!22 M 4MY-AL_[= A<82PM&VD^KVHKNYC1-X#J+:#2(U*/FCM/>[LMWV*D7J4%2ZZ M W05#F@_@][O":QTZ+9>H*+1&O*IY#H-OJ73J- 'Z8>Z%R)J.O)R3$B)?5,/ MS4#)U-XGFR]G%9YD2;ELN'QS#FD,)_1B[[+KC;OSN%%^)G$G@7UPDGMC7[KC MW\7-&FHP7'"J<_?B8HQ17V@O6'@IR5,'C5F,B,I13#?D9I?>-)R"/QS<":;K M"]$>TE%SKE'_#&MC$G%'M+$"?1^66Q4 7 +YTU!%HYF'X(AEH.@#53X'/COJ MAOCLFVR!^W\"1=NO"BF?=\YQ]J,@<[?6O\N=3$_,R$IF255IS>E19(%-6M#( M RSR.'RSK7!?[6BIMYHR5;S1O[0[]$1*7UK=6LQ+03/)\^_!-1,4&Q)LRH"4 MA:8*D,<_\>#(!3XVF9JGS>73K.4D/1YH!Q61,^,CA9]?AKS@%C41,&8>M W% MD,2BMC+] J2_RKGGC_0$ZKWY18CTS;5:W?VM:HSR,AY++5OA347Y:L2C#AE) M_F;K4#4Z;/;2H]IFCF^@:NHI-F[U=2,Z$/V3N> 3"^;[;^RDJ9@U'ULS5M7D M\2L!-- AD$0YX0]4WOC02N4.)\%R"8SG.Y_LM&F"FVFZ7K?JO>*JR_/F,@ZS M8*:$,MNND(7&K5ER0*/V-)P9BL2-WXVGZX\X()IJ&3LEO;G6[5CIDV]S.2;^ MC?:W*,-#K:U-DL,=G\9H8;]S_J0"_OOA[GNPWN[NZ1?>^2 ST0_&'"$[!@[<*6 (:*CP1(9 MF\PF9RE+6 HI>UXP@429):;/)V5[O!_&D4IQM5G-;TU]/*ED*<0";7*NH*HMO!M M#V.JEF\0P;+,,/*NU2'?F([@@,S4$_?NSG^X,)4*H^G1*^S]<:N1=BO(Y5=Y65NXRI9_LC/8^Y'?W01894B9 M*7KS%SF%D18['33I[VU0ZYA7YS23Q>R'\JWX A,TWS;VRA1%?2IQ1YEJJ<8"A62M_$LQ6!@IKIY4CHLZW0FL(9792J MB$?6K8%9HQM3GS_J_"*"4:1Y].0B*:$3*DR_:3V"/,DTSVY;N%SEBQ3\3FX= MT<:IM9L-6ZEU.!H'UWV-R5"(OR"9BU#+LQ%5E3F[04LSK_?/F&S]/P4&;9"5 M\/MB$.I8JR%=F@8'^J0FT$POLLT^[PD'2\_#'-#3T*AH38)?O&EHW+V"L7_B M%-(>QZ8+IYX]'(2J3J!4 ^LT!OVX#W4?N;!!)X5_]GY]@6(R/K3LI_P!RN+3 M39E'FODA9WIZ+#XH;RZRA0[]QTYW,+LG-(&=6^_;@CZ>I7&^],4LUJK'!6OE M\"VQ/I1?O2(48O9GD( F8^*-A"?I'- ->A+)%?(E,G6P!IZ^"*U/,FN:,;-1 M7RHYTC#+=\PC7?#,!0[(=SUNG,ASG(Y6YE9"W< &F?FQY?K,\3HIU8=B]EMV^GM1ZE#Y'^FUH3,** MTJ.ZY,!-X:FR-M=&W4=5%^[=K2K7_N>KQ0?Y1W#Y6%^4;ZFW@B_VSCWJ\R.]6GLW8(N+,I"M\[TPDDR\==36.,*DZ+^ZNN[B MU04C&) 75^??3+HQKU 78PUYO=Y9?'>RF54+F+),73:6SE'PF=YW5N:Y9J!K M 5*3R[IYW(8_Z@ 'M'K_,[GEMW(Z B=_LU4^M'Y,0QL?/%K1@?G'X=W$ MYDUNW#JP8MA[V0-@P%QH,FD6&SN7U(Z2-/1\10_;8!.(MW+-=<8^#B.'@N%W MPF&G*L@V.<>,>RE=%G-;420(4T*C'5R=S13UH(6.MEZTF8L.GU5&(\ZH4_Q# M/I\B0I>_7ST=KY*0-JF@H7CWI%+)3.>VW">(5=Y#98:.JKWUHD-A4%GO*8)# MRMI8GK7^Q4BDRVAUZV:*LXH*<91U_G4KF)6 (Y$T8L"-T.YZNGN),WR]3>X" MIM_92J63\(_]#;=O(MGIBN>L-)_M+=?M/F-V,[E0Y06=*Z:\Y]@#T+U&1@A3 M>NALK\W3)J-Z@.!7;O!LRK0Q=^)VT^.0)U.$8VN2O0T+H5J*YC5Z/WO"RA$$ MLLS\!-PN'J-O8=_0$/!MI_R/J>GXVXW-8!5P48@#28\I1H?1_\/"/,]66?$K5HLOZ?HY]M&V-G/&%_I_=F_+74YK#>XR^_?W+ M.53;@U;I'UPPE:$=N^CX5F552"WJ,5.K%/YJ\,W4P?IG]QI3OUO==5H4-?&, MFPI)$29<[K)6F>A\R.-U5:T,'1AP,R\VKCYI8=XA?$5-S>/4W+N>X@3/*+;R M4IS83O1[5-L4!U33A2%7"K(OZLUV4@:J9*9]OGOKMB\:3ZET'6B+*GVZ9BPA[2F"1HTJ M2,(OYHSA_;."_.<&OCNU//#B7SQF;5/A7B87$=0]'=E;LQEML*4;?^;%>J]2 MT=9AL9U^H)9R$'*WRWS#7^/@>PGL#.G!=LVXF%9^73+\W%PLF=\MF&&#[VZK"A!M!$Z[9IR;,='CHY MMO!YD]W7\+ $J[#.,,2MB&ON%7FX3W@ <9 #BLUA[T6$TAM)7$Z5Q1EIP>^N M=S>E-&2_I_KE0=?+VB0V"0,[M=VDO J9B,)7074P! ;8\LFVDICMD MN>&S*[ 2$K*=5?9##L)J-!)FJM$G7S/U)MC'Z0Y6W#+DJ=?C*1M@DZCBJR=T MH4/AFTM-PD4!D%!E9";*$ ,X8I)WA5:YM3*O!GQ?=^'IC[DC^%9AF* O(7GH MRHC9\ZN;K:/7+64$0=AAW(]PMN"9OX__83""R 17BGE3F!=GK6[U-=E2Q?,. MU#=4#)5?,"L\/8\_:N\ILE\Y@+?O"L9+E_3 [A!.Z.6=(OWG!4HW @BFO=;/ M_.@Y-[HZ1S,OU.6&F4XT_6\]N*S%?AO\47N3E7:?2WH&PJ(>L(DSTB @(I.N M3V!NMHPIU1M)659V4T:S0J25RZ_['QNBN0]J1);G8&5NN O ME7GQJ]7,:9W^R9.LF4&VS-M94G%DBIH3Q.(W-AM"*L MS4><^OFF]&B+A@R MK?3]$@$3_]JYX*;I!"5]8'>8YZOH\QIS:=.TQ]\4#IR?3DYF;LYIT/63: ' M>E)HN:S")7K;W$7I2R^-(V8O\N*?6Y9T"8@)NCF__,47EGXP.4!6R\U?_>C MF8EW(HPXKO:3 M+47U?/GY0U3Y_<:<8E6'!9-?,N]H%R]S$U G/-3'^L7TF<3AI%J;D/'?D]IC MWVV-Q5ZV_SV7]K_X"'$KD\=%'%"/%@?DC6&<-%+B@$;L^I%:J+8#J'E>5".: ME;C;S7ZIOK+=/8O&6XG.F7+[ C?H:( 2W&2H]W."BWT;"D.>L]X/SYZ,]][N MZEEJTG/_=.SLP&7>7"KZ$0:P6']$K)7XLBZ'T ,@,9!J0PFJ[KB?AL@2<.WR9!?/)2C/RD9Q\^JA8V0.TU@PLL@JV4_*Z8 M-R\7;(W8Y)Y?<9_7?_]Z\F3K)M6/S49BU] 3]J1,C!C[HO^N$1DGY8%U0;%JD:+6\=0H=X>Q-=-KI[5+ER M1A$+YX!J:6_JN?;4'_O;@;3(%"DC*7\1FASIPAUL42)!5C%<@3G"'*2;A6 I MGTU0%"%-):YAB5;#6\EYV(&;0Y?2!G5* 6GVP7> (QU_SI;RI!6<"C?2!^'I"N532":?&EPM@7*+L0 M/!%W*Q=ZZ&Z&S4Q8I(]?9?T%<5/*W0\4MSO\+1JS M@X)H\ S*ZW(XN=F$]WKBA@!1?R/JZ8N E-O%'], <"1%6:>'/Z<*8:;P\*3.RPX''O]@NYRY/7CV_,SO.EZ% M]2O7YU0*2A*W(!*HMA,X+XPL^RM;@B[ZGFG$<&C''EB&5?PF@&EK)1B/YK"F M^QD4@8?JX).T7Y0(253$R+S+>>J:^>7AV]YC/G==(X)/06]_TZY46QO#+JQ_ MA]I6JFPZD^=7V*9D+%,\ ^]VZB.7B<;(-JD6'\/"0W4 HB'[4,X&"9<^T_]Z M\_PRU51]P&;W4Z079E(H'M-(7'6>A29 ]FWY:W1B^+$>HQIUGR%?C,!FQT=U M9,'7GWO:S?3!7J+B8N$KW:6<:4; 7L,]XS-8;>/;*R]WWT?O)(],*Q QG4O%/L8!5Z"36K0H>H['G) 0FK( MO^7R&Y?2^8+.M5+4N]*2WU/#9K--A69I8Q]NO7]]#74:$G7' _WZ L\>R/- MI*-:)7$#0M?NNOWW>%,V,Q"NHS1^!W;(53ORLQ0M5C30'[JV=F0=8SXQ4X E=. $CL!,W\-U./[9T-?%S-:&9*<8M M..:>I_S*>16G]_YY]8D#H#-D>!6!Z9F&5\9FD]X.B)1;"]/= [P_.V/T#+'# MC!"+U;@G%_F&(8""J>S;FQTO=;I%2'MZ0\%UR@S*QES& ;_"G'7-QUG MBS#ECO$**\OP)G59XUDCF*_N+<)'\&W3,-'1-YQF&UWON?ED849R>.^,5U\P M6+G*[P.0P!3E)7EQ_8(?8QWMY!##[J5ZW,B:C2H(9WA=1YU;?(H_S3"P]N_Z M_4W&Y-SHG4VG![COA' M52W.:3"/Q,Z&<].')XJNBJ8G+>L@J8YCV-=MJ M]PE+W9(>S=A\W7!P.OXG=\+W)T&>8H"'>MT8,<29IYU 60]U?ZM_A9M=AJ.+ M[[F\:Y?.VX5?IY:YIC6 "(&[4PQG;DVFB/*RF2KKLH4GS:+;60H=2/E$G2?+ M#V=GU4;4Y9?M%T!D$TN??TIB$T?3I'HRCB(M&XG1'4C^XK4DU M/6*D\W[%\/2WY(,G'0NW]X1(T&JR M.SM<-H"983&PFUK(4^)YE#"?!.O[^V+:>^#?%AJ$^]?%[)O*9(ONO?XDFO9*9*.=V/ NZ&8395N& UN[B;D+NH>E* M-E]L?CBP1=!T.^0^#NB),UO4\MJ'<=1L^%MB=,U18CUJ.$!Q$GUNQZJLL(5_ MB)4$(>5B#D!(A6 @G0-J+P2@S!-@()N5S8"R3V[O)A#8_8L18.H?PV9=UFO8 MIT:#G0$>L#!UC?=L6U+6I?>G<6T+]C@^&!]QS"_J[*N>E)!5E-1ZA,^ MR)/G$P-*3U\QJ-W0X&8];N#,(0U<6ICMD)FUX"87\(3:[3$$#":B4 NTI'D=04& +M1M+/R",51F,Z M$Y-#OR)N1V08?)T,]]@\MY+Z4JR3/8D";#!/(,!UZ&'O)M/.=3XN&LYE\,CY M=6TZJA[VP&A0I:K+?[SV6G_F,;S(Q?*5A\QH>Q?C0R.R%P:>*%\PT7'-._C8:&7W^_B'H^@'$WV,'371MB.\Z72D[T7#/ M._:4W'ZZ'HD[X3F&-B0K6)N^X48GX^LOR\&&P>##O>6K3\O?23M=?,2L9XG1 ME;](F>)Q";NF<75)2@W?0]2,9,_T#!6\N5U9E'(W57/ \>7^ZYH=&:GF.ALH M-(1$A/U8GS5-5::*EP&6QE86L[;:2>[OE_5#RW6#,;7./TU!WY;WWMGN#[GW M,]PD5:X5++X884>KSHW33[?QT[EII5:2T105\?[CR5^E OY^KMBO3 NN$A0@ M!^TA/-S,D [=ZV]TC'D;E8(YJ&TC1\\5P!YI>V55/.4,[TW".)3IMTD02@,AH0-0PUQ'OG7B(>X MII9LUY67"U<>(@9QSP6#W50 #)M/C:' %*&C?68'A1 20RL7ND<+"+YURBEIQ&SZ:AS$/Z^H-2ZU E2=/TS45_!K>$ MN8&[W5D.M;IRS*)NL5_ -WU\U[EZ)PW L1W.?_J[=%SV=^FX$\(^6,T!J=QA M[W M0C MO."5:S>C.CFL$P9-!42+]7U%F]M-XH?HL]/$3F"EE7VM^X"M]EJK.BR- M3N&&(8,.,:MWBTUZ#\A*)4EZAR^N';'T:GG%_SQP'%MSYA)>?-[ MKGA>0;QA[CR$%)LU-(DDH!I*SG:E795X9&B1UI4H9FN\\0@D SJ G&0/X !+ M;B&*J0FG')B%)2)! (3&BS;T.#PJU57&JGWK&EVM'N#1E!^A-0"\67J=TGK- MQ?_+%T4IR%X4*0-:RP&M#LZAI.'H-J,][,YQY(D?KCZ%QS^R?XY6H>K4UNYM MGK2J=='O_K33YVZV>JF2.B-_1Z7%0=7+MV[IBI[MT$AX^'9#M!I*^UG\WI*( M4"==]B8PPN:;(F-$X=ULOD\,^-*,<.+"G#/&;)N01!Y+\0;' M^*%O P83HQC@P2 ECJ&+.,+E<3"]]QIU/:E5CF[9N<^EN8DJ(W?\X^.9:*=O MV5.D%^!8S6&:CI[N/O9']AC)PE: M_>C" NS#LE,\QD\Q+DG$OW)-(3;=VJ0/;*'E=J$G^+3'6?K3L90S(W%F']]N MSIQ-=DH/JJ]KJ@W[&0+8^6Q8Z#99^34L=G/]G_T@72W@&4.%>9$N0,9-EN,Q M@JWXN0*U4.@A>O:M[^S^4OK=+WW^=W7#!M*>2@<9S7[=[XUYN'8 R--?-4"C$8V-+_RR0K3U;_% 4V)@%='Q7&*A3>.PLZU M!B^Z/YJ*82Q1I]@'+S#TD<,H?J8:"2O!5 ;&UN-;1 \V?/=_P*3HU+U]&>\] MFS4VEVF7<_7L='R L^+"1QM!;D+="[D'Y5MABXV%X&(CPS#OX.K+!I0SRT2G MT;G<"W.9]TTSXP8"^)O>R84Q]Z3FW_QZ?D*^U[N47^=BZ?N3.^[*ZO=WG/-\ M+7KAG8HS35-V4%ZWXK%R'^(&1*OU%*IG49Q(DQB!_!%IQ!(M +6;[(,H0,N) M59M->_()@.10HT\F!F(YH ?+^X1D7T\6,6 MNU]B?E-63#=73/?[(T3S9>6VB#+D$:)#2%F$_A"*+ ? $EJXPTS\BPGV.?B_)HY0^&U HM*VKAN:=_[H_&K:[8]]X!*_9.9K_ 7AWFIM< MC1OO9>X$9')=J%;V\FGWZ?.*)>.+Y'"F6&V;/N0)5T6G83_&ZCZK6(_DKBV, M;X0U-)@ECPR^Z=NTZ+S4VPQR1*M>&@ATZV0XH=K<#!T8XL@>8K5>.RK!2>]Q M!=-_%O6$+3XFT25WNLXY"29X-=CG\&MM@_@?4R'JPU^G'K_&?@U.VXVEHMD' M;P*B<]P1+Y&P3V;4 #"M$<\!)11"F0H$!]I,,2\-E2UZ!=.:2+Z?(5PK-&,0 M^FTQ%TN=8!\\SM!G#W- @AA$E&:J3FBTR] [LKF>4;^,K']W'4IZWI7FFF M^FQ.@.S>KA;#E'3-('/ET>*NR8MFMJ7H8OVT.*=:WUX?8K:UOU/KN\F(6N78 MBKR'/JY*V^ GD#JUA<:_"^7\[$&_65A*$V_WH,@4'==6[=NJ.!0R92"@$M%5 M+JQKEE72-6-V1B^C90T/,AGZLTXI8HC0_5RX"H=!7*)7,G38$T;[Z8[4.?./ M852A!$/;H*RTJ9_U3:JM+C4J!T^$@IJ.W3?VZ!4\<=/EU^?34'6.QF"U"M MXP"4]3"W!PG;81.[2I2&VG]XA]CE:!( MB9":18H_E6>S$VE O_K:U^W$:.GFNL8J%A;R#G;OXKT7!"N)EXO-1N9K5B$. M<\PFN[=-UB4>_-9YK.F3I1'*7M;,_$JUC)0FGZ94GM=)G_,"&+C!*,P+L""* M] 9Z#$(JA0(6N"GI+Y$SL>05G"S\ZK7JL:H66W+4_B=^#<^BCK0XQPBM_0KV M@UUP%.4?6FM_],F0ERFR0OK.*L>1LMQ. 3QEC =P41+Q$:Y._1X5$J.#V_][ MLU=B72%-PVCJ8I^>.K;F1%6)OS=MW\;$>L)J/4,$<8J5B 1/PZ'D\)@M&-_O MQHV(QC3G\EZES0.$0YL6@ZHEZI=F^A]9Z^<"6#E46RNQFMB!EK&95;,A927F M9G:\]A''VXV&K-@_6(3<;_R8NB=C='_;>NZMCXS3C[$)^*%,J:!W4L\#XR[4 MC=Z"-M^<3IU(2FIQ'K'JCGF_XZD<[G?1B9D(!BZAGL@)T*7_XZQS IXHA%3O MII:UA[4JCJ:\^2P>JYLBH_9Y?\.W0U6K/34)@?+^V(7YH+,VBV"F'!<[)2^2 M'NNQ#IHEZP/]R+T%(WK :K%D?*YH#V04A%^@VQT534%V[:R7:%WY5\-0+F^M /#$T+VY)C M]87RDZ=PV&1^]]=_?HJDR!Z&?-V5?)U.[V6U9J-W >FRM M2C*K".(UR(<<@_#\&4Q@7QR&-"(49LW294WPE)M.K"*1:YFF.0(E20G&$!7! METMI;EE6R?&B9XN2WN:E7.BRGB)H6DWYAVB52^@')2ZCVS!T^3+F$4L2EGD4 M1C-&/>. A'5LGH()#4CEYF'!O-+E,%H3 L"+-5M]Z&L_9.A*%".1P%)\+O..Z%Z->SO3:W]'8F)ZPLNO8KY3[][ MA/&_TY"MSX#3L3^E&,E>8+O.P .&T3[]Y");Z[-A3>8N][ MM?>S\NPB4ZRMJDDT]\PQ0/SSC$PFF MC1>#)ST/:_$PK@RH2^?,G_?AV]E]> [<@:(K":UN4\-I@4!9.TP$H3,2BMH+ M%]<2C_&X^&>1H)T9<-LX3$E"(8QG?8;Y0W+@0*1*JF9BSU'JJ-<- >$;Y4Y^ MDJ>#L$GV>0[./GXYT1;OFV/--TJWP8-HIKA#AY$&%4RQ ]Q@3\%UO+&M%^$= M2PW#Q&]_=]H2NO$"2L27699*58;K+8--E\"'C*[S#?[68![MI1T''#I1]#-K M6*HT"4>Y^?;WW8$+YZ[\4ZOV/?W.(;]ZS_L' MLP@\M,%@Q@WN/,M"[J.G3+LSX,6SD/9H(6>J[#BQ;CELPB'2=8QLQ_?&1TWI M6>EQNUL2JI>NZ^]QM:-SD0["FPHN7]$NNB$XNN1D$9146X8TE58.+?Y<']FH MLN_FS$)MLTWX"%=P]8^!9ASSNWNECM: MDZ@[45;/TW%I^-+^FSF(U2E+J3>@NSQ\4YNFS".,+WH-TU@_\WLVF49XT/!-UJ9S^1;4X*J2K:P:<.%-U3+L%=0E: MH[%Z$ BG"0(46@Z0_242$OMJ3%**=EO*.:EY.N>'TL><&9^]:P]X@O;@&N@%"$J_W:GVVFZUNO!*E\MGL?JGYJE M9>?:?72P46KY\:,KC"1R&5O K5LVB#NZN,<<$$W+C0-:.C.Q/+A*9IQFGF<] M;^%#Z "#;4T2C[<<,@:SB%8-PGDY9R7Z,GV^5+P3)%E MHD*APV+^T;S(JP6,EF;3++VMQOX"L;/#<)B'M/)F P<4L?-WU?<;!Y3IA?-8 M9Z1S0'_$/F.'P?3C*.9K Q*$E<3]OOA>%1=]INA-4AE%B:%%AY"V4Q 2K%I@ M\0OD+KMM&%*_3F&WT0P<:AM8S)LEPP\>F]K,F$W59O6"_(:1!YB" &YU#$!? M!I0?U^%6H?ST^S\*S\\^4-=02G6VUKQI M5W:#HA+40W.>V5TI;>FV/'S*GH;V4PQ]86N,.$?X[T^RN 03MV';VE$Y('9' M"M>*7JN/UG 9[(+&LF59KY!B\-@V(_417'W+N=D\2>WI&[T4D39:>03/A(WF M24<)A:8/"M55/QM%98PTLTY$7;$-F)K4_OI.XM3YJK+-MK^.&=5V!,EUAFTV MK?OIS5T8X3\P.6-1M&]@WVUL66](#IX_.R\'UHZ!"$ MKJ:QF@(P:">X01_9J@;G)9'3 M?>6XZV??@QB6-&Y>1G(ELPW"%'U/#R>#XR!DD:'ZYG6*RA2*8M#+ >G/]=[> M7ON490]-.^IN)A/2'T*LPZZ.D3 $+L$*ZX&56?4D#NB@4"SBZB^4MP_7X12. M4.3^H?XT9OR057*MZ91&5&@U\LH_1V[KS2U__+E;J'LSK[V]XN0KRNLD*T9C M_5;81-5OY3A2H%L,L,GF#X_@UA13W('#70FSXX*A.Y&EJ5?FL M0+1:_8I-O0_!O'$<^\LO"ZV >.^ZWR-HPU+D2B9L'$(/M?EB0_? TJ]#@!@. MJ+.$ >7>Y@.JX0_XSPR*H!==3 %[O,BZN<$ U]Q, M70Z(7)6# O!XK<'@DB4)A\9@\S>]VK56JFFNVF_F90LC4LGJ#^=-CH(NZK>$ MOI@5+4LJO= V6^I::<3+>[15XYEN':'G9Y?? 7O]SI(=_TU((8RN;M.!DF': M >@O!5&S-A1>$B:9K3&A'=5O[R^$U_=,JF*G^?FA5Y)JM$-$( "SZ@F)NSN$;E,[[W3U84"6\42]9Y.Z MR; 4R36B[^7ON)Y]7R47/H-I^=QT>179SP$UZ+[S05$ER/;/L+YA]M6.IF]- M@T/=(X&.(@]S=;725,>];T&P^U^.+;GJ,"_UJL65Q=%>S)G;6;T/2?4FM?]-Y4K*'Q-3RI3=_^[8Q2G?!/TS,[C1M=WWZM9;HI M_5;Z&36W>X"%YM(Y'[P?=0>N(T8W![;-@&1"C6IXMH_J=G;V*4&RM(N+N6+I MGL4 UJ>V;K$V]A 1N :;]*+5T#.B9KG9!G%\J!XLXGM#$@NK"!6@**W?@T2: M&Y=05=/E2G^(*Z?[\2/",]KAN4=/Z8>\?Q_F>_373M'$9/]'QRUS1D/3V.\9 M_EK; =?%A2J\VZSD2F=S15J+58ZB3Y5A-!FO=8>1-O[OUWR>W=8#S_XAN = M?EIVHE^F*Z*X:3-M-.!9(G:R.MU&IHPI)\D!G1H$(*P7*T(L'=^QW>,,#607 M5 !R=Y#WIS=4P/#P*[J&=4MH^NKMJXR5\>M7ZD;.^7B>.0AJUM63"=5QH.%9 M"6P)-A%Z:!4A2_7#@X$L>+#5Z-RX?R6D+F#5L+DNT?N&%6VX8U%X\!3A-K8_ M_]Y>(]_LHT,N-H?6:O-))7G^EZT(I_WE;D.M"_3\EW?=)%G./\J5-QMW,,\A MC6#F^\M ,(O"-1(67A5@*0ZHYR6;JW8?6C"[6=,3*]NI*%(N=#];D?UU%_*E MP*\-ZD^W>W7,*CZ!58T"I_VJU48M'3S_\8&XQZ99<&'P];]''378/+Z0ZA3, MZK9>S#93_L/+09X85NU;(;7^J1E16AJ$8+-[+9792P2'['&;EKOPY4JF?H!H M2R#F=J1&K*N11I)KP^99^)F4QE @B#F8CR)-V.Q">L=&M^3< MWL^"K0)/M?CAJX/"*:]S4\Q[+!B3S2M^*YL&OR^WY]_9E7^=J-*M\U]^R=C? M8].QO:A?!/9?O](?Q0&5E$-K[>; #5"FZ"+7R!R5P#NIIU&CVB% UM*,W*>H M?B,PQ7E*J+9GI3HOM&)(R]/D; ?:=]?ZR,"I>4^D_4TFQM5\PK+= M%HW47[P?#IEKANAS)Q\'/""NCLU!)P?)O)TP,;0<''>+&OYD"RKJMB15B.7W M40D.]CK<][2Z;?^-EXU?+YEFME[?HYQ/_+M8BVJ[W>+(T&+/0 ]!O&"QD5 \ M>N_*=MAN=!Y\KJ,IQ I&_@KSW%!(_"$\CX?)^+XQ.1X#/F5;J_S'E!R.MQ(E MX? 00;H!WAXZV2H#%.;X%_O8%X9D1&<-SRC%']O^VK?>H&W[Z4=UE[ER+G5P M2I1]T L0H.U.A% <9@?Q*5J=3@V9H/H&G$2V4S2A7?+EM1&G7M$6]X*G]G=? MU1[AL8IZ&7"V[%E_H<;%Q4KCX(W.R0VB5P\AJ=$NRJBQ.OE#JO:G4Y,7U9&B M"*.6SY^Y4YZ'E)&].97[ M\LF'3-?/0.HB@B$#DQ%VDQ^_G3^V:L2-FK:S2![$<5:%#B;52!: T%"=X".] MX49%E:@'RR*LHK54+XA7!.' 3U3SL>X'#B,>AB9?SENY%]OJ<>TOX@/ZSV.)R_"]K2P3&N,8,!:">1KN,4#6F?4046G]8+\2-4@*R\ M2H(/(=E!Z_?V:19&]&J@U#EO%\,;51.@#&F/4F0.^SNQ-CP&Y2<4-U$H0$\B M6_J5TM:C'++E$\_SBH2=GORUFN!T'>ME\Y0Q-I@S]W-QZ0JLT MW5N;R(>XGCJL(?I#Z(AO38&M_ST?M;;,-:?;-(-S7,LU+QDD\9F6LCUA,-VV'-#B.1+QV;TE_X^ZB GT-Y# 5>.W)G M]!4')!'ZLBY%\Z+;=J<]-A#1\%;=ZS36)ZW(Y]Q'BHFGI"&/_$,K.(JB3(8) M+V, __55XOO;I7V%$L.M\GXKY7S?ZP)=+%7;QTV[+^W]>4HY^2OO#2T6[V\. MZ.\N'X+0:N![)J@.4,X$T$Y-SE/3O P_6YB^Y\?$7WJ$?Q;(J.A#5G$OA+*/ MM-M78L[GX0G)M;Y9(Q'#.?=^!A2:PF9D M\6H;S_GG]H$O6W94R$KV5)P>L)HMN%?0RBMHZ;8V["I6N7!G8ZG^_@0>5K"& M/,-T9&4:*C'N_MUYS1;W@XKA2*\A0G?HH62UDS-6HE>XX/N77GT+#[KL)P.[ MZ@+8) ?G!CJXV!*>+GDM M/+>U+,(G/;B_;D)C#WCU17=]I WE(#=_E[(P') O[&FA$-4AA2U+6(Z<>*1* MV>* A,S]WT-]OB^%T39RW)_)-^2>#RLNW'.UB_?2 4.]I_!#1KJ9WCTE[_ $ M[<\%QX(^5:H6^34SK7I=*0_A!WL.&[A.E4=%%N[CEDG1K%C(_?,04D&3*1XJ MMM(JQ2I$R!N:WBV4'EL-F;>\K1/2V&1FW'Y*[J&WU$J4V7*$E^9>3=2%%DM& M%"*:*W.GX8-DB4=_H(D8/I2OS9..R^HQI3YO#EMO_E/7X#W[U/B$1@'LE.G> MGSE*-L_CR(Y^V^&T#-:+5AGV#Z@0BBQ&SR-11+LB^?O4[S:,WIGQ?\/?H_2L M2^ZT;JWZEN<#K4.D7 3@P*NP";U:#!ZAOOL^D&$]!"EY7*I=:.N@]YN8='[ MRI*>H'13V9\;755E!VZKWWIT>3\_0(]*JF$:'2#7>NI_^V1D>LQ"S_?;NX8R MWNGR/(?VT1<[[QPC5G8>#/:BZ&=@<5O$OR(R"N7;JO2PJ1D+:6:9ME>[3$ZW MUUX.BNNR'8JQO_E3./8F>RS7LS6; ^)%P(^K59(;3<;JQ%6.NN^!3)X[1(H" M0?9 L1@1'.DE9)^1!G)<2J\;+ P',Z[.HA-*ZS VX[B&4+[6 5K967!MR5EDS4?Y_]Y78J)&>7A5FZ ^H#?SX M(M,5//IKTY4>L>9=TZ/%8>PXX"*]TUGI5]N\W;"]2'_-2S&*:;RU^/;,Y**TP$!?&/5W/C(\8,3G(SQ=5^B3.N$X2E$+SJ?"Q'K: M>1D&YU+/)6YP0+/'/<<"ZY7=M&B"VG-?YZQ?Y[NC4LS+S1M+7F]M:N_&&>\O M#O!W71O#_EC"D9+ #=';E'FN)/P!4.A0#0$?Y!&2I;#(]\[OG0:/ELYM5,X]_865 M>:%,Q=J<;B,'ZA08NL(\I=UH01-6JI4LA<7SQ;I]-4Q%OWFX7F)>NC6_K[@] M+)=R,==B!FDZ%>*PT,@\S^C";4&\P=NSD1!R]XP.E]>,2QP03G1B"%4^J<$Z ME,T6R-[!'&!_IB:P1+G3VP9P0+^$AG-5-IW9,M%ST%UPG1"#>A$,S*US6?V= M]0I%?,9-1PXUT%U)#::$QJ;0G_5DR&],-ELH@0.21[X8@N82_Z?&"6#X!#N! MLH_-M#'=_/_N?%_ZO[8:C8[ MGEL:'>AEXEE1G!VZGH'XCOT/6.[;^A_E-V-WN F_9]')%$,\!/8=8 M>&/[8?^I+1[=XL M-$;Z_4^-_Q-,RS3N#%W]N^MQGNW^+ZC_@OHOJ/^"^B^H_X+Z+ZC_@OHOJ/^" M^B^H_X+Z+ZC_@OHOJ/^"^O]14%>&KU/9+I!=0FW300"VYZ#VZL[?CD:ZVN]LY0K5K6XQAW8&D\ZO6@O%G;N=KV1^,_=7W>N?3I_- ME.]7C(WX?=_!L^6F&5=00UQJ]8CG<:G*17H*YVVS>PJ\$:Y8*.+.2 RA5BGS#HJQ"SRP3'1 MILR+S;0G7"IQ6?-"38\#2EM9Y#^UNZ"P0YS!L\)G(;O''+A,J8?L*'"I0(\* M_[N,8[R/ SKE!.. %+AQ(13 *H+\?H6:%[#B_D+D3GNBT:>G[/#M#QR0*QW- MCA?C@ !_&[;9+N2_,&ITU5U( 6L5\N^0_QWROT/^=\C_?QUR.+BVFRD>/IL0 MBU1V=$%<&D.1-8 *W*?/]5;ZP^/PHVF,WTZG1M1QT\'U\:8]9I[TV<2W<]7" MX3=14?IG6^4#U>7J_+IE[3XV$^R4%%EWIZPBM%'7H(*M)WYCQ!&B9? D?%-* M:WFQ[X=GE("B"XX21?M#[?SN>7 HQ54-3JE=3"0 MEN+PA5#Q93GRSH,ZM2^,?R3/.U[:IQ C#Y(Y4H&K!?\7[PQU?=2-%Q4<=BYF M:.&)1SX@;&(74HKG#L+.2I413XL*-D<:.@V+K779%C1PO7%5@"E2)/8"JW>[$T35@ ME.:*%7UVK:*X66]HU8K(\2A7GKYJ8:>I[OP >;%4PV1R#OJ0#<5K]>]:IRLK M'W>?>-C9<9)Y?LC0ZNV51U;OX>D'1M>JI)N%Y<^]B58PEAO[K1]RRN?F3!JP M53W9ZJ]\<^_8&95KA#&VT!8E#'$00+,%\:,.SHD0.:92C?^%O.UL*<$W2]I7 M1XTUGR].]4$KD87(+E3C8CL'-#7X9;T2H4\]%/DDZU4T[I^/4 7;$?/?2D_R M'T7ISPL*'ILXP+B&:I.$>&D0#/#ANN$ ML%RZBI#OSB!-A,L8N]]@P(0#$D9BI \';RGL(.VJ("S9%5%XI"MTI22_^L M9;R9A,2K9BV+/6H]>;>F05J1RJ@>&6_]9Z15CIY$RQ]A1E%5W K=O4J=OP6- M>#PK.S^Y5[#GO4DTR):H0P$#9C\Z:N%+CE=53._S*<@G]]\\$Y@,#D$$.'=* MOG''V+H,'#VS&=35>ZM8,6^EJ94#BDDG O8:1TOB4&3Q[P."^OV#[(MNFPQE M]D\I4XI2X,G,0"]6TNRIZSUJ+8.:*B]D__%_%*2?>;%)-!;MV@R$/>WADG-[Q%J" M+";31A%O _/S069;OG2N#_E$EA9*)-;"VG$@WW$H(5*O Y;<*@BP2^]U\*VK M@6\XEJ5\DX_S)@5V7_BRYKUOE;7/K99J'>?Y;FGBG)O/;K+PM-//:U/I\(*K M"N_6^)^;CK=,D8*G-%?^@V2.S#L ]MF"/C85=\^YE[B'X-R' M'Y@X\H #>N(=MY)4'I7'EU"N0NU2B>D^H807EC>)8YH#J>,J"!Z&2. MB"CV_@!/W+80W^1YW.[C=NR-YH.-U"6%P+H+L&Q%CURZ)JT;ZQGJ M'D8 H4:/!AKQQ*,0[\/J-%JW9>W(_ @"3)K6[Y"$P8RZ#Q7Z&&^>,".9B_:E M>S Z^?T*Z+94KTX.J%:(*39(2Z%.=$=[M.66S/#2> 5"OIV8&SB>VG@PG^LX.R*^:OX-$P?^VY ML/%-%U2)JW468%JC&*XTGR:Q1@KX)G]O!&' ,*%K=6+D6BR!;IMQX^Y4Q/$W MD\N[K3DTQXG5L,;[QHT9_:=.^"](&MT*PL/Z>$Q0ZAP0J8PH O$10D, *^A_ M8^_-PZ$,_[[AD;+&*#LQ60I9II+(,I.$) UM0DR2/5O"R)@1V4D(19:2*,MD MSY*QJR1;]IB%[,L,-2YF>Z??<[SO^]R_^S[NYWC?YSZ.YWF/]_?'=;C^<'ZO M\_RNG\\UYW5^^1GGJ#\A? Q-(E0:A6N7J4)=[$'\T#(T*6R#5;L>>=U;4ONY M/M-:!JYS8Q"DT79S;=\G[TYXC6\R70';=IT-\H'&LQ02R+-F%)4V-DAP1?>X M<8K^G GS=;MRO^QTA''>R8Y37+LFM\S7()RIZM(N "HXABD0789MAQ,)@NU9 M,GFO:!;KK&\IBN>+OSZ2O]';F)+!OV#$I4,Q;T\!M$Q[&!I^D2Y=$!&X&T)R M*5^F=@HN]!-P:752M20<1/&L[^J>CB&UC!PC="WP$5^,"B+5BJYP/U'_@2?. MXG;.A?3TT[DGL4O=0Q%&*21>AE@6R;T'$3?I%XV&892376ZX._BM(6.;3?.;TO2EQHTYTAYL 2R*A?7)4E%M2,KJ'[;(?LU9U%3@VG%-ZRK9=%6Z9UO3H8F M/YWC_AU>3]S]1/'?_E[6$@G%[ M)$*<*KEV@@W:ITB=3Z2CO9![T9ID>"22'UO]6U#(Q7RD1=4X]"3 \BX\NA)^ MPKFQ]KK(/4$ER4RKH?WGSAYM+F4)&!4S@D;AQ+?8#_W)MMO(N"XD[7)#T?C.92*L/ M(PF$%Y7_*+,ZRD-^%*\0^'*/1?<9'(@323C,>"F=%]L&:SF*OIB .CSZX)-: M60U4W]34Y\I2=&V>94"M>X9FG0F=>AB4L:885HN8IQ/;\XN \XAB7++*KAI!C1 ME3%1QOD?/E< SQOVIFN+U8\Z\VYE7>T0;// _=(S"5 .^]P^]Q0\CV"(]O=P MM :_#054B]N@7 PMH)XR3.:)IN)(94Z"5&M*3[R&SAG)+GO82JG/Q97/&5.Z M-K=FVOFY ]\'#D _N0'CL6Y?&RJ M])8SIQMINNJ6?>@_./L]5"G#[?#J!>U6WJ6CN-))%-:B$8]OJ*^JK(I>U_+U M53[0Y2>SY]OZM[/7000^L* -2C(KML/^>09;COOG(MTS'Z.2Z M09/!8DY&FIK+$3FPVQ5C7"26F$N@6$-2D/7]JR<"J(7=+7N!JZ2-V'J8T(\W M=*XGR^LKG=L#YL>^G&P?>KZV:OAY+O%+ZMM,:T&_)/1;< 228KTAC2JFN3#3 M#?=1TEL)^T]!X_&R: GTQ=%X9YVLQVC^-Y,=!_(>5,88J[_*1)%CIH]<2IM( M/;?)M:MBBE*)#4)R($@^CZ&;X14"MY^A9['E_FR>ZGN33[(*?DZFO25;]KI[ MSC\B&:MQJ:3>53A)W=.%5J>=XCA''I!#1C#$^!C[J?!D##?C6N(52C(A7H-A M3FGN%]._/E+TXSBB>,94& ?:- MN$=_^J.=),.\DR?KZJE[PAX/_$F[\QT_2$ M4?6;'*WG,.,;AP9XEWS$=Y@X3O7_>^9@E+U?*SP.*])L0(F<(HUU;T@N8@YD M=63#IQ;&:KA+(S5]OQ=L)H9&UHVFB=2GWT3[,-]SQK-!"?+B M@$2^8+,!"1J5_1[E;DOE3?J],NWX9]I]E?*SW]MG7]%(?>HA?L.+FY\W#ZZ> M31%,X_J-7-VBFP+:M#+ UG/6#^1M088($J8=)Z8(136C*QIU]2GP^9KV1G3*MAU+\(E]LITO>': M]X"\ &3P?_ARC5>4NF4%)+\'I.\ R'*4BC$5.IF:O="EKSE:[D)#G_XC,C5M MCW]^^9MN3@2WZV4SV%X 0@_ C"-E\,0W!%FX^P6&*5UG:3N?Y\&TBDW.+3\N M[_OF[Q/I-[7V:,"G;O=\N"R6MI;;,*N'&Y9A=#$?8W^Y0Z9R6%TI?&S04C&B M #R$X&JKF$*I6*1T;NM;;<3-5L<'629KC5HZJ"<^+;A(Z5).,PS(_'+-4^Z9 MB&"EM/X(@X$9A,@:NQ.2-LT#T0I^UAO1#>F%-<=&=3C"SC-M6LB?/, 28>?B^? MBU,S/(<,A5YC^H>!^=F.R0=K6B^(>!&-U/<_I\YUI?'#^I5^2CT3HM??+KNM MB9UPH.T%7LTBQGMI;@"!,H 6 P)F#0P^J70U;G19726/EL-PLW$5)VA]!C?B M?_L_<2DDNP?,:LP)E9^_LR7\!)V9@*5=Q')+<=K9%B?& @D]J MD6RCU-\"-,E2IP1SC73F1I5#E477#UK*:#BD?P'MN/Y(\^_FFNCA.EI.>J,/GLPL3S\OO<"_;X?[4%!%("WO;[<2U@"68DEW5.G&RS-T M*#V<]+QW/4@]7/L6U;:#[L!4MZ'$YQD?"K'5#_\YINA]?S7^>;%0YE+:^Y^\ MC$/J;)"*#F< DP.\H@;PORLF/VFSA.% ;P'#D"/;&FU*^41UV!!E6"> !5"V MYQ_S^P5],@M['GFD^59-4M1)N4(ECW7;PY"+J.I9]TX]K(_=Y]PRBW@]-&.JWGT8=N"=]:>S.K<-@45"+&\+$J1:98K_=SK0EQC(D MZEG\CXB?@J_"&DC@QY,M\25?^YN_!/J0>DM<[TQO+O88K73AB:^'&,>8-?"[ M^9.QL[9M_1'VYS/E149P^S:ZH1+ T+K0W67:MDAUKO"8S[=$D;3SXS'>%X); MQ,^H@N"6;) G E"U380)<>SFA'4'3VQ<&C(T@$=CCB_9SQ>6>4G:7)J,?E?Y MH?%CO,_7SY452PI678.L*ZVWGW:L[#*4@6H*_N^Y Q$L D?;FK+DUF:J:4H* M2^#+>R#.Z.?3+V56;! ?W>GST0<*+XYDP%$-'86->5*CW9_(3"R+OXONBB&P MN)@Y?=]S*/2_G\6:)Y?_=N#_-HF--#SO\CBS-KY>8[_/KX;&$TG<AABEI9 "B?]G@!BZ3IMI/)SA.M *"D,(>KH?=]1H;[)(U>31FLNBG65T$_MH40-^ %E'5 M"(20U-;0NL1II:[=:XBWW;:71^4=^ G6B2EIQ*_K\\9;OG<"T\]"/M38$O&K M8W3=?YQG5N&-K[M<3H;SHXVH[IUK<+(PCLB$.''NPQ&F(RUB1>_)G4N9F;O7 M)TT.W;_[XJ!'=N#>N%E0-5.(?OYONS^6(>8'EIO#D.3<[:B0=L+D2>SCAU:M M5%R$+\,N0#*&I=S2KTBP<:CD4(C,'N#]J(W.WI2)&RHQ:E).'=ZW/:G 3" MD0[5S93+N =!0N=&^^8;-X]:W> Z=%+_@)1'HJIAYM(M28:H":V)6-T&P.Z.0ALT%?1?\V91N7WV"#+NL^X.)= M5>&XG@NU9\V6\U<02*2H=Q/VKL,..@(J[;09E7@_A@E/44FO>,=47"9J[4>' MJ-C+,]((2)!$U<2Q0?BV'.ZSV*^-$P206)"B80U;4I\3'ZI MI\P''S^+2(M93?>2?*0-;?+L:_2VA]/9G(*5^35OT-UL%/PCCP]"J(S M6:"GC2"/$5PF4%* +9-JM],^:M YY$3FD>3R]L*3=]..A[H>6]LBK$J^G\(, MXRD!*FLZU, VCA0/AB$E)/+41JSMPT^E/!]&:E,U:S;+[H,S;SSRF3E].+^1'?E 7B?JN M+^:JI'X6\O;WOSMT\N]K.FYLGS(;]+&'-6Z[^ ?CSY'82MBR@*]SV$R=^/P\ M&[2>OH/Q8."[_7:4*O.WP1Q+MC(V*9GUDC'-U]]Z:4\X+%N/.W8%'LEMCQ(? M*HPY\?%P9!D/F#?2^X\N390:T@&9 I.*DVI7<(\@@J=T*4WOS??;'WE#GCUQ MZH5R^T?Z1]Q7&2;'+2*5V* OC8Q;;%#%%S;HS9!MO^M)#"&]$#^'/8W227K' M_'1H;]J#MV_G7MY9G^77*;4JA?6%YAW098BYM*8!55-7(-78]MH860N?O&]V M4SLGJYLO51V@H7VMD[AZ+,!*^!_XFK$4EA2#BYF*D6-811&A[7T79WL.C#=G M'O2H2RTJGKR7/4?JW%LWU/1P_X+.SG7DZWR*S<:.*:05O$MZC5W*NS@L&/_N M6)"KYM J_O/OC^8)@8=NV&7?4?_8,/2V2')U:4GK+H[BX+LK!UUM3=#NFINB.B!LC/O>@-6%AS]>>'D_UR?CF_-@R[3W/GB30,=R:"J6' MV))*T29!>I+-216YA9[U]1+57BSYH<'#*=8Q\T.V-T=/_"I\]LR,2 HQ*W^9 M)/#7X; H&C::0+& 2 )D[U6/WQ/V049?%X+XKLT6EVU5^'N66/7/Z"4SSU5]W_Y.%_E/Y,7AA[!TPH(*/92E;$1'"Z&MC# ?L0+OW2"DM@I'GO ^I^W7VD%+2# M/[$FH%O@WB$)>;?9'J^=!18_&S2+BX?! )<*(,PDG93;TX8 KUP]KV48XCL& M+7:0W!HY[ZW(VZK0\_SL?L0WT*Q;VIQ56)_1/1Q6I[:YW^N3@/7-B]=+\.4C M14XG7I8,7W?1\JA5&W(B/W8)DIZ>T*VZMXPYQFJ#[&\Q8I@!_+-RW*8( <"= M?)6[U%/BMD,ACH:NI[Z/UDM.:*7"6K4_BAA+&X%C5V'"C$O,6K0#16"+6!]Y M:AIZ:1@\H>/M?2K6.MM&[ I\0YR[XLJ5ZU%S4EOI3;\VH8 :Q\&?"&')(9$/ M\-$/OVGW$&4WUHZ.$*TUUZ%[I#*4OHN_/E#S*&7:60U$#/S=G4\W]X)4"T>5 MHJ9F?_6W)RMU2=Z(W_1^M6"T;J=O\T2QT+[+"/;[HL;5-\96#.-N)MJ%G1AE%@O4>@586]*:FR86Y M?S1!B^ZC6,YB$PV5OV_B8FL=$J6*[A>]C5=6U-6;U>("K;-%B@"FV M#-%JFO0CG7*!CDZD!.S834O7A1FS0QZ+5&YHFG!PJ/HQK5\[>697+@^(8S2 M>JK\UBQO%T0$*+66]3,T+>DON9C3&Y=4)3G^9JO66, H M>")U;0()3A_&K> M#D@B2]*O?E'BQ-=Z,LQ^P)'/_Q;WYFKFT?A8/3>;%:?+TN9I-<1:AX>ZI3M* M5)9DX>/=O,#GMV\7W7AF6V7EV/WR[8_Y]!4I!Z.7OFJRH&^&SY.'C_,#IPK]>U7(!/]I2*]5_KCQ[:Q%&LH M+^,X4$1Q[Y+9A^N$5_0'>,E>S:HE@U* M^J,.GI@BW8B>_>1]-H>L.994X_ZIMBH7_G I),MC5LK@FOC>61#3>ZC4;&G3 MSOB(CT13T,PVW+IO$^)SN?Z'JP!*P+_XV(W"RS8E64HLW9-I[Q>^95<';P1> MG?5CB,Z20H'9(H!N/\!0(:7$YO$.OFG"5]8,$VMJ?U2<3VJK$!?C21;98\P; M>JPYN97E@QE"'OA-F.RA/:VMI("C&&=(1C+KFT:0B$ 8L_&4L19 EH:O[J^%*"@K;3[B_O&M'%F:MI;JH% MS[']-SLN=":Y]YH13T^6!M*;M A MDX1;U(QTVS4KDYM3T_.$&:/ 6<(J-V7*GIF!-B?"!5'N'?RS.&%4\"19<,41 M-F-TQ>ZI]ODAJVJ,K\SD^3L(A9S4T7^D5> GB: M?*/&3"K&'CL=M9"B=G7#Y]S#/5[>W=KO+M?)]SO9^JW4 M+>B*.%/&FWNTOJ-\SGGIY,D'1*(K=)NOI2?,Y&095%_. $Q:7,:C*,*K P M:C"$U\2@RZ:7DQ=DTFSJ1EMZO]QKCDQ0K0A<./<_Z"#QGUXM"7]K'+;M;!!^ MO*>;X/Z1;E9*]+EQ.\CH^&E["6+XV_TO-0JX4EN?@H3Y;B!S/6WV/Q$W=G.) M ,UECV;8#66_E,LVNI2CU^V*^NSR0=3_'6\A,GT]K\^H?S&6--;I*$KNCWRP M<0 58E,_\L#GQ@&C\A\JZHJ_#S]YWQHI\%3@J3$H4MVKY2]O/O-\=O?L!']?_:?^W]R86YR M$!JG^!_P>P"9,"H-K=-_GD/<)S,NX/@)PAD 4 MW^Z"C%^UH#KE[LTZB(:-N30W\[UY5O/1A!L_<.%V?T'? V>-4K.%Z,[!EU6- M7V6G*"WXZ.]XEE W "U&TX-0[#Z9T/*I^.A36&[6]QE)ZE[/ M8%-:+3GBF"W9%%ES*OL'<;T=X,W&?V:#)_!Y(W<;J=<\WO51M MLDKGQGZL;W.\RZ$\'>W>@ ][5@^JQ]PNO,_HY$KC\;ZGPPL-M;BU\^1$YV#G M592AE7Y+GUV]K#(CQW,:^HVI075??4%-)X5T:%ZT' YQ)Y6J9GN7>M0^/I[Q M>?KYZ*5#U,D&_$0B2;(3DC"V^QC#T]+TP3(X.HC?^0?FL_C-NJ'6XQH\4A1^ MVGP=GOA$7[<+GP*A6.(AJ)3N%B4J,EDG1=ZI3^*1?&7)E_ODT7TWMZ1??'CU M:ZM11+C-:9HNSX Z?33*,F>+"N2VOR8#E]YX=!:X3VZ'5"5;J'7_95VPZ%IYP4'W6=U4RDF MI.BL=A_N&Y]^U-II_O!^&-VYIK%:_N5<9YK@@K+[X]8-IR@V:.\.,QU.L@9N MH7".4?)*H\[,;Y>;QQWJ]6!/?HHN'C?RGG>TI9T$1LI1KQV]%CK&AI;3?\H6 M-WB/&W8<79NJG@_J"VD1!&SI%@Y S\5TFX]4STK+S]D+F(_2Z ^SP>8YG[OO M'U/.4CF6MJ5?Q? ],D^8E/HF=*/08RA%O49B+,1A"A?6,DK_SLDH2MO'_\UO MMOEP7_R$>2>\%IK$ OWT%%T46<(*MJB, QMVCF9V-QSB-._A7IVOOY8\4K3E M6WC[4(&\4\A=$";J=01,D5F")S[;[>_Q ]1P$1C-I1:EX0>$F&*Z/@C4^]G_C1 G\?,DU%:G_$)#\;G8_G& ,/O*/2:4G $H=?/VG&#&$\NXK#6%*\Z'/SI+>\IE?3YOJKF])L:U4TPM9O%SR AK %Z)BVKA M0\5V(;G2SP/8$A3F^MC:FQ'A5[.RX5JTZ>$UD1IYIWR%&,B)YKJ&@Y<>F:F'4JQPO MKMA3KT?7C;BR^E&S]94-N2*\3V_]5*P^<[/GJV0Q)PE583ZSE)E-?\]4@XNV M' 3,ML\/-YO/6O)IWO,-BB^*^7K4\N/1H^8)9PX)57Z0M6E06D&>YZ@;CI:E M2JZ=8^D.KAD&$!$1V>Z/VR9*9CR<#$=P?Z2>*DS>B?21Y_N9*<#G:0VR^*+$ M2R)(<9*9#-[3D@T"5."=?A,XBU$65WEL(@X*K6 ==FHI5HECN&TB<\:G;.(< M5NMSGYNE73[2N",J**)\DE7)>:8&9A3/@SF#MLVRH\SD$U,F\LDA';F71U4U M?K-!$-@K/]ASUMDG+L?,O8/$)U_HGHR6^":V!LU_CMK"MJFR5-$' !.Z/+:= MB]POB%KH05;53Q&#J-'3,SG%0*3@&LSAS'7W2-D7SB*Q-@([OJ<5WRF)[QZP M:X%2,U,I] [;A]\_O5]J/)I27)P3A"VY551;6W57J%_IZ?N3YLK;!6!)9CX, MACX/5-)O,6Y2NDO?H (1%,F.,"-9RX3U2=G8QA\Z*XDZGUHN+ 1?"[NIF#=R M+>YZXF?B4^N2;\P/;) +&R3"&H74U+>&]4Y] J'5 ,<*1Q3^UM"Z_(U/HT$> M:]_T;][LQ"#3!:T"U#/3CSP^JP#*_@..)-0B.L"3EFOYE(H6)4"PAS#1(XFE M/$%%#E^G0_WR/Z?26'H5M B8.\?43S&ML[0:YHNB0?1>0UT2.!YV:/0!01RE M>RMO[&NBY4B95F&>M-QKD\-F M2Z@7T\@]??I&W7/@&T V7Q M+]!Y47C:I;\]A%!A1,FX/Q"A&:#'@C)?7M@7^O:GU='GPXZ($.5[.&6+HZTJ M5IV=? H?P-);$"YLFR9,C<$+J-,U5UKV4<$1KX$)NB%P$<'G%;R;[@B/-70L M_FER\*>]3OMY+86I4R=ZQ=HECK75GV^K1!9GFGLXM E:\;Q!$U1O:+8!7PZA.^7RZ7J>_>XHQR><6W&,L2B:,>I&VM*U*O$E"?H_3/<8_. M<1EA.41>B%JS+;$KT;)]NIVOPNFF0FYA0XU"GL1QO6_]VP_'XE;@E(N$)TC1 M4QM3EE>IV#B6N&X\UG-CSY+3H<';0T)_6O(+?MI-(J?XWGHJALH<<8B#8PIJ M'E]$/X^XAFM9;X$"EWO(R;A'"U3S6&=J^9\HK[H92/A%\1$MC9&O.E\=)+;L M18COGFH-F&EG+Y9PS_E-]M/XJ+$]*1,XFC\E./4=RHMP%8#/]O.B"NTR-\D/ M(N>G+AS^6=1P\T6V6<]ZQWLUUM&+'4-8E_P40E7/&IB:>!V0>\]0_D1!=*^A M4%7+4"DCAN[,P5'E^H29=;+4VNL'+0G& A<40S7CG.N_]:BLV:MRSQ, Y?Q5 M'[+?.)AVD()O[Y=7-/ZX]#T^27O^6,SMY8: J+# M6[5!4LPCIF(@F__@LGV. M-. WZ4?MI+:G^WE6A'_AT@E7IL]'MO9S:>%OTC M?_*$O>FATRMSAC%\-',QEQ/=;]:^**0S7T-!:D\/ M7-"%HA(!XUH,:0R.QF)+)YP(J&'KT'F);7[QLB$I'T4[&50GZ]:KG[[&:1)@ MCD\Q1"&=A#H\0T*2YD'E\-&8C3_@J#R>@=I>K-ARIOR1<(GE;K)#**N[TJBV M4_=5V2D,F(;6^Z'FLQ M(ESO7(@H7[:%03Y\4H%[Q%JDD6',YN5#4:;J '_T4PPR( M)_?O!0+I'/@EH7-]E'$]B/DJ*)!9BC+\9EGE*:?(!G&HM<;%Q*T'1-MBF[/R M!G0G3"M! .L[!14TH9IT9&5O,Q3T"T9KU,IU^DPN?!R&GN5R?^*M1GJJ3Q0) M0;_9<]S,F_=O@S<"$=&*3\ALT1]L%F(6SOH8[0_&'*8>K2Y!95VKO,+7*:F? MM'VPJTUISI68.I"]NR6*O"!\5*L0 MA[;D7Q]Y,(4]L$QKM.J:ZZVR+*I,6/)QR>>-=XEW1!QKW4(ZV9R%Z#,N<)(: M KT'P)'Z8W9]*XF>(QB11?ER&&0BBR8)6-'E -U; RUR /3RP"K:QG_LX52?QF3T3+WZ'NGU=5\G MBW7^_805QQ8Z%K4PZE$ SC!4XT 4AB!\GQ?<>;Y5B'#X/%HW_4 M\\'C3NGY-29OOOB/'H ]%(MPJ5-O^L=6VEG @!I(>S&,.;',DL3'DIVR_/9E M>V[P0;Q0Q)\1H>=&H=TF(CS2)'.CUS0UU4-,09M$5Q;(YL\PN;B MKZ@0%C^2(DJ.R2"N6/;'TG;/,6 ?])$Q\Y29=^&DJ7*9@=R^O=I+6\;'NOMZ MM59/*+],\U[45^7^AG=-&2>0BE>O$AWZA1DG*.6XF%/3EW>M$-;. 3K3,T4A M*H2/#0VY]N;MNFR$%WZ51#^#^L<& MKP*T/A!6R ;]MQU>M%VW?%K#WQU>2E\[^G)G;O0V05Y\69 #B4\-GI5W(?EQ MEH6/Q'NEB#+N#1N>H?G%SYP<*AC427:GGUMB3;B#LWYUS9V*V=N3 ?F66BK7 MG)Z>+S&,)<8@J[42=(#59G%RF#I8W$M7IJ7ZK0/#F'K(WNU=T!D>SZ/5#E0_ M!;2J0J&20*$4"%S.R0TJSRQIS-?)_ [$HRV/_+U?/F2.F;0,/9#R/3SP M-KW\<^V1@W8G+>76,EW2$&CLN"AM'P7)$.TEY@"6[?>]'M85EA(LRX#TSH?- M!(^19IMWWP)UUGX49P8;\9K*OTD+;_]O!]#_]Y?Z5BQ+F(<-RK9@@P)2F!]P M@\O__/U17Q\;-*VRR1CZ+\=E/]2_TUM,9G4@A4J%XV0OK[OM!?XC8O M7V](NI3R)WX7=TK0X=\.+ZF-@)-.X.,J1?NWE/]HZ.Q9W<"BK4C=>H)D? M!WAWM"CB!W\CQ>ZQAB.GO&J_M[:"M64'1#J/F\D^ZK@;<,M1W"8]L=FN!2+N M (9[GO,]66UK5>Q6-C)FEIL?5&!C*G[T?_+3KI(8KIS_TC/J??_)_!V?:6LVJ'09@][+^:]\ MBN4@Y8\&3(EA_D$(]\$A6=;LX^53;2/N+Q",NO42[,@?.&Q/^ [2*N-7<*U7 MKU/B'_<_MH_S#H;)7]HRC,5_TOY8*O/[AMPKUHB@ZB)K*$6,PLUO&5 M*\N\K6/RTHVY]7 :3Z'F2V6Z268\EJBJ/K#;IY\P,OIID(J(I0(R:7DVUU6- M0H_4]YKOPD^COU"W6,+5%+<<$CVN109]ABI<6MJ8$;/0>;++TULPV.405.DS M[W;(T7!3= @=ROH".80E-D-JKZ(V>L8:DYQ$+$9T_$0L^!.&AJ:%,5VW8W]! MOW#9*H1(W+?8P=O"_I[&C8=4;;<;>6F:L$3"<**WVJ>>>D\^J_>/VN!3%P6[ M746Z "$=#[%1OPTJ H7C K#JB]FU^W#! M.D_=I);>N8U^L>? M$+716&#U'9&:\%S\4^]CA !HFS0 MOM<4> \A\;23W) AE"SJ0N8.A\3ZS397Y3DZ.5P+41U]=R)[JN\ _IF; "0I MXW,%>%:2(9'G#KA0)2\/,*"Z41A%E,.EZM$'0*T@7_D)[8S2 MN4*SO3DZ]MU%/=^P^%!)X5VJ/&?2?8BCG7X@BR2P?M_=&O+.W$L[5D'%NC*]XO57?.W^Z?>^QLW9B M)SY[#5 X*S0QIVQ$W&X&LH@X*> Z&T3BKJ?F1C/J*,^HE^SJ(Y%5[6F2\=ED M\@D9RYJ,(!4/G>4974YIO8<"]\ /&@:0U8+\Y#Q7J#*C'CI,Q0ZG3((%/LU! MZ>X8V)=G&/K47]#5F*MNSJV"<>YO7S'&":#%_@U3[S]SJ[+6XYS[R\RW'>1HYUEJY;> >I^OQZ ME:1F;0KV%M4\'K87-=81Z'G?(3SO^[;#T$'UY\7"Z(4&7455":.H;UM\QQQ! M0GF&6^U8BCT4C#X[C#[B1]J(A9T::[Y._F1[ZGV(KK2?/Y>J M[4+SS-,;@E7E742?'7DR=/G:@6J*.XN_B#)&-.\L5^EZ"&8H8R<;3Y>_7['6 MF7\[9KP>I([R6<\^1VSZ=?B<[@F#Q(.7/3[)>C?X2N<\N^;J6K3AMCVR)(;S M2_W5\O>'^5$4O TKF1*M ^?U'NTKG)GPE%?^*),<]>6UEZ2@_*+$3ZL%1PTA MQ;*JGT-N%R8FYH_>S6M\Z+WKL.#_.D%= MN_F?2_G_5=))X'@,_Q#>-Q_08/8_,@QQ%6Z@T&GAE-.Y9&^H,%(EIWCY(:TX MT/]=N*'*=F!XGJ!U)3_WWE!EY^\"3 )2F34*KX9W;G"Q)F8.,0MA_.,>&-6Q M0LHL2KN[9?^(#GBUBVKVK+JVKVRTWL%.X5/]B[F>ET7*3VZ<&R3*@&A,) T+ MV!&A\M N-88"25.V$R,UM.X,4TR\G#"S/-19XIE:9+K_SF3$VKU'21'J\],0 MEL#V>W@[E@=]9Q0C0EC$5B^D!'G+:5M1K\T<3OZ3H^=7D3G:>Z5YB/'TPX25 M\M.G7X*4OU8K>)B&T##JP!>Z(_8>2KT;PMW3WA^#41X($E*_A1]#(UW#RGMI MB:$*UVIKA[-1 5E?TBPS#!X>]9Y#3(2P^'O>,W@ 71(BQGY[59H.1Q&Z62(7 M'D11]6E@X8KX\JGV-M$K.0\0[\/+7W/-:/N&7!1VDZT'@0O_^ %J(9U(:>VCM!/#9N?.=GL*>;_K4S! M/51QK\"..TM@'R<+B%#'UESI$%8O1*1%#J7P0&<49N!A?Z.Z>!FF%2:8(^?5 M:YLY1C]J%CEY/7O(TSD]Z#-<4<-G[L+-U^&/.,/Z\G0 !XX8+>8'V&'O1N@X M6HEZ<;M=&W6'#5KSMV2^K=.7F9R&:![Z(O'E$7+FO>]R4ZS.9E$^0Q0[Z_:( MPRJ&*+ H<&3:5@]>B WR0 #VA1U*=I46M>6G(2*W9C3\?TICOJ5]\3O9&'_7 M^KB)CZ\J]Q)T$LX2B"83)G)F)=LA,8TI;9KFG6S0@1;-19D,9ET*"2]2]..& M??3+NA*?Y,Z! M'<*,%2XJ[WN/OA1K.7S/3PJ>Z^)W)]:ZX+[!@>H:9LDK;Y%-Y>K%O#M_' ME2IYZ,-GG 'S+1ODADUP.O9W3R%JHQ.C 8B[TRW1NB,//AV%Q^ICBLD^L*F. M&?Z&F*.2,:QV*N5NYER\Z4^)L9-E8=;0KQ(1>O I05KW(-8//U%,VPM4%GC6 M3^JD), ]D<)EV4$KZOW. ?<:^\H[-7HWZR8*GO(<.AE];S\9;^.]F4C$,D35 M9VTCX,0\;&5^!].DKI9(7> MZSWH=NL"5Y+X;7PXMLT83G*[A>F&']!H$?9@@Z:0HD'ABE;0LXEK Q."=NL7 M(J9?N#TPE5A20HP%;/J__W;N*;@7E_APYA69(('J9PD8O0U_O]E+PG:%64F: M2?SZ17?OF-9Y.UA[=4^I?4>O"Y.$&6>#*-;&= ,4@<0;R8"0 MPA 0U,)L1M^JDWA]T]A5T\&YA*$)+;=,[UFQJ?MIYK_>^'_>S-23NN(=!81P M_$F 4_R/4-1-*9@B"H(T4QM6O.B_)&D_MZL,F;2MTMBCTNA9M[[U/)*^NWYF MQ$ EOR,E"BL#=W,4I"5_H*A[P>0:[?XP#R,M7=WAZ85>$I6. MC1TO[GTX5/M-^[RU?]?$->X/'$L^9_AYP(GI7%I6DY/&IJJIH_QX.L/382,;*8.2 @G&T M#J#^&K5B43.V)3:] MM+\//&(E!^I%^RI?Z/F:]&T<5DRW8GUC@\2:.15\'XA*B&/848[UTS(!O_=+ M#R]AA1\P$9V3X?6QS:*!^R]!A9C1L\0OFE\.)G[4K'"]22M /M,$A5^E[\., M3T+7MNE' 7-R]Z.W!(]1F.H3TMUAG)U3F&"B]PL?7P4W9$9=W]Z(XZ1GZK?= MQ5?%-T,8!V1ICE3NLZ.5-Q M,KK)":L>KLG/_+]*\5R_?2WS8E^F%^?+-50)A?^/X3%\6.:>LI M"7 MGIB,,%A6_XHGF7G#?XO6LT$M!(8J&Q0M7<8PFL.A82@'X^NOF4I:8 M&X/_QS)P8LP/>&_K%C M5Y,O;%HY'I+.LXO^YC_4-GN[^/*-9J?O?3K F_Y\+*D3PH=?=/F[]?L1#OY./HP- MZHB#'< .]% A;!#W*G[G8 H0P-L.W95B*7%22'@6&Z1H.X"D%.KD[_)/L4$$ M/Y88MCUI%+NHXL<&A>,!&V9.#.L\A+I?SY85X;P-WX*%LT&Q(FA%-NA5"AG. MXIW ;AZ!4,C@Q\C?)QCF;% KAYZ>QQ7\9[HM_,=,X60I?QP3U+&.G4?3V2#A MPX I&V0"Z<0RP%5LT-Q%^#]K!&G\;V?&T8"V'1M4D(MGTCA;&W\.].H_GN=A._[Y_DQ5/O<69'!;- V1]'1D(F/?G/& M;)!(1S1VD0<2R 9I+Q#^G6UL_@/%[ K^IZX-K_8G?(YB*<0*<-:T'[; N__/5?_OJ_Q%^;_";8(!:_+*68]A#(<"?GZ%)5XG2$#!:J4^P;(L/" M/%&=7U,[Y!VQCRL/BSX]R27_XC_7NQ[Q.!7]56#!3+*C0J;CQA/%)P("-B&7 MIW2J?_R/,%=%Q]K_/NCO7S+^=Y!QS-+OD7WII;V3-1:08*MU($'">TNP8YHR6PNV!+-BAB@0U*+ ";OVZ>98EIL$&_Y3F!SM7/ M!DER/)7CMXM&4!9W/DLKPD@^82L%L.9,9^ ADL$+9SA"**\XS+3@-QX0Q@*- MH-\/U;_#2>OP8!<0M?1!"U&R],&?/S[[%G0L /E%\7&R35(H&R[;S4QI-1AJIJ[_Y= MV+&:*")' ;?%RR'7;H!QI,0DIZP;0'RH.04LN- M,R\D"@/)B?22S+#XBKNY=K]X+&2]&A1L0=:\8XV^Q7YE2Y3IB9\F0=[^D1?> M1G?T',LS41?F@[TNQCT]S'S'./+WLW1F#8L7\\4>WI&(%6# J-LQN%\43!-/ M&<$]AM:7;?&@[=Y@M7NO:WJ?]OUAQ6CEN5!(-Q+0\SX/G'G%&LQ33"?%%)6A MM(E^2648>4_[3YEU^51;[VIUYNOI#-+-U5=U#R:W#*OVR/'=JIL$,65?M_@! MYG1SU@#KS!#Z;!!A8J4]6_R'_JF'6;%^&BS5MG>+DZOK5R72;FDFW'*H&W7; MVE=6^?3EB<^X[YRRKMLQ*YG$L.#,^@20$425;*O#: />?H5 U>[*M09J;C^M M/F[:Q26@N!<\L>U0V#6OVN 0Z]QV(.HSB%GP&G^<#7*# \=2.OHGKK+XO>G' MS2F%Q+Q2B29JX_R&.1!(*450M0GZ%[+29;-RKC8YDF=.^V^H*XG1SPDU<;G2 MS6EW@ 5J&!F:7,L$D_/;]%JD.0(=3(**EW?=$XE4^?326#?;>.5-S84GUUJ/ M.('XSNP/BPAB@PYAO9 QR&KQO-P JCH9^@@FWU;:U.,,C:^E6QV!VNW)NIG< M&7>HQ%59*^"C>_DU0(%^AZ'(?/O'8 4:0Q!C'4(;-P^1[39\&#ID!TU[APOC M:[:IMU._JAGN&=\[MA#+.&0Y*P0AL4%K171N;\SAA.5P44N.?@+#Y.I>P(JU M._'.&@8RW7K.)TNGG!4*X8"9:_F34[1P:@CC('P6FKP!.[@".=@,)KWX M'1;NWK[[-KV<89!SW;/64H\\%6CT1E?6)?2*XZ"2VHE595\]$'UTF[S]^'=_ M?)V30 ,5'EO.<'UG=[K(L^#+NW/9N2/OT\H-@[N:1^/$#W^\4A#5+SYH2\[O M24F$J0(<;?"",=]E\MO]HK&4[.7LXM5I9\\BP LADJP_9567MFUCL(#/5.-+ MX(N%_FIJ$-B3>5M]>0H":,72;%NADT@;*K(]K%\0?8N9I?!DMK.%-ZM3+< ' MN[\CJ(S6F& =O+^X.0-4\\+?G(J0?!(\OD PZIC7=J]]"Z#KXJ!-QX0 UX M,DL<;0D8%#-0 %<():4=*X0VBZ7P!!V2#Y/9 46QP$'V]E]\5%-.^(QKE%M)0"7,J2:TUX .,HF%-"L7TTE$<31LF%L4 )& MG3+:$/0:5!&G7#^T)@7=M6%[_18-,TP;*+%D9ZE)\:U/2U.T5U-9(/V MQ0(I=/32V(P68$PWZ"#[1=-@*ECAEL)0JG"_%56@1_;]%]3NK3JZTEG9D*PC M0U_/O52;A:,'>.-1<): (UV/84+5?)M<@!F [*WM<[%^:NKM4@PL6#8T- 0. M7CGULAIR6WW*>R>/F8PYP^"F0ABR-F1$5.,%&KYG[5T_"$6;F&\_&[T(Q]!\;FIVOQ]H8GZ"% /^TX$$#7PGRWQ8#Q0#7= M"M7?2KN"7*KV5GL[L53JZ9$8$EJ"?#[O>I;ZM2E-3<8LGB(HOI]K6_()(_P5 M6I,27$B&B*[8(V(-X6_.^?K],;JR:6!@H!IK=R3SW &Q$(VS[Q@JY#YH3XOX M<-"TX)7A/^6B]C4);!#BAX;6P?E1ULPUL-C@Q<=O4AM/5E6E28D8'QZ;!Z]Q MPFF?6!VS!DM,)]3U1 ;A^)P8AL K"O)B.*0+(Y?'U)%ZM?6!-G9C[$+)T?H7 M+O?+7,QV0HU3\X.9*2Q-QE6 PT#V5C+3?%B2:(5$65V&>&P7H1;'$)VB35*^ MIU-FIMKP$K"]0-CU(4/$W3SMK34-3=]34^3&W">OQ$L\Y\[79Y]_W'7 S?2J M7O=7@&:YR^'8$I&H$> %(0E)!8W)]P)U:_Y5!-4R@4ZN>G MC\SK#1,'UQW?5.>TLXLX8#[$I8 M)YEU>&?LY#(D"LMSAPIM!_, #ITSHB.&H65 PX/ ,(V']Y;"3N?>T73S+ED; MW([<,IGW?V]R%P0>1H 8Q@.88X N@BH9_>>34F<>9(0D*2&3EQ$J]RMWU;VP MZY1KZEC4US3U.RWGV:!(?C;HZR&\.XXN=IL#%F9:FO[I^SH4LQQS!B@F976& MJ0N!K]'%WS3>"P%#)EZE:[EF6/2^,A(/FTW8E6^Q9#9CYW">!!HO)];,$;?& M&_2&&V%7DZ@Z'JX51=)Z3>57/5D\MM%LD".;O5G2CP!6F5_ M=)/+R YTB/O'& >_2@NRL-7>"Y;J2S53;_)F/'WFDWXI)W^MRK]S1OPWH;U? M!#G-ZH$=_I1)6W?X/+I8MJ$M;0MR$7I)O75*>2%(#=X,R$.Z1KK/#'?:EO=) M-835:I0U>N6]/6^?TK.#FZ^[\8VB:% Q;?!+J,FS_W)P_:^KZ?1S*5MOQZ+ M<3*;7Y%T/]N95C6_.HLT'G_MO GX"UP!W!=_T$M_WW8,I@,;YCI?Q"F^BL$I MF/TWO_/U7]T9,?-L^[HY_&VI??;=:/N-+KH7&]3T:WARX]LDTOU5!JG_ -% M]8WU*UG:W*&%>+>H"7@N?727D]JC'R(>2X8D0Z08ZF2]FIR5G/$_TMV+!5:G M)V\\QU;6G91]M927L:RO&ZV3+\_Z8B_^)-[_]LB1FV\LDN85<]PT'/P7-N^(XJO M#G0[O[=N*[M&O?ZZX?;ZPH.=>AM[K\PFO'8B%=*UD0P[,-PR]@Y6[.X]XWGJ M^6D51#.Z#&HS)OZ*-YEE,'TVS2P[QUPQYH:,:YV4O#$;9.N8'X5&E +JM(>C M?U+B)-.F<^_")S3669Z']'UNTF:3%W(_B?\?[+UW4)-?VRX:!:6)2&]"5*1( M%:E*"1:ZB()T(2HB34"E)$A(E-XC(*"H!$&D"1'I-=(%1*1W0@*"*"6AA ?2 M=OQFGS/G_/8^^SUGSS=[SYQY_UA_,#S/LZ[[7G>[,FO=RP2^U,0$4:XWDDT[ M(/':@_U$WO#M< GU1_HFC( S3XFZ<;-)@M/ON$T4@Y=N+#W9>U.N97\J6CBN M[$FQEG28Q84-E6U?:+JJ$["\4$:IT5RDPAO50Z?!UE5)[-_/.3U76!X91@20 M.190[6^5UJ8ZMIRG_+GON[B!:JGAXKH5D! \7 PD(S/26=*/M# ML_[+$')L:.\1^R7SQ_CV+)6M@[HRU;"YLY5U0#CU]-QDV0HY=BHC%9O[2/.8 M4IULK;^\#T5&?Y];I&DL??A;"6(T/XZBF]UO:[-;O]T4LNO0M(&_W(TBE!N> M1/UH98+2M/$T_P8U(<0=H'.^7_)JR\@.E]^ITFN\?Z[VCFV?5^_$YZ: M^(I2C$CAV$2&IC.]3,2LZJOTGON=#)A-2?V^"._.#;=GA+=>-#MZ5;E)OHQ! M;:PT44\2UFKLA;S&4;[:DU//-AQ7.*#P87$G9&9K

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end

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